













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 








IDENTIFICATION OF NOVEL ACCESSORY 
PROTEINS ENCODED BY INFLUENZA A 





Rute Maria dos Santos Pinto 
 
 
College of Medicine and Veterinary Medicine 
The Royal (Dick) School of Veterinary Studies 
The Roslin Institute 
 
 
Dissertation submitted for the degree of Doctor of Philosophy 






Declaration of authentication 
 
Edinburgh, August 2019 
 
I hereby declare that this thesis entitled “Identification of novel accessory 
proteins encoded by influenza A virus segment 2 that prevent interferon induction” 
was produced by myself, that the work and illustrations contained herein are my own 
except where otherwise explicitly acknowledged. This work has not been submitted, 












I would like to dedicate this dissertation to my grandparents Victor, Maria 
Joana, Paulo and Olga. 
Their wealth of knowledge, consistent teaching, patience, encouragement and 
unconditional love have been absolutely crucial for my personal and professional 
development and therefore a key for the success of this scientific body of work. 
For that I will be eternally thankful. 
 
 
É com muito gosto que dedico esta dissertação aos meus quatro avós Victor, 
Maria Joana, Paulo e Olga. 
Tê-los presentes na minha vida é uma das minha maiores sortes. Todo a riqueza 
de conhecimento, o ensino constante, a paciência, a coragem, o carinho e o amor 
incondicionais por eles cedidos e demonstrados têm sido fundamentais para o meu 
crescimento pessoal e professional que, entre outros, resultaram no sucesso deste 
estudo científico. 







Little did I know what an enjoyable and memorable experience this would be. 
I’ve got my name attached to the front page of this work, but none if this would have 
been possible without the help and support of the following people. 
Primarily, I would like to thank my supervisor Professor Paul Digard who 
kindly adopted me into his laboratory and so generously offered me the opportunity to 
develop a project which I am so passionate about. His broad knowledge and guidance 
made the success this thesis. I would also like to thank my second supervisor Professor 
Bernadette Dutia for her patience and encouragement and for kindly providing 
delicious Victoria sponge cakes which can make any mood as light as the cake itself. 
Professors Digard and Dutia successfully provided me with the best scientific and 
academic training a PhD candidate could ever ask for. Our Thursday afternoon 
meetings were always occasions of intensive and thrilling learning and will truly be 
missed. 
Thank you to previous and current members of the Digard and Dutia 
laboratories, who have provided essential help and advice. Particularly Dr Helen Wise 
who so brilliantly initiated this project and Dr Liliane Chung for the training, the 
friendship and for managing to work beside me without kicking me out the bench. I 
would like to extend my appreciation to Dr Marlynne Quigg-Nicol (for all the help 
with the in vivo experiments), Dr Lita Murphy (for the support during the writing 
period), Dr Elly Gaunt (for believing in my crazy ideas), Dr Saira Hussain (for the egg 
training), Dr Nikki Smith (for keeping us all in order) and Ian Bennet (for advice in 
molecular biology techniques). Big thanks to Dr Samantha Lycett and Dr Pip Beard 
for their help with the bioinformatics and histopathology analyses. 
It is with delight that I belong to the “Digardians of the Galaxy” and it was a 
pleasure to work alongside lab friends Dr Seema Jasim, Dr Matty Turntables, Dr Becca 
Dewar, Dr Mariya Goncheva, Dr Anabel Clements and Dr Carina Conceição. Thanks 
for the coffee breaks, the lunch breaks, the Friday bars, the karaoke sessions, the 
Popworld, the FluFighters exhibits, the gossip dinners, the “what bus are you taking?” 
and honestly… All the fun… Thanks for making that sweet line of people with “I-
need-coffee!” faces in the audience of scientific conferences that I was always so proud 
to belong to. You guys really made it worth it. 
Thanks to the newbies Susi Keane, Lizzie Billington and Cal Donnely. Thanks 
for taking my suggestions (even when they were wrong…). Keep going, guys, I believe 
in you! If I made it, you’ll make it as well. And don’t forget… We still have to build 
a plaque assay throne! 
Acknowledgements   
VI 
A big thanks to all the members of the virology community at the Roslin 
Institute. Thanks to Dr Finn Grey and Dr Christine Tait-Burkard for the questions at 
the internal seminars and to Dr Bob Dalziel for the knowledge sharing and for caringly 
getting some sense in my head when needed. Thanks to Dr Jack Ferguson and Dr Inga 
Dry (for the fun times in the lab and for increasing my love for pints), Dr Spring Tan 
(for the rides in the early mornings) and Elle McLuskey (for being my long hair 
buddy). 
An enormous gratitude to the Microbiology Society for the career development 
opportunities and the financial support to attend national and international 
conferences. 
A massive appreciation to my MRes supervisors and lab mentors at the MRC-
University of Glasgow Centre for Virus Research: Prof Massimo Palmarini, Dr David 
Bhella, Dr Mariana Varela and Colin Loney, who were vital at the early stages of my 
virology training, made me believe I could survive this adventure and kept supporting 
me throughout its entire duration. 
Thanks to my first ever Glasgow friends Helena and Mario (now respectful 
Doctors) for the encouragement and the enjoyable meals with loads of politically 
incorrect jokes. 
Huge thanks to my flatmates, Rui and Joy, for telling me off when I left the 
kitchen a mess and for making me tidy my room when it desperately needed an 
intervention. I don’t think I could have shared a home with better people. You were 
the reason why I didn’t work on (all) Sundays. 
I could not miss my bonkers group of friends: João, Fábio, Martins, Carolina, 
Daniel, Laura, Cajó, Ana, Marcelo and Pedras, who, despite the distance, make me 
believe that home will, invariably, always be home. Thanks to Di and Falâncio who 
give meaning to the premise “Os amigos da Faculdade são para sempre” (If you’re 
friends in Uni, you’ll be forever friends). A massive thanks to Sofia and Anabela, the 
sisters from another mother who were always, always there. 
Lastly, I want to thank my family, from the very north to the very south of little 
Portugal, ranging from aunts, uncles, cousins, grandparents and great-grandparents 
who shaped me into who I am today and always fully supported and encouraged my 
decisions. 
The very final and most special thanks goes to my mom Paula, my dad Luís 
and my siblings Manuel and Mariana. 
 





Table of Contents 
        Page 
Declaration of Authentication ……………………………………………………… III 
Dedication …………………………………………………………………………. IV 
Acknowledgements ……………………………………………………………….... V 
Table of Contents …………………………………………………………………. VII 
Lay summary ……………………………………………………………………... XV 
Abstract ………………………………………………………………………..... XVII 
Abbreviations …………………………………………………………………..... XIX 
List of Figures …………………………………………………...………..……. XXIII 
List of Tables ………………………………………………………………..… XXVII 
 
CHAPTER 1: INTRODUCTION: INFLUENZA A VIRUSES, ACCESSORY 
PROTEINS AND INNATE IMMUNITY ...………………..……………………... 1 
1.1. General Introduction to Influenza A viruses ...………………………………. 1 
1.1.1. Taxonomy and nomenclature …………………………………………………. 2 
1.1.2. Ecology and host adaptation ………………………………………………….. 2 
1.1.3. Antigenic shift and antigenic drift ……………………………………………. 3 
1.1.4. Prevention strategies against IAV: Diagnostic, Vaccination and Antivirals …. 4 
 
1.2. Influenza A virion structure …………………………………………………... 6 
1.2.1. Virion morphology ……………………………………………………………. 6 
1.2.2. Virion composition …………………………………………………………… 6 
1.2.3. RNP structure and composition ………………………………………………. 8 
1.2.3.1. The heterotrimeric RNA polymerase …………………………………… 10 
 
1.3. IAV genome organisation and respective protein coding strategies ………. 11 
1.3.1. Canonical translation to produce the essential IAV gene products ………….. 11 
1.3.2. PB2-S1 …………………………..................................................................... 14 
1.3.3. PB1-F2 ………………..................................................................................... 15 
1.3.4. PB1-N40 .......................................................................................................... 16 
1.3.5. PA-N155 and PA-N182 ................................................................................... 17 
1.3.6. PA-X ................................................................................................................ 18 
1.3.7. M2, M42 and other segment 7 gene products ………………………………... 19 
1.3.8. NS2, NS3, tNS1 and NEG8 ………………………………………………….. 21 
 
1.4. Influenza A viral life cycle …………………………………………………… 22 
1.4.1. Receptor binding and internalisation ………………………………………… 24 
1.4.2. Fusion and uncoating ………………………………………………………... 25 
1.4.3. RNP nuclear import ………………………………………………………….. 25 
Table of Contents   
VIII 
1.4.4. Viral genome transcription and replication ………………………………….. 26 
1.4.4.1. Cap snatching, transcription of vRNA and polyadenylation ……....…… 27 
1.4.4.2. Processing of viral mRNA ……………………………………….…..… 30 
1.4.4.3. Mechanisms of vRNA replication …………………………………....… 31 
1.4.4.4. Regulation of transcription and replication by viral factors …….…….... 33 
1.4.4.5. Regulation of transcription and replication by cell host factors ……...… 34 
1.4.5. Nuclear export and trafficking of vRNPs ……………………………………. 35 
1.4.6. Virion assembly, budding and release ……………………………………….. 37 
 
1.5. Innate immune responses against Influenza A viruses …………………….. 39 
1.5.1. Interferons ........................................................................................................ 39 
1.5.2. RNA sensing and type I interferon induction ………………………………... 40 
1.5.2.1. Intracellular viral RNA ………………………………………..…….…. 40 
1.5.2.2. dsRNA or ssRNA delivered through endosomes ……………..…….….. 44 
1.5.3. Signalling responses to type I interferon …………………………………..… 45 
1.5.4. Interferon-stimulated genes …………………...…………………………….. 46 
1.5.4.1. Myxovirus resistance proteins ………………………………..………... 46 
1.5.4.2. 2’ 5’-oligoadenylate synthetases …………………………...…………... 47 
1.5.4.3. Protein kinase R …………………….………………………..……….... 48 
1.5.4.4. Interferon-induced transmembrane proteins ………………...…………. 48 
1.5.5. Interferon induction by IAV infection ……………………………………….. 49 
1.5.5.1. Induction of RIG-I by the IAV “panhandle” ………………...……….… 49 
1.5.5.2. Defective genomes and defective interfering particles ………..…….….. 51 
1.5.6. Interferon antagonism and prevention by IAV ………………………………. 53 
1.5.6.1. NS1 ……………………………………………………….……..….….. 54 
1.5.6.2. Viral polymerase ………………………………….......………….....…. 56 
1.5.6.3. Haemmagglutinin ………………………………………………………. 57 
 
1.6. Aims and approaches ……………………………………………………..….. 58 
 
CHAPTER 2: SEGMENT 2 AUG CODONS 10 AND 11 AND THEIR EFFECTS 
ON VIRAL FITNESS IN VITRO ……..………………………………………..… 59 
2.1. Background and aims ……………………………………………………...… 59 
 
2.2. Results ………………………………………………………………………… 62 
2.2.1. Translation initiation from AUG codons 10 and 11 …………………………. 62 
2.2.2. Generation of PR8 segment 2 mutant viruses ………………………………... 65 
2.2.3. Viral protein expression in infected mammalian cells ………………………. 69 
2.2.4. Propagation of segment 2 mutant viruses in mammalian cells ………………. 73 
2.2.5. Propagation of segment 2 mutant viruses in avian systems …………………. 77 
2.2.6. Evaluation of the polymerase function of mutant PB1 proteins and the ability of 
segment 2 peptides to support viral gene expression ……………………………….. 81 
  Table of Contents 
IX 
2.2.7. Analysis of the packaging efficiency of segment 2 mutant viruses ………….. 91 
 
2.3. Discussion …………………………………………………………………….. 93 
 
 
CHAPTER 3: TYPE I INTERFERON IN RESPONSE TO SEGMENT 2 
MUTANT VIRUSES ……………………...…………………………………….. 101 
3.1. Background and aims ………………………………………………………. 101 
 
3.2. Results ……………………………………………………………………….. 102 
3.2.1. Quantification of type I IFN production during infection with segment 2 mutant 
viruses …………………………………………………………………………….. 102 
3.2.2. Ability of segment 2 mutant viruses to replicate under established antiviral 
conditions ………………………………………………………………………… 109 
3.2.3. Assessment of innate immune recognition of mutant vRNPs ……………… 111 
3.2.4. Fitness of segment 2 mutant viruses in IFN-deficient systems ……………... 113 
 
3.3. Discussion …………………………………………………………………… 119 
 
 
CHAPTER 4: IN VIVO STUDIES WITH SEGMENT 2 MUTANT VIRUSES 
…………………………………………………………………………………….. 123 
4.1. Background and aims ………………………………………………………. 123 
 
4.2. Results ……………………………………………………………………….. 124 
4.2.1. Weight loss of infected 129Sv/Ev WT and IFNAR-/- mice ………………... 124 
4.2.2. Virus fitness in 129SV/Ev WT and IFNAR-/- mice ………………………... 129 
4.2.3. IFN-β induction in infected mouse lungs …………………………………... 130 
4.2.4. Histopathology of infected mouse lungs …………………………………… 132 
4.2.5. Cytokine and chemokine profiling of infected mouse lungs ………………... 135 
 
4.3. Discussion …………………………………………………………………… 141 
 
 
CHAPTER 5: STUDIES ON THE MECHANISMS OF THE INHIBITION OF 
TYPE I IFN INDUCTION BY PB1-N92 AND PB1-N111 …..………………… 149 
5.1. Background and aims ………………………………………………………. 149 
 
5.2. Results ……………………………………………………………………….. 150 
5.2.1. Expression and cellular localisation of PB1 shorter products ………………. 150 
5.2.2. Suppression of IFN induction by PB1-related polypeptides ………………... 155 
Table of Contents   
X 
5.2.3. PB1-related polypeptides and the obliteration of RNA polymerase II promoter 
activity ……………………………………………………………………………. 161 
5.2.4. Identification of steps in the IFN pathway modulated by the PB1-related 
polypeptides ………………………………………………………………………. 163 
5.2.5. IRF3 phosphorylation in cells infected by segment 2 mutants ……………... 169 
5.2.6. Effects of IRF3 phosphorylation inhibition on fitness of segment 2 mutant 
viruses …………………………………………………………………………….. 171 
5.2.7. Effects of TLR3 inhibition on viral fitness of segment 2 mutants ………….. 175 
5.2.8. P65 (NF-κB) phosphorylation in segment 2 mutant infected cells ………… 179 
5.2.9. Replication of segment 2 mutants following NF-κB inhibition …………… 182 
5.2.10. Effects of TRIM25 knockout on viral fitness of segment 2 mutants ……… 186 
 
5.3. Discussion …………………………………………………………………… 188 
 
 
CHAPTER 6:STUDIES ON THE STRAIN-DEPENDENCY OF AUG CODONS 
10 AND 11 ………………………………………………………………………... 195 
6.1. Background and aims ………………………………………………………… 195 
 
6.2. Results ……………………………………………………………………….. 196 
6.2.1. Conservation of frame 1 AUG codons in field isolates ……………………... 196 
6.2.2. Selected IAV strains ………………………………………………………... 201 
6.2.3. Translation initiation from segment 2 AUG codons 10 and 11 of the selected 
viruses …………………………………………………………………………….. 201 
6.2.4. Evaluation of the transcription activity of mutant PB1 proteins of the selected 
viruses …………………………………………………………………………….. 205 
6.2.5. Propagation of the wider panel of segment 2 mutant viruses in MDCK cells. 207 
6.2.6. IFN induction by the wider panel of segment 2 mutant viruses …………… 210 
6.2.7. Phosphorylation of IRF3 in cells infected with the panel of segment 2 mutants 
…………………………………………………………………………………….. 212 
6.2.8. Effect of BX-795 on the propagation of the panel of segment 2 mutant viruses 
…………………………………………………………………………………….. 215 
6.2.9. Fitness of Mallard segment 2 mutants in avian cells ………………………... 218 
 
6.3. Discussion …………………………………………………………………… 220 
 
 
CHAPTER 7 CONCLUDING REMARKS ……………………………………. 237 
7.1. General conclusion ………………………………………………………….. 237 
 
7.2. Future work and directions ………………………………………………… 241 
  Table of Contents 
XI 
7.2.1. Identification of the potential function of AUG 10 and 11 in virus packaging 
…………………………………………………………………………………….. 241 
7.2.2. Identification of binding partners of PB1-N92 and –N111 …………………. 241 
7.2.3. Elucidation of the mechanism of expression of PB1-N92 and –N111 ……… 242 
 
CHAPTER 8: MATERIALS AND METHODS ……………………………….. 245 
8.1. Materials …………………………………………………………………….. 245 
8.1.1. General reagents ……………………………………………………………. 245 
8.1.2. Radiochemicals …………………………………………………………….. 247 
8.1.3. Enzymes ……………………………………………………………………. 247 
8.1.4. Bacteria cells ……………………………………………………………….. 247 
8.1.5. Eukaryotic cells …………………………………………………………….. 247 
8.1.6. Solutions and media ………………………………………………………... 248 
8.1.6.1 Eukaryotic cell culture media and cell passage solutions …….…..……. 248 
8.1.6.2. Bacterial media …...…………………………………………………… 249 
8.1.6.3. Competent bacteria preparation solutions ………………...……...…… 250 
8.1.6.4. Nucleic acid gel electrophoresis buffers ………………………...…..… 250 
8.1.6.5. Protein buffers and solutions ………………………………….…..…... 250 
8.1.6.5.1. Lysis buffers ……………………………………………..………. 250 
8.1.6.5.2. Acrylamide gel electrophoresis ………………..………………… 250 
8.1.6.5.3. Western blotting …………………………………….…………… 251 
8.1.6.5.4. Immunoprecipitation buffers …………………………..………… 251 
8.1.6.6. Fluorescence-activated cell sorting buffers …….………….………… 251 
8.1.7. Drugs, inhibitors and compounds ………………………..………………… 252 
8.1.8. Plasmids ……………………………………………………….…………… 252 
8.1.9. Viruses and reverse genetics systems ………….…………………………… 253 
8.1.10. Oligonucleotides ………………………………………..………………… 255 
8.1.10.1. Oligonucleotides used for sequencing of constructs and viruses 
……………………………………………………………………………...….. 255 
8.1.10.2. Oligonucleotides used to subclone viral sequences into indicated vectors 
……………………………………………………………………………...….. 255 
8.1.10.3. Oligonucleotides used for site-directed mutagenesis ………….....…... 255 
8.1.11. Immunological reagents and dyes ………………………………………… 256 
 
8.2. Molecular techniques and nucleic acid handling ………………………….. 259 
8.2.1. Polymerase chain reaction (PCR) …………………………………...……… 259 
8.2.2. DNA gel electrophoresis …………………………………………………… 260 
8.2.3. Purification of DNA fragments ……………………………..……………… 260 
8.2.4. Restriction enzyme digestion ……………………………………….……… 261 
8.2.5. Extraction of DNA fragments from agarose gels ………………..………… 261 
8.2.6. Ligation of DNA fragments ………………………………………...……… 262 
8.2.7. Preparation of antibiotic selection agar plates ……………………………… 262 
Table of Contents   
XII 
8.2.8. Preparation of competent bacterial cells …………………………………… 262 
8.2.9. Transformation of competent bacteria cells ….……………………..……… 263 
8.2.10. Bacterial culture ………………………………………………….……….. 263 
8.2.11. Plasmid DNA extraction and quantification ………………………….…… 264 
8.2.12. Site-directed mutagenesis ………………………………………...………. 264 
 
8.3. Eukaryotic cell culture, isolation and manipulation ………………………. 265 
8.3.1. Cell passage ……………………………………………………...……….... 265 
8.3.2. Cell counting …………………………………………………………….…. 265 
8.3.3. Isolation of bone marrow-derived macrophages …………………………… 266 
8.3.4. Cytotoxicity assays ………………………………………………………… 266 
8.3.5. Plasmid transfection of mammalian and avian cells ……………..………… 268 
8.3.6. RNP reconstitution reporter assays ………………………………………… 269 
8.3.6.1. Transcription (firefly luciferase) reporter plasmid ……………….…… 269 
8.3.6.2. Transcription (GFP) reporter plasmid ………………………………… 271 
8.3.6.3. Replication (firefly luciferase) reporter plasmid ……………….……… 271 
8.3.7. Protein shut-off assays ……………………………………………….…….. 271 
8.3.7.1. Renilla luciferase measurement ……………………………………..… 272 
8.3.7.2. β-galactosidase measurement …………………………………….…… 272 
8.3.8. Plasmid-based β-IFN and ISRE promoter reporter studies …………….…… 273 
 
8.4. Virus related assays …………………………………………….…………… 274 
8.4.1. Generation of P0 viral stocks ……………………………………………….. 274 
8.4.2. Generation of cell-grown P1 viral stocks ……………………..…………… 274 
8.4.3. Quantification of viral stocks and samples be plaque assay ……………..… 275 
8.4.3.1. Plaque assay staining of pandemic human IAVs (Cal04) ……………… 275 
8.4.4. Quantification of viral stocks and samples by haemagglutination assay …… 276 
8.4.5. Quantification of plaque sizes ……………………………………………… 276 
8.4.6. Viral RNA isolation and sequencing ………………………………….……. 277 
8.4.7. Quantification of viral genome by quantitative RT-PCR ……………..…… 278 
8.4.8. Virus infection of eukaryotic cells …………………………………..……… 280 
8.4.9. Viral multicycle growth kinetic analysis ……………………………..……. 280 
8.4.10. HEK blue assay ……………………………….……………………..……. 280 
 
8.5. Protein purification and detection …………………………………………. 281 
8.5.1. SDS polyacrylamide gel electrophoresis ………..……………….…………. 281 
8.5.2. Western blot …………………………………………………………….….. 282 
8.5.3. Densitometry ……………………………………………………………..... 282 
 
8.6. Radioactive isotope experiments …………………………………….…….. 283 
8.6.1. 35S-methionine/cysteine metabolic labelling of infected cells …………….. 283 
8.6.2. Autoradiography of dried polyacrylamide gels …………………………….. 283 
  Table of Contents 
XIII 
8.7. Fluorescent imaging and detection ……………………………….……….. 284 
8.7.1. Immunofluorescence staining …………………………………..………….. 284 
8.7.2. Confocal microscopy ……………………………………...……………….. 284 
8.7.3. Fluorescence-activated cell sorting (FACS) …………………………….…. 285 
 
8.8. Mouse experiments …………………………………………………..…...… 287 
8.8.1. Ethics statement ……………………………………………………………. 287 
8.8.2. Viral infections and sampling ……………………………………………… 288 
8.8.3. Tissue homogenisation and viral quantification …………………………… 288 
8.8.4. Histopathological analysis …………………………………………………. 289 
8.8.5. Enzyme-linked immunosorbent assay (ELISA) …………………………… 289 
8.8.6. Mouse cytokine arrays ………………………………………………..……. 290 
 
8.9. Bioinformatic analysis …………………………………………...…………. 291 
 
8.10. Statistical analysis ………………………………………………….……… 291 
 
8.11. Structure modelling ……………………………………………………….. 292 
 












“Flu” is a respiratory infectious disease caused by influenza A viruses (IAV). 
IAV circulate in aquatic birds where they mainly cause mild or asymptomatic 
infections. However, through adaptation, these viruses are able to infect other avian 
and mammalian species such as poultry, pigs, and humans, causing severe clinical 
symptoms and high mortality rates, leading to losses in food production and economic 
burden. Moreover, the unpredictable occurrence of human pandemics could result in 
the deaths of millions of people worldwide. Given the current lack of a definitive 
prevention method, it is vital to fully understand how IAV replicates and causes 
disease. 
Similar to humans, mammals, and indeed every other living organism, viruses 
also possess a genome - coding for several proteins which they need to replicate. The 
IAV genome is composed of eight segments. Gene overlapping is widely employed by 
these viruses to generate genetic novelty while retaining a small genome size, meaning 
that the same genomic sequence encodes for more than one protein. Therefore, from a 
small genome, IAV is capable of expressing not only their ten essential proteins, but 
also an additional ten accessory proteins which have also been identified in different 
IAV isolates/strains. Although not crucial for virus propagation, many of these 
accessory proteins have been shown to counteract the host immune response, halt the 
host protein synthesis, or increase cell death, contributing to a more severe viral 
pathogenesis and faster disease progression. 
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In this work, we have identified two additional accessory proteins, PB1-N92 
and PB1-N111, which are expressed from IAV segment 2. Mutant viruses lacking 
these peptides induced a stronger innate immune response (interferon response) and 
struggled to replicate in cell lines, in embryonated hen’s eggs, and in mouse models. 
However, when the innate immune response was weakened, the mutant viruses 
recovered their replication. Moreover, these proteins were individually expressed 
separately from the virus and were able to counteract the interferon response by 
themselves. 
Bioinformatic analyses predicted the likely expression of these peptides in the 
large majority of IAV isolates, and research into human pandemic, seasonal, and swine 
strains corroborated the importance of PB1-N92 and PB1-N111 in IAV infection. 
However, deleting the two proteins in the context of a duck virus did not affect virus 
replication nor innate immunity induction in mammalian cells, but reduced the growth 
of this virus in avian cells, showing a possible species specificity in the function of 
PB1-N92 and PB1-N111. 
Therefore, the data described in this study suggest the existence of two 
additional proteins coded in IAV segment 2 which are interferon antagonists. Further 








Influenza A viruses (IAV) are a major group of pathogens that infect a broad 
range of mammalian and avian species and in humans, cause of annual epidemics and 
occasional pandemics. IAVs are orthomyxoviruses containing an 8 segment negative-
sense single-stranded RNA genome encoding 10 core polypeptides essential for virus 
replication. Alternative translation events that produce additional viral polypeptides 
have been shown to be significant in IAV biology. 
IAV genome segment 2 is a virulence determinant known to encode PB1, PB1-
F2 and PB1-N40 proteins, starting from AUG codons 1, 4 and 5 respectively. Work in 
this thesis investigated the expression of two additional polypeptides, arising from 
translation initiation at AUGs 10 and 11 of segment 2. These codons are highly 
conserved in IAV and direct the translation of two N-terminally truncated versions of 
the primary PB1 product (PB1-N92 and -N111 respectively). 
Mutation of AUGs 10 or 11 in the background of the A/PR/8/34 strain had 
minor effects on virus replication kinetics despite giving elevated levels of IRF3 
phosphorylation and type I IFN secretion compared to the WT virus. However, 
simultaneous mutation of AUGs 10 and 11 severely decreased viral fitness. Similar 
patterns of defective replication and elevated innate signalling were seen when 
mutating AUGs 10 and/or 11 in other mammalian virus isolates. The propagation 
deficit of the PR8 ΔAUG10,11 mutant recovered in IFN-deficient models, including 
IFN α/β receptor (IFNAR) knockout bone marrow-derived macrophages and in vivo 
Abstract   
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in IFNAR-/- mouse lungs. Moreover, expression of PB1-N92 or –N111 polypeptides 
blocked poly I:C- and TBK1-, but not IRF3-induced activation of the IFN-β promoter 
in transfected cells, suggesting the polypeptides blocked innate immune signalling 
downstream of RIG-I-like receptor signalling but upstream of IRF3 phosphorylation. 
Consistent with this, addition of a TBK1/IKKε inhibitor increased growth of the 
mutant viruses. 
In conclusion, IAV segment 2 expresses two previously undescribed N-
terminally truncated versions of PB1 which play a role in antagonising the host IFN 









Abbreviation Full name 
bp Base pair 




cDNA Complementary deoxyribonucleic acid 
CFP Cyan fluorescent protein 
cRNA Complementary ribonucleic acid 
Ct Cycle threshold 
CSF1 Colony Stimulating Factor 1 
DAPI 4’,6-Diamidino-2-phenylindole 
DIP Defective interfering particles 
DMEM Dulbecco’s modified Eagle’s medium 
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Introduction: Influenza A viruses, accessory 
proteins and innate immunity 
__________________________________________________________ 
 
1.1. General Introduction to Influenza A viruses 
Influenza A viruses (IAV) are members of the Orthomyxoviridae family and 
possess an 8-segment negative-sense single-stranded RNA genome. Additional genera 
within Orthomyxoviridae include: influenza viruses B, C and D, Thogotovirus, 
Isavirus and Quaranjavirus. IAV is known to cause acute febrile respiratory illness in 
several species and is responsible for seasonal infections or outbreaks with high 
morbidity and mortality, being therefore a substantial economic burden to society. 
Hospitalization occurs mainly among high risk groups. Nevertheless, 
worldwide, annual Influenza epidemics are estimated to result in 3 to 5 million cases 
of severe illness, and between 290,000 and 650,000 respiratory deaths (World Health 
Organisation, 2019). In the most recent season (winter of 2018/2019), 5,505 IAV-
positive people were reported hospitalised in a network of 24 trusts in England. Across 
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all of the United Kingdom, 3,157 people were admitted to an Intensive Care or High 
Dependency Unit as a result of confirmed Influenza, of whom 312 deceased. Overall 
the 2018/19 season resulted in an estimated 1,692 deaths associated with IAV (Public 
Health England, Surveillance of influenza and other respiratory viruses in the UK 
Winter 2018 to 2019). 
 
1.1.1. Taxonomy and nomenclature 
In order to be better catalogued, IAV can be serologically subtyped, according 
to the antigenic properties of their glycoproteins haemagglutinin (HA) and 
neuraminidase (NA). So far, 16 HAs and 9 NAs have been identified circulating in the 
avian reservoir but only H1N1, H1N2, H2N2 and H3N2 subtypes are known with 
certainty to have circulated in humans. More recently H17N10 and H18N11 subtypes 
were also found in bat species (Tong et al. 2012; Tong et al. 2013). Conventionally, 
influenza virus isolates are titled according to their type (A, B, C or D), host, location, 
strain identifier, year of isolation and HA and NA subtype. Therefore, an H5N2 isolate 
from a Pennsylvanian chicken in 1983, strain number 1370 would be named 
A/chicken/Pennsylvania/1370/1983 (H5N2). In human cases, the species designation 
is omitted. 
 
1.1.2. Ecology and host adaptation 
IAV has waterfowls from Anseriformes and Charadriiformes orders as its 
natural host and reservoir for the majority of the isolated subtypes (Webster et al. 
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1992). In these hosts IAV primarily replicates in gut epithelium-lining cells, often 
asymptomatically, leading to virus spread via the faecal-oral route (Webster et al. 
1978). Moreover, in addition to bird-to-bird transmission, the virus can undergo 
adaptive mutations, acquiring zoonotic and epizootic potential, allowing infection of a 
variable group of mammalian and avian hosts including human, canine, equine, swine, 
galliform birds, migratory birds and a small number of sea mammals such as seals 
(Joseph et al. 2017). 
 
1.1.3. Antigenic shift and antigenic drift 
IAV is fast-evolving. Although its adaptation to and efficient transmission 
between new hosts usually involves multifactorial genetic changes, rapid gain of these 
attributes have often been associated with antigenic shift. Given the segmented nature 
of the IAV genome antigenic shift is possible upon coinfection of individual cells 
within a single organism with two or more antigenically distinct IAVs. As a result of 
the segmented genome, virus replication will originate progeny virions that 
incorporate mixtures of genome segments from the different parental strains; 
something termed reassortment (Steel and Lowen 2014). This dramatic change can 
allow the emergence of novel viral serotypes and facilitate crossing of species barriers. 
In fact, various reassortants between pig, human and/or avian strains are thought to be 
the cause of several of the human pandemics which occurred in the last century (Smith 
et al. 2009; Scholtissek et al. 1978). 
In contrast to antigenic shift, antigenic drift refers to less drastic changes in the 
antigenicity of circulating strains within an individual host species. These changes are 
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associated with the lack of proof-reading mechanisms of the viral RNA polymerase, 
leading to point mutations in several segments (Drake 1993). Functional changes in 
HA (and to a lesser extent NA) result in structurally distinct antigenic regions which 
can no longer be recognised by established adaptive immune responses: neutralising 
antibodies (Boni 2008). 
 
1.1.4. Prevention strategies against IAV: Diagnostics, Vaccination 
and Antivirals 
In order to prevent and monitor disease and host transmission, several clinical 
strategies are put in place. Diagnosis of influenza is mostly based on clinical 
presentation and epidemiological likelihood of infection. However, for management 
of individual patients, and public health surveillance reasons, nasopharyngeal swabs, 
nasal wash or a combination of both can be sent for confirmation. Diagnostic assays 
vary in sensitivity, cost and time and include virus culture, qRT-PCR, and antigen 
testing (reviewed in Krammer et al. 2018). 
Aiming to elicit an adaptive immune response against IAV and further limit 
infection and symptoms, vaccines are also used as a preventive measure (Salk and Salk 
1977). The membrane-distal end of the surface of HA constitutes the main humoral 
antigen of IAV. Therefore, inactivated virus, or live-attenuated virus are the vaccine 
types currently in use. These types are usually tetravalent and contain two IAV 
subtypes, a H1N1 2009 pandemic and a currently circulating H3N2 strain, as well as 
two influenza B strains. In some cases, trivalent vaccines only containing one B strain 
are still used. Inactivated virus vaccines are the most commonly used. These are 
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generally developed in embryonated hen’s eggs, after which the viruses are purified, 
formaldehyde-inactivated and treated with a non-ionic detergent (Wong and Webby 
2013). This type of vaccine is also in place for poultry. Avian influenza vaccines are 
often monovalent, containing either H5 or H7 strains (Swayne et al. 2014). However, 
a bivalent H5 and H7 vaccine has recently been used to great effect (reviewed in Wei 
and Cui 2018). Vaccine efficacy was analysed by large-scale surveillance in poultry 
markets and farms before and after vaccine administration where a 95% reduction in 
the number of H7N9 occurrences was observed (Shi et al. 2017; Shi et al. 2018). 
Despite the effectiveness of vaccination, HA evolution and the emergence of 
new subtypes reduces its efficacy. Therefore, antivirals are used as a rapid response to 
IAV infection. The current IAV antiviral repertoire is dominated by neuraminidase 
inhibitors. These inhibit the later stages of infection by diminishing NA activity and 
preventing virus spread (Colman 1994).  
Another class of anti-IAV drugs to be developed, the adamantanes, are 
blockers of the M2 ion channel, acting at early stages of the virus life cycle by avoiding 
acidification of the virion and the subsequent release of RNPs in the cytoplasm (Cady 
et al. 2010). However, due to the emergence and spread of resistant strains, 
adamantanes are now clinically obsolete (Zaraket et al. 2010; Furuse et al. 2009). 
A novel class of polymerase inhibitors targeting the cap-dependent 
endonuclease activity of both influenza A and B viruses has been approved by the 
FDA in 2018 to use in cases of uncomplicated influenza and adolescents (Hayden et 
al. 2018). 
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1.2. Influenza A virion structure 
1.2.1. Virion morphology 
Influenza virus particles are pleomorphic, being able to assume spherical, bacilliform 
or filamentous morphologies. The classical IAV representation, spherical particles, 
have a diameter of approximately 120nm and are observed in lab-adapted strains 
(Figure 1.1A). However, bacilliform particles of ~ 95 nm diameter but 250nm length 
and similar or slightly smaller diameter filaments reaching 30µm lengths (Figure 1.1 
B and C) are also frequently found in clinical and veterinary isolates (Mosley and 
Wyckoff 1946; Cox et al. 1980; Calder et al. 2010). A more recent cryotomography 
study showed the formation of viral filaments with bulbous heads (Archetti bodies) 
(Figure 1.1C.V), many of which seem to lack any genomic content (Vijayakrishnan et 
al. 2013; Archetti 1955). Studies have suggested that the filamentous strains have 
higher neuraminidase activity and are more readily transmitted but the role of this 
morphological type of virion in the influenza virus infectious cycle remains poorly 
determined (Campbell et al. 2014; Dadonaite et al. 2016). 
 
1.2.2. Virion composition 
All forms of influenza virions obtain their bilayer phospholipid envelope from 
the host cell membrane during viral budding (Shaw et al. 2008). This envelope is 
decorated by incorporation of the viral transmembrane glycoproteins: the trimeric HA 
and tetrameric NA in a ratio of 4:1, making HA the main surface antigen (Webster and 
Pereira 1968)Also embedded within the envelope is the ion channel M2, which is 




Figure 1.1: IAV virion structure. (A) Schematic representation of a spherical IAV 
virion. (B) Tomography of filamentous and spherical influenza virions: Overall 
representation of purified A/Udorn/307/1972 virions. (C) Distinct IAV morphologies: 
(I) bacilliform, (II and III) filaments, (IV) spherical and (V) Archetti body. Scale bars 
represent 50nm. (D) Diagram of budding of different virion morphologies. 
Micrographs were taken and/or adapted from Prof Paul Digard, Vijayakrishnan et al. 
2013 and Dadonaite et al. 2016.  
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present in smaller quantities (Pinto et al. 1992). The envelope is structurally supported 
by an underlying matrix protein 1 (M1) oligomer and filled with 8 individual viral 
ribonucleoproteins (vRNP; considered in more detail below) which, by electron 
microscopy studies, were shown to present a 7+1 rearrangement, suggesting a specific 
packaging mechanism (Noda et al. 2006). 
Additional constituents of the viral particle include two proteins originally 
thought to be non-structural: NS2 (also known as nuclear export protein or NEP) and 
NS1, but now known to be low abundance components of IAV virions (Richardson 
and Akkina 1991; Hutchinson et al. 2014). Membrane-bound and cytoplasmic host 
cell proteins such as tetraspanins CD9 and CD81 and annexins A1 and A2 have also 
been reported to be included in virus particles (Hutchinson et al. 2014; Shaw et al. 
2008). Of note, these studies have largely been carried out on spherical particles as 
filamentous viruses are more difficult to purify; therefore less is known about inclusion 
of host proteins in filamentous IAV.  
 
1.2.3. RNP structure and composition 
Representations of RNP structures are shown in Figure 1.2. Each segment of negative-
sense, single-stranded genomic RNA is bound to nucleoprotein (NP) monomers with 
high affinity at approximately 24 nucleotides per NP molecule. This NP-RNA binding 
is known to occur through the phosphate backbone and therefore in a relatively 
sequence unspecific-manner (Scholtissek and Becht 1971; Compans et al. 1972; 
Ortega et al. 2000). 
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Figure 1.2: Structural models of the IAV ribonucleoprotein complex. Schematic 
representation (A – adapted from Prof Paul Digard) and negatively stained electron 
micrograph (B) of a vRNP showing its shape and structural components. Viral RNA 
is linked to the heterotrimeric RdRp complex by its 5’ and 3’ ends and associated with 
NP monomers. (C and D) Electron micrograph and cartoon showing the antiparallel 
double helix organisation of internal vRNA regions. (E) Detail of the association of 
vRNA with NP monomers (Arranz et al. 2012; Hutchinson and Fodor 2013; Coloma 
et al. 2009).  
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Electron microscopy studies have revealed an overall antiparallel double 
helical arrangement of RNP molecules (Figure 1.2D-F), which is kept by intra-RNP 
NP interactions (Wu et al. 2009; Compans et al. 1972; Jennings et al. 1983; Arranz et 
al. 2012). The 5’ and 3’ ends of vRNP ends share partial Watson-Crick base-paring 
and form a panhandle-shaped duplex structure (Desselberger et al. 1980; Hsu et al. 
1987), which is in turn bound by the RNA-dependent RNA polymerase. 
 
1.2.3.1. The heterotrimeric RNA polymerase 
The viral polymerase is a trimeric complex consisting of polymerase basic 
protein 1 (PB1), polymerase basic protein 2 (PB2) and polymerase acidic protein (PA) 
subunits (Skehel and Hay 1978; Digard et al. 1989; Detjen et al. 1987). Initial 
biochemical studies suggested an N-terminal to C-terminal linear interaction 
arrangement between the subunits: C terminus of PA interacts with the N terminus of 
PB1 (Perez and Donis 1995), the C terminus of which binds to the N terminus of PB2, 
with an apparent lack of interaction between PA and PB2 (Digard et al. 1989; 
Gonzalez et al. 1996; Perez and Donis 1995; Toyoda et al. 1996). However, more 
recent 3D-imaging acquired from electron microscopy and crystallisation followed by 
X-ray diffraction studies have revealed the globular structure of the polymerase and 
the intrinsic interactions between the three subunits (Pflug et al. 2014; Reich et al. 
2014; Moeller et al. 2012; Coloma et al. 2009). Transcription and replication functions 
of the viral polymerase will be further described in section 1.4.4 and the crystal 
structure of the viral polymerase can be found in Figure 2.10. 
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1.3. IAV genome organisation and protein coding strategies 
In total, the IAV genome is ~13.6kb, comprised of 8 segments with lengths 
ranging from 0.89 to 2.3kb, which encode all the viral polypeptide products. Following 
genome transcription to positive sense mRNAs, polypeptide expression can occur 
through different translation mechanisms: canonical translation of unspliced or spliced 
mRNA transcripts produce 10 long-established “core” proteins, but further differential 
splicing events as well as ribosomal frame-shifting and alternative translation initiation 
events also occur, leading to the expression of additional accessory polypeptides 
(summarised in Table 1.1 and Figure 1.3). 
 
1.3.1. Canonical translation to produce the essential IAV gene 
products 
All IAV vRNAs contain a long antisense coding region flanked by shorter untranslated 
regions (UTRs). Each segment contains a principal (generally the longest) coding 
region which is translated from the first AUG codon into the primary gene product of 
the segment. This mechanism leads to expression of the three elements of the 
heterotrimeric viral RNA-dependent RNA polymerase (PB2, PB1 and PA from 
segments 1, 2 and 3, respectively), the glycoproteins (HA from segment 4 and NA 
from the 6th segment), the RNP constituent nucleoprotein (NP from segment 5), M1 
and NS1 from segments 7 and 8 respectively (Figure 1.3, dark blue bars). 
Unlike many other RNA viruses, IAV RNA synthesis occurs in the host cell 
nucleus, giving access to the cellular mRNA splicing machinery. mRNA splicing has   




Figure 1.3 IAV gene products. mRNAs from the 8 segments are symbolised by 
horizontal black lines. Coding regions are represented by boxes with colours defining 
different reading frames (dark blue: primary products, frame 1; light blue: secondary 
products, frame 1; magenta: secondary products, frame 2). mRNA splicing in segments 
1, 7 and 8 is denoted by dashed deflected lines connecting two coding regions. 
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Table 1.1: IAV gene products and respective expression mechanism and functions. *Segment and protein sizes were based on 













PB2 Canonical translation initiation 759 85.7 
Component of the heterotrimeric viral RdRp. Promotes viral RNA 
expression through 5' end host mRNA binding and "cap-snatching". 
PB2-S1 mRNA splicing 508 55 Inhibitor of the RIG-I signalling pathway. 
2 2341 
PB1 Canonical translation initiation 757 86.6 Component of the viral RdRp. Involved in elongation. 
PB1-N40 
Alternative AUG initiation 
(translation reinitiation) 
718 82.4 Unknown. It's known to interact with the viral polymerase. 
PB1-F2 
Alternative AUG initiation (leaky 
scanning) 
87 10.5 IFN antagonist. Pro-apoptotic activity. 
3 2233 
PA Canonical translation initiation 716 84.2 
Component of the viral RdRp. Viral RNA endonuclease responsible for 
cleaving host pre-mRNAs to produce capped primers. 
PA-X Ribosomal frameshift 252 29 Exhibits endonuclease activity, contributing to host cell shut-off 
PA-N155 Alternative AUG initiation 562 62 
Unknown 
PA-N182 Alternative AUG initiation 535 60 
4 1778 HA Canonical translation initiation 566 61.5 
Trimeric surface glycoprotein. Mediates receptor binding, virus entry 
and budding. 
5 1565 
NP Canonical translation initiation 498 56.1 
Encapsidation of vRNA (to form vRNP complexes). Required for 
transcription activity and vRNP nuclear import. 
eNP - 504 56.8 Virulence factor for H1N1 IAVs (Wise, Gaunt et al., unpublished). 
6 1413 NA Canonical translation initiation 454 50.1 
Heterotrimeric surface glycoprotein. Exhibits sialidase activity allowing 
release of virus progeny from the cell surface. 
7 1027 
M1 Canonical translation initiation 252 27.8 
Matrix protein. Known to interact with RNPs and glycoproteins. 
Involved in genome nuclear export, virus assembly and budding. 
M2 
Canonical translation initiation 
followed by mRNA splicing 
97 11 
Acts as proton ion channel. Required during virus entry (uncoating) and 
for membrane scission at the budding stages of infection. 
M42 mRNA splicing and leaky scanning 99 13 Variant of M2 with common functions 
8 890 
NS1 Canonical translation initiation 230 26.8 Broad-spectrum IFN antagonist. 
NS2/NEP 
Canonical translation initiation 
followed by mRNA splicing 
121 14.2 Involved in nuclear export of vRNPs. 
NS3 
Canonical translation initiation 
followed by mRNA splicing 
187 21 Unknown 
NEG8 - - - 
Unknown. Protein expression bioinformatically proposed, but yet not 
experimentally detected. 
tNS1 Alternative AUG initiation 
150/15
2 
17 Involved in inhibition of IRF3 
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long been known to occur for transcripts from segments 7 and 8, giving rise to mRNAs 
encoding the M2 and NS2/NEP proteins respectively (Lamb and Lai 1980; Lamb et 
al. 1981). These polypeptides are also produced by canonical translation initiating at 
the first AUG codon in the mRNA, while the splicing event directs translation into an 
alternative reading frame downstream of the splice junction (Figure 1.3). M2 and 
NS2/NEP are produced by every strain of IAV and, outside of specialised laboratory 
settings, are considered to be essential for virus replication; these two polypeptides 
therefore complete the suite of the 10 core virus proteins. However, the IAV proteome 
is further elaborated in a virus strain-dependent fashion by the expression of further 
polypeptide species that tend to be low abundance and non-essential for virus 
replication. These “accessory” proteins are produced by further minor mRNA splicing 
events and/or examples of non-canonical translation, including leaky ribosomal 
scanning and frameshift events. The following sections will describe the essential and 
accessory peptides coded in overlapping reading frames which are produced by these 
and other mechanisms, and their function within the IAV life cycle. 
 
1.3.2. PB2-S1 
Identified in 2016, PB2-S1 is the result of expression from a spliced mRNA 
from segment 1 in which the region corresponding to nucleotides 1513 to 1894 of the 
PB2 mRNA is deleted and the mRNA continues in the +1 frame to encode the S1 ORF 
(Figure 1.3) (Yamayoshi et al. 2016). Despite being highly conserved among pre-2009 
human H1N1 virus isolates, the splice donor and acceptor site nucleotide sequences 
which allow the expression of PB2-S1 are not present in human H1N1pdm09 and 
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H3N2 viruses. Localisation of PB2-S1 is mainly mitochondrial and occurs via an N-
terminal mitochondrial localisation signal shared with PB2 (Carr et al. 2006; Graef et 
al. 2010). This polypeptide was shown to inhibit the retinoic acid-inducible gene I 
(RIG-I)-dependent/ mitochondrial antiviral-signalling protein (MAVS) interferon 
signalling pathway and interact with the PB1 subunit of the viral polymerase, 
negatively interfering with its activity. Nonetheless, abrogation of expression of PB2-
S1 did not alter virus fitness in vitro nor its virulence in murine in vivo systems 
(Yamayoshi et al. 2016). 
 
1.3.3. PB1-F2 
PB1-F2 is an 87-101 amino acid polypeptide first identified as a short-half-life 
protein that interacted with mitochondria and postulated to be responsible for induction 
of apoptosis in immune cells (Chen et al. 2001). Further studies revealed that PB1-F2 
translocated into mitochondria via Tom40 channels and that it contained a C-terminal 
region responsible for interaction with two other mitochondrial proteins, VDAC3 
(inner membrane) and ANT1 (outer membrane), both of which are part of the 
permeability transition pore and play important roles in apoptosis stimulation (Gibbs 
et al. 2003; Yoshizumi et al. 2014; Belzacq et al. 2002; Zaid et al. 2005). A more 
recent study has related these PB1-F2-mitochondria interactions to a reduction of 
mitochondrial inner membrane potential leading to oxidative stress deregulation and 
contributing to the early stages of IAV replication cycle (Shin et al. 2015). PB1-F2 has 
also been shown to interact with the immune response modulator MAVS 
(mitochondrial antiviral signalling protein), blocking its function and therefore leading 
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to an indirect inhibition of type I IFN induction (Varga et al. 2012). PB1-F2 expression 
is thought to occur by leaky ribosomal scanning from the fourth initiation codon in 
segment 2 (Chen et al. 2001; Wise et al. 2011; Wise et al. 2009), although more recent 
studies have suggested further regulation of PB1-F2 expression from sequences 
located downstream of the AUG codon (Buehler et al. 2013). 
Despite thorough molecular characterisation in vitro, elucidation of the roles 
of PB1-F2 in vivo have at times given conflicting results, possibly reflecting viral 
strain- and host-dependent effects (reviewed by Kosik et al. 2013). Consistent with 
this, not all IAV strains possess a full-length (≥ 87 codon) ORF; in general, avian 
strains of IAV tend to have full length genes while human and swine viruses often do 
not (Kamal et al. 2017). For example, PB1-F2 sequences from 2009 pandemic H1N1 
strains have an early stop codon at position 11 and studies confirmed its minimal 
impact on virulence in mouse models (Hai et al. 2010). Conversely, PB1-F2 
truncations are not only rare in avian isolates but in experimental infections of chickens 
with H5N1 and H9N2 strains, lead to an attenuation of virulence, accompanied by 
prolonged virus shedding (Leymarie et al. 2014; James et al. 2016). 
 
1.3.4. PB1-N40 
PB1-N40 corresponds to an N-terminally truncated version of the main 
segment 2 product PB1 (Wise et al. 2009). The absent first 39 amino acids include the 
primary PA interaction site (Perez and Donis 1995; Pflug et al. 2014; He et al. 2008) 
and therefore PB1-N40 lacks heterodimerisation function and consequently, nuclear 
import and transcriptase functions (Wise et al. 2009). It nevertheless retains some 
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ability to interact with PB2 and the polymerase trimer, as well as with a variety of 
cellular proteins (Wang et al. 2019; Wise et al. 2009). Despite its AUG codon (codon 
5 in segment 2) being highly conserved in IAV isolates, PB1-N40 function remains to 
be clarified. Single knockout of PB1-N40 expression (by mutating its AUG codon, 
with consequent mutation of the full-length PB1 protein) slightly reduced viral fitness 
of the H1N1 A/Puerto Rico/8/34 (PR8) laboratory strain in vitro. However, double 
deletion of PB1-N40 and PB1-F2 resulted in WT-like virus propagation (Wise et al. 
2009). Moreover, regardless of its lack of viral polymerase activity, overexpression of 
PB1-N40 lead to increased vRNA production and an increase in genome:PFU ratios 
of released virus particles (Tauber et al. 2012). 
 
1.3.5. PA-N155 and PA-N182 
PA-N155 and PA-N182 are translated from the 11th and 13th AUG codons, 
respectively, of segment 3 mRNA (Muramoto et al. 2013). The mechanism by which 
these AUG codons are accessed by ribosomes has not been elucidated. These initiator 
codons are highly conserved among IAV sequences and are present in isolates from 
different host species. The precise roles of these truncated PA polypeptides within the 
IAV life cycle have not yet been elucidated. Recent studies on these polypeptides from 
an H5N1 virus suggested interactions of -N155 and -N182 with (chicken) cellular 
proteins involved in RNA processing, protein transport and various cellular signalling 
pathways (Wang et al. 2018). Many, if not most of these interactions might be common 
to the full length PA protein and their significance is unclear. Nonetheless, mutant 
H1N1 A/Wilson-Smith Neurotropic/33 (WSN) laboratory strain viruses unable to 
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express PA-N155 and/or -N182 following mutation of the relevant AUG codons 
showed delayed virus replication in vitro and reduced virulence in mouse models 
(Muramoto et al. 2013). As with PB1-N40 mutants however, it must be borne in mind 
that the strategy used to ablate expression of the accessory proteins also mutates the 
primary gene product of the segment. 
 
1.3.6. PA-X 
PA-X expression occurs through a ribosomal frame shift event, driven by a rare 
arginine codon next to a sequence that facilitates tRNA realignment, leading to the 
production of a fusion peptide containing the first 191 amino acids of the PA 
endonuclease domain and a variable strain-specific C-terminal domain translated from 
the +1 reading frame of segment 3 mRNA (the X-ORF; Figure 1.3) (Jagger et al. 2012; 
Firth et al. 2012). The frameshift site is highly conserved amongst IAV strains, but the 
length of the X-ORF varies, with common polymorphisms being either 41 or 61 
codons long (Shi et al. 2012; Rash et al. 2014). Expression of PA-X is not required for 
in vitro and in ovo virus replication (Jagger et al. 2012; Hussain et al. 2018). 
Nonetheless, this protein is known to selectively destroy host RNA polymerase II (pol 
II)-derived mRNA transcripts and contribute to host cell shut-off through the activity 
of the endonuclease domain shared by PA (Jagger et al. 2012; Khaperskyy et al. 2016; 
Desmet et al. 2013).  
In mouse models of IAV infection using H1N1 and H5N1 strains, the absence 
of PA-X resulted in augmented clinical disease and immune responses (Jagger et al. 
2012; Gao et al. 2015b; Hu et al. 2015; Rigby et al. 2019). Conversely, infection with 
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wild type (WT) and PA-X-deficient H9N2 avian viruses resulted in opposite 
phenotypes, suggesting that in this viral context, the presence of PA-X increases 
virulence in vivo (Gao et al. 2015c). In other host species, such as chickens (adult or 
the in ovo model using embryos), ducks and swine, mutation of PA-X mostly but not 
always increased pathogenicity (Hussain et al. 2018; Nogales et al. 2017). In addition, 
in vitro studies of PA-X activity found that the length of the X-ORF-derived sequence 
(specifically the 41-61 polymorphism) influenced endonucleolytic activity of the 
protein (Bavagnoli et al. 2015). This 20 amino acid-truncation is commonly observed 
in swine and canine isolates and viruses harbouring truncated PA-X products were 
shown to enhance virulence and transmissibility in pigs (Xu et al. 2016). Conversely, 
other studies on H1N1 2009 pandemic viruses have suggested that the additional C-
terminal 20 amino acids are beneficial to PA-X shut-off activity and increase virulence 
in murine models (Lee et al. 2017; Gao et al. 2015a). Therefore, as seen for other 
accessory proteins, PA-X also exhibits virus strain- and host-specific functions. 
 
1.3.7. M2, M42 and other segment 7 gene products 
In addition to the primary unspliced transcript which encodes M1, segment 7 
is known to produce up to three other transcripts originated from alternative splicing: 
mRNAs 2-4. These splice variants use a common splice acceptor site but use different 
splice donor sequences (reviewed by Dubois et al. 2014). Virus strain-dependent 
variations in the sequences of these splice donor sites leads to variability in their use. 
As discussed above, mRNA2 is produced by virtually all strains of IAV and encodes 
the ion channel, M2. The M2 ORF has the initiator codon and the first 9 codons in 
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common with M1 but the C-terminal 88aa are coded in the +1 ORF (Lamb and 
Choppin 1981).  
mRNA3 is known to be produced from the most 5’-proximal splice donor site, 
but lacks obvious protein-coding potential (encoding a 9 amino acid peptide in its 5’-
proximal ORF) Lamb et al. (1981). Production of mRNA3 has however been proposed 
to negatively regulate segment 7 protein expression at early stages of infection (Shih 
et al. 1995). However, its presence is non-essential for virus growth in vitro and protein 
expression from the mRNA has also not been detected (Shih et al. 1995; Chiang et al. 
2008; Jackson and Lamb 2008). Production of mRNA3 has become enshrined in 
influenza text books through its early discovery (Lamb et al. 1981), but it is not clear 
if all strains of IAV produce it; the PR8 strain for example, accumulates far lower 
quantities of mRNA3 than other human strains of IAV (Wise et al. 2012). 
A small fraction of IAV strains produce appreciable amounts of a third splice 
variant, mRNA4 (Shih et al. 1995; Wise et al. 2012; Dubois et al. 2014). This mRNA 
is predicted to express a 90 amino-acid long internally deleted version of M1 from the 
first AUG codon, but no protein product has been detected yet. However, in the PR8 
strain, the transcript has been shown to express a variant form of the ion channel, M42 
(Wise et al. 2012). M42 shares the same C-terminal domain as M2, but is initiated 
from a different AUG codon in a +1 frame downstream of segment 7 AUG1. M42 can 
functionally replace M2 during virus replication, despite having a different cellular 
localisation (Wise et al. 2012).  
There is also evidence for further potential gene products from segment 7, produced 
not by differential splicing but by non-AUG initiation at CUG codons in the + 1 
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reading frame (Yang et al. 2016). Evidence for this comes from readily detectable 
expression of a well-defined T cell epitope, artificially engineered into the M2 ORF. 
Expression of this peptide could not be blocked by the small molecule inhibitor of 
splicing, spliceostatin A, but was abrogated by mutation of M2 codons Leu59 and 96 
(Yang et al. 2016). Translation initiation at Leu59 in a WT virus would produce a 40 
amino acid C-terminal M2 fragment; this has not been detected however, and any 
functional significance to virus replication remains unknown. 
 
1.3.8. NS2, NS3 and tNS1 
Similarly to segment 7, the NS segment is also known to be differentially 
spliced to express NS2/NEP (Lamb et al. 1978; Lamb and Choppin 1979; Lamb et al. 
1980). This 121 amino acid protein shares its N-terminal 10 residues with NS1. 
However, the remaining C-terminal region is expressed from the +1 reading frame. All 
strains of IAV produce NEP as it is required to ensure the export of vRNPs from the 
nucleus and therefore essential in the virus life cycle (O'Neill et al. 1998; Neumann et 
al. 2000). 
An additional spliced mRNA from segment 8 has been defined as encoding the 
NS3 protein, which constitutes an internally truncated version of NS1 missing amino 
acids 126-168 (Selman et al. 2012). Activation of NS3 expression by the alteration of 
its splice donor site (along with nonsynonymous M124I and D125G changes in the 
NS1 ORF) resulted in increased virus propagation in murine but not human cell lines. 
Despite this gain-of-function phenotype, the function of NS3 within the IAV life cycle 
is still not fully understood. As with segment 7 mRNA 4, production of NS3 is likely 
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to occur in only a small minority of IAV strains, but it has been proposed to be a feature 
particularly associated with viral adaptation to a new host species (Selman et al. 2012). 
More recently, N-terminally truncated versions of NS1 have also been 
identified (Kuo et al. 2016). These “tNS1” polypeptides are expressed from the 2nd 
and/or 3rd AUG codons of segment 8, lacking the first 79 or 81 amino acids of NS1. A 
mutant PR8 virus lacking these AUG codons induced higher levels of IRF3 
phosphorylation and hence greater IFN-β induction (Kuo et al. 2016). A priori, this 
could be due to the non-synonymous mutation of NS1, and/or failure to express the 
tNS1 polypeptides. However, exogenously expressed tNS1 polypeptides displayed 
differential localisation (cytoplasmic versus nuclear) to the WT protein and were able 
to antagonise IRF3 activation, supporting the suggestion that loss of their expression 
contributed to the phenotype.  
 
1.4. The Influenza A Virus Life cycle 
IAV replication occurs mainly in respiratory and gastrointestinal (depending 
on the host) epithelial cells. Mathematical modelling from an H1N1 human in vivo 
infection suggested that it takes only 6 hours between infection of target cells and 
virion release (Baccam et al. 2006). Nevertheless, experimental data showed that, in 
permissible cell lines, it takes 8-10 hours for the replication cycle to reach its full 
completion (Gaush and Smith 1968). The life cycle of IAV can divided into the 
following stages: receptor binding and entry, fusion and uncoating, RNP nuclear 
import, replication and transcription of the viral genome, genome nuclear export,   
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Figure 1.4: The IAV life cycle. Virions enter the host cell through receptor-mediated 
endocytosis after attachment of HA to sialic acid (1). Endosome acidification triggers 
fusion of the viral envelope with the endosome membrane and the release of vRNPs 
into the cytoplasm (2). The RNPs undergo nuclear import (3) where the preformed 
trimeric viral RdRp initiates viral transcription (4). Newly synthesised viral mRNA is 
processed and translated to produce viral polypeptides which will constitute novel 
RNPs in the nucleus (5). Progeny RNPs are exported to the cytoplasm (6), trafficked 
to the apical plasma membrane (7) and assembled into offspring viral particles (8) 
which are released from the cell surface (9). Cellular and viral structures are not to 
scale.  
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packaging, budding and release. A schematic representation of IAV life cycle is shown 
in Figure 1.4. 
 
1.4.1. Receptor binding and internalisation 
The life cycle initiates with the attachment of IAV to the host cell. The primary 
receptor for influenza viruses is N-acetylneuraminic acid, also called sialic acid (SA), 
which is recognised and bound by the receptor binding pocket of the viral glycoprotein 
HA (Johnson et al. 1964; Gottschalk 1959). SA is attached to its underlying galactose 
ring by either α2,3 or α2,6 linkages. It is well established that α2,3 linkage SA 
predominates in avian species and avian IAV strains preferentially use this isoform as 
a receptor. In contrast, human IAV strains generally have a higher receptor specificity 
for the α2,6 conformation, as this form predominates in the human upper respiratory 
tract (Weis et al. 1988; Connor et al. 1994). The “HA”s of the recently-found bat H17 
and H18 IAV strains do not bind to sialic acid (Sun et al. 2013); the receptor for these 
viruses has recently been identified as MHC class II molecules (Karakus et al. 2019). 
Interactions between HA and sialic acid are believed to be low affinity. However, 
multiple HA molecules are used to bind several glycoproteins, resulting in high-avidity 
binding to the cell surface (Sauter et al. 1989). Upon receptor binding, spherical virus 
particles are internalised by dynamin-dependent clathrin-mediated endocytosis 
(Matlin et al. 1981) whilst filamentous virions have been suggested to use 
micropinocytosis (Rossman et al. 2012). This internalisation process may involve 
triggering of cellular receptor tyrosine kinase signalling (Eierhoff et al. 2010). 
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1.4.2. Fusion and uncoating 
Once engulfed within the endosome the virion requires the release of its 
genome into the cytoplasm. To do so, the inactive precursor HA (HA0) molecule must 
previously have undergone proteolytic cleavage by host cell proteases into HA1 and 
HA2 domains. While HA1 mediates endocytosis via its receptor-binding site, the new 
N terminus of HA2 liberated by the cleavage event contains a highly conserved 14 
amino acid-long fusion peptide, required to mediate fusion (Nobusawa et al. 1991; 
Stegmann 2000). The low pH environment of late endosomes induces the HA 
conformational changes which expose and position this fusion peptide towards the 
endosomal membrane (Maeda and Ohnishi 1980; Carr and Kim 1993). The fusion 
peptide is then inserted into the target membrane, while further HA conformational 
rearrangements bring the two membranes into close proximity, which results in their 
integration and the formation of a fusion pore (Tsurudome et al. 1992; Spruce et al. 
1989; Melikyan et al. 1993). At the same time, the ion channel M2 allows entry of 
positively charged hydrogen ions, acidifying the viral core, disrupting M1 protein-
protein interactions and permitting the release of vRNP complexes into the cytoplasm 
through the HA-mediated formed pore (Bui et al. 1996). 
 
1.4.3. RNP nuclear import 
Upon release from the late endosomes, vRNPs are translocated from the 
cytoplasm into the nucleus, where viral genome transcription and replication takes 
place (Herz et al. 1981; Shapiro et al. 1987). vRNPs are thought to diffuse through the 
cytoplasm with no input from either microtubules or actin filaments (Martin and 
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Helenius 1991b), but the peri-nuclear localisation of late endosomes may reduce the 
distance needed for travel (Lakadamyali et al. 2003). Given the large size of vRNPs, 
they are not able to passively diffuse through the nuclear pore complex (NPC). 
Nonetheless, all protein components of the vRNP complex possess nuclear localisation 
signals (NLS; reviewed in Hutchinson and Fodor 2013) Moreover, the pH-induced 
dissociation of M1 from vRNA leads to the exposure of the NLS contained within the 
first 13 amino acids of NP, allowing their active import via the cellular classical 
karyopherin import pathway (Stewart 2007; Cros et al. 2005; Wang et al. 1997). These 
NLS regions are recognised by importin-α which in turn binds to importin-β to allow 
nuclear import (O'Neill et al. 1995). Once in the nucleoplasm, importins-α and β are 
dissociated from vRNPs by exportin CSE1L, after which importins can be recycled 
back to the cytoplasm (Kutay et al. 1997). 
 
1.4.4. Viral genome transcription and replication 
Within the nucleus the heterotrimeric viral RNA polymerase transcribes the 
vRNA into 5’capped and 3’polyadenylated mRNAs which are exported to the 
cytoplasm to be translated by cellular ribosomes into newly synthesised proteins. 
However, the viral polymerase is also responsible for the replication of vRNA to create 
new copies of the virus genome. This is performed by the formation of an intermediate 
uncapped and non-polyadenylated “complementary RNA” specimen (cRNA) which 
serves as template for the production of new vRNAs (reviewed by Fodor 2013). 
Transcription and replication are functionally and temporally distinct (Figure 1.5A): 
expression of mRNA peaks earlier while synthesis of vRNA-like molecules 
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predominate later in infection (Hay et al. 1977; Smith and Hay 1982). The mechanisms 
behind the shift between transcription and replication are still to be fully elucidated. 
Nonetheless, newly synthesised NP has been suggested to account for the differential 
levels of the three RNA types, since free NP is required for full-length cRNA synthesis 
and NP mutations have be shown to affect cRNA and mRNA levels (Beaton and Krug 
1986; Medcalf et al. 1999). Moreover, the levels of the three viral RNA species at 
different times post infection suggest that the switch between transcription and 
replication relies on the stability of cRNPs, which is only possible after the 
accumulation of newly synthesised NP monomers and polymerase trimers (Vreede and 
Brownlee 2007). Nevertheless, overexpression of NP does not seem to alter 
transcription or replication activities (Mullin et al. 2004) and additional studies have 
suggested that the switch is regulated by the concentrations of the vRNA 5’ termini 
(Olson et al. 2010), while others have proposed a stochastic nature of switching 
between transcription and replication (Mondal et al. 2015). 
The next sections will describe in detail the processes by which the polymerase 
performs genome transcription and replication. 
 
1.4.4.1. Cap snatching, transcription of vRNA and polyadenylation 
As described in section 1.2.3, the incoming RNPs are already associated with 
a viral polymerase complex. This allows the immediate transcription of vRNA. 
Transcription is primed by a “cap-snatching” mechanism (Figure 1.5B). This requires 
a 5’ fragment of a 7-methyl guanosine (m7GpppXm)-capped pre mRNA from the host 
cell transcriptome which is recognised by and bound to the cap-binding domain of PB2  
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Figure 1.5: Transcription and replication of vRNA: (A) Kinetics of viral mRNA, 
cRNA and vRNA accumulation in a single infectious cycle. Adapted from Prof Paul 
Digard. (B) Schematic representation of vRNA transcription. (C) Schematic 
representation of the first step of vRNA replication. Evens in the light grey boxes 
represent the inside of the polymerase active site. In all illustrations vRNA is 
represented in dark blue, cRNA in dark green and mRNA in light green lines and/or 
letters. NP monomers in vRNPs and cRNPs are omitted. Adapted from Lo et al. 2018 
and Fodor 2013. 
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(Blaas et al. 1982), followed by the cleavage of a 10-14 nucleotide fragment 
mediated by the endonuclease domain of the PA subunit (Plotch et al. 1981; Dias et 
al. 2009). This fragment is then used as a primer by the PB1 subunit to initiate 
transcription of the vRNA template (Braam et al. 1983). 
Transcription elongation proceeds until reaching a conserved 5-7 nucleotide 
polyuridine stretch located 15-17 nucleotides upstream of the 5’ end of the vRNA 
template (Robertson et al. 1981). Given that the 5’ end of the vRNA template is 
proposed to remain bound to PB1 (Tiley et al. 1994), once reaching the U-rich 
sequence the polymerase cannot proceed further given the steric hindrance imposed 
by the persistence of the 5’end-PB1 interaction. Therefore, the template slips, 
effectively producing a sequence of repeated U nucleotides which results in a poly(A) 
tail (Poon et al. 1999).  
 
1.4.4.2. Processing of viral mRNA 
Due to the presence of the m7GpppXm cap and the poly-A tail, viral mRNAs derived 
from vRNA transcription resemble mature host mRNAs and this allows them to be 
exported from the nucleus and translated by the cellular protein expression machinery 
(York and Fodor 2013). Nuclear export of many but perhaps not all of the viral mRNAs 
is facilitated by the primary cellular mRNA nuclear export factor 1 - NXF1 (Hao et al. 
2008; Read and Digard 2010; Herold et al. 2000; Erkmann and Kutay 2004). In 
addition, IAV gene expression is temporally regulated, with NP and NS1 being 
regarded as “early” genes, the M1, HA, NA and the spliced gene products M2 and 
NEP as “late” genes, while the polymerase subunits are expressed at lower abundance  
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throughout infection (Skehel 1973, 1972; Hay et al. 1980; Shapiro et al. 1987; Chua 
et al. 2013). This temporal distinction is not as marked as with some viruses (e.g. the 
large DNA viruses) and the mechanisms behind it remain ill-defined. 
 
1.4.4.3. Mechanisms of vRNA replication 
In contrast to transcription, IAV genome replication requires a full-length 
positive-sense RNA intermediate which will constitute the template for the formation 
of progeny vRNAs. Thus, replication occurs in two independent steps: replication of 
vRNA into cRNA (Figure 1.5C) and then copying of the newly synthesised cRNA 
back to vRNA. The replicative intermediate cRNA does not include a 5’ cap nor 3’-
poly(A) tail, and therefore requires primer-independent initiation and termination 
mechanisms that are distinct from the viral mRNA expression (Hay et al. 1980).  
Biochemical studies have suggested the formation of cRNA by the preformed/resident 
polymerase (Vreede and Brownlee 2007; York et al. 2013). 
The first replication step initiates by the translocation of the 3’ end of vRNA 
into the PB1 active site, followed by unprimed terminal initiation - the synthesis of a 
AG dinucleotide complementary to the vRNA 3’end (Deng et al. 2006). Elongation 
then proceeds as in mRNA synthesis. However, in contrast with transcription, the 5’ 
end of the vRNA template is released from the PB1 subunit, assuring that it is copied 
without stuttering on the preceding poly(U) stretch. As cRNA is formed, its 5’ end is 
bound to an additional polymerase trimer. The second polymerase recruits NP 
molecules which translocate through the surface of the polymerase to associate with 
cRNA (Vreede and Brownlee 2007; Vreede et al. 2004). Subsequent NP monomers  
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are recruited through groove and tail-loop interactions (Ye et al. 2006; Shen et al. 
2011) between NP monomers and form new cRNP complexes (Turrell et al. 2013; Ye 
et al. 2006). These are also double-helical vRNP-like structures (York et al. 2013; Lo 
et al. 2018). 
In the second replication stage, the newly formed cRNA acts as template for vRNA 
synthesis (Figure 1.5D). Copying of vRNA from a cRNA template occurs by internal 
initiation on residue U4 followed by transcription of C5 to form an ApG dinucleotide. 
This acts as a primer after being re-aligned with the terminal UpC residues of the cRNA 
3’-end, enabling transcriptional elongation into a full-length vRNA (Deng et al. 2006). 
This step is dependent on the recruitment of a trans-active or trans-activating 
polymerase trimer (York et al. 2013). In order to explain the requirement for this 
additional polymerase complex, two independent models of this second replication 
step have been suggested: 
 One suggests that considering the optional catalytic activation of the second 
polymerase, this fulfils a trans-activating, rather than a trans-acting role (York et 
al. 2013). A recent study has shown that, despite the ability of purified vRNPs to 
perform mRNA and cRNA synthesis in vitro, purified cRNPs cannot synthesise 
vRNA either de novo or in the presence of an ApG primer. However, the addition 
of purified RdRp to purified cRNPs results in synthesis of vRNA (York and Fodor 
2013), suggesting the requirement of a second catalytically-active polymerase. 
Therefore, this model proposes that the trans-activating RdRp induces a 
conformational rearrangement within the active/resident polymerase, favouring 
the transfer of the 3’-end of cRNA to the active site or/and favouring initiation at 
this terminus. Moreover, it hypothesises that the trans-activating polymerase will 
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constitute the de novo assembled vRNP complexes and recruit NP in a similar 
fashion to that observed in the first stage of cRNP formation (Te Velthuis and 
Fodor 2016). 
 An alternative model involves a catalytically active trans-acting RdRp which gains 
access to the cRNA 3’-end, which enters its active site where cRNA to vRNA 
replication is carried out. In this model, a third polymerase complex is proposed to 
bind to the 5’-terminus of nascent vRNAs to assemble new vRNPs. This trimer of 
polymerase complexes has been seen in cryo-EM studies (Jorba et al. 2009; 
Moeller et al. 2012). 
 
1.4.4.4. Regulation of transcription and replication by viral factors 
In addition to the potential contributions of NP in the switching between 
genome transcription and replication described earlier in section 1.4, other viral 
proteins have been suggested to play important roles in IAV gene expression and 
replication. NS1 and NS2/NEP have also been suggested to regulate transcription and 
replication. NS1 interacts with NP during mRNA synthesis and splicing (Garaigorta 
and Ortin 2007; Robb and Fodor 2012; Marion et al. 1997). In addition to mediating 
the nuclear export of newly synthesised vRNA (further developed in section 1.4.5), 
NS2/NEP, has been shown to have roles in regulating vRNA synthesis (Robb et al. 
2009; Manz et al. 2012; Bullido et al. 2001). 
  
Chapter 1   
34 
1.4.4.5. Regulation of transcription and replication by cell host factors 
Given the occurrence of IAV transcription and replication in the nucleus, 
specific interactions between vRNPs and cellular nuclear-localised proteins have been 
proposed to also contribute to viral RNA synthesis. These can broadly be broken down 
into those that support viral transcription and those that support genome replication. 
Only a subset of the better characterised factors are described here, further information 
has been previously reviewed (Josset et al. 2008; Watanabe et al. 2010).  
Transcriptional support factors include chromatin remodellers CHD1 
(chromodomain-helicase-DNA binding proteins 1), nuclear matrix protein 2 and the 
pol II modulator CLE (Marcos-Villar et al. 2016; Rodriguez et al. 2011). These are 
thought to target vRNPs to the nuclear matrix and chromatin nuclear compartments 
where viral transcription and replication are proposed to take place (Mayer et al. 2007; 
Bortz et al. 2011; Jackson et al. 1982). Moreover, to access nascent capped host 
mRNA, the viral polymerase is known to directly interact with the serine-5 
phosphorylated C-terminal domain of pol II (Martinez-Alonso et al. 2016; Engelhardt 
et al. 2005). Moreover, this interaction also likely contributes to bringing newly 
synthesised viral mRNA to sites of high concentration of splicing factors. Of these 
factors, SFPQ (proline-glutamine rich splicing factor) has been shown to bind to 
vRNPs and increase the efficiency of viral mRNA polyadenylation, while the RED-
SMU1 complex (SMU1: suppressor of mec-8 and unc-52 1; RED: named after a region 
rich in arginine (R)/glutamic acid (E) or arginine/aspartic acid (D) repeats) has also 
been shown to be recruited by the viral polymerase to control viral mRNA splicing 
(Fournier et al. 2014; Landeras-Bueno et al. 2011; Te Velthuis and Fodor 2016). 
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Although being a cellular helicase involved in DNA replication, the 
minichromosome maintenance complex (MCM) is known to interact with the pol II 
C-terminal domain to stimulate IAV vRNA replication. Moreover, the MCM also 
binds to PA to induce the transition of de novo transcription initiation to elongation on 
the vRNA template (Kawaguchi and Nagata 2007). Proteins belonging to the ANP32 
family have also been associated with viral genome replication. Recent findings 
suggest that ANP32A contributes to the recruitment of the second trans-acting/trans-
activating polymerase to the cRNP-bound polymerase, and thereby facilitates vRNA 
synthesis (Sugiyama et al. 2015; Long et al. 2016). Notably, the identification of this 
support factor also resolves the long-standing question of why viral polymerases with 
a glutamate residue at PB2 position 627 generally do not function well in mammalian 
cells (Subbarao et al. 1993), as a length variation in ANP32A between chickens and 
mammals prevents a successful functional interaction between the viral polymerase 
and the longer mammalian support factor (Long et al. 2016). 
 
1.4.5. Nuclear export and trafficking of vRNPs 
Upon the formation of newly synthesised vRNPs, these are exported from the 
nucleus and moved to the apical plasma membrane where they are assembled into new 
virions (Shapiro et al. 1987; Rodriguez-Boulan and Sabatini 1978; Rodriguez-Boulan 
et al. 1983). RNP nuclear export happens via the nuclear pores through the Ran-GTP-
powered cellular β-exportin chromosome maintenance region 1 (CRM1)-dependent 
pathway in which M1 and NS2/NEP also play important roles (O'Neill et al. 1998; 
Paterson and Fodor 2012; Martin and Helenius 1991a). IAV NS2/NEP contains two 
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separate nuclear export signals (NES), both in its N-terminal domain, lying between 
amino acids 12-21 and 31-40. The first NES constitutes the predominant CRM1 
interaction point whilst the second one has been shown to bind to cellular 
chromodomain-helicase-DNA-binding protein 3 (CHD3) which aids recruitment of 
RNPs to chromatin and exposure to CRM1 (Neumann et al. 2000). Direct interactions 
between NEP and vRNPs have not been identified. However, M1 is known to directly 
bind to vRNPs whilst its N-terminal region interacts with NEP (Yasuda et al. 1993; 
Akarsu et al. 2003; Shimizu et al. 2011; Noton et al. 2009). Therefore, it is thought 
that M1 works as a bridge between vRNPs and NS2 in a proposed “daisy chain” 
interaction model (vRNP-M1-NEP-CRM1) which is responsible for nuclear export of 
vRNP complexes. 
Originally, RNP nuclear export was held to be specific for vRNPs, with cRNPs 
remaining in the nucleus (Shapiro et al. 1987). This requires the discrimination of 
vRNPs from cRNPs, a step thought to take place in the nucleus by somehow sensing 
differences in the terminal panhandle RNA structure (Tchatalbachev et al. 2001). 
However, more recent studies have shown that cRNP complexes are also exported to 
the cytoplasm, but in a CRM1-independent manner (Chaimayo et al. 2017). Although 
both RNP complex types are present in the cytoplasm, the same study also suggested 
that the vRNP/cRNP segregation (thus avoiding packaging of cRNPs) occurs through 
specific interactions with M1 during viral assembly. 
Following arrival in the cytoplasm, vRNP complexes disassociate from the 
CRM1-RanGDP dimer and accumulate by the perinuclear microtubule organisation 
centre (MTOC) from where they are transported to the cell surface to be packed into 
progeny virions. This concentration is aided by interactions between the RNPs and the 
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cellular protein YB-1 (Kawaguchi et al. 2012). Diffusion of the RNPs towards the cell 
membrane has been reported (Babcock et al. 2004). Nevertheless, more rapid 
trafficking of vRNPs to the apical membrane is believed to occur via Rab11- and 
microtubule-dependent vesicular transport, where the interaction between PB2 
polymerase subunit and Rab11 mediates the “piggy-backing” of vRNPs on Rab11-
containing vesicles (Amorim et al. 2011; Bruce et al. 2010; Eisfeld et al. 2011; 
Momose et al. 2011). A further refinement of this transport model suggests that rather 
than the Rab11-positive membrane structures being derived from the recycling 
endosome, they are actually tubulated membranes derived from the endoplasmic 
reticulum (de Castro Martin et al. 2017). 
 
1.4.6. Virion assembly, budding and release 
Assembly of IAV progeny occurs at the apical membrane of polarised cells 
(Rodriguez Boulan and Sabatini 1978). To achieve virion assembly, the essential 
virion constituents are required at the budding site: these are the membrane-associated 
HA, NA, M2 and M1 polypeptides, as well as the internal virion components of the 
genomic RNPs along with minor components, NS1 and NEP. HA, NA and M2 are 
translated at, and undergo oligomerisation in, the rough endoplasmic reticulum (Doms 
et al. 1993). HA and NA undergo glycosylation here and in the Golgi apparatus, after 
which all three viral proteins are specifically transported to the apical plasma 
membrane (Kundu et al. 1996; Hughey et al. 1992). Here, HA and NA accumulate in 
cholesterol- and sphingolipid-rich regions – so called lipid rafts (Scheiffele et al. 1999; 
Zhang et al. 2000), while M2 congregates at the edge of these structures (Leser and 
Lamb 2005). M1 may reach the apical plasma membrane by binding to the cytoplasmic 
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domains of HA and NA and following them through the exocytic pathway (Ali et al. 
2000). 
In order to form an infectious particle, the packaging of all eight genomic 
vRNPs is also necessary. Both random and specific mechanisms have been 
hypothesised to explain the packaging of viral RNPs. However, the observed ratio of 
infectious versus incomplete virus particles in the overall population of released 
virions is significantly higher than what is statistically predictable by the random 
method, if only 8 segments are incorporated per virion (Donald and Isaacs 1954; 
Hutchinson et al. 2008). Instead, much evidence suggests that specific packaging of 
one copy of each of the segments happens by virtue of packaging signals consisting of 
conserved sequence regions in the 5’ and 3’ termini of each vRNA (Gog et al. 2007; 
Fujii et al. 2003; Duhaut and McCauley 1996). The specific mechanism by which 8 
segments are preferentially packaged is yet to be fully elucidated, but it is presumed 
to comprise a network of RNA-protein and/or RNA-RNA interactions, with recent 
studies favouring the RNA-RNA interaction model (Gerber et al. 2014; Dadonaite et 
al. 2019). 
Once at the correct site, all viral membrane-associated proteins have been 
suggested to drive the budding process, which requires a network of interactions 
between these and the other structural viral complex of the RNPs (Rossman and Lamb 
2011). M1 is likely to be a major driver of budding (Gomez-Puertas et al. 2000), 
because it not only interacts with the cytoplasmic tails of the glycoproteins (Ali et al. 
2000; Zhang et al. 2000) and M2 (McCown and Pekosz 2006), but also with the vRNPs 
(Zvonarjev and Ghendon 1980; Ye et al. 1999; Noton et al. 2009), being therefore a 
crosslink between all the structural components. In addition, all three viral 
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transmembrane proteins probably cause some degree of membrane curvature which 
aids the formation of a viral bud containing the collected vRNPs (Rossman et al. 2010; 
Dou et al. 2018) from which newly assembled virions emerge with a compact fringe 
of HA trimers. In particular, the raft-edge accumulation of M2 is thought to 
concentrates M2 tetramers at the neck of budding virions to mediate virion scission by 
pinching off the neck of progeny virions (Rossman et al. 2010). Finally, once 
membrane scission has proceeded, NA mediates the cleavage of sialic acid therefore 
preventing the binding of virus-associated HA to the receptor and thus allowing the 
detachment of progeny virions from the cell membrane (Palese et al. 1974). 
 
1.5. Innate immune responses against influenza A viruses 
Innate immune responses represent an early barrier to IAV infection. 
Interferons (IFNs), vital constituents of this response, are a group of secreted cytokines 
which elicit diverse antiviral effects (reviewed by Randall and Goodbourn 2008). 
These next sections will explore the molecular mechanisms underlying the induction 
and signalling of IFN (particularly type I) upon IAV infection, ways by which it leads 
to inhibition of infection, and countermeasures developed by IAVs to prevent and 
avoid these effects. 
 
1.5.1. Interferons 
IFNs are cytokines which were firstly discovered in the 1950s (Isaacs and 
Lindenmann 1957) and can be divided in three classes: type I, II and III, each with 
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different structural homologies and class-specific receptors (reviewed in Platanias 
2005; Wack et al. 2015). Type II IFN has only one member: (IFN-γ), which is secreted 
by natural-killer cells and is also known to contribute to innate antiviral defence 
(Iwasaki and Pillai 2014). Type III IFNs (which includes IFN-λ1, 2, 3 and 4) are also 
induced in direct response to viral infection (Ank et al. 2006) and share pathway 
components with type I IFN (Onoguchi et al. 2007). Type I IFNs in human include 
IFN-α, -β, -ω, -ε, -τ, -δ and -κ, the first two being the better characterised ones and 
which will be the ones referred to by “type I IFN” from now onwards. An overview of 
the induction and signalling of type I IFN can be found in Figure 1.6. 
 
1.5.2. RNA sensing and type I interferon induction  
The innate immune system detects viral infections by the recognition of 
pathogen associated molecular patterns (PAMPs) by pattern recognition receptors 
(PRRs). IAV can be detected by Toll-like receptors (TLRs), retinoic acid-inducible 
gene I (RIG-I)-like receptors (RLRs) and nucleotide oligomerisation domain (NOD)-
like receptors (Sabbah et al. 2009). Each of these types of receptors are located in 
different cell compartments and are activated by different PAMPs. 
 
1.5.2.1. Intracellular viral RNA 
Cytoplasmic IAV vRNAs can, at least in theory, be detected by RLRs such as 
RIG-I, melanoma differentiation-associated protein 5 (MDA-5) and laboratory of 
genetics and physiology 2 (LGP2). Amongst all these, RIG-I is thought to be the 
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predominant sensor for IAV single-stranded 5′-triphosphate RNAs (Pichlmair et al. 
2006; Rehwinkel et al. 2010), despite the fact that MDA-5 has also been reported to 
be involved in ISG upregulation against the virus (Benitez et al. 2015). In contrast, 
overexpression of LGP2 has been shown to decrease IAV-driven IFN-β induction in 
cells infected with H3N2 viruses (Malur et al. 2012). For full activity, RIG-I requires 
ubiquitylation, which is mediated by the cellular tripartite motif-containing protein 25 
(TRIM25) (Gack et al. 2007), RIG finger proteins leading to RIG-I activation 
(RIPLET) (Oshiumi et al. 2009; Cadena et al. 2019), or Mex-3 RNA binding family 
member C (MEX3C) (Kuniyoshi et al. 2014). Upon activation, RIG-I recruits and 
activates mitochondrial antiviral signalling protein (MAVS) – also known as CARD 
adaptor inducing IFN-β (Cardif), virus-induced signalling adaptor (VISA) or IFN-β 
promoter stimulator protein 1 (IPS-1) (Seth et al. 2005; Xu et al. 2005; Hiscott et al. 
2006). Once engaged, MAVS interacts directly with tumour necrosis factor (TNF) 
receptor-associated factor 6 (TRAF6) (Xu et al. 2005) which recruits receptor-
interacting proteins 1 (RIP1) (Seth et al. 2005). Once recruited, TRAF6 ubiquitylates 
itself and RIP-1 (Chen 2005) and the polyubiquitin chains are recognised by TAK-
binding proteins 2 and 3 (TAB2 and 3) which recruits transforming growth factor β-
activated kinase 1 (TAK1) to the TRAF6-RIP1-TAB-TAK complex. In association, 
TAK1 directly phosphorylates the IKKβ subunit of the IKK complex (Wang et al. 
2001), resulting in the downstream phosphorylation, ubiquitylation and eventually 
degradation of IκB, leading to the nuclear intake of NF-κB and the subsequent 
upregulation of IFN-β and pro-inflammatory cytokines (Kim and Maniatis 1997; Liu 
et al. 2017). At the same time, MAVS is thought to also recruit TRAF3, which directly 
interacts with TRAF family member-associated NF-κB activator (TANK)   
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Figure 1.6: Innate immune recognition and the interferon system. Schematic 
representations type I IFN induction and signalling pathways in the context of IAV 
infection. IAV dsRNA are recognised by cytoplasmic RIG-I and MDA-5 and 
endosomal TLRs 3 (blue arrows) and 7 (red arrows). A panoply of signalling cascades 
takes place to ultimately result in the activation of transcription factors IRF3, NF-κB 
and AP-1 which upregulate IFN-β expression. Secreted IFN-β functions in an auto-
paracrine fashion, being recognised by IFNAR and activating the JAK/STAT 
signalling pathway which leads the phosphorylation and dimerisation of STAT1/2, the 
formation of the STAT/1/2/IRF9 trimeric complex and the resulting regulation of 
ISRE promoters and the expression of ISGs (green arrows). “+u” and “+P” represent 
ubiquitylation and phosphorylation, respectively. 
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(Li et al. 2002). TANK associates with TANK-binding kinase 1 (TBK1) (Pomerantz 
and Baltimore 1999)which along with IKKε interact with and phosphorylate IRF3 
(Fitzgerald et al. 2003). Phosphorylated IRF3 monomers undergo dimerisation 
followed by nuclear import where it acts as a transcription factor to upregulate several 
genes (Grandvaux et al. 2002), including IFN-β. 
In the context of intracellular RNA signalling, NEMO (a component of the IKK 
complex) interacts with TANK (Zhao et al. 2007), being therefore an adapter for both 
NF-κB and IRF3 activation. 
 
1.5.2.2. dsRNA or ssRNA delivered through endosomes 
RLR-dependent RNA sensing in IAV infection is common in most cell types. 
However, phagocytes such as plasmacytoid dendritic cells and macrophages use TLRs 
3 and 7 to detect IAV RNA (Kawasaki and Kawai 2019). Detection of dsRNA and 
ssRNA in endosomes or phagosomes is mediated by TLR3 and 7, respectively. 
Binding of TLR3 to dsRNA is initiated with the dimerisation and 
phosphorylation of TLR3 (Sarkar et al. 2004) as well as the recruitment of its adapter 
Toll-interleukin-1-resistance domain-containing adaptor inducing IFN-β (TRIF) 
(Yamamoto et al. 2003). Similarly to RLR RNA recognition, engagement of TRIF 
signals the activation of both NF-κB and IRF3 through the recruitment of TRAF6 and 
RIP1 (Hacker et al. 2006) as well as TRAF3 (Oganesyan et al. 2006) and both pathway 
arms develop as described in section 1.5.2.1. 
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Contrary to dsRNA, if recognised from endosomes, ssRNA is detected by 
TLR7 (Diebold et al. 2004). The mechanism of IFN-β induction following from TLR7 
activation show some differences compared to TLR3-driven IFN expression. TLR7 
uses myeloid differentiation factor 88 (MyD88) as its adapter. In turn, MyD88 recruits 
a trimeric complex formed by the kinases interleukin-1 receptor-associated kinase 4 
(IRAK4), IRAK1 and TRAF6 (Hacker et al. 2006). The recruitment of TRAF6 
activates NF-κB through the already described TAK1-TAB2-TAB3 complex. In 
contrast to the IRF3 activation observed from TLR3 induction, given the constitutive 
expression of IRF7 in dendritic cells, TLR7 engagement has been suggested to occur. 
In this case, the MyD88-IRAK1-IRAK4-TRAF6 complex directly interacts with IRF7 
(Honda et al. 2004; Kawai et al. 2004) which is polyubiquitylated by TRAF6 and 
phosphorylated by IRAK1 in a TBK1/IKKε-independent fashion. Upon 
phosphorylation, the entire complex of IRAK1-TRAF6-MyD88-IRF7 is translocated 
to the nucleus where it stimulates transcription of IFN-β (Honda et al. 2005). 
 
1.5.3. Signalling responses to type I interferon 
Once translated and secreted, IFN-β acts in an auto-paracrine manner via a 
common heterodimeric receptor: Interferon-α/β receptor (IFNAR), composed of 
IFNAR1 and IFNAR2 (reviewed by (Randall and Goodbourn 2008). While the 
IFNAR1 subunit is associated with tyrosine kinase 2 (Tyk2), IFNAR2 is bound to 
tyrosine Janus/just another kinase 1 (JAK1) and signal transducer and activator of 
transcription 2 (STAT2). Ligand-induced dimerisation of the receptor induces 
conformational changes, leading to tandem phosphorylation cascades which result in 
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the phosphorylation and consequent dimerisation of STAT1 and 2. The STAT1/2 
dimer associates with IRF9 monomers to form the heterotrimeric interferon stimulated 
gene factor 3 (ISGF3). This complex is imported into the nucleus where it is acetylated 
(Tang et al. 2007) and binds to the IFN-stimulated response element (ISRE) to regulate 
the transcription of IFN-stimulated (ISGs) and repressed (IRGs) genes. 
 
1.5.4. Interferon-stimulated genes 
As previously described, the induction and recognition of type I IFN results in 
the transcriptional stimulation of hundreds of ISGs (Shaw et al. 2017), some of which 
restrict viral propagation through distinct mechanisms. The following sections will list 
some of the ISGs which have been found to be antiviral against IAV. 
 
1.5.4.1. Myxovirus resistance proteins 
Mx1 is a nuclear-localised mammalian guanosine triphosphatase (GTPase) and 
was the first ISG protein found to restrict IAV replication (Haller et al. 1980; Staeheli 
et al. 1986b). Moreover, a follow up study further correlated the susceptibility of 
BALB/c and CBA/J mice to IAV infection with large deletions or a nonsynonymous 
mutation in the Mx1 gene (Staeheli et al. 1988; Staeheli et al. 1986a). Murine Mx2 is 
also an ISG. However, Mx2 is cytosolic and has no antiviral activity against IAV 
(Zurcher et al. 1992). 
The human Mx1 orthologue, MxA, is also known to inhibit a large variety of 
viruses, including IAV (Haller et al. 2009; Netherton et al. 2009). Studies on MxA 
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have suggested that its oligomerisation around RNPs prevents their nuclear import and 
thus blocks viral replication (von der Malsburg et al. 2011; Turan et al. 2004). 
Inhibition of IAV by Mx1 is also thought to be mediated by the disruption of NP-PB2 
interactions, resulting in reduced vRNP assembly and abrogated polymerase activity 
(Verhelst et al. 2012). A more recent study has suggested that MxA also has an indirect 
antiviral affect in IAV inhibition by positively regulating the induction of type I IFN 
(Schattgen et al. 2016). The murine Mx2 and its human orthologue MxB are 
cytoplasmic and, in spite of inhibiting other RNA viruses such as HIV-1, they present 
no antiviral effects against IAV (Goujon et al. 2013). 
 
1.5.4.2. 2’ 5’-oligoadenylate synthetases 
The 2’ 5’-oligoadenylate synthases (OAS) act alongside ribonuclease L (RNase 
L) in order to degrade cytosolic-localised viral RNA (reviewed in (Silverman 2007). 
OAS is enzymatically activated by dsRNA binding, converts ATP into 2’-5’-
oligoadenylate which activates latent RNase L, leading to the cleavage of viral and 
cellular RNA and the cessation of viral infection (Chakrabarti et al. 2011). Moreover, 
RNase L-cleaved products have been shown to activate RIG-I in a positive feed-back 
to enhance IFN secretion (Malathi et al. 2007). The importance of the OAS1/RNAse 
L pathway to IAV has been shown by large reduction of IFN-β-mediated inhibition in 
RNase L knock-down and knockout cells (Min and Krug 2006). 
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1.5.4.3. Protein kinase R 
Although ubiquitously expressed, protein kinase R (PKR) is upregulated by 
type I IFN (Shaw et al. 2017). PKR is activated by dsRNA, resulting in auto-
phosphorylation. Upon activation, PKR phosphorylates the alpha subunit of eukaryotic 
initiation factor 2 (eIF2α), increasing its affinity to eIF2β and rendering it inaccessible 
for subsequent initiation events and thus contributing to a general translational block 
and reduced viral protein synthesis (Pindel and Sadler 2011; de Haro et al. 1996; Gale 
and Katze 1998). PKR also targets IκB, which further activates NF-κB and induces 
IFN expression, resulting in a positive loop of ISG activation (Kumar et al. 1994). 
 
1.5.4.4. Interferon-induced transmembrane proteins 
Interferon-induced transmembrane proteins (IFITMs) are a family of dispanins 
which have a common double transmembrane domain configuration (Sallman Almen 
et al. 2012). IFITM1, 2, 3, 5 and 10 have been identified in humans and of these, the 
first three are known to have antiviral functions against multiple viruses (Zhang et al. 
2012; Perreira et al. 2013). While IFITM1 localises to the cell surface and early 
endosomes, IFITM2 and 3 are enriched in late endosomes and lysosomes (Mudhasani 
et al. 2013) and are thought to prevent IAV viral entry (Brass et al. 2009; Feeley et al. 
2011). Additionally, IFITM3 has been identified as important in restricting mortality 
and morbidity against IAV in man and in vivo models of infection (Everitt et al. 2012). 
IFITMs seem to be specific inhibitors of viruses which take advantage of the 
endosomal pathway to ensure entry (Huang et al. 2011), suggesting a block in viral 
fusion in the endosome, potentially by interfering with HA fusion activity. 
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Nevertheless, the exact mechanism by which this takes place has not yet been fully 
elucidated. 
 
1.5.5. Interferon induction by IAV infection 
As reviewed above, IFN induction in the context of IAV infections results from 
detection of PAMPs through RLRs and TLRs. The next subchapter will review the 
two main IAV IFN inductors: the RNA “panhandle” and defective interfering particles. 
 
1.5.5.1. Induction of RIG-I by the IAV “panhandle” 
As previously mentioned in this chapter, the 5’ and 3’ termini of IAV genome 
segments respectively contain 13 and 12 nucleotide highly conserved sequences 
(Desselberger et al. 1980; Robertson 1979). These sequences have partial 
complementarity with the potential to form a “panhandle” structure which acts as the 
vRNA promoter and is involved in the initiation of transcription (Fodor et al. 1994; 
Tiley et al. 1994). This structure has been shown to form a stable partial duplex of 
approximately 15bp in length between the conserved termini through Watson–Crick 
and non-Watson–Crick base pairing - Figure 1.7A - (Cheong et al. 1996). Therefore, 
by virtue of the 5’ppp being directly adjacent to a small stretch of partially dsRNA, 
this panhandle is a potent RIG-I ligand (Killip et al. 2015; Liu et al. 2015). Moreover, 
observations of RIG-I activation by RNA extracted from IAV-infected cells, from 
purified virions, or from RNP reconstitution assays also provides evidence of 
panhandle-dependent IFN induction (Pichlmair et al. 2006; Rehwinkel et al. 2010).  




Figure 1.7: vRNA and cRNA promoter conformations. Schematic representation 
of the (A) vRNA “panhandle” and vRNA and cRNA “corkscrew” secondary 
structures. Adapted from (Ferhadian et al. 2018). 
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Despite the formation of this dsRNA region in naked vRNA, studies have 
shown that, when encapsidated by the viral RdRp, its structure is altered. RdRp binding 
to the vRNA termini leads to the formation of a ‘forked’ or “corkscrew”-like secondary 
structure which is critical for viral polymerase activity (Tomescu et al. 2014; Killip et 
al. 2015). Besides, this polymerase-dependent conformational switch allows a smaller 
number of inter-strand base pairs, making this RNA region potentially therefore less 
likely to be detected by RIG-I, as the RNA extremities do not engage in binding and 
dsRNA is not formed (Flick and Hobom 1999) (Figure 1.7B). 
 
1.5.5.2. Defective genomes and defective interfering particles 
These were first identified in the 1940s as incomplete viruses capable of 
inhibiting the replication of a wild-type virus (Gard and von Magnus 1947). Defective 
viral genomes (DVGs) were identified upon serial passage of the virus in embryonated 
chicken eggs at high multiplicity and described as ‘incomplete’ non-infectious viruses 
derived from full-length genome segments (von Magnus 1951a, 1951b). Defective 
interfering particles (DIPs) were defined as a viral particle which contained the 
standard structural components but possess a DVG (Huang and Baltimore 1970). 
IAV DVGs have been shown to have suffered loss of long internal sequences 
that still preserve the vRNA terminal regions (Duesberg 1968; Davis et al. 1980; Davis 
and Nayak 1979; Nayak 1980). These preserved terminal sequences tend to include 
approximately 200bp at the 3’ end and 250bp at the 5’ end (Duhaut and Dimmock 
2000; Duhaut and Dimmock 2002), which includes the segment-specific packaging 
signals. Given their smaller size, coupled with the ability to be packaged and replicated 
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by the viral polymerase, these DVG segments can outcompete the full-length 
segments. Several studies have shown that these deletions are particularly associated 
with the largest IAV segments - segments 1, 2 and 3 (Sivasubramanian and Nayak 
1983; Nayak et al. 1982) – where the size advantage of the DVG RNA is 
proportionally greater and that furthermore, the defective segments specifically 
compete with the parent segment at the stage of incorporation into virions (Duhaut and 
McCauley 1996; Odagiri and Tashiro 1997; Ueda et al. 1980). 
For a long time, the generation of DIPs was considered a tissue culture-
associated artefact of virus preparations, as serial passage resulted in the generation 
and accumulation of high number of DVGs (Perez-Cidoncha et al. 2014). However, 
more recent studies have suggested the importance of DIPs in naturally occurring IAV 
infections. DVGs with internal deletions have been identified as occurring in 
experimentally infected mice (Tapia et al. 2013) and humans (Saira et al. 2013). 
Additional studies on DIPs in IAV pathogenesis supported that the presence of DIPs 
negatively correlates with increased lung pathology in a mouse model (Rabinowitz and 
Huprikar 1979). In this study, mouse infections with DIP-enriched viral preparations 
presented decreased numbers of inflammatory cells infiltrated in lungs, compared with 
wild-type virus, leading to the assumption that DIPs protect against viable virus 
particles. In contrast, the presence of DIPs in H1N1 2009 pandemic infections in 
humans have been correlated with severe clinical outcomes (Vasilijevic et al. 2017; 
Saira et al. 2013). 
Evidence that DIPs are involved in IFN induction has accumulated over the 
years. Studies have shown that IFN-inducing particles are not productively infectious 
(Marcus et al. 2005). Conversely, DVG RNA was directly implicated in a stronger 
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RIG-I recognition and subsequent IFN induction, in contrast to full-length genomes 
which are not bound to RIG-I during infection (Baum et al. 2010). 
 
1.5.6. IFN antagonism and prevention by IAV 
Like every virus, IAV has evolved several mechanisms to counteract and 
circumvent the IFN response. It is likely that some of these strategies involve masking 
viral PAMPs. First, if IAV genome replication took place in the cytoplasm, vRNA and 
cRNAs could constitute cytoplasm-localised RIG-I and MDA-5 ligands and lead to 
the activation of an IFN-driven antiviral response. Therefore, unlike most other 
negative-strand RNA viruses which replicate in the cytoplasm, IAV RNA synthesis 
takes place in the nucleus (previously described in the chapter) and it is possible that 
this makes these RNA species inaccessible to detection by RLRs. However, recent 
studies have suggested the presence of nuclear-resident RIG-I which binds to vRNPs 
in the nucleus (Liu et al. 2018; Liu et al. 2019). Nevertheless, synthesis of cRNA and 
vRNA is closely coupled with the incorporation of NP monomers and RNA 
encapsidation (Ye et al. 2006; Vreede et al. 2004).  
A second strand of IAV IFN evasion mechanisms involve active interference 
with the sensing and response systems of the IFN pathway. These evasion mechanisms 
arise because the IAV genome encodes proteins which antagonise the IFN system 
(reviewed in Garcia-Sastre 2011). The major protein responsible for this is NS1. 
However, in addition, several other viral proteins have been associated with inhibiting 
the IFN response, such as PB1-F2 and PA-X (described above), HA and the viral 
polymerase. 
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1.5.6.1. NS1 
Despite more recent discoveries of accessory proteins with IFN antagonism 
activity, NS1 still remains the main IAV blocker of IFN induction, for which it has 
evolved multiple mechanisms (reviewed by Hale et al. 2008; Engel 2013; Krug 2015). 
Although often acting in a strain-specific manner, NS1 has been shown to inhibit the 
induction of IFN-β by directly targeting multiple components of the IFN induction 
cascade and/or by generally inhibiting host gene expression. 
Activation of key transcription factors such as IRF3, NF-κB and AP-1 have 
been shown to be inhibited by NS1, leading to the reduction of IFN-β expression 
(Talon et al. 2000; Wang et al. 2000; Ludwig et al. 2002). Position 196 of NS1 has 
been associated with the ability of NS1 to inhibit IRF3 activation, as viruses containing 
E196 were apparently more efficient at blocking IRF3 phosphorylation than strains 
with K196 (Kuo et al. 2010). However, direct interactions between NS1 and these 
transcription factors have not been described. Instead, NS1 prevents IFN induction by 
acting upstream of IRF3, NF-κB and AP-1 transcription factors (Krug 2015). Direct 
interactions between NS1 and RIG-I have been described (Mibayashi et al. 2007). 
Additional binding of NS1 to the factors involved in RIG-I activation, TRIM25 (Gack 
et al. 2009; Koliopoulos et al. 2018) and RIPLET (Rajsbaum et al. 2012) have also 
been identified. Additionally, NS1 binds to PACT, another cellular protein important 
for RIG-I activation (Tawaratsumida et al. 2014; Brisse and Ly 2017). In each case, 
these interactions are thought to inhibit RIG-I ubiquitylation and activation and thus 
the following IFN-β transcription. 
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NS1 is also known to bind to dsRNA, preventing RLR recognition (Hatada and 
Fukuda 1992). For this, the positive charge on NS1 residue R38 in the N-terminal 
RNA-binding domain has been shown to be essential, but adjacent basic amino acids 
also make strong contributions to the affinity of binding, i.e. K41 (Wang et al. 1999). 
Point mutations of these amino acids results in RNA binding deficits, increased IFN-
β induction and virus attenuation in a murine model (Donelan et al. 2003). In addition 
to limiting RIG-I activation, the dsRNA-binding function of NS1 has also suggested 
to impair the function of ISGs which have been shown to have direct antiviral functions 
against IAV, such as the OAS/RNase L duo (Min and Krug 2006) and PKR (Min et 
al. 2007; Bergmann et al. 2000). 
In addition to the above specific effects on the innate immune response, NS1s 
from many strains of IAV also have a general inhibitory effect on cellular gene 
expression. Various points of inhibitory interaction between NS1 and the cellular 
splicing machinery have been proposed over the years (Fortes et al. 1995; Qiu et al. 
1995; Wang and Krug 1998; Wolff et al. 1998), but while these may contribute to 
overall host protein shut-off, they may contribute towards regulation of viral mRNA 
splicing (Tsai et al. 2013). NS1-mediated inhibition of cellular mRNA export has also 
been proposed to play a role in limiting antiviral gene expression (Satterly et al. 2007), 
though this proposal is not easily reconcilable with much evidence indicating that 
many of the viral mRNAs use the same cellular pathway for nuclear export (Hao et al. 
2008; Read and Digard 2010; Wang et al. 2008) and that interactions between NS1 
and this machinery have a positive role for export of the viral late gene mRNAs 
(Pereira et al 2017). What is less contentious, is the establishment that many, but not 
all, NS1s potently repress cellular gene expression by inhibiting processing and 
Chapter 1   
56 
polyadenylation of the 3’-end of cellular mRNAs (Nemeroff et al. 1998). This 
mechanism, mediated by inhibitory interactions between NS1 and both cleavage and 
polyadenylation specificity factor 30 (CPSF30) and poly(A)-binding protein II 
(PABPII) achieves specificity for host gene expression because, as described above, 
the mechanism by which viral mRNAs are polyadenylated is totally separate. 
However, not all strains of IAV use this approach; for example the laboratory strain 
PR8 and pdm09 viruses do not (Kochs et al. 2007; Hale et al. 2010). 
 
1.5.6.2. Viral polymerase 
The role of the viral polymerase in IFN inhibition has been suggested by 
systems biology analysis (Shapira et al. 2009) as well as partial UV inactivation studies 
(Marcus et al. 2005). The mechanism of cap-snatching performed by the polymerase 
contributes to a general host mRNA shut down (Schmolke and Garcia-Sastre 2010) 
and consequent restraint of the expression of IFN-β, RLRs and ISGs. Moreover, virus 
strains with higher polymerase efficiency present an increased replication speed and 
are able to outrun the IFN response (Grimm et al. 2007). However, in addition, to 
mechanisms related to polymerase RNA synthesis, both the individual components 
and the overall trimeric polymerase complex have been shown to directly inhibit 
aspects of the IFN pathway. Direct interactions between the polymerase and RIG-I 
have been identified. However, the association of each individual virus polymerase 
component with RIG-I failed to significantly affect dsRNA- or 5’ triphosphate RNA-
elicited IFN induction and IRF3 phosphorylation (Li et al. 2014). However, another 
study has again suggested an interaction of RIG-I with the polymerase of incoming 
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vRNPs. (Liedmann et al. 2014b). This interaction was dependent on amino acids 398E, 
524S and 536I of PB1 and 351E of PA (the ESIE motif) and was proposed to be 
responsible for inhibiting IFN induction at very early stages of infection. These 
specific PB1 and PA residues had also been identified as determinants of IFN 
inhibition and virulence of IAV (Liedmann et al. 2014a). 
Counteraction of IFN stimulation by individual subunits of the polymerase 
have also been described, as PB2 from some strains of IAV has been shown to localise 
to mitochondria (Carr et al. 2006) and this has been linked to inhibition of RLR-
signalling through MAVS (Graef et al. 2010; Iwai et al. 2010). 
 
1.5.6.3. Haemagglutinin 
The HA conserved fusion peptide has been shown to interact with STING, and 
reduce STING-driven IFN induction (Holm et al. 2016). However, this proposed 
function of the HA fusion peptide is inconsistent with the localisation of both HA 
fusion peptide and STING. Although both proteins can be found in membranes of the 
Golgi apparatus, STING faces the cytoplasm whilst the fusion peptide in kept in the 
lumen (reviewed in Sriwilaijaroen and Suzuki 2012). Moreover, HA of a lab adapted 
H1N1 strain has also been suggested to interact with IFNAR, leading to IFNAR 
ubiquitylation and its subsequent degradation (Xia et al. 2015), resulting in limited 
induction of ISGs. 
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1.6. Aims and approaches 
As introduced in section 1.3, several accessory peptides have been shown to be 
encoded by the IAV genome in overlapping and/or alternately initiated open reading 
frames. Several of these IAV accessory peptides, although not necessarily crucial for 
virus replication, have been shown to modulate cellular responses and affect IAV 
virulence. The overall goal of this dissertation was to assess the expression of 
alternative polypeptides from segment 2 of IAV with special attention to AUG codons 
10 and 11 in the PB1 reading frame and any functions of these polypeptides in the IAV 
replication cycle. 
Chapter 2 describes assessment of the translation initiation potential of 
segment 2 AUG codons 10 and 11, using plasmid-based reporter constructs and mutant 
viruses made in the background of a laboratory adapted IAV strain, and the effects of 
mutating these start codons on viral fitness in vitro and in ovo. A more detailed 
phenotypic characterisation of the mutant viruses is presented in Chapter 3, where the 
interplay between virus and the type I IFN system was considered. Chapter 4 includes 
murine in vivo studies of an AUG mutant virus. Chapter 5 describes studies of the 
individual proteins that arise from AUGs 10 and 11 and their effects on the IFN system. 
Finally, Chapter 6 is dedicated to the analysis of the sequence conservation of these 
segment 2 AUG codons and their importance in a broader panel of IAV strains. 
Concluding remarks and future research directions are discussed in Chapter 7, and the 










Segment 2 AUG codons 10 and 11 and their 
effects on viral fitness in vitro 
__________________________________________________________ 
 
2.1. Background and Aims 
Influenza A virus virulence is multidimensional and has been shown to be 
dependent on both viral and host features. Determinants of virulence are regulated in 
a polygenic manner in which segment 2 plays an important role (Baigent and 
McCauley 2003; Basler and Aguilar 2008; Kawaoka et al. 1989). 
Segment 2 is known to encode three different proteins; PB1, PB1-F2 and PB1-
N40. As reviewed in Chapter 1, PB1 is the primary product of segment 2. It complexes 
with two other subunits (PB2 and PA) to form the viral RdRp and is therefore 
indispensable for virus replication. PB1-F2 and PB1-N40 proteins are expressed from 
alternative AUG codons. PB1-F2 is a small accessory protein, initiated from the fourth 
AUG codon in segment 2 (in frame 2), which acts as a mitochondria-localised innate 
immune inhibitor and is also known to induce cell death (Varga and Palese 2011). 
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PB1-N40 (or simply N40) was first described in 2009 and consists of an N-terminally 
truncated version of PB1 lacking the first 39 amino acids, the region required for the 
binding to the PA polymerase subunit (Wise et al. 2009). N40 translation initiates from 
the fifth segment 2 AUG codon (in frame 1) by ribosomal reinitiation (Wise et al. 
2011). Although it is known to localise in the cytoplasm, PB1-N40 function remains 
unclear, although it has been associated with altered production of vRNA (Tauber et 
al. 2012). 
Examination of the 5’ end of segment 2 of the A/PR/8/34 (PR8) strain further 
revealed that, in addition to the AUG codons which initiate expression of PB1, PB1-
F2 and N40, a number of other AUG codons are found (Figure 2.1): 
 Frame 1: AUG codons 10 and 11 
 Frame 2: AUG codons 2, 3, 7, 8 and 9 
 Frame 3: AUG 6. 
Studies on PB1-F2 expression in vitro also suggested the expression of a PB1-F2 
C-terminal fragment from subsequent frame 2 AUG codons; one or more of AUGs 7, 
8 and 9 (Zamarin et al. 2006; Kamal et al. 2015). Given that these potential PB1-F2 
initiation codons are in medium strength Kozak consensus settings while AUG codons 
10 and 11 are in strong contexts (Figure 2.1), the potential for protein expression from 
these latter AUGs was also considered. Accordingly, this chapter aimed to investigate 
possible protein translation initiation from segment 2 AUG codons 10 and 11. 
Furthermore, the importance of these AUG codons for IAV biology was assessed by 
measuring the replicative fitness of mutants of the lab adapted PR8 strain lacking these 
AUG codons in several in vitro and in ovo systems.  




Figure 2.1. Diagram of the 5′ end of segment 2 mRNA. Open reading frames from 
the three frames are indicated by boxes. AUG codons are colour-coded according to 
the relative strength of their Kozak consensus: green-strong (-3A/G and +4G), amber-
intermediate (-3A/G or + 4G), red-weak (-3U, +4U). Characterised AUG initiation 
codons and respective products are indicated by arrows (PB1, PB1-F2 and PB1-N40). 
Adapted from Wise et al., 2009. 
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2.2.  Results 
2.2.1. Translation initiation from segment 2 AUG codons 10 and 11 
Initially, protein expression from AUGs 10 and 11 was examined in the context 
of plasmid transfection. In order to do this, the first 380bp of PR8 segment 2 cDNA 
were cloned into a green fluorescent protein (GFP) expression plasmid, so that the 
reporter gene was positioned into frame with AUG codons 1, 5, 10 and 11 (Figure 
2.2A). This recombinant construct (termed WT), was used as a template to mutate 
frame 1 AUG codons by site-directed mutagenesis as described in Table 2.1. These 
constructs were generated by Dr Helen Wise (Wise et al., 2011 and unpublished data). 
After confirmation by DNA sequencing, the panel of WT and mutated constructs were 
individually transfected into 293T cells and after 48 hours, the expression of GFP-
fused products was investigated by SDS-PAGE and western blot for GFP and tubulin 
as a loading control. All samples contained similar amounts of tubulin (Figure 2.2B), 
confirming equivalent loading. As a negative control, a sample from mock transfected 
cells was included, which did not contain detectable GFP peptides (Figure 2.2B, lane 
1). The detection system was validated by the transfection of a GFP-only plasmid 
positive control, where a major polypeptide product was seen at 27kDa, the expected 
molecular mass for GFP (lane 2). When transfected with WT PB1-GFP plasmid, cells 
expressed fusion peptides corresponding to PB1 and PB1-N40, detectable by the 
presence of the expected 41 and 36kDa products (lane 3) which were absent after the 
mutation of AUGs 1 and 5 respectively (lanes 4 and 5). WT plasmid-transfected cells 
also expressed two smaller peptides whose sizes corresponded to proteins initiating at 
AUGs 10 and 11 (30 and 28kDa). Furthermore, the 30kDa product was no longer
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Figure 2.2. Expression of PB1 related species cDNA in transfected cells. 293T cells were transfected with a panel of GFP-fusion plasmid 
for 48 hours. (A) Diagram of the AUG codon and ORF structure of the 5’ end of PR8 segment 2 mRNA with GFP fused into frame 1. The 
position of molecular mass markers (in kDa) is indicated on the left. (B) Lysates from cells transfected (or mock transfected) with the 
indicated panel of plasmids were analysed by western blot with anti-GFP serum; α-tubulin was used as loading control. Quantification of the 
relative expression of the different PB1-related products, PB1 (C), N40 (D), N92 (E) and N111 (F), was performed by densitometry following 
single technical repeats from three independent experiments. Statistic annotations are the result of an ordinary one-way ANOVA test. *p-
value <0.05, **p-value <0.01, ****p-value <0.0001.
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Table 2.1. Summary of segment 2 frame 1 mutants. Nucleotide, codon and amino 
acid changes resulting from the mutations in each construct are given, as well as a 






Predicted frame 1 products 
PB1 PB1-N40 PB1-N92 PB1-N111 
ΔAUG1 A25U AUG- UUG Null WT WT WT 
ΔAUG5 A142U AUG-UUG M40L Null WT WT 
ΔAUG10 A298G AUG-GUG M92V M53V Null WT 
ΔAUG11 A355G AUG-GUG M111V M72V M20V Null 
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expressed when AUG 10 was mutated (lane 6). Likewise, the 28kDa product largely 
disappeared when AUG 11 was deleted (lane 7) and the amounts of both polypeptides 
were markedly reduced after the simultaneous deletion of AUGs 10 and 11 (lane 8). 
These data suggested that protein expression was initiated from AUGs 10 and 11. 
Consistent with previous nomenclature, the AUG 10 and 11 initiated polypeptides 
were named PB1-N92 and PB1-N111 respectively, considering the predicted omission 
of the first 91 and 110 amino acids of WT PB1, respectively. 
Quantification of the individual peptide species by densitometry from this and 
replicate experiments showed that the above pattern was reproducible (Figures 2.2 C-
F), further supporting the conclusion that AUGs 10 and 11 directed translation 
initiation. The amounts of the remaining PB1 fusion products were not generally 
affected by mutation of another start codon, except for a small but statistically 
significant increase in PB1-N111 accumulation after mutation of AUGs 1 or 5 (Figure 
2.2F). 
 
2.2.2.  Generation of PR8 segment 2 mutant viruses 
After detecting the expression of further N-terminally truncated PB1 
polypeptides from transfected DNA, we asked if the same products could be detected 
in virus-infected cells and if so, whether loss of their expression would have an impact 
on viral fitness. To address these questions, reverse genetics was used to create 
segment 2 mutant viruses in the PR8 background. 293T cells were co-transfected with 
eight PR8 pDUAL plasmids individually encoding a different IAV segment 




Figure2.3. Scheme of reverse genetics system. 293T cells were co-transfected with 
8 pDUAL plasmids, each driving the production of mRNA and ‘vRNA-like’ RNA 
from pPolII ( ) and pPolI ( ) promoters, respectively from each segment of the IAV 
genome. 
  





Figure 2.4. Growth of PR8 segment 2 mutant viral stocks. MDCK cell monolayers 
were infected at low MOI (<0.01). Supernatants were cleared, stored and titrated by 
plaque assay at 48 hpi. Data represent the mean ± SEM of at least two independently 
rescued virus stocks. Statistic annotations are the result of an ordinary one-way 
ANOVA test. *p-value <0.05. 
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(de Wit et al. 2004). These plasmids contain both RNA polymerase II (polII) and RNA 
polymerase I (polI) promoters, which facilitate the expression of mRNA (leading to 
IAV protein translation) as well as the production of ‘vRNA-like’ RNA, essential for 
genome replication (Hoffmann et al. 2000). Mutant segment 2 plasmids harbouring 
‘ΔAUG’ mutations in which start codons were changed to leucine or valine codons 
(Table 2.1) were generated by site-directed mutagenesis and used to replace the WT 
segment 2 plasmid. These mutant plasmids included ones with individual AUG 
alterations (ΔAUG5, ΔAUG10 and ΔAUG11), three with double mutations 
(ΔAUG5,10, ΔAUG5,11 and ΔAUG10,11) and a triple mutant (ΔAUG5,10,11). A 
negative control transfection was included where segment 2 was replaced by an empty 
pDUAL plasmid vector and which therefore should have been unable to generate 
viable virus particles. Wild-type PR8 plasmids were used as a positive control and to 
generate a comparator WT virus. Forty-eight hours after transfection, cell supernatants 
were collected. These were termed ‘P0 stocks’ (Figure 2.3). These stocks were used to 
infect MDCK cells at low MOI (<0.01) and propagated for an additional 48 hours to 
generate P1 stocks which were clarified, titrated by plaque assay and used for 
subsequent experiments. In independent (including the virus rescue stage) replicate 
experiments the empty plasmid negative control did not produce detectable levels of 
virus (the limit of detection was 2 PFU/mL), while PR8 WT replicated to an average 
titre of over 108 PFU/mL (Figure 2.4). Individual mutation of AUG codons 5, 10 or 11 
did not alter the levels of virus output compared to the WT virus. Comparable, 
although slightly lower titres were also seen for the double mutant viruses ΔAUG5,10 
and ΔAUG5,11. However, the simultaneous mutation of AUG codons 10 and 11 
resulted in a severe (~106-fold) reduction of the P1 viral titres to around 103 PFU/mL. 
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The same drop in titre was seen with the triple mutant ΔAUG5,10,11 (Figure 2.4). 
These results provided the first evidence for a role for AUG codons 10 and 11 in 
determining viral fitness. 
In parallel, RNA extractions were performed on P1 supernatants followed by 
RT-PCR and Sanger DNA sequencing of segment 2, which confirmed the presence of 
AUG mutations (data not shown). The produced virus stocks were not plaque purified 
and therefore can be considered a mixed population. Nevertheless, stocks were only 
passaged once from the respective P0, the performed Sanger sequencing didn’t show 
any additional mutations than the ones purposefully introduced, and plaque assays 
performed showed uniform, size-consistent plaques. 
 
2.2.3. Viral protein synthesis in infected mammalian cells 
In order to determine whether PB1-N92 and PB1-N111 were expressed in the 
context of virus replication, the WT and the majority of the mutant viral stocks were 
used to infect MDCK cells at a MOI of 10. The ΔAUG10,11 and ΔAUG5,10,11 
mutants were not tested because the stock titres were too low to carry out high MOI 
infections. Seven hours post infection (hpi), the cells were pulsed with 35S-methionine 
and at 8 hours, cell lysates were collected and fractionated by SDS-PAGE followed by 
autoradiography. No viral components were detected in mock-infected samples 
(Figure 2.5A, lane 1), whereas all infected samples showed expression of the major 
viral components: the RdRP, HA, NP, M1 and/or NS1 (lanes 2-7). Expression of these 
proteins was comparable between PR8 WT and the various segment 2 mutants.  
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Figure 2.5. Protein synthesis by PR8 WT and mutant viruses in mammalian cells. 
(A) A549 cells were infected at a MOI of 10, metabolic labelling was performed using 
35S protein labelling between 7 and 8 hpi after which cell lysates were collected. 
Lysates were subjected to SDS-PAGE and radiolabelled proteins were detected by 
autoradiography. (B) Schematic of the expression and respective sizes of PB1-related 
peptides. mRNA and proteins are represented by lines and blue rectangles, 
respectively. Green areas represent the potential V19 antibody binding region (from 
residues 50 to 370 of PB1). (C) The lysates used in (A) were used to detect PB1-related 
polypeptides by western-blot. NP was blotted as an infection control and alpha tubulin 
was used as a loading control. (D) Densitometric quantification of the different PB1-
related polypeptides from infected cells. Bands were quantified in ImageJ and 
background levels from the mock-infected sample were subtracted from the original 
values, before scaling to WT values. Data represent the mean of single technical 
repeats of two independent experiment for WT and single mutant viruses or simply 
one for the double mutants ΔAUG5,10 and ΔAUG5,11. In cases where two 
independent experiments are plotted, error bars represent SEM. 
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The same lysates were also subjected to western blot analysis using an anti-PB1 serum 
raised against amino acids 50-370 of PB1 - V19 (Digard et al. 1989). As the majority 
of the epitope residues are common to PB1 and the family of shorter products (Figure 
2.5B), V19 would be expected to detect all of them. Additional controls included the 
detection of α-tubulin as loading control, and NP was blotted to confirm infection. As 
earlier observed in Figure 2.5A, NP levels were consistent throughout all the segment 
2 mutants. Blotting with the α-PB1 V19 antibody revealed similar expression of the 
main product, PB1, for all the viruses (Figure 2.5C. PB1-N40 (82.4kDa) was also 
strongly detected in WT virus-infected cells but absent in samples in which its initiator 
codon, AUG5, was mutated (lanes 3, 6 and 7). Also visible on the blot was a pattern 
of shorter polypeptides migrating faster than the 75 kDa molecular mass marker two 
of which were clearly virus-specific and one (the fastest migrating) which was also 
present in lower abundance in the mock-infected sample. The amount of the largest of 
these polypeptide species (marked with an asterisk on Figure 2.5C) was unaffected by 
any of the AUG mutations. However, the band pattern for the middle species (labelled 
as PB1-N92, predicted molecular mass of 76.7kDa) showed a subtle reduction 
following AUG10, mutation while the smallest band (PB1-N111, predicted molecular 
mass of 74.5kDa) showed a rather clearer lowering of staining intensity in samples 
from viruses lacking AUG11.  
Densitometric analysis of replicate blots provided a more quantitative 
confirmation of this visual assessment (Figure 2.5D). Given the presence of a 
background product migrating similarly to PB1-N111 in mock-infected cell samples, 
the density of this band was subtracted from the values for PB1-N111 bands from 
infected samples. This analysis showed predictable fluctuations in the heights of the 
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various peaks according to which AUG codon had been mutated. However, while the 
deletion of AUGs 5 and 11 resulted in an 80-90% reductions in PB1-N40 and PB1-
N111 expression respectively, mutation of AUG10 led to a weaker reduction (~ 30-
50%) in accumulation of the putative PB1-N92 polypeptide. 
Overall, data from this section suggested that segment 2 AUG11 was used for 
translation initiation in the context of virus infection. However, evidence for use of 
AUG10 was more equivocal. 
 
2.2.4. Propagation of segment 2 mutant viruses in mammalian cells 
To better understand the impact of mutating AUGs 10 and 11 on viral fitness 
in mammalian systems, growth kinetic analyses were performed. MDCK cells were 
infected with the panel of viruses at a MOI of 0.001, samples were collected at several 
times post infection and titrated by plaque assays. No virus was detected in mock 
infected controls (data not shown). In MDCK cells, PR8 WT reached titres of 108 
pfu/mL by 24 hpi and then plateaued, and individual mutation of AUGs 5, 10 or 11 
did not affect viral replication at any point post infection (Figure 2.6A). The double 
mutant ΔAUG5,10 virus also showed a WT-like growth pattern, while the ΔAUG5,11 
virus showed a statistically significant attenuation at 24 hpi, but nevertheless reached 
WT-like titres by 36 hpi (Figure 2.6B). In contrast, both the PR8 ΔAUG10,11 and the 
triple mutant ΔAUG5,10,11 viruses grew only slightly more slowly than WT virus 
until 8-12 hpi but then showed a strongly attenuated phenotype with ~1000-fold 
reductions in titre between 24-48 hpi (Figure 2.6C).  





Figure 2.6. Growth kinetic analyses of PR8 WT and mutant viruses in 
mammalian cells. MDCK and A549 cells were infected at a MOI of 0.001 and 
samples were collected at the indicated times post infection. PR8 WT results are 
duplicated between panels A-C for comparison. Data represent the mean ± SEM of 
single technical repeats of three independent experiments. Statistic annotations are the 
result of an ordinary one-way ANOVA test (performed individually for each time-
point). *p-value <0.05, **p-value <0.01.  




Figure 2.7. Plaque morphologies of PR8 WT and mutant viruses. Representative 
images of PR8 WT and mutant virus plaque phenotypes in MDCK cells (A) and 
quantitative measurements of the plaque area for each virus (B). A minimum of 50 
plaques from two independent experiments were measured for each mutant virus. 
Statistic annotations are the result of an ordinary one-way ANOVA test. Multiple 




Chapter 2   
76 
As a further test of virus fitness in mammalian cells, growth in A549 cells was assessed 
at 48 hpi. In this cell line, PR8 WT titres reached 107 PFU/mL and although the single 
mutant ΔAUG5 did not quite reach this value, it was not significantly lower (Figure 
2.6D). However, in this system, discrete ΔAUG10 and ΔAUG11 mutations led to 10-
fold reductions in viral titre. A comparable 10-fold attenuation was also observed for 
the ΔAUG5,10 and 5,11 mutant viruses. Similarly to the MDCK growth kinetic 
analysis, double mutant ΔAUG10,11 and the triple mutant ΔAUG5,10,11 showed a 
1000-fold decrease in viral titre at 48 hpi. 
To further characterise the capacity of the mutant viruses to spread, virus 
propagation was assayed by assessing their ability to form lytic plaques within a cell 
monolayer. MDCK cells were infected with 10-fold serial dilutions of P1 viral stock 
and incubated under a semi-solid overlay medium. 48 hpi, cells were fixed and plaques 
visualised by toluidine blue staining. Plates were scanned and cell-absent areas were 
measured in ImageJ. WT PR8 virus gave the largest plaque size (Figure 2.7A). Plaques 
produced by the PR8 PB1-N40 knockout virus (ΔAUG5) appeared similar in size. 
However, single mutation of AUG10 or AUG11 produced an obviously smaller, 
although somewhat variable plaque phenotype compared with WT PR8. The same 
level of reduction was also found in the double (ΔAUG10,11) and triple 
(ΔAUG5,10,11) mutants. These observations were confirmed by quantification of the 
plaque size, which showed that, with the exception of ΔAUG5, the mutant viruses 
produced statistically significantly smaller plaques than the WT virus (Figure 2.7B). 
Overall, growth kinetics and plaque phenotype data confirmed the importance 
of segment 2 AUG codons 10 and 11 in supporting PR8 virus replication in vitro. 
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2.2.5. Fitness of segment 2 mutant viruses in avian systems 
The PR8 strain used in this study is a descendant of the National Institute of 
Biological Standard and Control’s vaccine strain that had been passaged six times in 
MDCK cells before cloning (de Wit et al. 2004). However, prior to that, the virus had 
had a long history of adaptation to growth in embryonated hens’ eggs. In this setting, 
viral progeny is largely a result of replication in the chorioallantoic membrane, mostly 
composed of endothelial and mesenchymal cells (Ribatti 2016). Therefore, to test the 
effects of mutating segment 2 AUG codons on virus replication in this in vivo avian 
system, 100 PFU of each virus was introduced into 10-day old eggs. Studies of IAV 
growth in eggs have typically been measured at 48 hpi (Wise et al. 2009; James et al. 
2016). However, in initial experiments using this time point, plaque phenotype and 
subsequent sequence analyses showed that reversion of the mutated AUG10 and 
AUG11 codons (particularly AUG11) from GUG back to AUG had occurred (data not 
shown). Accordingly, to reduce the likelihood and/or impact of such reversion events, 
in subsequent experiments both allantoic fluids and embryos were harvested and virus 
titres measured at 24 hpi. At this time point, instances of reversion were greatly 
reduced and the majority of the egg-grown viruses did not show restoration of altered 
AUG codons (data not shown). In cases where reversion was detected, samples were 
excluded from the analysis. 
When grown in eggs, PR8 WT reached average titres of 3×109 PFU/mL in 
allantoic fluid, and 7×105 PFU/mL in macerated embryos, albeit with a wide range of 
variation between individual eggs (Figure 2.8). PR8 ΔAUG5 replicated to comparable 
titres to the WT virus in allantoic fluids (Figure 2.8A), consistent with previous data   




Figure 2.8. Viral fitness in ovo. Ten day old hen eggs were infected with 100 PFU of 
PR8 WT or mutant viruses and viral titres of the allantoic fluids (A) and embryos (B) 
were acquired by plaque assay 24 hpi. Data points represent titres for each individual 
egg as well as mean ± SEM. Three independent experiments were performed with 4-
6 eggs infected with each virus. Statistic annotations are the result of an ordinary one-
way ANOVA test. Multiple comparisons were performed against PR8 WT. *p-value 
<0.05, **p-value <0.01, ***p-value <0.001, ****p-value <0.0001.  




Figure 2.9. Growth kinetic analyses of PR8 WT and mutant viruses in QT-35 
cells. Cells were infected at a MOI of 0.001 and samples were collected at the indicated 
times post infection. Data are mean ± SEM of single technical repeats of four 
independent experiments. PR8 WT results are duplicated across panels for 
comparison. Statistic annotations are the result of an ordinary one-way ANOVA test 
(performed individually for each time-point). *p-value <0.05.  
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from 48 hpi (Wise et al. 2009). However, replication of this mutant in embryos was 
marginally but significantly reduced, reaching an average titre of 2×105 PFU/mL 
(Figure 2.6B). In contrast to results obtained in MDCK cells, but similar to the A549 
multicycle system (Figure 2.6A and B), the single AUG mutants PR8 ΔAUG10 and 
ΔAUG11 were attenuated in both allantoic cavity and embryos compared with WT 
PR8. The double and triple mutants PR8 ΔAUG10,11 and PR8 ΔAUG5,10,11 also 
showed lower levels of replication, producing 2-2.5 log10 less virus than WT PR8. 
Thus mutation of segment 2 AUG10 and/or 11 also led to a loss of virus fitness in ovo. 
Given the pattern of gradually decreased titres from infected eggs and 
mammalian cells with the deletion of sequential segment 2 AUGs, it was hypothesised 
that this effect would be host species-independent and therefore also seen in avian cell 
lines. Accordingly, kinetic analyses were performed in quail fibroblast (QT35) cells. 
Confluent cell monolayers were infected at a MOI of 0.001, supernatants were 
collected at 6, 8, 12, 24, 36 and 48 hpi and titrated by plaque assay. Both PR8 WT and 
ΔAUG5 showed similar growth kinetics, reaching a maximum of 2×108 PFU/mL at 
36 hpi (Figure 2.9A, B). Contrary to the observation in egg allantoic fluid and 
homogenized chick embryos, the single mutants PR8 ΔAUG10 and PR8 ΔAUG11 did 
not show any attenuation in quail fibroblasts, reaching similar titres to PR8 WT (panels 
C, D), and nor did their combination with ∆AUG5 affect virus growth (panels E, F). 
On the other hand, consistent with all the replication models tested so far, the double 
deletion of AUGs 10 and 11 conferred a significant loss of replication fitness on the 
PR8 strain (panels G, H). Thus, although the sequential decrease in viral fitness from 
mutating increasingly 3’-wards AUG codons in segment 2 was not seen in quail 
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fibroblasts, attenuated viral replication was observed when both AUGs 10 and 11 were 
removed. 
Overall, endpoint and kinetic data acquired from hen’s eggs and quail 
fibroblasts supported the results from mammalian systems and reinforced the 
importance of segment 2 AUG codons 10 and 11 to virus fitness. Moreover, the genetic 
reversion of AUG 10 and/or 11 mutations detected in hen’s eggs further implied a 
critical role for these PB1 methionine codons in the IAV life cycle. 
 
2.2.6. Evaluation of the polymerase function of mutant PB1 proteins  
As shown in both mammalian and avian systems, simultaneous mutation of 
segment 2 AUG codons 10 and 11 led to a severe decrease in viral fitness. Two 
possible explanations for this were considered next: 
1. The proteins whose translation is initiated at AUG codons 10 and 11 play 
important roles during the IAV life cycle and their cumulative loss leads to a 
deficit in viral fitness. 
2. Alteration of AUG codons 5, 10 and 11 required the introduction of amino acid 
mutations within the PB1 protein: namely mutation of methionine at position 40 
to a leucine as well as methionine residues 92 and 111 to valines (Table 2.1). As 
PB1 is the core subunit of the trimeric RdRp, these mutations could lead to altered 
polymerase transcription or replication activities and thus result in the observed 
deficits in viral propagation. 
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Figure 2.10. Polymerase structure and PB1 domain organisation. The structure of 
the trimeric IAV RdRp with vRNA promoter is depicted as ribbon (A) and surface (B) 
representations. The three polymerase subunits are colour coded: PB1-blue, PB2-
magenta, PA-green. In (A), spirals represent α-helices and arrows represent β-sheets. 
Amino acids M40, M92 and M111 are also mapped on the structure and annotated in 
amber. (C) A diagram of the domain organisation of PB1 with annotated residue 
positions is also shown (Pflug et al. 2014). Influenza virus PB1 core subunit displays 
a typical viral RdRp domain organisation possessing, among others, ‘fingers’, ‘palm’ 
and ‘thumb’ regions. ‘N-ext’ and ‘C-ext’ represent the N- and C-ends of the protein, 
respectively. Amino acids M40, M92 and M111 are also annotated and belong to the 
first “fingers” region. 
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The crystal structure of a complete heterotrimeric bat influenza A polymerase 
bound to the vRNA promoter has been published, revealing similarities between the 
influenza RdRp and previously published viral polymerase structures (Pflug et al. 
2014). In particular, the PB1 central region (residues 21-669) shows a close 
resemblance to the typical right-handed RdRp fold which has been observed for other 
single-stranded RNA viruses such as hepatitis C or Norwalk viruses. This structure 
comprises fingers, fingertips, palm and thumb domains. PB1 methionine residues 40, 
92 and 111 were mapped on this RdRp crystal structure and were shown to localise to 
the PB1 fingers domain, with M111 being present at the surface of the enzyme (Figure 
2.10). Thus, alteration of any or all of the AUGs 5, 10 or 11 could be functionally 
important for PB1 function. 
As described in chapter 1, IAV genome replication and transcription occur in 
the host cell nucleus and require the formation of the RNP complex, constituted by the 
heterotrimetric polymerase in conjunction with the nucleoprotein and viral RNA 
(Portela and Digard 2002; Huang et al. 1990). Therefore, in order to determine whether 
the introduced mutations affected PB1 polymerase activity, RNP reconstitution 
reporter assays were performed. Plasmids encoding PR8 segment 2 mutants were 
introduced into highly transfectable 293T cells along with the wild type PB2, PA and 
NP segments as well as synthetic vRNA (containing negative–sense firefly luciferase 
or GFP coding regions flanked by the IAV UTRs) reporter plasmids (Lutz et al. 2005) 
(Figure 2.11 A-C). In these systems, measurement of luciferase expression or 
fluorescence levels are assumed to be directly related to viral mRNA levels and thus 
polymerase transcription activity. When using the GFP reporter plasmid, an empty 
eGFP-N1 plasmid was used as a positive control which consistently produced strong   




Figure 2.11. Mutant PB1s transcription activity. 293T cells were co-transfected 
with pDUAL PR8 plasmids expressing the protein components of the vRNP complex: 
PB2, PB1, PA and NP (A) alongside PolI driven reporter plasmids expressing negative 
strand vRNA-like GFP or firefly luciferase RNA (B and C; PolI T indicates an PolI 
transcription terminator sequence) to measure polymerase transcription activity (D and 
E). Fluorescence or luciferase activity were measured 48 hours post-transfection. In 
D, eGFP-N1 empty plasmid was used as a positive control. Data represent the mean ± 
SEM of three technical repeats from at least three independent experiments. Statistic 
annotations are the result of an ordinary one-way ANOVA test. ****p-value <0.0001. 
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fluorescence values (Figure 2.11D). A transfection control such as a plasmid 
overexpressing Renilla luciferase was not included, once the components of the 
polymerase have protein shut-off activity which could skew the ratios between the 
measurements. 
In the presence of WT RNP proteins, there was high level expression of 
fluorescence or luciferase (Figure 2.11D, E respectively), to which all the other 
measurements were scaled to. In the absence of PB1 segment (2PNP), there was a 
statistically significant decrease in reporter gene expression to background levels. 
However, regardless of the reporter plasmid system used, none of the PB1 mutants 
showed a significant difference in gene expression activity compared to WT PB1. 
As these assays were carried out with a single dose (50ng) of PB1 plasmid 
which could have potentially saturated the system, the same type of analysis was 
performed in a PB1 plasmid dose-dependent manner. In order to achieve this, the 
amounts of PB2, PA, NP and reporter plasmids were kept unchanged, but the PB1 
plasmid was titrated and the output luciferase expression values were fitted to a 
variable slope dose-response model. Luciferase measurements of samples of the 50ng 
dose of PB1 plasmids was used as maximum control (Figure 2.2A). The resulting 
curve for WT PB1 showed a plateau phase which reached 1 ng (suggesting that the 
original experimental setup could indeed have had saturating amounts of PB1), after 
which luciferase readings decreased with the reduction of added PB1 plasmid. 
Luciferase activity of the lowest dose of PB1 plasmid represented 0.1% of the original 
50ng dose. The curve for the AUG5 mutant virtually overlapped that of the WT 
enzyme (Figures 2.12A), while when AUG10 or 11 were mutated, the mutant curves   




Figure 2.12. Measurement of dose-dependent transcription activity. Luciferase 
activity was measured from RNP reconstitution assays in which the PB1 plasmid was 
titrated and all other plasmids kept constant. Normalisation was performed to the 
maximum luminescence within each individual titration set. Grey dashed lines indicate 
100% and 50% of the maximum of each individual data set. PB1 WT results were 
duplicated for comparison. Data points represent individual measurements, while lines 
are minimum squares curve fits. At least four independent experiments were 
performed each one with three technical repeats. 
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were shifted only slightly to the right of WT (Figures 2.12B). Small shifts were also 
observed when either AUG10 or AUG11 were mutated in combination with AUG5 
(Figure 2.12 C). Notably, the ΔAUG10,11 double mutant and the triple ΔAUG5,10,11 
mutant also gave curves that were very similar to that of WT PB1 (Figure 2.12D). The 
half maximal effective concentrations (EC50) values for the various PB1 plasmids were 
estimated from the curve fits, showing that all constructs were less than 2-fold different 
to the WT, including the most defective (in terms of overall virus fitness) 
∆AUG5,10,11 enzyme (Table 2.2). None of these differences were statistically 
significant, with wide overlaps of the 95% confidence intervals. However, variability 
in the replicate data points led to overall low R2 values for the curve fits, so although 
the conclusion that any of the mutants differed from the WT protein with regards to 
transcriptional activity could not be drawn, the possibility of small differences 
remained. 
To further probe the function of the mutant PB1 polypeptides, the same RNP 
reconstitution assays were performed using a firefly luciferase cRNA-like reporter 
plasmid (Figure 2.13A). In this version of the assay, viral mRNA can only be produced 
after the input cRNA molecules have been replicated to provide a vRNA template, so 
the system interrogates genome replication as well as transcription. Cells were 
transfected with the RNP components as before, lysed 24 hours later and luciferase 
expression levels measured. As expected, transfection with WT PR8 components 
resulted in high levels of luciferase expression, around 5000-fold greater than 
compared to the 2PNP negative control lacking PB1 (Figure 2.13B). However, all the 
segment 2 mutants had a WT-like polymerase phenotype in this system. 
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Figure 2.13. Measurement of mutant PB1s replication activity. 293T cells were co-
transfected with pDUAL PR8 plasmids expressing the protein components of the 
vRNP alongside a PolI reporter plasmid expressing positive strand cRNA-like firefly 
luciferase RNA (Shown diagrammatically in (A)). (B) Luciferase activity was 
measured 24 hours post-transfection. Data represent the mean ± SEM of four 
independent experiments performed in triplicate. Statistic annotations are the result of 
an ordinary one-way ANOVA test. ****p-value <0.0001. (C-F) A dose-dependent 
titration of the PB1 plasmid was performed using the cRNA-like reporter. 
Normalisation was performed to the maximum luminescence within each individual 
titration set. Grey dashed lines indicate 100% and 50% of the maximum of each 
individual data set. Data are individual points of three independent experiments 
performed in triplicate and a minimum squares curve fit. Values relative to WT PR8 
RNP reconstitution were repeated from C to F to allow comparison.
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Table 2.2. Replication and transcription activities of mutant PR8 PB1 subunits. Titration curves were used to calculate EC50, 95% 
Confidence Intervals and R2 values. Calculations were performed in Excel and GraphPad Prism software. 
PB1 construct 
Replication Transcription (Firefly Luciferase) 
EC50 (ng) 95% Cl (ng) R2 EC50 (pg) 95% Cl (pg) R2 
WT 2.086 1.42 to 3.04 0.87 239.7 148.1 to 383.2 0.49 
ΔAUG5 0.357 0.21 to 0.60 0.80 279.2 143.5 to 529.7 0.60 
ΔAUG10 2.942 1.76 to 4.69 0.82 372.9 196.3 to 675.5 0.53 
ΔAUG11 0.833 0.52 to 1.33 0.82 383.6 233.2 to 610.6 0.72 
ΔAUG5,10 0.642 0.35 to 1.26 0.74 196.0 91.6 to 413.4 0.40 
ΔAUG5,11 0.760 0.48 to 1.22 0.83 309.4 139.0 to 665.1 0.34 
ΔAUG10,11 2.038 1.35 to 3.05 0.86 288.7 179.5 to 456.1 0.77 
ΔAUG5,10,11 1.095 0.52 to 2.54 0.68 442.2 262.7 to 717.9 0.71 
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Plasmid saturation was also considered for the RNP reconstitution replication analysis. 
Therefore, to provide a more sensitive examination of PB1 replication activity, the 
amount of segment 2 plasmid was titrated and the luciferase expression values were 
fitted to a variable slope enzyme kinetic dose-response model. In this system, maximal 
activity with the WT plasmid was only reached at the highest dose tested (50ng; figure 
2.13C). The dose-response curves for the PB1 mutants were reasonably similar to that 
of the WT enzyme, with the mutants generally being shifted leftwards to slightly lower 
plasmid concentrations (Figure 2.13C-F). In this assay, the R2 values of the curve fits 
were generally satisfactory (mostly > 0.7) and several of the mutants had estimated 
EC50 values whose 95% confidence limits did not overlap with that of the WT plasmid, 
suggesting statistical significance (Table 2.2). However, with the exception of PB1 
∆AUG5, where the difference in EC50 was ~ 5-fold, the rest were within 2- to 3-fold 
of the WT plasmid, indicating, at most, only minor changes in activity. 
Although not shown in this dissertation, PB1 transcription and replication 
activity in an infection context was analysed by performing single cycle infections. 
MDCK cells were infected at a MOI of 5, virus was adsorbed for 1h at 37ºC and cells 
were subjected to an acid wash and media change. Every-two-hour time points were 
collected up to 12 hpi, and supernatants were titrated by plaque assay. Preliminary 
results from the single mutant viruses showed no differences in viral titre at any points 
post infection between WT PR8 or any mutant virus (data not shown). 
Overall, this section did not show evidence for a deleterious effect of the PB1 
amino acid mutations M92V and M111V on viral genome transcription and replication 
activity; a finding consistent with the apparently normal viral gene expression seen in 
previous experiments (Figures 2.5A and C). 
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2.2.7. Analysis of the genome packaging efficiency of segment 2 
mutant viruses 
Several regions of segment 2 that contribute to vRNA packaging signals have 
been identified. However, these have mainly been located at the 3’ and 5’ ends of 
vRNA (Liang et al. 2005; Wise et al. 2011; Marsh et al. 2008). Nonetheless, packaging 
efficiency of the segment 2 mutants was analysed. MDCK cells were infected at a 
multiplicity of 0.001. Forty-eight hpi, supernatants were clarified by centrifugation and 
viral titres were quantified by plaque assay. In parallel, vRNA was extracted from the 
same supernatants. In order to ensure consistent RNA extractions between samples, 
the lysis buffer was spiked with a consistent amount of porcine reproductive and 
respiratory syndrome virus (PRRSV; kindly provided by Dr Christine Tait-Burkard). 
RT-qPCR was then performed to detect 4 different RNA species: PRRSV genomic 
RNA and IAV segments 2, 5 and 7. Following this, the PRRSV Ct (cycle threshold) 
values were similar, varying between 17.69 and 19.88, giving confidence that the RNA 
extraction had been performed consistently (Figure 2.14A). The Ct values acquired for 
IAV segments 2, 5 and 7 were transformed into copy number using a standard curve 
and genome/PFU ratios were calculated based on the infectious viral titres (Figure 
2.14B). Assuming that each virion contains a single copy of individual segments 
(Hutchinson et al. 2010), these values could be considered as an estimate of the 
particle/PFU ratio. The values obtained for WT PR8 varied between 15 and 33 (Figure 
2.14B), which is in accordance with previous estimates of 10-100 particle:PFU 
measurements (Donald and Isaacs 1954; Hutchinson et al. 2008; Hutchinson et al. 
2010; Nakajima et al. 1979) As a positive control, a known packaging mutant was 
used. This mutant virus harbours synonymous mutations in the 5’-ends of HA (in   




Figure 2.14. Genome copy/PFU ratios of segment 2 mutant viruses. PR8 virus 
stocks were grown in MDCK cells, titrated by plaque assay and (in parallel) vRNA 
extracted after spiking with aliquots of PRRSV as an extraction control. (A) qPCR 
analysis for PRRSV showed comparable extraction efficiencies of the samples. (B) 
qRT-PCR analysis for segments 2, 5 and 7 was performed and IAV genome copy 
numbers derived in comparison to standard curves for each of the indicated segments. 
Genome/PFU values were then calculated. Data represent mean ± SEM of at least 2 
independently generated virus stocks which were analysed in duplicated in a single 
qPCR reaction (with exception with the 46c6 mutant which segments 2 and 5 were 
only analysed from one virus stock). Statistical annotations are the result of a two-way 
ANOVA test. Multiple comparisons were made against the WT virus. *p-value <0.05, 
****p-value <0.0001.  
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codons L546-A548) and NA (S451-D453) vRNA segments (Kudryavtseva 2014). 
This mutant showed an overall 10,000-fold increase in particle:PFU ratio. The segment 
2 single AUG mutant viruses showed an essentially WT-type phenotype, while double 
mutants ΔAUG5,10 and ΔAUG5,11 showed a slight augmentation in the genome/PFU 
ratio, with up to a 10-fold increase seen in segment 5 values. However, the highly 
attenuated mutants ΔAUG10,11 and ΔAUG5,10,11 had very poor particle:PFU ratios, 
with a 1000-fold or greater increases in genome copy number when compared to the 
number of infectious particles. These data suggested that, although not altering PB1 
polymerase activity, the ∆AUG mutations led to the production of virus particles with 
severely decreased infectivity, potentially associated with a modification of the 
packaging efficiency of the virus progeny. 
 
2.3. Discussion 
Previous work has shown that segment 2 of IAV expresses the accessory 
proteins PB1-F2 and PB1-N40 in addition to the canonical gene product PB1 (Wise et 
al. 2009; Wise et al. 2011; Chen et al. 2001). These non-essential minor gene products 
are translated from internal AUG codons 4 and 5 which, unlike the PB1 AUG1, are set 
in strong Kozak translation initiation contexts. Following the identification of PB1-F2, 
a first approach to knocking out its expression (to probe its biological significance) 
involved the deletion of its initiator codon (AUG 4) and the introduction of a stop 
codon at its 8th amino acid position (Chen et al. 2001). However, this second mutation 
led to a non-synonymous change in PB1 codon 40 of M to I and, as was subsequently 
shown (Wise et al., 2009), the ablation of PB1-N40 expression, thus further 
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complicating interpretation of the mutant phenotype. A further study showed that this 
double PB1-F2/PB1-N40 knockout mutant was not attenuated for growth in vitro, but 
showed diminished virulence and mortality in a mouse model (Zamarin et al. 2006). 
However, as this knockout virus had simultaneous deletion of two accessory proteins 
and a non-synonymous change in PB1, the basis of the phenotype cannot be 
unequivocally determined. Moreover, a more recent study that examined both PB1-F2 
and PB1-N40 showed that individual ablation of either protein was not 
disadvantageous for the virus, but the double deletion of PB1-F2 and PB1-N40 results 
in an attenuated phenotype in vivo (Tauber et al. 2012). These studies highlight the 
importance of accounting for potential protein expression from other AUG codons 
when designing knockout strategies in RNA regions encoding overlapping accessory 
proteins. 
In this chapter, evidence for the expression of two additional polypeptides 
species from IAV segment 2 AUG mRNA was presented. These proteins, here named 
PB1-92 and PB1-N111, are N-terminally truncated versions of the primary product, 
PB1 arising from translation initiation at AUG codons 10 and 11 respectively (codons 
92 and 111 in the mRNA), which are both in strong Kozak signalling contexts. This 
evidence was first obtained from the observation of two lower-molecular-weight 
peptides produced by plasmids containing a gene fusion between the 5’-end of segment 
2 and GFP whose expression levels altered predictably according to the presence or 
absence of AUGs 10 and 11 in this DNA-based setting. Given the caveats originating 
from the PB1-F2 knockout strategy studies discussed above, in order to minimise the 
changes within overlapping segment 2 ORFs, AUG 10 and 11 mutations were 
designed to solely affect frame 1 proteins. 
                                                                                                Segment 2 AUG codons 10 and 11 and their effects on viral fitness in vitro  
95 
GFP-tagged transcripts are useful to identify alternative translation start sites 
in a given mRNA. Nevertheless, mRNA expressed from the peGFP-N1 plasmid is 
under the control of the CMV promoter, which results in higher levels of transcription 
compared to the ones detected in infected cells. In addition to better expressed, the 
polypeptides expressed from GFP-tagged plasmids are shorter and easier to detect in 
a western-blot. 
Further evidence of translation initiation from AUG codons 10 and 11 came 
from western blotting experiments for PB1 polypeptides produced in cells infected 
with mutant PR8 viruses lacking either AUG10 or 11. Although background reactivity 
of the anti-PB1 serum with cellular and/or other viral polypeptides was a problem, 
mutation of AUG11 clearly led to loss of expression of a polypeptide of the expected 
molecular weight for PB1-N111. Weak evidence for production of PB1-N92 was also 
obtained, but the presence of a probable background species running at the same 
position prevented a clear conclusion from being drawn. Multiple attempts at detecting 
PB1-N92 and -N111 by immunoprecipitation of radiolabelled cell lysates were also 
made, but although expression of PB1-N111 could be detected (data not shown), the 
presence of PB1-N92 was either obscured by a background band or alternatively, 
insensitive to mutation of AUG10. On balance, given that previously published work 
(Wise et al. 2009; Wise et al. 2011) and the data shown here show good agreement 
between the effects on protein expression of mutating segment 2 AUGs 4, 5 and 11 in 
the background of the GFP reporter plasmid and the virus itself, it seems most likely 
that PB1-N92 is expressed by PR8, but that it cannot be detected by the approach tried 
here. 
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The fitness of segment 2 AUG mutant viruses was evaluated in a variety of 
different models. PR8 with PB1-N40 knocked out was able to replicate to WT-like 
levels in all replication systems used, in the exception of chicken embryos. Single 
mutation of AUGs 10 or 11 resulted in growth kinetics similar to WT PR8 in the 
MDCK and QT35 cell lines. These single mutations resulted in a minor, but 
statistically significant attenuation in A549 cells and embryonated hen’s eggs and 
allantoic fluids. However, the simultaneous deletion of AUGs 10 and 11 led to a 
severely attenuated phenotype in all the models tested, reinforcing the importance of 
these AUG codons during infection. 
The mutation of frame 1 AUG codons leads to the inevitable introduction of 
point mutations within the PB1 ORF (Table 2.1). Within the PB1 structure, these 
mutations sit in the fingers domain of the core polymerase. Although no function has 
been specifically associated with this domain in IAV, studies on HCV have established 
a critical role of this domain in the transition from de novo initiation with GTP to the 
elongation of the growing primer-template RNA (Mosley et al. 2012). Various 
mutational analyses on PB1 transcription and replication activities have been 
described (Chu et al. 2012; Biswas and Nayak 1994). However, these studies have 
mainly been focused of the SSDD motif and surrounding areas (residues 303 to 482), 
not including the area affected by the deletion of the AUG codons. In addition, PB1 
M111 is located at the surface of the polymerase structure. This could potentially 
compromise the interaction between PB1 and other viral and host factors, for instance 
the formation of PB1-driven polymerase-polymerase associations, leading to a 
decrease in RNA synthesis activity (Digard et al. 1989). Therefore, the introduction of 
mutations in PB1 could potentially alter overall viral gene expression and/or 
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replication and explain the attenuated phenotype of the double and triple mutants 
(ΔAUG10,11 and ΔAUG5,10,11). Therefore, genome replication and transcription 
activities of mutant PB1 specimens were assessed using cRNA- and vRNA-like 
reporter plasmids in RNP reconstitution systems. Fixed dose and dose-dependent 
assays showed no major differences in polymerase activity for any of the reporter 
systems, suggesting that the introduced changes were not detrimental for either PB1 
transcription or replication activities. These data are in agreement with the apparently 
normal levels of expression of viral proteins in cells infected with the AUG mutant 
viruses (Figure 2.5A, C) which further support a WT-like function of the mutant PB1 
polypeptides as well as indicating that RNP function is not dependent on the shorter 
PB1 peptides. Nonetheless, the ΔAUG5 data reported here does not recapitulate the 
replication deficit in the PB1-N40 knockout system previously shown by Tauber et al. 
2012. However, that study was developed only using the A/Wilson Smith Neurotropic 
/1933 (H1N1) virus (WSN), while our data originated from the PR8 strain, which 
could potentially explain the discrepancy between the two studies. 
PB1 interacts with the PA polymerase subunit though its N-terminal domain. 
This region is not present in PB1-N40 which has previously been shown to lack 
detectable transcription function (Wise et al. 2009). Therefore the further loss of 
functionally important sequences in PB1-N92 and -N111 would strongly predict that 
these would also be non-functional as polymerase subunits. However, these 
polypeptides share the PB1 C-terminal PB2 interaction site (Poole et al. 2007; Toyoda 
et al. 1996; Ohtsu et al. 2002; Gonzalez et al. 1996; Pflug et al. 2014). Moreover, 
studies on segment 2 accessory proteins have shown that the absence of PB1-N40 
expression also has a negative effect on the viral polymerase (Tauber et al. 2012), 
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making it possible to hypothesise the potential association of PB1-N92 and/or -N111 
with polymerase functions. Nevertheless, transcription and replication activity of the 
polymerase in the absence of the initiation codons of these peptides is not altered, 
therefore discarding this hypothesis. 
Apart from amino acid changes, the introduced mutations involved the 
alteration of the vRNA. In addition to containing essential sequences for viral 
transcription and genome replication initiation, conserved vRNA motifs have been 
suggested to be functionally important as packaging signals and to be involved in 
RNA-RNA interactions (Kobayashi et al. 2016; Marsh et al. 2008; Gog et al. 2007; 
Cobbin et al. 2014; Liang et al. 2005; Liang et al. 2008). The 3’ and 5’ ends of segment 
2 vRNA (vRNA2) have been widely shown to be highly conserved and essential for 
adequate packaging of vRNPs (Liang et al. 2005; Liang et al. 2008; Cobbin et al. 
2014). Although AUGs 10 and 11 are not included within these packaging signals, 
they are highly conserved (Gog et al. 2007; Gong et al. 2014). Furthermore, functional 
sequence-specific interaction analysis between genomic vRNA segments showed 
inter-vRNA interactions of nucleotides 125-384 in vRNA2 (region which include both 
AUGs 10 and 11 codon) and 256-435 of segment 8 vRNA (vRNA8), suggesting the 
co-packaging of these two segments. Moreover, this interaction is of an almost perfect 
complementarity with vRNA8 between nucleotides 289-309 of vRNA2, which 
includes AUG 10 (Gavazzi et al. 2013). Viruses harbouring mutations in these regions 
presented a packaging defect and lower viral titres in comparison to their WT 
counterpart. However, this study was conducted using an avian H5N2 virus 
(A/Finch/England/2051/91). In PR8, complementarity between vRNA2 289-309 and 
the supposedly equivalent region in vRNA8 was seen in solely between 3 nucleotides 
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which are not included in the AUG10 codon (data not shown). Accordingly, 
measurements of genome copy:PFU ratios of the single mutant PR8 ΔAUG10 
suggested a WT-like packaging efficiency. Unexpectedly, a dramatically increased 
genome copy:PFU ratios were seen in the double and triple mutants; similar to those 
seen with a bona fide packaging mutant created by deliberate mutation of conserved 
segment terminal sequences thought to be likely candidates for segment-specific 
packaging signals (Gog et al. 2007; Kudryavtseva 2014). However, the “4c6c” 
packaging mutant contains a total of 9 nucleotide substitutions across 2 segments that 
act synergistically to create a highly defective virus (Kudryavtseva 2014). For a 
genome packaging defect to explain the results obtained here with the segment 2 
mutations would require that the two nucleotide changes required to mutate both 
AUGs 10 and 11 to act synergistically, as the phenotype was not strongly present in 
the single ΔAUG 10 or 11 mutants or in the double mutants ΔAUG5,10 and 
∆AUG5,11. Another possible explanation could be the surface-exposed change of PB1 
amino acid M111, which could lead to the diminished interaction of PB1 with other 
viral proteins involved in genome packaging. However, again, the largest increase in 
genome to PFU ratios was seen in the double and triple mutants ΔAUG10,11 and 
ΔAUG5,10,11 and not in the ∆AUG11 single mutant. Therefore it is unlikely that the 
surface M111 amino acid is the cause of the packaging deficiency of the mutants 
ΔAUG10,11 and ΔAUG5,10,11. Alternatively, it is possible that the defect in genome 
copy:PFU ratio seen here for the segment 2 mutants is not the result of a packaging 
defect, but instead represents a deficit in efficiency of plaquing (EOP) arising from 
some other mechanism. Additional thoughts on packaging deficiency will be discussed 
in following sections. 
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Overall, the data described in this section adds an additional polypeptide to 
the list of IAV accessory proteins. Functional studies of these peptides in the context 
of in vitro and in vivo infections and their conservation in IAV field isolates will be 














3.1. Background and aims 
As described in the previous chapter, AUGs 10 and 11 in IAV segment 2 
constitute translation initiation sites and lead to the expression of PB1-N92 and PB1-
N111. Moreover, viruses harbouring mutations that simultaneously ablated expression 
of these two peptides showed significantly attenuated viral fitness, despite the WT-
like RNA replication and transcription activities of the altered PB1 proteins. However, 
as shown in Figures 2.6 and 2.9, although diminished at later time points, propagation 
of the PR8 ΔAUG10,11 and ΔAUG5,10,11 viruses was comparable to WT PR8 at 6-
12 hpi. Previous studies have detected IFN-β mRNA expression induction as early as 
4 hours after polyinosinic:polycytidylic acid (poly I:C) treatment (Abe et al. 2012) and 
IFN secretion and STAT1 phosphorylation have been detected at 8 hpi following IAV 
infection (Liedmann et al. 2014b). Therefore we hypothesised that the attenuated 
viruses might either lack an IFN counteraction mechanism or provoke stronger IFN 
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induction; both of which could result in the observed phenotype of attenuated virus 
replication at later times. 
Hence, this second chapter aimed to determine other reasons behind the 
severely attenuated phenotypes of viruses with the ΔAUG10,11 lesions, bearing in 
mind the biphasic pattern of multicycle replication kinetics and thus focusing on host 
type I IFN responses. IFN sensitivity and IFN induction by the segment 2 mutant 
viruses were assessed. PB1-related defects which could be associated with an IFN 
response were also be approached. Moreover, IFN-defective systems were used to 
assess viral fitness in the absence of a fully established type I IFN response. 
 
3.2. Results 
3.2.1. Quantification of type I IFN production during infection with 
segment 2 mutant viruses 
As a first test of the hypothesis that the severely attenuated phenotype of 
segment 2 mutant viruses resulted from a failure to control cellular innate immune 
responses, the levels of active type I IFN secreted during infection with WT and mutant 
viruses were measured. To do so, a reporter cell line (HEK-Blue IFN-α/β cells) was 
used. These cells express human secreted embryonic alkaline phosphatase (SEAP) 
under the control of the ISG54 promoter (https://www.invivogen.com/hek-blue-ifn-
ab) (Bluyssen et al. 1994). Therefore, SEAP expression can be detected upon 
JAK/STAT signalling and ISRE activation which is induced by exogenous type I IFN. 
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The experimental design involved the infection of the human IFN-competent 
A549 cell line at a range of multiplicities (3, 0.3, 0.03 and 0.003). Twenty-four hpi, 
cell supernatants were collected and half was UV-treated in order to inactivate 
infectious viral particles. Treated and untreated supernatants were then added to HEK-
Blue reporter cells and after a 24 hour incubation, the levels of secreted SEAP were 
measured by absorbance at 600nm following addition of substrate (summarised in 
Figure 3.1A). To test the success of the original infection rates, cells were fixed, 
permeabilised and immunostained for the presence of NP at 24 hpi. Mock-infected 
cells showed no NP-positive staining, while at MOI 3, the majority of the cells were 
positively stained (Figure 3.1B). Approximate 10-fold drops in infection levels were 
observed for MOI 0.3 and the two lower multiplicities, thus verifying the variable 
MOIs of infection. The success of the UV-treatment was also tested. Pre- and post-UV 
treatment cell supernatants were titrated by plaque assay. Mock-infected cells showed 
no detectable titre (Figure 3.1C) while MOI 3 infections produced viral titres of 107 
PFU/mL. As observed for the proportion of infected cells, the titres of released virus 
also showed approximate 10-fold reductions between each multiplicity step. In 
contrast to the non-treated supernatants, the infectious particle load for UV-treated 
samples was below detectable levels, confirming an efficacious inactivation. 
Once the assay foundations had been established, the levels of type I IFN 
induction upon infection with the panel of the different PR8 segment 2 mutants were 
quantified. Experimental design was performed as in Figure 3.1A. Varying 
concentrations of universal type I IFN were also incubated with the HEK-Blue cells to 
create a standard curve (Figure 3.2). SEAP secretion levels increased with IFN 
concentration, demonstrating that the HEK-Blue cells were responding to exogenous  




Figure 3.1: Establishment and validation of the HEK-Blue cell type I interferon 
reporter assay. (A) Schematic diagram of the protocol. (B) A549 cells were infected 
at decreasing multiplicities. Twenty-four hpi cells were fixed and immunofluorescence 
against viral NP was used to test the success of infection. Nuclear staining was 
achieved by DAPI staining which is shown in blue. Micrographs shown are a 
representation of one of the independently performed experiments. (C) Cell 
supernatants from the previous infection were collected and one half was UV-treated 
to inactivated infectious virions. Effective inactivation was assessed by plaque assay. 
Viral titres pre- and post-UV inactivation for PR8 WT infections for the different 
MOIs used are shown. Data represent mean ± SEM of at least three independent 
experiments with single technical repeats and the dotted line represents the assay limit 
of detection (2 PFU/mL).  
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type I IFN. Negative controls included supernatants from mock-infected A549 cells, 
HEK-Blue cells only and SEAP assay substrate only which set the background levels 
of the assay; approximately equivalent to 5 U/mL of the universal type I IFN. A549 
cells infected with PR8 WT did not produce IFN above this background level, 
regardless of the MOI. As a positive control, a PR8 NS1 RNA-binding mutant virus 
was used - NS1 residues R38 and K41 were mutated to alanines (R38K41A - 
mutagenesis performed by Dr Helen Wise) - which is known to be deficient in IFN 
antagonism (Talon et al. 2000; Newby et al. 2007; Gack et al. 2009; Turnbull et al. 
2016). As expected, a strong type I IFN induction was observed when A549 cells were 
infected with this virus, at MOI 3, 0.3 and 0.03, while infection at MOI of 0.003 only 
resulted in background IFN levels. In general, levels of IFN induction were higher in 
the non-UV treated samples for all mutant viruses and MOIs (compare figures 3.2A 
and B). In the absence of UV treatment, all viruses with mutated AUG codons induced 
statistically significant higher IFN levels than the WT virus after infection at MOI 3, 
with a gradient of ∆AUG5,11 > ∆AUG5,10 ~ ∆AUG11 > ∆AUG10 > ∆AUG5. 
However, for UV-treated samples, this increased induction was only statistically 
significant for the double mutants ΔAUG5,10 and ΔAUG5,11 when compared to WT 
PR8 (Figure 3.2A). High multiplicity infections with the double and triple mutants 
ΔAUG10,11 and ΔAUG5,10,11 were not possible due to the low titres of the P1 stocks 
(as described in the previous chapter). Therefore, infections with these viruses could 
only be performed at MOI of 0.003. Nevertheless, for these infections a stronger IFN 
induction was also observed when compared to PR8 WT infections at the same 
multiplicity (Figure 3.2A). Similarly to the remaining mutants, a more pronounced 
(and statistically significant) difference was also observed in non-treated samples  




Figure 3.2: Measurement of Type I IFN induction during infection. HEK-Blue 
cells were treated with supernatants from A549 cells infected with the PR8 segment 2 
mutant virus set or PR8 NS1 R38K41A at MOIs of 3, 0.3, 0.03 and 0.003. Twenty-
four hpi, cell supernatants were inactivated and incubated with HEK-Blue cells for a 
further 24 hours, after which SEAP activity was measured by measuring absorbance 
at 600nm (A600). A600 for inactivated (A) and non-inactivated (B) supernatants are 
shown. Data represent mean ± SEM of at least four independent experiments 
performed in duplicates. Statistical symbols represent individual one-way ANOVA 
tests performed between mutant viruses used at the same MOI. Dunnett’s multiple 
comparison tests were performed having WT PR8 as control. *p-value <0.05, **p-
value <0.01, ***p-value <0.001, ****p-value <0.0001.  
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Figure 3.3: A549 virus titres pre-UV treatment. Supernatants collected from the 
different MOI A549 infections (from Figure 3.3) were titrated by plaque assay. Data 
represent mean ± SEM of four independent experiments performed in duplicates and 
the dotted line represents the assay limit of detection. Statistical symbols represent 
one-way ANOVA tests performed within each MOI. Multiple comparison tests were 
performed with WT PR8 as control. *p-value <0.05, **p-value <0.01, ***p-value 
<0.001, ****p-value <0.0001. 
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(Figure 3.2B). 
As noted above, non-UV treated samples gave an overall stronger response 
compared to the treated supernatants. However, the increased levels of SEAP by HEK 
Blue cells could potentially be explained by the accumulation of type I IFN secreted 
by A549 cells and additional IFN being expressed by HEK Blue cells when infected 
by infectious viral particles released from the previous A549 infection. Therefore, 
supernatants from the A549 infection were titrated, to assess if such a mechanism 
might have skewed the outcome because of major differences in virus titre (Figure 
3.3). Mock-infected cells did not show detectable infectious particles (the limit of 
detection was 2 PFU). WT PR8 titres ranged from ~ 107 down to ~ 104 PFU/ml, 
decreasing around 10-fold with each 10-fold reduction of MOI. When infected at MOI 
3, concordant with previous infections in A549 cells, the segment 2 mutants produced 
slightly reduced viral titres (Figure 3.3A). At the other MOIs, with the exception of 
the ΔAUG5 virus at MOI 0.3 (Figure 3.3B), all mutants showed equivalent or lower 
titres than WT PR8, despite showing equal or higher type IFN induction levels. 
Therefore, with exception of the ΔAUG5 mutant, it was possible to associate the 
increased levels of IFN induction to deficiencies in the mutant viruses and not to 
greater stimulation of the reporter cell line by higher amounts of infectious viral 
particles. 
In global terms, this set of data allowed the conclusion that segment 2 mutant 
viruses provoked a stronger induction of the type I IFN response in comparison to their 
WT counterpart. 
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3.2.2. Ability of segment 2 mutant viruses to replicate under 
established antiviral conditions 
Given the increased IFN induction in ΔAUG mutant virus infection, we next 
evaluated whether these mutant viruses would replicate in the presence of an 
established IFN response, using cells that had already been stimulated with type I IFN. 
A549 cells were preincubated for 20 hours with different concentrations of universal 
type I IFN prior to a 48-hour infection at a MOI of 0.001 with PR8 WT and the 
different segment 2 mutant viruses. Virus titres of infected cell supernatants were 
determined by plaque assay, and titres were scaled to those from the no IFN control 
(Figure 3.4A-D). The replication of most viruses was unaffected by IFN 
concentrations of 10U/mL and below while high concentrations of universal IFN 
preincubation (300 U/ml and above) inhibited virus replication by several orders of 
magnitude, relative to the no-IFN control samples. In general, the single ∆AUG 
mutants and the double ∆AUG5,10 and 5,11 mutants appeared more sensitive than WT 
virus and fitting of dose-inhibition curves showed shifts to the left of WT (Figures 
3.4A-C). Within these mutants, although not substantially different, the most 
pronounced shift was observed for PR8 ΔAUG11, followed by the ΔAUG10 and 
ΔAUG5 viruses. Similar shifts were observed with the double mutants ΔAUG5,10 and 
ΔAUG5,11 (Figure 3.4C). The ΔAUG10,11 and ΔAUG5,10,11 mutants showed a 
comparable magnitude but surprising rightwards shift compared to WT PR8, 
especially at higher IFN concentrations (Figure 3.4D). From the fit curves, half 
maximal inhibition concentrations (IC50) values were estimated. These varied between 
12.3 and 19.8U/mL, with a trend towards lower values for the viruses lacking AUGs 
10 and 11 (Figure 3.4E). However, due to the variability of the data, differences  
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Figure 3.4: Ability of viruses to replicate in the presence of pre-established 
antiviral conditions. (A-D) A549 cells were pre-treated with the plotted 
concentrations of universal type I IFN for 20h followed by infection with PR8 WT and 
mutant viruses at MOI 0.001 for 48 hours. Virus in the supernatant was titrated by 
plaque assay. Plotted data are percentage of the no-IFN control for each virus of single 
technical repeats from three independent experiments. Dashed lines indicate 50 and 
90% inhibition levels. WT PR8-relative data is repeated between panels for 
comparison. Data represent individual data points and respective curve fits. (E and F) 
From curve fits, IC50 and IC90 values were calculated. Plotted data are mean ± SEM 
of the three independent experiments performed with a single technical repeat. 
Multiple comparison (one-way ANOVA) tests were performed using WT PR8 as 
control. NS: Non-significant.  
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between WT and segment 2 mutant, viruses were not statistically significant. IC90 
values were also calculated, but again with no statistically significant differences found 
between the different mutant viruses (Figure 3.4F). Therefore, although inducing 
stronger type I IFN levels, these data did not indicate that the segment 2 mutant viruses 
were less able to replicate in the presence of a pre-established ISG response. 
 
3.2.3. Assessment of innate immune recognition of mutant vRNPs 
As described in chapter 1, the IAV panhandle has been suggested to act as a 
potent RIG-I ligand, supported by (for instance) the induction of IFN by 
transcriptionally active RNPs reconstituted in cells through plasmid transfection 
(Rehwinkel et al. 2010). This 5’ppp RNA PAMP is normally hidden by the polymerase 
trimer (Klumpp et al. 1997). Given that PB1 binds to vRNA (Gonzalez and Ortin 1999; 
Pflug et al. 2014), point mutations in PB1 were hypothesised to potentially jeopardise 
this role, resulting in an increased number of exposed panhandle RNA structures, a 
stronger RIG-I stimulation and the observed type I IFN induction. To test this, RNP 
reconstitution assays were performed and the levels of IFN induction examined. 
Various amounts (ranging from 10 to 50ng) of pDUAL plasmids encoding the RNP 
components were transfected into 293T cells. Forty-eight hours post transfection, the 
supernatants were removed from cells and incubated with HEK Blue cells for 24 hours, 
after which the levels of SEAP were measured (Figure 3.5). Mock transfected and 
HEK Blue-only conditions showed low absorbance levels and were used to determine 
the background of the assay (< 50 IFN U/mL). The negative control where the PB1-
coding plasmid was replaced by an empty pDUAL plasmid (2PNP) resulted in  





Figure 3.5: Assessment of IFN induction triggered by WT and mutant RNPs. 293T cells were transfected with 10, 30 or 50ng of each 
pDUAL plasmids encoding the individual components of the RNP complex alongside 4, 12 and 20ng of reporter vRNA-like plasmid, 
respectively. Forty-eight hours post transfection, IFN levels were measured using the HEK Blue cell assay. Data represent mean + SEM of 
at least 3 independent experiments performed in triplicates. 
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background levels of IFN induction, confirming as expected (Rehwinkel et al. 2010) 
that the levels of 5’-ppp-containing vRNA produced by RNA Pol I transcription of the 
pDUAL plasmids was not enough to provoke an IFN response. In contrast, all active 
RNP (3PNP)-containing samples showed a dose-dependent IFN induction that 
increased with the amount of transfected plasmid (50ng>30ng>10ng). However, 
comparison of IFN induction between WT and mutant RNP reconstitutions did not 
show any statistically significant differences at any of the plasmid doses tested. These 
data did not support the hypothesis of a stronger detection of the RNA “panhandle” 
associated with the mutant PB1 subunits. 
 
3.2.4. Fitness of segment 2 mutant viruses in IFN-defective systems 
Given the pronounced IFN induction by segment 2 mutant viruses and their 
reduced propagation in INF-competent in vitro systems, it was hypothesised that 
mutant viruses might recover fitness in IFN defective systems. The first IFN-defective 
system investigated was embryonated chicken eggs at early stages of development. 
Chick embryos lack many mechanisms required to recover from viral infections such 
as the production of antibodies and delayed type sensitivity (Simonsen 1957; Trnka 
and Riha 1959). Furthermore, IFN inducibility and responsiveness only develop from 
day 8 and become stronger from then onwards (Isaacs and Baron 1960). Moreover, a 
correlation between the lethality of viral infections and the absence of a developed IFN 
system in early development chicken eggs has been noted (Baron and Isaacs 1961).  
Here, it was aimed to assess whether the attenuated viruses ΔAUG10,11 and 
ΔAUG5,10,11 propagated better in chicken eggs at an earlier developmental stage.   
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Figure 3.6: Virus growth in early development hen’s eggs. Eggs at development 
days 6, 7, 8 and 10 were infected with 100 PFU of PR8 WT, ΔAUG10,11 or 
ΔAUG5,10,11. Twenty-four hpi, allantoic fluids (A) and embryos (B) were collected 
and viral titres were measured by plaque assay. Data represent individual viral titre 
data points scaled to WT PR8 from 3 independently performed experiments (total 
number of data points varies between 18 and 24). Statistical annotations represent the 
result of a two-way ANOVA test. Multiple comparisons were performed against WT. 
*p-value <0.05, **p-value <0.01, ***p-value <0.001, ****p-value <0.0001.  
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The allantoic cavity of 6, 7, 8 and 10 day old eggs was infected with WT, ΔAUG10,11 
and ΔAUG5,10,11 PR8 viruses. Twenty-four hpi, eggs were humanely killed by 
overnight 4ºC incubation. Allantoic fluids and embryos were collected, the latter 
macerated and both titrated by plaque assay. WT PR8 replicated to titres of 109 and 
107 PFU/mL in allantoic fluid and embryos, respectively, showing no relationship to 
the egg development stage (data not shown). The average of these titres (within each 
independent experiment) was used to scale the titres for PR8 ΔAUG10,11 and 
ΔAUG5,10,11 egg infections at the different days of development (Figure 3.6). In 
contrast to WT PR8, the replication of the mutant viruses was egg development stage-
dependent. As shown in section 2.2.5. Fitness of segment 2 mutant viruses in avian 
systems, allantoic fluid titres of PR8 ΔAUG10,11 and ΔAUG5,10,11 were 
significantly reduced in comparison to WT PR8 in 10 day-old eggs, replicating, on 
average, to approximately 1% of the WT virus titre (Figure 3.6A). A similar outcome 
was observed when these mutant viruses were used to infect 8-day eggs. The double 
mutant ΔAUG10,11 presented slightly (but not statistically significant) lower titres in 
8-day old allantoic fluids, while the triple mutant showed an equivalent phenotype 
when compared to 10-day old infections. However, higher titres of these two viruses 
were observed when infecting pre-day 8 eggs. An at least 10-fold increase in titre was 
seen when comparing viral titres from 7- with 8-day old allantoic fluids from eggs 
infected with either mutant virus. An additional, not as pronounced, increase in viral 
titre was also observed between 7- and 6-day old allantoic fluids. Similarly to in 
section 2.2.5., embryo viral titres were also acquired from these infections (Figure 
3.6B). These titres were more variable than the ones obtained from the allantoic fluids. 
In this case, WT PR8 replicated to 107 PFU/mL in 6-day old eggs, but only to 106 
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PFU/mL in 10-day old eggs (data not shown). Nonetheless, given the variability of the 
data, this difference was not statistically significant. After scaling the viral titres of the 
mutant viruses to those of PR8 WT, the expected growth pattern was observed for the 
embryo titres of the mutant viruses; a 100-fold reduction in comparison to WT PR8 in 
10-day old embryos. Overall, although still statistically significantly diminished in 
comparison to PR8 WT, an increased replicative fitness of the attenuated viruses was 
observed in all egg ages under 10-days old. However, unlike what was observed in 
allantoic fluid titres, a 10-fold increase in virus fitness was seen in 8-day old embryos. 
Similarly to in allantoic fluids, this fitness increase also progressed in 7- and 6-day old 
eggs. 
The second IFN-defective system used was type I IFN receptor knockout 
(IFNAR-/-) bone marrow-derived macrophages (BMDM) as described in section 8.3.3. 
Isolation of bone marrow-derived macrophages. The suitability of macrophages as a 
model cell type to access ex vivo IAV infection is arguable as IAV primarily targets 
airway and alveolar epithelial cells and the use of those could have constituted a more 
clinically relevant cell type. However, the main objective was to compare naïve and 
IFNAR-/- conditions. BMDMs were mainly chosen given the existence of an already 
established extraction and differentiation protocol available in the laboratory and the 
fact that they were previously known to be susceptible to PR8 infection. BMDMs were 
prepared from the femurs of female 129Sv/Ev and IFNAR-/- mice (Muller et al. 1994) 
and infected at a multiplicity of 0.001. Supernatants were collected at different points 
post infection and titrated by plaque assay (Figure 3.7). WT PR8 replicated with 
similar kinetics in WT and IFNAR-/- BMDMs, with the exception of a non-statistically 
significant 1 log10 difference observed at 24 hpi, reaching titres of 10
7 PFU/mL in both   
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Figure 3.7: Growth kinetics of PR8 WT and segment 2 mutants in bone marrow-derived macrophages. WT and IFNAR-/- BMDM 
were infected at a MOI of 0.001. Supernatants were collected at various times post infection and viral titres were determined by plaque assay. 
Data relative to WT PR8 is repeated between panels to allow comparison. Data represent mean ± SEM of two technical repeats from at least 
3 independent experiments (each experiment was performed with an independently extracted and differentiated batch of BMDMs). Statistic 
annotations are the result of t-tests performed individually for each time-point and WT and mutant virus between WT and IFNAR-/- BMDM. 
*p-value <0.05, ** p-value <0.01.   
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cell types (Figure 3.7A). In this system, single mutation of AUG5 gave comparable 
end-point titres to the WT virus but showed a 2-log10 attenuated growth at 24 hpi in 
WT macrophages, which was fully restored by the IFNAR knockout (Figure 3.8B). 
Single mutants ΔAUG10 and ΔAUG 11 replicated less throughout the entire span of 
infection in WT macrophages, with 1000-fold reductions in titres at 24 and 36 hpi and 
a 10-fold lower end-point titre (Figure 3.7 C and D). Like PR8 ΔAUG5, this 
attenuation was not present in IFNAR-/- BMDMs, with both viruses reaching WT-like 
titres at 24, 36 and 48 hpi. Similar behaviour was seen for the double mutants 
ΔAUG5,10 and ΔAUG5,11 (Figure 3.7 E and F), although it was noticeable that the 
ΔAUG11 containing mutants were slightly more attenuated than their ΔAUG10 
counterparts. Replication of PR8 ΔAUG10,11 and ΔAUG5,10,11 in WT BMDMs was 
especially attenuated throughout the entire course of the growth curve, reaching peak 
titres more than 10,000-fold lower than WT PR8 at the 48 hpi end point. However, in 
the IFNAR-/- cells, replication of the ΔAUG10,11 and ΔAUG5,10,11 was much 
improved, with both viruses achieving end-point titres of ~106 PFU/mL (Figure 3.7 G 
and H). Nevertheless, this recovery was not complete, with these mutant viruses 
showing 10-fold lower viral titres than WT PR8 in the knockout cells at any given 
timepoint post-infection. Thus overall, the ∆AUG mutant viruses showed replication 
defects in the BMDMs that were either not present or substantially less severe when 
the cells were unable to respond to type I IFN. 
Globally, the improved growth fitness of segment 2 mutant viruses in the IFN-
defective systems tested: early development eggs and IFNAR-/- BMDMs, was 
consistent with the previous data showing their increased IFN induction and supported 
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Having identified novel translation products from IAV segment 2, the function 
of said peptides became the next question. The use of an engineered cell line allowed 
the measurement of type I IFN induction from WT- and the ΔAUG- infected cells. 
These assays showed increased levels of IFN secreted from cells infected with 
ΔAUG5, 10, and most pronouncedly with ΔAUG11-containing viruses. However, 
these mutant viruses didn’t seem to be more sensitive to IFN treatment which might 
indicate a problem with IFN induction rather than aggravated sensitivity to particular 
ISGs. 
The attenuated phenotype of ΔAUG10 and/or 11 viruses seen in data from 
recovery experiments described in chapter 2, has now the caveat that virus stocks 
themselves contain varying levels of type I IFN, which may have effects on the 
subsequent infection of fresh cell monolayers. However, the viral stocks were prepared 
from canine cells and much of the growth kinetics presented in chapter 2 as well as all 
the IFN-related experiments described in this chapter were performed in human cells 
which are not responsive to canine IFN (data not shown). 
Stronger IFN induction generally correlates with increased upregulation of 
hundreds of ISGs, some of which have well known antiviral properties. An example 
of one is BST2/tetherin which has been shown to restrict the release of several viruses 
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by retaining newly-formed enveloped viruses at the cell surface. However, the 
inhibitory effects of tetherin against IAV infection has not been fully elucidated, with 
disagreement between different studies (Gnirss et al. 2015; Watanabe et al. 2011). 
However, an additional ISG involved in the late stages of infection is CIG5/viperin. 
Viperin was shown to perturb lipid rafts and inhibit IAV packaging/release (Wang et 
al. 2007). Moreover, serpin1 was also shown to modify the extracellular environment 
and prevent IAV maturation (Dittmann et al. 2015). Hence, one can speculate that the 
observed upregulation of type I IFN upon infection with PR8 ΔAUG10,11 and 
ΔAUG5,10,11 can lead to the overexpression of these three ISGs, which combined 
affect may contribute to the packaging-deficient phenotype of these double and triple 
mutants, previously described in section 2.2.7. 
The increased IFN induction by ΔAUG mutant viruses could be attributed to 
different reasons: 
1. As previously mentioned earlier in chapter 2, the introduction of ΔAUG mutations 
translates into single amino acid mutations within the PB1 protein. Therefore, the 
observed IFN induction could be due to PB1-related defects such as greater 
sensing of the viral RNA panhandle by RIG-I due to a mutated PB1. However, 
data presented in this chapter suggested that IFN induction from mutant vRNPs 
was unaltered when compared to WT vRNPs. However, detection of panhandle 
from mutated cRNPs was not assessed and further assays to fully determine the 
implications of the detection of viral RNA could be tested by using RIG-I 
knockout cell lines. 
2. The mutated polymerase can result in greater DVG formation and lead to the 
increased IFN induction. This hypothesis is consistent with the high genome/PFU 
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ratios described in section 2.2.7, once the oligonucleotides used to measure the 
number of genomes were designed against the 3’ end of vRNA which has been 
shown to be present in both DVGs and complete vRNAs (Gog et al. 2007; Nayak 
1980; Nayak et al. 1982). However, specific measurement of DVGs in segment 2 
of other segments was not performed and a more detailed qPCR and or sequence 
analysis would be necessary to fully address this theory. 
3. Mutations introduced in PB1 jeopardise its IFN antagonist function. As described 
in chapter 1, studies on the polymerase and the IFN response have suggested that 
the viral polymerase complex exhibited an inhibitory activity on IFN-β promoter 
activation through the interaction of PB2 with MAVS (Iwai et al. 2010) or the 
interaction of the PB1-PA dimer of incoming vRNPs with RIG-I at the very first 
stages of infection (Liedmann et al. 2014b). Although not inducing a stronger IFN 
response (according to results in section 3.2.3), the mutant vRNPs can potentially 
also be defective in this pre-packaged IFN inhibition mechanism. 
4. The shorter forms of PB1 hold IFN antagonist function and their ablation hinders 
that control. Considering the lack of expression of PB1-N92 and –N111 from the 
ΔAUG10 and ΔAUG11 viruses, the over induced type I IFN expression can also 
be associated with these two polypeptides. Given the sequence overlap of PB1 
and its shorter products, PB1 mutations downstream of amino acids 91 and 111 
are also present in PB1-N92 and/or PB1-N111. Recent genome-wide studies 
showed that the point amino acid mutation in PB1 L155H is associated with IFN 
sensitivity (Du et al. 2018). The WT leucine is a highly conserved amino acid 
(although coded by varied codons) and is shared by ORFs of all four PB1-related 
polypeptides (Gog et al. 2007). However, mutation of this residue in the 
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background of WSN did not lead to increased levels of IFN-β, compared to its 
WT counterpart (Du et al. 2018). 
To further correlate the increased IFN induction with the attenuated phenotype 
of segment 2 mutants, viral fitness was assessed in IFN defective systems 
(embryonated eggs under development day 8 and murine IFNAR-/- BMDM) where, in 
general terms, there was a better propagation of the mutant viruses, in comparison to 
the IFN competent counterpart. The obtained recovery in underdeveloped eggs 
correlated with previous studies of influenza B virus (IBV) NS1 which involved the 
use of 6, 8 and 11day old eggs to assess viral fitness. In these, wild-type IBV replicated 
to high titres in embryonated eggs regardless of their development age. In contrast, the 
growth of IBV ΔNS1 virus gradually declined with the increasing age of the eggs 
(Dauber et al. 2004). 
Overall, this chapter revealed reasons behind the attenuation of the segment 2 
AUG mutants – a stronger induction of type I IFN. The implications of this over 












In vivo studies with segment 2 mutant viruses 
__________________________________________________________ 
 
4.1. Background and aims 
The previous chapters characterised the segment 2 mutants in vitro, concluding 
that the ablation of PB1-N92 or/and PB1-N111 expression by the mutation of their 
initiator codons, lead to the attenuation of virus replication in several model systems. 
Moreover, these mutant viruses were shown to more strongly induce the type I IFN 
response, compared to their WT counterpart. Furthermore, replication of the attenuated 
mutants recovered in IFN-defective systems. 
In vivo studies in murine models have been used to characterise important roles 
of IAV accessory proteins in pathogenesis, disease progression and viral fitness 
(Yamayoshi et al. 2016; Wise et al. 2012; Jagger et al. 2012). Therefore, since it was 
possible that the phenotype of the ∆AUG mutants resulted from loss of an accessory 
gene product, this chapter assessed whether: 
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 The discrepancy in viral replication and the recovery of the attenuated mutant 
in an IFNAR-/- context was also seen in an in vivo model; 
 The attenuated replication of the ΔAUG10,11 virus was reflected in its 
virulence; 
 Cytokine profiling in the context of viral infection corroborated the differences 
found in the viral titres and observed pathology. 
To answer these questions, 129Sv/Ev WT and IFNAR-/- mice were infected 
with WT or ΔAUG10,11 PR8 viruses. These mice lack the type I IFN receptor and 
therefore do not respond to IFN α or β (Muller et al. 1994). Weight loss was measured 
at two different infection doses, while virus replication and IFN-β expression were 
assessed from infected lung tissues and histopathology analysis was carried out on 
H&E stained sections. Finally, innate immune and cytokine responses were also 
assessed by analysis of lung homogenates. 
 
4.2. Results 
4.2.1. Weight loss of infected 129Sv/Ev WT and IFNAR-/- mice 
To first assess the ability of the segment 2 mutant virus to cause disease in vivo, 
weight loss was measured during infection of 129Sv/Ev WT and IFNAR-lacking mice. 
To test a suitable infectious dose (i.e.: not overly severe) for both types of mice, a 
small-scale pilot study was performed in which groups of 2 WT and 2 IFNAR-/- mice 
were infected with 200 PFU of WT PR8 under anaesthesia, through the intranasal route 
in a 40µL droplet. Mice were weighed at the same time each day and clinical scores 
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(based on marked piloerection, hunched position, moderate to marked staining around 
eyes and/or nose, greatly reduced spontaneous activity, poor response to external 
stimuli, or clinically-apparent dehydration) were also recorded. Both WT and IFNAR-
/- mice showed weight loss from day 3 post infection but the IFNAR-/- exhibited more 
weight loss than WT mice (Figure 4.1A). By 6 dpi IFNAR-/- mice had lost an average 
of 22% of the initial weight while WT mice had only lost 12%. The severity of clinical 
symptoms correlated with weight loss, with IFNAR-/- mice presenting with more 
ruffled coats, lethargy, trembling and hunching (data not shown). Due to the overall 
severe clinical score of IFNAR-/- mice, this pilot study was halted at day 6 post 
infection. 
To investigate the extent to which IAV pathogenesis varied depending on 
mutation of segment 2 AUG codons 10 and 11, having the pilot study as reference, the 
200 PFU dosage was used in a larger scale experiment. This time, cohorts of 2-5 seven-
week old WT and IFNAR-/- mice were inoculated with 200 PFU of WT and 
ΔAUG10,11 PR8 viruses, or sham inoculated with PBS (Figure 4.1B and C). Once 
again, weights and clinical scoring were recorded daily. Mock-infected animals 
showed minimal weight loss and no clinical signs throughout the entire experiment. 
All WT PR8-infected mice showed weight loss from day 3 (Figure 4.1B), reaching a 
12% weight loss at day 5 post infection. PR8 ΔAUG10,11-infected WT mice, although 
non-statistically significant, showed a delay in weight loss, which was only observed 
from day 4 post infection. However, these mice reached equivalent levels of 
percentage weight loss by the 5th day post infection to PR8 WT-infected WT mice. 
Similar to the pilot study, IFNAR-/- mice showed a more rapid progression of clinical 
symptoms, reaching 21% weight loss at day 5 post infection (Figure 4.1C). A  
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Figure 4.1: Weight-change of infected 129Sv/Ev mice. (A) Groups of two WT and 
IFNAR-/- mice were infected intranasally with 200 PFU of WT PR8 virus. Weight was 
monitored daily and mice were euthanised at day 6 post infection. Data represent mean 
± SEM of one independent experiment. (B and C) Cohorts of WT and IFNAR-/- mice 
were infected with 200 PFU of PR8 WT or ΔAUG10,11, or mock inoculated with 
PBS. After 5 days of monitoring, mice were euthanised at day 5 post infection. 
Experiment was performed once with the following mouse numbers: WT/mock n=2, 
WT/WT n=2, WT/ΔAUG10,11 n=5, IFNAR-/-/mock n=1, IFNAR-/-/WT n=2, IFNAR-
/-/ΔAUG10,11: n=5. Data represent mean ± SEM. (D and E) As in B and C but mice 
were infected with 50 PFU of each virus. Experiment was performed once with the 
following mouse numbers: WT/WT n=5, WT/ΔAUG10,11 n=4, IFNAR-/-/WT n=5, 
IFNAR-/-/ΔAUG10,11: n=5. Data represent mean ± SEM.  
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comparable phenotype was seen for IFNAR-/- mice infected with PR8 ΔAUG10,11. At 
this time mice were euthanised for ethical reasons, given the severe clinical scoring of 
IFNAR-/- mice. 
The 200PFU dose caused severe symptoms in the animals but without showing 
a statistically significant difference in weight loss between ΔAUG10,11 and WT PR8 
viruses in WT or IFNAR-/- mice. Therefore, a lower infectious dose was administrated 
to test if this might separate the WT and ΔAUG10,11 weight loss curves. Groups of 5 
five-week old mice were inoculated with 50 PFU of either virus and weight-loss was 
monitored daily (Figures 4.1D and F). With this dose, WT mice exhibited a delayed 
and less accentuated weight loss compared to the 200 PFU virus dose, with no change 
in weight until day 4 post infection and only reaching 8% weight loss at infection day 
6. Animals infected with the mutant virus showed an immediate weight loss, which 
merged into the WT PR8 weight loss curve from day 3 post infection. Similarly to the 
results for the high dose study, IFNAR-/- mice were more susceptible to infection, 
starting to lose weight at day 3 and reaching an average 13% of weight loss at day 5 
post infection, but as observed with the 200 PFU infection, there were no weight loss 
differences between WT and mutant virus-infected animals throughout the entire 
course of infection. IFNAR-/- animals were culled at day 5 because of increasingly 
severe clinical signs. However, hoping to see possible differences emerging at later 
time points, WT animals were only culled at day 6. Nevertheless, although disease was 
minimal, there was no differences between WT and ΔAUG10,11-caused weight loss. 
In summary the data presented here indicated that the mutation of segment 2 
AUG codons 10 and 11 (and the predicted removal of N-terminally truncated PB1  




Figure 4.2: Virus titres from infected mouse lungs. Groups of at least 2 mice were 
infected with 200 (A) or 50 (B) PFU of virus. Five or six days post infection, mice 
were euthanised and the left lung was removed and homogenised in serum-free 
medium. Virus titres were measured by plaque assay. Data tagged with “#” correspond 
to an euthanasia and lung collection at day 6 post infection. Experiment was performed 
once. Data represent individual mouse data points as well as mean ± SEM. Statistic 
annotations are the result of t tests. *p-value <0.05. 
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products) in the background of PR8 did not affect weight loss in vivo, irrespective of 
the ability of the mice to respond to type I IFN. This was a surprising outcome in light 
of the strong attenuation of the ∆AUG10,11 virus in vitro and in ovo. 
 
4.2.2. Virus fitness in 129Sv/Ev WT and IFNAR-/- mice 
The replicative fitness of WT and mutant viruses was measured in infected 
mouse lungs. Mice infected with 200 or 50 PFU of each virus had been euthanised at 
5 or 6-days post infection, as described above. Left lungs were extracted, homogenised 
and clarified by centrifugation, and infectious virus was quantified by plaque assay. 
Mock-infected mice did not have detectable (> 20 PFU/mL) levels of infectious virus 
(data not shown). Both inoculated viruses replicated in vivo, but the degree of 
replication varied significantly depending on the presence or absence of the segment 
2 AUG codons (Figure 4.2). WT PR8 replicated to titres of ~ 105 PFU/mL in mice 
infected with either 200 or 50 PFU, regardless of the mouse type. However, PR8 
ΔAUG10,11 grew to significantly lower titres in mice with an intact IFN system, 
reaching 10-fold less viral titre. This mirrored the in vitro findings in BMDMs (Figure 
3.8). Further correlating with the in vitro replication findings, replication of PR8 
ΔAUG10,11 recovered in IFNAR-/- mice such that there was no significant difference 
in titre between the two viruses. 
Given the reversion of the ΔAUG10,11 virus previously seen in embryonated 
eggs, viral content from lung homogenates was sequenced. No reversions of the mutant 
virus were detected in any of the infected mice. Examination of potential revertant 
viruses was performed by Sanger sequence by which, for instance, a 1% reversion 
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would not be detected and therefore to have certainty of the absence of reversion, a 
more sensitive sequencing method could have been applied. However, as previously 
seen in section 2.2.4, a corresponding smaller plaque phenotype was also observed in 
ΔAUG10,11-infected viral samples, compared to lung homogenates from WT PR8-
infected mice (data not shown). 
Hence, although the attenuated virus caused similar weight loss in infected 
mice to WT virus, viral replicative fitness correlated with the in vitro data. PR8 
ΔAUG10,11 replication was attenuated in WT mice and not in IFNAR-/- animals. 
 
4.2.3. IFN-β induction in infected mouse lungs 
Given the increased level of type I IFN induction seen in A549 epithelial cells 
(Figure 3.2) and the fact that IAV infection occurs mainly in epithelial cells in in vivo 
infections, we hypothesised that the same trend would be seen in infected mouse lungs. 
Therefore, the lung homogenates from a 200 PFU dose infection were used in an IFN-
β ELISA test (Figure 4.3). Both WT and IFNAR-/- mock-infected samples gave assay 
background levels of IFN-β induction. PR8 WT infected mice had minor but 
statistically significant increased levels of IFN-β compared to mock-infected animals. 
However, in ΔAUG10,11-infected mice, the detection of IFN-β was higher in 
comparison to WT-infected mice. A similar IFN-β production pattern was observed 
for IFNAR-/- mice. These data corroborated those previously obtained in the in vitro 
system and showed that infection with segment 2 mutant viruses also resulted in 
increased induction of the type I IFN response in vivo. 
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Figure 4.3: IFN-β induction from infected mouse lungs. Groups of mice were 
infected with 200 PFU of virus. Five days post infection, mice were euthanised and 
the left lung was removed and homogenised in serum-free media. IFN-β concentration 
was determined by ELISA plate and concentration of cytokine for each sample was 
performed based on a standard curve. Experiment was performed once with technical 
duplicates. Data represent individual mouse data points and mean ± SEM. Statistic 
annotations are the result of a two-way ANOVA test. *p-value <0.05, ***p-value 
<0.001, ****p-value <0.0001. 
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4.2.4. Histopathology of infected mouse lungs 
To visualise the extent of the inflammatory response and compare the severity 
of tissue damage induced by WT PR8 and the attenuated ΔAUG10,11 
mutant,histopathology of infected lungs was performed at 5 days post infection. Right 
lungs of infected mice were simultaneously inflated and fixed with a neutral buffered 
formalin solution. After embedding in paraffin wax, sections were cut and stained with 
haematoxylin and eosin (performed by the Easter Bush Pathology Unit), allowing 
pathology scoring by light microscopy. Samples were scored for epithelial cell 
degeneration and necrosis, peribronchial/peribronchiolar inflammation, perivascular 
inflammation, interstitial inflammation and interstitial necrosis as described in section 
7.8.4, giving an overall score between 0 and 3 to represent the severity of pathology. 
Image acquisition and pathology scoring were performed blindly by Dr Philippa Beard 
(The Pirbright Institute, Surrey, UK). The following paragraph was adapted from the 
pathology report provided by Dr Beard. 
Mock-infected samples showed no evidence of influenza infection, presenting 
only incidental changes (peracute multifocal mild haemorrhage and congestion with 
occasional mild crush artefact). The remainder of the images displayed evidence of 
histological changes consistent with murine influenza virus infection. The 
predominant changes identified were epithelial degeneration and necrosis 
accompanied by peribronchial and perivascular inflammation, and inflammatory cells 
within the alveolar airspaces with minimal necrosis of the alveolar walls. The 
inflammatory infiltrate surrounding blood vessels and airways varied from mixed 
(macrophages, lymphocytes and neutrophils) to predominantly lymphocytic. The 
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overall severity of the pathology was not particularly varied, however the specific 
pathology (such as the extent of inflammation of the interstitial tissues) did vary 
between images. In WT-infected lung samples, the pathology focused mainly on the 
airways and blood vessels with very little involvement of the alveoli or interstitium. In 
ΔAUG10,11-infected lung sections, there was a substantial number of mainly large 
foamy macrophages (and fewer lymphocytes and neutrophils) within the airspaces of 
alveoli with occasional necrotic intra-alveolar cells. 
Graphical and statistical analyses of the tissue section cores provided by Dr 
Beard indicated that infection of IFNAR-/- mice with either WT or ΔAUG10,11 PR8 
viruses did not result in statistically significant differences between the viruses in the 
overall score nor in any of the specific pathology scores (Figure 4.4). However, in WT 
mice, despite the lack of difference in the overall score between mutant and WT 
viruses, there was significantly reduced interstitial inflammation in ΔAUG10,11-
infected mice in comparison to WT PR8. Comparison of specific pathology scores 
between virus/mice sample groups did not identify any statistical differences between 
WT and IFNAR-/- mice infected with PR8 WT. However, PR8 ΔAUG10,11 infection 
resulted in differences between WT and IFNAR-/- mice. IFNAR-/- mice infected with 
ΔAUG10,11 had more severe perivascular, peribronchial and interstitial inflammation 
and a higher overall pathology score compared to ΔAUG10,11-infected WT mice. 
Thus overall, in WT mice, pathology did not correlate with virus titre, with the 
exception of interstitial inflammation, which was markedly lower in ∆AUG10,11 
infected animals. However, the mutant virus provoked signifcantly more inflammatory 
damage in IFNAR-/- mice (where virus titre recovered) than WT mice, indicating that, 
consistent with the elevated IFN-ß levels, it might be intrinsically more inflammatory 




Figure 4.4: Histopathology of infected mouse lungs. Mice were infected with 
200PFU of each WT or ΔAUG10,11 PR8 viruses. Five days post-infection, right 
mouse lungs were inflated, fix, processed and H&E stained. (A) Lung pathology 
severity was blindly assessed by Dr Philippa Beard and scored out of 3. Experiment 
was performed once with the following mouse numbers: WT/WT n=2, 
WT/ΔAUG10,11 n=5, IFNAR-/-/WT n=2, IFNAR-/-/ΔAUG10,11: n=5. Data are mean 
± SEM. Statistical annotations are the results of a 2-way ANOVA test. *p-value <0.05, 
**p-value <0.01, ****p-value <0.0001. (B) Representative figures of the assessed 
pathology. Images were acquired and kindly provided by Dr Beard.  
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than WT PR8.  
 
4.2.5. Cytokine and chemokine profiling of infected mouse lungs 
To further explore the underlying reason behind the differences in pathology 
and viral titres but similar weight loss with WT and ∆AUG10,11 viruses, cytokine and 
chemokine profiles from mouse lungs were measured. Lung homogenates of 1-5 mice 
from day 5 post infection with 200PFU of virus were pooled and applied in a cytokine 
and chemokine immunoblot array as described in section 7.8.7. The number of mice 
used for each homogenate varied between conditions. Two mice per homogenate were 
used for PR8 WT-infected WT and IFNAR-/- animals infected while 5 mice of each 
background were used for ΔAUG10,11-infected mice. The spot intensities of two 
duplicate arrays were averaged and relative expression of each cytokine was scaled to 
its signal in the respective mock-infected sample. Cytokines were subdivided into 3 
categories: proinflammatory agents, interleukins and chemokines. Fold-induction 
values were ranked in descending order of relative quantity of certain cytokine in the 
PR8 WT/WT mice sample values in each category and presented as a heat-map (Figure 
4.5A, B). The majority of the cytokines measured were up-regulated in both WT and 
IFNAR-/- mice infected with either virus, compared to mock-infected mice, as 
expected. However, also visible was a general pattern of higher upregulation in 
animals of either genotype infected with the ∆AUG10,11 virus. All inflammatory 
markers (with the exception of siCAM-1 whose expression was unaltered in 3 of 4 
conditions) were up-regulated in infected animals. The main examples of this were 
TIMP-1 and TREM-1 which were upregulated 8-fold in WT mice and 288-fold in the  
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Figure 4.5: Cytokine and chemokine profiling of infected mouse lung. (A and B) 
The levels of various cytokines and chemokines were determined using an immunoblot 
spot array from pooled lung homogenates of mice infected with 200PFU of virus and 
culled at day 5 post infection. Values represent mean fold-induction relative to mock-
infected samples and are plotted as a heat map. Experiment was performed once with 
technical duplicates with the following mouse numbers: WT/mock n=2, WT/WT n=2, 
WT/ΔAUG10,11 n=5, IFNAR-/-/mock n=1, IFNAR-/-/WT n=2, IFNAR-/-
/ΔAUG10,11: n=5. Values were ranked in descending order of relative abundance 
from the WT PR8/WT mice samples.(C) Ratios between ΔAUG10,11 and WT PR8 
expression of each cytokine for each mouse background were calculated. Green 
upwards arrows indicate “overexpression hits” while red downwards arrows designate 
“underexpression hits” (see text). 
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IFNAR-/- counterpart mice, compared to the respective mock-infected animals 
(comparing the average of both viruses). Similarly, all the chemokines tested had 
increased expression in infected animals. The monocyte and NK cell chemotactic and 
pro-inflammatory cytokines CCL2, CXCL10 and CXCL9 were examples of this, 
presenting maximum fold induction ratios of 457.1, 15.1 and 87.1 over PBS-inoculated 
mice, respectively (Figure 4.5 A and B). WT PR8-infected WT mice showed a clear 
reduction in interleukin production when compared to the PR8 ΔAUG10,11 infection 
in the same type of mice (Figure 4.5A). However, this generic difference in interleukin 
induction between viruses was not as pronounced in the context of the IFNAR-/- 
(Figure 4.5B). 
In order to better interrogate the differential cytokine expression by WT and 
∆AUG10,11 viruses, we divided the cytokine induction levels of ΔAUG10,11 by the 
WT PR8-infection-related values (Figure 4.5C). This confirmed the visual impression 
from the heat maps that indeed, the majority of cytokines were upregulated more by 
infection with the ∆AUG10,11 virus than WT PR8 in either mouse strain. Exceptions 
were the inflammation markers TIMP-1, C5/C5a and siCAM-1. In addition, 
examination of the graphs highlighted specific cytokines that were differentially 
regulated by WT versus ∆AUG10,11 infection was performed. 
A further ratio between the WT and IFNAR-/- mice was performed (here 
determined “double ratio”) (Tables 4.1 and 4.2). Cytokines whose double ratios were 
greater than 2 were considered “overexpression hits”. These hits represent cytokines 
where the ΔAUG10,11/WT ratio was considered higher in WT mice and therefore the 
potential cause of the ΔAUG10,11 attenuation. These over expression hits were 
entirely from the interleukin-related category: IL-12, IL-4, IL-5 and IL1ra. These are   




Table 4.1: “Overexpression hits” between WT and IFNAR-/- mice. Description of the activation mechanisms and main role(s) of each 
cytokine are provided. Fold-change values represent the abundance of protein in ΔAUG10,11 infection relative to PR8 WT-infected sample. 








) 𝒐𝒇 𝑰𝑭𝑵𝑨𝑹−/− 𝑺𝑽𝟏𝟐𝟗
. 
 
Cytokine Alternative name Function Reference(s) 
ΔAUG10,11/WT PR8 Double 
ratio WT SV129 IFNAR-/- SV129 
IL-12 P70 
Produced primarily by antigen presenting cells. 
Enhances proliferation and cytolytic activity of 
NK and differentiation of Th1 cells. Stimulates 
their IFNγ production. 
(Trinchieri 
1994) 
7.62 1.01 7.57 
IL-4 - 
Regulator of Th cell differentiation into Th2. 
Regulator of cell proliferation, apoptosis and 
gene expression in lymphocytes, macrophages, 
fibroblasts and endothelial cells. 
(Luzina et al. 
2012) 
2.85 0.5 5.71 
IL-5 - 
Major eosinophils maturation and 
differentiation factor 










Anti-inflammatory. Antagonises the IL-1 
receptor, inhibiting IL-1α and IL-1β. Decreased 
expression of IL-1ra leads to uncontrolled 
systemic inflammation and polyarthropathy. 
(Horai et al. 
2000) 
4.64 1.84 2.51 
  




Table 4.2: “Under expression hits” between WT and IFNAR-/- mice. Description of the activation mechanisms and main role(s) of each 
cytokine are provided. Fold-change values represent the abundance of protein in ΔAUG10,11 infection relative to PR8 WT-infected sample. 








) 𝒐𝒇 𝑰𝑭𝑵𝑨𝑹−/− 𝑺𝑽𝟏𝟐𝟗
. 
 
Cytokine Alternative name Function Reference(s) 
ΔAUG10,11/WT PR8 Double 





JE, MCP-1 (monocyte 
chemoattractant 
protein 1), small 
inducible cytokine A2 
Chemotactic for monocytes, memory T-cells NK 
cells to sites of inflammation. 
(Deshmane et 
al. 2009) 





Pro-inflammatory. Activator of macrophages 
and CD8+ T-cells. 
(Trifilo et al. 
2003) 




Selectively recruits eosinophils by inducing 
their chemotaxis. 
(Jose et al. 
1994; Ponath 
et al. 1996) 
0.77 2.27 0.34 
IL-3  
Produced by T cells. Works alongside GM-CSF 
and IL-5 in the activation of myeloid cells. 
Involved in the production and activation of 
mast cell and basophil. 
(Broughton et 
al. 2012) 








Pro-inflammatory. Chemotactic for type II 
helper T-cells. 
(Vestergaard 
et al. 2004) 
2.79 6.40 0.44 
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mainly anti-inflammatory functions (with the exception of IL-12) and share functions 
such as lymphocyte and eosinophil maturation and differentiation. Important roles and 
activation mechanisms of each of these chemokines are described in Table 4.1. The 
same analysis was performed to determine “underexpression hits”. These would have 
a double ratio of lower that 0.5 and would represent cytokines where differential 
expression between the two viruses was considered increased in IFNAR-/- mice. This 
increment could therefore be related to the higher pathology score of ΔAUG10,11-
infected IFNAR-/- mice, compared with WT mice infected with the same virus (Figure 
4.4). Underexpression hits included cytokines from the interleukins and chemokines 
groups: IL-3, CCL2, CCL3, CCL11 and TARC, which are all pro-inflammatory (Table 
4.2).s 
In general terms, these data show that infection with ΔAUG10,11 stimulated a 
stronger inflammatory response in the lung than WT PR8 in WT mice. Moreover, the 
differences between WT and IFNAR-/- mice cytokine responses correlated with the 
viral titres acquired from the same lungs and suggested that the overexpression of pro-




The previous chapters 2 and 3 showed a fitness penalty adjacent with the 
double deletion of segment 2 AUG codons 10 and 11 in the background of PR8 virus, 
as well as the recovery of this attenuation in IFN-depletion conditions in in vitro 
systems such as IFNAR-/- murine bone marrow-derived macrophages. In this chapter, 
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given the complexity and the variety of the cellular environment of in vivo systems, 
PR8 WT and ΔAUG10,11 viruses were characterised in 129Sv/Ev WT and IFNAR-/- 
mouse hosts to further validate the conclusions taken from the previous sections. 
WT and IFNAR-/- were infected with 200PFU of either WT or ΔAUG10,11 
PR8 viruses and weight loss experiments were carried out over 5 days, in which 
IFNAR-/- mice consistently showed more severe clinical signs. These observations 
were consistent with previous studies where these mice were more susceptible to viral 
infections (Muller et al. 1994). In further correlation with the observed findings, 
previous studies on PR8 infection of IFNAR-/- mice resulted in altered recruitment of 
monocytes, translating into increased production of neutrophil chemoattractants and 
elevated numbers of neutrophils in the lung, resulting in the observed increased 
morbidity and mortality (Seo et al. 2011). 
Previous in vivo studies on IAV viruses lacking IFN counteractive measures 
(WSN NS1 R38K41A) showed a decreased weight loss in naïve BALB/c mice 
compared to WT WSN (Donelan et al. 2003). Therefore, comparison of weight loss 
between WT and ΔAUG10,11 PR8 viruses was also performed where surprisingly no 
notable difference was found between the two viruses, despite the severe attenuation 
and the increased type I IFN induction of PR8 ΔAUG10,11 previously seen in in vitro 
systems. However, it is possible that the induced IFN levels led to a more severe 
cytokine storm which would result in the observed equal levels of clinical symptoms 
and weight loss between WT and ΔAUG10,11 viruses. Moreover, given the higher 
particle/PFU ratio of the attenuated mutant (previously shown in section 2.2.7), the 
dose of 200PFU of PR8 ΔAUG10,11 will have contained a higher number of viral 
particles (potentially DIPs), compared to the WT PR8 infection, which could also 
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contribute to a more severe weight loss than expected, considering the lower lung viral 
titres (Rabinowitz and Huprikar 1979). 
In order to further support the results acquired from BMDM, lung viral titres 
were measured from euthanised mice. Regardless of the comparable weight loss 
between WT and ΔAUG10,11-infected WT and IFNAR-/- mice, viral titres at 5 days 
post infection supported the observations made in the previous chapters, showing the 
attenuation of the mutant virus in WT mice and its recovery in IFNAR-/- animals. This 
observation is also consistent with previous studies where IAV that are incapable of 
IFN counteraction (which harbour mutations, truncations or the deletion of the NS1 
gene) replicate to lower titres in mice lungs (Donelan et al. 2003; Jiao et al. 2008). 
However, considering the stronger IFN induction of the mutant virus and given that 
viral titres were only assessed at one single point post infection, it is therefore not 
possible to distinguish if: a) the viral titres had not reached WT levels (which could 
also be related to its packaging deficiency) or b) the increased type I IFN levels induced 
an ISG/cytokine response which suppressed viral propagation and an earlier viral 
clearance in mouse lungs. 
Lung histopathology was assessed from H&E stained tissue sections and 
concluded that WT PR8 caused comparable degrees of tissue damage in WT and 
IFNAR-/- mice, with small but non-statistically significant increase in perivascular and 
peribronchial inflammation in IFNAR-/- mice. This could explain the increased weight 
loss and more pronounced clinical symptoms observed in knockout animals. 
Moreover, PR8 ΔAUG10,11 infection also caused increased histopathology in 
IFNAR-/- mice. 
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Despite strong evidence demonstrating extensive antiviral properties of type 1 
IFN, several studies also suggest pathogenic roles for IFN during influenza virus 
infection. Type I IFN signalling is known to be amplified by the production of several 
proinflammatory cytokines and chemokines. Studies on type I IFN in murine 
immunity to viral infections show its critical role in the control of secretion of innate 
and proinflammatory cytokines, including IL-12, TNF-α, IL-6, and IL-1 (Lousberg et 
al. 2010). Therefore, in order to further correlate the lung viral titres with observed 
histopathology, cytokine arrays were performed. WT PR8-infection elicited a general 
increment in abundance of proinflammatory cytokines in WT mice. Comparison 
between WT and ΔAUG10,11 viruses showed that the mutant virus was able to induce 
more cytokines, particularly interleukin-like proteins such as IL-12, IL-4, IL-17, IL-
23 and IL-5. IL-23/IL-17 expression has been shown to occur through the NK-κB 
pathway, signalling which is common to the IFN-β induction pathway (Cho et al. 
2006). Moreover, expression of IL-5 has been shown to be regulated by the 
transcription factor GATA3, which is also known to be activated by STAT4/STAT4 
phosphorylation following JAK1-IFN-β interaction (Kaminuma et al. 2005). 
Therefore, augmented expression of type I IFN in the context of a ΔAUG10,11 
infection correlated with the increased abundance of this interleukin. 
Over- and underexpression “hits” were calculated as an attempt to explain the 
differences in ΔAUG10,11 between WT and IFNAR-/-mice: the reduced viral titres in 
WT mice and the histopathology in the lungs of knockout mice. Elevated levels of 
some of these hits, (CCL2) was found in the serum of H5N1-infected patients 
compared to patients infected with less virulent strains and less severe clinical 
symptoms (de Jong et al. 2006; Peiris et al. 2004). The previously seen association of 
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CCL2 expression and increased pathology was also seen in our data set with the 
increased levels of histopathology of IFNAR-/- ΔAUG10,11-infected mice. 
In general terms, proinflammatory cytokines were pinpointed as relevant in 
understanding these phenotypes. We therefore hypothesise that: in WT mice, the 
increased IFN induction caused by the mutant virus leads to a stronger induction of 
immune responses which results in a more efficient clearance of the virus and therefore 
reducing the severity of the observed histopathology in WT mice, particularly in 
interstitial inflammation. 
IFNAR-/- mice infection resulted in equivalent lung viral titres for both viruses, 
similar IFN-β induction and comparable histopathology scores for either virus. 
Conversely, in these mice, there was still a substantial increase in cytokine and 
chemokine upregulation in ΔAUG10,11-infected mice, compared to WT PR8. 
However, in addition to IFN-β induction, the NF-κB arm of the IFN pathway is also 
involved in the expression of pro-inflammatory cytokines in the ΔAUG10,11 mutant. 
If the AUG 10 and/or 11 expressing peptides are IFN inhibitors, they might also 
counteract the activation of NF-κB, resulting in the observed upregulation of 
cytokines. On the other hand, the observed increased cytokine response can be due to 
the presence of non-infectious particles present in the ΔAUG10,11 viral preparations. 
Given the augmented levels of genome/PFU ratios of the ΔAUG10,11 virus, 
since the submission of this dissertation until the date of its examination, additional in 
vivo experiments were performed in naïve and IFNAR-/- mice, comparing the 
behaviour of ΔAUG11 virus (which genome/PFU ratio is WT-like) in comparison to 
its WT counterpart. Groups of five naïve and IFNAR-/- 129Sv/Ev mice were infected 
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with 200PFU of WT and ΔAUG11 viruses or mock-infected, weight changes and 
clinical signs were monitored daily. Mice were euthanised at day 5 post infection and 
lungs were harvested for further histopathology examination, quantification of viral 
load and cytokine profiling. 
As observed with the 200PFU infection with ΔAUG10,11 virus, IFNAR-/- 
infected mice lost more weight that their naïve counterpart. However, no differences 
in weight change were observed between PR8 WT and ΔAUG11 viruses in either type 
mouse. Nonetheless, consistently to what observed in the ΔAUG10,11 infection, an 
approximately 10-fold reduction in viral titre was observed in ΔAUG11 in comparison 
to WT PR8 in naïve mice. Difference which was lost in IFNAR-/- mice, were no 
statistically significant differences in lung viral titre were observed. However, in 
contrast to the ΔAUG10,11 infection, no substantial differences in cytokine expression 
were observed between WT and ΔAUG11 PR8 viruses in either WT or IFNAR-/- mice, 
potentially relating the differences of cytokine expression with the higher number of 
viral particles administrated in the ΔAUG10,11 infection. 
Overall, this chapter supports the principle that modulation of type I IFN 
signalling/production required balancing in order to effectively control viral infections 
not promoting excessive inflammation, as seen by the comparable weigh loss between 
PR8 WT and ΔAUG10,11 viruses, despite the differences in IFN and cytokine 
induction. Moreover, these in vivo studies of PR8 WT and ΔAUG10,11 viruses 
supported the results acquired from growth kinetics in murine BMDM: virus 
propagation was impaired in IFN competent systems (WT mice) and recovered in IFN-
defective conditions (IFNAR-/- mice). These data, in addition to the stronger 
expression of cytokines via the type I IFN-β pathway and/or upregulation in the 
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context of higher IFN levels provides further evidence that AUGs 10 and 11 are 
involved in IFN expression, perhaps with PB1-N92 and –N111 playing important roles 
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5.1. Background and aims 
In the previous chapters, the expression of PB1-N92 and –N111 was 
characterised. Viruses which lacked expression of these peptides were shown to be 
attenuated in in vitro and in vivo models, most likely due to the induction of a stronger 
IFN response. Data were presented suggesting that changes in RNP function were not 
the reason for this increased IFN induction. Therefore, it was hypothesised that the 
enhanced IFN production resulted from the absence of the shorter products, PB1-N92 
and PB1-N111, and their potential involvement in IFN counteraction. The experiments 
described in this chapter therefore focused on testing and understanding the inhibitory 
effect of PB1-N92 and PB1-N111 on the IFN induction pathway. In order to test and 
better describe these functions, PB1-related peptides were assessed in transfection-
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based assays. The peptides were expressed in mammalian cells and their abilities to 
interfere with activation of the IFN-β promoter assessed after stimulation of innate 
immune pathways. Moreover, IFN pathway steps which were inhibited by the PB1-
related peptides were then assessed in the context of ΔAUG segment 2 mutant virus 




5.2.1. Expression and cellular localisation of PB1 shorter products 
In order to understand the function of PB1 truncated peptides in counteracting 
the IFN induction and dissect the mechanisms behind the stronger IFN induction in 
their absence, full length PB1, N40, N92 and N111 ORFs were individually cloned 
into the pcDNA3.1 expression plasmid, commonly used in transient expression assays 
(Figure 5.1A). Although different in size, these proteins share the same C terminus and 
therefore can be detected by the same antiserum to PB1 (V19, Figure 2.5). 
Aiming to test the expression of the different peptides, 293T cells were 
transfected with 500ng of each plasmid and PB1 polypeptide expression was assessed 
by western blot (Figure 5.1B). The cellular protein α-tubulin was used as a loading 
control and was detected at similar levels in the different lysates. No PB1 polypeptides 
were detected in cells transfected with an empty pcDNA construct (Figure 5.1, lane 1). 
Proteins of the expected size were expressed by all four plasmids (PB1: 86.6, PN1-
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N40: 82.4, PB1-N92: 76.7 and PB1-N111: 74.5kDa), with all PB1 polypeptides being 
detected between 75 and 100kDa. Given the nested set nature of the ORFs, the PB1- 
 
Figure 5.1.: Expression of PB1-related polypeptides from pPolII expression 
vectors. (A) Schematic representation of the individual cloning of PB1, PB1-N40, 
PB1-N92 and PB1-N111 coding regions (from AUGs 1, 5, 10 and 11, respectively) 
into the pcDNA3.1 plasmid. Asterisks represent AUG codons. (B) 293T cells were 
transfected with 400ng of each pcDNA. Expression of PB1 polypeptides was tested by 
western-blot using polyclonal antibodies against PB1 (V19) and α-tubulin was used as 
loading control. 
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expressing plasmid also expressed lower levels of the other three polypeptides PB1-
N40, -N92 and -N111 (lanes 2). The same was also observed in the PB1-N40-
expressing plasmid which, in addition to N40 also expressed N92 and N111 (lane 3); 
and the expression of N92 also resulted in the production of N111 (lane 4). 
Since the various PB1-related peptides contain common sequences, it is not 
possible to differentiate their expression from the pcDNA plasmids by 
immunofluorescence. Therefore, in addition, constructs expressing N-terminal FLAG-
tagged versions of PB1-related peptides were also created (Figure 5.2A). In order to 
assess the intracellular localisation of the PB1 proteins, FLAG plasmids were also 
constructed and transfected into 293T cells. Twenty-four hours post transfection, cells 
were fixed and stained using an αFLAG antibody and, to validate the FLAG detection 
and the structure of the tagged peptides, co-stained with an αPB1 antibody. DAPI was 
used to determine nuclear boundaries (Figure 5.2B). No staining with either primary 
antiserum was visible in cells transfected with empty vector plasmid, while in all other 
samples, strong staining was seen in which co-localisation of the FLAG tag (green) 
and the PB1 (red) antibodies was always present. Full-length PB1 localised in the 
cytoplasm, with minor evidence of nuclear staining. Although IAV transcription and 
replication take place in the nucleus in a PB1-dependent manner, PB1 nuclear 
translocation only occurs in the presence of PA (Nieto et al. 1992; Fodor and Smith 
2004), which was absent in this system. PB1-N92 and –N111 also showed primarily 
cytoplasmic localisation. 
Next, intracellular localisation of the shorter products in the presence of PA 
was examined. Like PB1-N40, PB1-N92 and -N111 also lack the sequences primarily  
                                                             Studies on the mechanisms of the inhibition of type I IFN induction by PB1-N92 and PB1-N111 
153 
 
Figure 5.2: Cellular localisation of PB1 polypeptides: (A) Schematic representation 
of the N-terminal FLAG-tagged versions of PB1, PB1-N92 and PB1-N111. (B) 293T 
cells were transfected with 500ng of N-terminal FLAG-tag versions of PB1, PB1-N92, 
–N111 and empty pcDNA. Immunofluorescence staining was performed against 
FLAG (green) and PB1 (V19 antiserum, red). DAPI staining (blue) was used as 
nuclear marker. Image acquisition was performed with a Zeiss 710 confocal 
microscope using a 63x objective. Images are representative of two independent 
experiments performed with a single technical repeat. Scale bars represent 10μm.  
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Figure 5.3: Ability of PB1 polypeptides to induce PA nuclear translocation. 293T 
cells were transfected with plasmids expressing the indicated PB1 products along with 
a GFP-tagged PA-expressing plasmid. Twenty-four hours post transfection, cells were 
fixed and imaged after staining with DAPI to delineate nuclei. Images were acquired 
in a Zeiss 710 confocal microscope with a 63x objective. Images are representative of 
two independent experiments performed with a single technical repeat Scale bars 
represent 10μm.  
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responsible for binding PA. As mentioned above, since PB1 and PA only undergo 
efficient nuclear import as a heterodimer, it was predicted that PA would not complete 
nuclear import in the presence of N92 or N111. To test this hypothesis, 293T cells 
were transfected with pcDNA plasmids expressing the full PB1 or its shorter versions, 
along with C-terminal GFP-tagged PA (PA-GFP) and monitored by fluorescence 
microscopy (Figure 5.3). Transfection of PA-GFP with an empty pcDNA plasmid 
resulted in the cytoplasmic localisation of PA. However, when expressed in 
combination with full-length PB1, PA-GFP was predominantly (but not exclusively) 
localised in the nucleus. In contrast, when PA-GFP was co-expressed with either N92 
or N111, it remained mostly cytoplasmic. These observations are similar to the 
previously reported behaviour of PB1-N40 (Wise et al., 2009) and agree with the 
predicted inability of the shorter PB1 fragments to form a stable PA-PB1 heterodimer 
complex. 
Overall, this section showed the successful expression of the PB1-related 
peptides from a mammalian expression plasmid. Moreover, it confirmed the prediction 
of their incapacity for PA nuclear co-translocation, and therefore their cytoplasmic 
intracellular localisation. 
 
5.2.2. Suppression of IFN induction by PB1-related polypeptides 
Once their expression in transfection assays had been confirmed, the ability of 
PB1-truncated polypeptides to inhibit the induction of IFN-β and ISRE promoters was 
assessed using IFN::Luc and ISRE::Luc reporter plasmids. (Figure 5.4A and B). These 
plasmids (kindly provided by Prof Richard Randall, The University of St Andrews, 
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UK) contain the firefly luciferase ORF under the control of the IFN-β promoter or four 
tandem repeats of the interferon stimulated response element (ISRE) region, 
respectively (King and Goodbourn 1994, 1998; Didcock et al. 1999; Hagmaier et al. 
2006). Induction of these promoters was achieved by transfecting 
polyinosinic:polycytidylic acid (poly I:C), a synthetic mimic of dsRNA which is 
recognised by dsRNA sensors such as RIG-I and MDA-5, leading to IFN-β and 
consequent ISRE upregulation (Yoneyama and Fujita 2004; Kato et al. 2006) and, in 
this case, the expression of firefly luciferase. Therefore, luciferase levels are an 
indicator of the upregulation of either promoter. Moreover, by transfecting the PB1-
related peptides expressing plasmids alongside the reporters, it was possible to 
measure the effects of their presence on IFN-β and ISRE induction. A plasmid 
expressing the NS1 from the isolate A/green-winged teal/Ohio/175/1986 (H2N1) (NS1 
O175A) has been shown to be an effective inhibitor of IFN induction (Turnbull et al. 
2016) and therefore was used as a positive control effector plasmid. As IAV NP is not 
known to influence the induction of either IFN-β or ISRE promoters, a plasmid 
encoding PR8 NP was used as a negative control. 
293T cells were transfected with 50ng of either reporter plasmid and 400ng of 
PB1-related polypeptide or NS1 O175A or NP, here designated as “effector plasmids”. 
Twenty-four hours post transfection, cells were stimulated or mock-stimulated by 
transfecting 5μg/well of poly I:C or by solely adding Lipofectamine, respectively. 
Twenty-four hours post stimulation, cells were lysed, and luciferase readings were 
taken. Additional negative controls included the mock-transfected cells as well as cells 
stimulated with poly I:C in the absence of luciferase reporter plasmid. Both of these 
controls gave luciferase readings several orders of magnitude lower that the reporter-
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containing lysates (data not shown). Stimulated and non-stimulated samples were 
performed for each tested effector plasmid. Fold-stimulation values were calculated 
by the division of relative light units obtained from stimulated over non-stimulated 
cells. This way, potential differences in basal expression of luciferase between 
effectors was accounted for. Transfection of IFN-β or ISRE reporters with empty 
pcDNA plasmids followed by stimulation with poly I:C resulted in an upregulation of 
an average of 30-fold luciferase activity in comparison to non-stimulated cells (data 
not shown). These values were used to scale the remaining data set values to 100% 
(Figure 5.4 C and D). Transfection of PR8 NP as effector plasmid resulted in similar 
luciferase expression levels to the empty pcDNA negative control for both IFN-β and 
ISRE reporters. On the other hand, the use of the positive control effector NS1 O175A 
gave a highly significant reduction of luciferase induction down to 6.5 and 5.9% of the 
empty control induction, respectively for IFN-β and ISRE reporters. Transfections 
with any of the PB1-related peptides also led to a significant reduction of the 
stimulation of the IFN-β promoter (Figure 5.5C). A similar outcome was seen for the 
IRSE promoter using the same effector plasmids, although this phenotype was not as 
severe as seen when using the IFN-β reporter. For the ISRE reporter construct, there 
was a stronger inhibition in PB1-transfected cells which was progressively diminished 
by further truncation of N-terminal sequences (Figure 5.4D). 
FLAG-tagged versions of the PB1-related peptides were also tested. These 
polypeptides also showed IFN-β and ISRE activation inhibition when compared to the 
empty control sample (Figure 5.4 E and F), although this was not as pronounced as 
seen for their untagged counterparts. In the case of the IFN-β promoter, there was an  
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Figure 5.4: Induction of IFN–β and ISRE promoters in presence of PB1 truncated 
products. 293T cells were co-transfected with one of the reporter plasmids IFN-β (A) 
or ISRE (B) alongside the different untagged (C and D) or FLAG-tagged (E and F) 
PB1 truncated proteins. Twenty-four hours post transfection, cells were stimulated by 
transfection with poly I:C and luciferase activity was measured after a further 24 hours. 
NS1 O175A and NP constructs were used as positive and negative controls, 
respectively. Data represent the mean ± SEM of three independent experiments 
performed with three technical repeats. Statistic annotations are the result of an 
ordinary one-way ANOVA test. *p-value <0.05, **p-value <0.01, ***p-value <0.001, 
****p-value <0.0001. (G) Lysates from C were analysed by western blot using 
polyclonal antisera against PB1 (V19), NS1 (V29) and NP. Alpha-tubulin was used as 
loading control. 
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inhibitory effect with the deletion of N-terminal PB1 sequences while the ISRE 
inhibition was constant for all the FLAG-tagged PB1-related peptides. Similar to as 
previously explained in section 2.2.6, a transfection control such as a plasmid 
overexpressing Renilla luciferase was not included, once the positive control (NS1 
A175A) is known to alter cellular proteins synthesis by its CPSF30 binding. 
Nevertheless, assessment of shut-off activity by the PB1’like specimens will be later 
described in this dissertation (sections 5.2.3). 
The expression of PB1 polypeptides (untagged versions) and the used control 
effectors was tested by western immunoblot (Figure 5.4G). The cellular protein α-
tubulin was used as loading control and was evenly detected in all samples. No specific 
bands were detected in cells transfected with empty pcDNA (Figure 5.4, lanes 13 and 
14). For all the remaining samples, expression of the PB1 truncated products as well 
as control effectors was seen in equivalent amounts in the presence or absence of poly 
I:C. The expression of the positive and negative control effectors NS1 O175A (lanes 
1 and 2) and NP (lanes 11 and 12) were detected for cells transfected with the 
respective plasmids. PB1 truncated products were detected using an αPB1antiserum. 
PB1 expression was detected in lanes 3 and 4, followed by PB1-N40 (lanes 5 and 6), 
PB1-N92 (lanes 7 and 8) and PB1-N111 (lanes 9 and 10). As previously seen in Figure 
5.1, the transfection of PB1-N92 also results in smaller, but detectable expression of 
PB1-N111. 
Despite some incongruences between the tagged and un-tagged PB1-related 
polypeptides, these data indicated that the PB1 shorter products were able to directly 
inhibit the activation of the IFN-β promoter and (perhaps) consequently minimise the 
induction of the ISRE promoter in poly I:C-stimulated cells. 
                                                             Studies on the mechanisms of the inhibition of type I IFN induction by PB1-N92 and PB1-N111 
161 
5.2.3. PB1-related polypeptides and RNA polymerase II promoter 
activity 
The inhibition of IFN-β and ISRE promoters seen in previous sections could 
be attributed to a) a specific obstruction of the IFN pathway or, b) a general restraint 
of host gene expression. Therefore, in order to determine whether the PB1-related 
peptides had a general shut-off activity, plasmid vectors containing constitutively 
active polymerase II promoters upstream of readily detectable reporter genes were 
used as targets. The first reporter plasmid contained the Renilla luciferase ORF under 
the control of the simian virus 40 (SV40) promoter, while the second one contained 
the gene for β-galactosidase enzyme (β-gal), the expression of which was controlled 
by a human RNA polymerase II (RNA PolII) promoter (Figure 5.5A and B, 
respectively). 293T cells were co-transfected with 100ng Renilla or 50ng of β-gal 
reporter plasmid with 400ng of effector plasmid. Forty-eight hours post-transfection, 
cells were lysed and levels of Renilla luciferase or β-gal were measured (as described 
in section 8.3.7). Background luminescence (luciferase) or A420 levels (ß-
galactosidase) were measured from mock-transfected samples. These negative 
controls gave values orders of magnitude lower than the tested samples (Figure 5.5 C 
and D). As a positive control, the PA segment from A/chicken/Rostock/1934 (fowl 
plague virus or FPV) was used. In addition to PA, this segment also expresses FPV 
PA-X, which has a high shut-off activity against cellular gene expression (Jagger et al. 
2012; Hussain et al. 2018). As negative controls, an empty pcDNA plasmid was used, 
as well as a temperature sensitive (ts) PA mutant, PA ts45. This mutant contains a 
single amino acid mutation in the PA endonuclease domain (F117C) which affects 
both PA and PA-X shut-off activity (Almond et al. 1979; Bell 2006). Transfections   
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Figure 5.5: Shut-off activity of PB1 related polypeptides. 293T cells were with one 
of the reporter plasmids Renilla (A) or β-gal (B) alongside PB1 truncated proteins. 
Renilla luciferase (C) or β-galactosidase (D) readings were measured 48 hours post-
transfection. FPV PA and ts45 PA-expressing constructs were used as positive and 
negative controls, respectively. Data represent the mean ± SEM of three independent 
experiments performed with three technical repeats. Statistic annotations are the result 
of an ordinary one-way ANOVA test. Multiple comparisons were performed in 
reference to the empty plasmid-transfected sample. *p-value <0.05, <0.01, ***p-value 
<0.001, ****p-value <0.0001 (E) Expression of PB1 shorter products and PA was 
assessed by western blot using V19 and V35 antisera, respectively. The cellular protein 
α-tubulin was used as loading control.  
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with the WT FPV plasmid resulted in a statistically significant ~5-fold reduction in 
both Renilla luciferase and β-gal expression, whereas the ts45 PA did not. Similarly, 
use of any PB1-derived polypeptide as an effector protein resulted in comparable 
levels of both Renilla and β-gal expression to the empty plasmid negative control, 
indicating a lack of inhibitory activity. To test for successful expression of the effector 
peptides, western blots were performed (Figure 5.5E). Alpha-tubulin expression, 
which was used as a loading control, was uniform in all tested samples. No 
polypeptides were detected from empty plasmid-transfected cells (lane 1). PB1-related 
peptides were detected with a αPB1 antibody (lanes 2-5), presenting the expected 
sizes, as well as the previously seen co-expression of N92 and N111 from the PB1-
N92 plasmid. PA was also successfully detected using an αPA polyclonal antibody in 
lysates of cells transfected with PA FPV and PA ts45-expressing plasmids. Overall 
therefore, these data showed that unlike PA-X, the PB1-related peptides do not 
generally inhibit cellular RNA Pol II-mediated gene expression. 
 
5.2.4. Identification of steps in IFN induction which are modulated by 
the PB1-related polypeptides 
In section 5.2.2, the ability of PB1-truncated products to inhibit the induction 
of IFN-β promoter following poly I:C stimulation was demonstrated (Figure 5.4). Poly 
I:C mimics dsRNA, which activates the IFN pathway cascade from its very early 
stages (Field et al. 1967; Dauletbaev et al. 2015). However, the reporter assays used 
did not identify where in the pathway the PB1-truncated versions were having an 
effect. This section aimed to identify at what stage of IFN induction the PB1-related 
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peptides acted. To achieve this, instead of inducing IFN from the dsRNA detection 
phase, the pathway was stimulated by transfecting plasmids coding for various 
components of the signalling pathway whose overexpression activates IFN-β 
expression from specific points within the cascade. For example, transfection of a 
MAVS-encoding plasmid will bypass RIG-I activation and induce IFN-β expression 
from a forward step (Xing et al. 2012). These plasmids are here called “inducing 
plasmids”. 293Ts were co-transfected with 50ng of IFN-β::Luc reporter plasmid, the 
same PB1 effector plasmids as in section 5.2.1 and 400ng of one of the inducing 
plasmids (kindly provided by Dr Andrew MacDonald, The University of Leeds, UK). 
Twenty-four hours post transfection, cells were lysed and levels of luciferase 
expression were measured. As in section 5.2.1, luciferase amounts were assumed to be 
proportional to the levels of IFN-β promoter induction. Background levels of firefly 
luciferase were set with mock- and IFN-β::Luc only-transfected cells. Co-transfection 
of IFN-β::Luc reporter with each of the inducing plasmids alone resulted in luciferase 
inductions of between approximately 25- and 2000-fold, depending on the induction 
plasmid (data not shown). Negative control effector plasmids included an empty 
pcDNA plasmid, to which all the remaining effector and control plasmids luciferase 
values were scaled. An effector plasmid expressing PR8 NS1 was used as a positive 
control when testing RIG-I and MAVS inducing plasmids. A plasmid expressing PR8 
NP was used as negative control. RIG-I/MAVS activation is the immediate step 
following foreign RNA recognition. Induction of the IFN-β pathway from these two 
stages was unaffected by the negative control NP while transfection of the positive 
control, PR8 NS1, significantly reduced the levels of promoter activation (Figures 
5.6A, B). Equivalent inhibition levels were also seen with the transfection of the PB1-
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related peptides. RIG-I/MAVS activation leads to the stimulation of other signalling 
pathways. These can be largely divided into two main arms: IRF3 and NF-κB (as 
reviewed in Chapter 1, Figure 1.6). To induce the NF-κB cascade, plasmids encoding 
the kinase IKKβ (which conjugates with IKKα and NEMO to form the IKK complex) 
and two NF-κB subunits, RelA and P50, were used. IFN-β promoter induction using 
these plasmids was not inhibited by the negative control PR8 NP, or PR8 NS1. This 
lack of inhibitory activity was also shared by the PB1family of proteins (Figure 5.6 C-
E). In addition to activation by RIG/MAVS, IFN-β induction has been shown to occur 
following triggering of TLR3 and/or 7, although TLR7 has been suggested to be 
dispensable for a full IAV-driven IFN induction (Wu et al. 2015; Jeisy-Scott et al. 
2012; Barchet et al. 2005). These activation mechanisms were represented here by 
induction plasmids expressing the TLR1/2/5/6/7/8/9 ligand MyD88 and the TLR3 
ligand TRIF (Kawasaki and Kawai 2014; Uematsu and Akira 2008) (Figure 5.6 F and 
G). IFN-β induction by MyD88 and TRIF was not supressed by PR8 NP or NS1. 
However, PB1, N40, N92 or N111-transfected cells all showed significantly reduced 
IFN-β activation upon the transfection of these two TLR adaptors. TRIF recruitment 
is followed by its association with TRAF3 together with TBK1 and IKKε complex, 
which subsequently promotes the phosphorylation, dimerisation and translocation of 
the transcription factor IRF3 into the nucleus (Sato et al. 2003; Fitzgerald et al. 2003). 
Aiming to test the effects of the PB1-related peptides in that cascade, inducing 
plasmids coding for TBK1, naïve IRF3 and a phospho-mimic of IRF3 (with serine 
amino acid residues 396 and 398 substituted to aspartic acid) were transfected into 
cells (Figure 5.6 H-J). As with the NF-κB root components, IFN-β induction by these 
plasmids was unaffected by the co-transfection of PR8 NP. Induction was also largely   
Chapter 5   
166 
 
Figure 5.6: Counteraction of stimulation of the IFN-β promoter pathway at 
different stages. 293T cells were co-transfected with an IFN-β::Luc reporter plasmid, 
effector polypeptides (PR8 PB1, N40, N92, N111, NS1 or NP) and one of the various 
IFN pathway component proteins: (A) RIG-I, (B) MAVS, (C) IKKB, (D) RelA, (E) 
P50, (F) MyD88, (G) TRIF, (H) TBK1, (I) IRF7, (J) IRF3, (K) pIRF3. Twenty-four 
hours post transfection, cells were lysed and luciferase activity was measured. Data 
represent the mean ± SEM of three independent experiments performed with three 
technical repeats. Statistic annotations are the result of an ordinary one-way ANOVA 
test. Multiple comparisons were performed in reference to the empty plasmid-
transfected sample. *p-value <0.05, ***p-value <0.001, ****p-value <0.0001.  
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Figure 5.7: Heat map representation of the inhibition of the pathway leading to 
IFN-β expression by PB1-truncated proteins: 293T cells were co-transfected with 
IFN-β::Luc reporter plasmid, effector polypeptides (PR8 PB1, N40, N92, N111, NS1 
or NP) and one of the induction plasmids. Twenty-four hours post transfection, cells 
were lysed and luciferase activity was measured. IFN-β promoter induction was scaled 
to the empty pcDNA control and plotted in a heat map. Colour saturation is associated 
with luciferase activity. Therefore, lighter colours represent a weak IFN-β induction, 
in contrast to dark colours which symbolise the lack of IFN-β counteraction. Induction 
plasmids were separated into different families/arms: RLRs, NF-κB arm, TLR7, TLR3 
and IRF3 arm.   
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insensitive to NS1 co-transfection, although there was a small (less than 2-fold) but 
significant reduction of TBK1-induced expression (Figure 5.6 H). In contrast, the use 
of PB1-related peptides as effector plasmids led to substantial and highly significant 
reductions in IFN-β upregulation induced by TBK1. However, this attenuation was 
lost in IRF3 or pIRF3-stimulated cells (Figure 5.6 I and J). Phosphorylation and 
nuclear translocation of the regulatory factor IRF7 also occurs via TBK1 (Iwamura et 
al. 2001; Ning et al. 2011). However, similar to IRF3, an IRF7-induced IFN-β 
promoter response was not inhibited by the PB1-truncated peptides (Figure 5.6 K). 
To aid visualisation and interpretation of these data, they were summarised in 
a heat map where strong IFN-β promoter induction is represented by dark shades, 
contrasted to weak promoter induction in light colours (Figure 5.7). No IFN-β 
induction was seen in mock-transfected cells in the absence of reporter. This diagram 
made it clear that transfection of NP did not negatively affect the induction of IFN-β 
promoter under any circumstances, while as expected (Turnbull 2017), expression of 
PR8 NS1 inhibited IFN-β promoter induction triggered by overexpression of RIG-I 
and MAVS. None of the effector plasmids affected IFN-β induction initiated at the 
stages of IKKβ, P50 or RelA/P65 (the NF-κB cascade). However, expression of PB1, 
N40, N92 or N111 supressed IFN-β activation with MyD88 or TRIF expression 
plasmids, but this repression was not shared by the positive control, NS1. Moreover, 
the same phenotype was observed when inducing the pathway at the stage of TBK1. 
This inhibition was lost when IFN-β activation was achieved by IRF3, pIRF3 or IRF7 
overexpression. Thus, considering the flow of the IFN-β pathway, these data indicated 
that PB1-related peptides counteracted induction of the IFN cascade occurring via the 
IRF3 cascade at the stages of TBK1. 
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5.2.5. IRF3 phosphorylation in cells infected by segment 2 mutants 
Given the ability of the PB1-related peptides to inhibit TBK1-induced IFN-β 
promoter activation, it was hypothesised that infection by viruses which did not 
express PB1-N92 and/or PB1-N111 would therefore result in increased levels of IRF3 
phosphorylation. To test this hypothesis, A549 cells were infected with PR8 WT and 
segment 2 mutant viruses at a MOI of 5. Twenty-four hpi, cell lysis was followed by 
the detection of IRF3 naïve and phosphorylated forms by western immunoblot (Figure 
5.8A). Infections with two further viruses were also used as controls: the PR8 NS1 
RNA-binding mutant R38K41A virus which (unlike WT PR8) is known to induce 
increased levels of IFN and higher levels of IRF3 nuclear translocation (Talon et al. 
2000; Turnbull et al. 2016), and the IAV strain A/Udorn/307/1972 (here abbreviated 
to Udorn) which is also known not to inhibit IRF3 phosphorylation (Kuo et al. 2016). 
As seen in chapter 3, infection with various segment 2 ΔAUG mutant viruses led to 
the upregulation of IFN expression. IFN functions in an auto-paracrinal fashion and 
leads to the upregulation of hundreds of ISGs, some among which are components of 
the IFN pathway such as RIG-I, TRIM25, TLR3 or MyD88 (Shaw et al. 2017) whose 
overexpression can induce IRF3 phosphorylation. Therefore, increased levels of IRF3 
phosphorylation in ΔAUG mutant-infected cells could be a result of a generalised ISG 
response. In order to assess the looping effect of type I IFN in IRF3 phosphorylation, 
cells stimulated with type I IFN were included as a control. NP was also blotted for to 
confirm viral infection and α-tubulin was used as loading control. Mock-infected cells 
did not express detectable levels of pIRF3 (Figure 5.8A, lane 1). WT PR8 showed 
higher IRF3 phosphorylation levels compared to mock-infected cells (lane 2). Relative 
pIRF3 levels were quantified by densitometry from 3 independent experiments and all   
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Figure 5.8: IRF3 phosphorylation levels in PR8 segment 2 mutant-infected cells. 
(A) A549 cells were infected at a MOI of 5 for 24 hours, after which cell lysates were 
collected. Lysates were subjected to SDS-PAGE followed by the detection of naïve 
and phosphorylated forms of IRF3 by western blot. Infection with PR8 NS1 R38K41A, 
poly I:C transfection and IFN incubation were used as controls. NP and α-tubulin were 
also detected to confirm infection and to act as a loading control, respectively. (B) 
Relative quantification of the phosphorylated IRF3 form was performed in ImageJ and 
scaled to the PR8 WT infection values. Plotted data are the mean ± SEM of three 
independent experiments performed with a single technical repeat. Statistic 
annotations are the result of an ordinary one-way ANOVA test. Statistical annotations 
are the result of multiple comparison tests. **p-value, <0.01, ***p-value <0.001, 
****p-value <0.0001.  
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tested conditions were scaled to the WT PR8 pIRF3 values (Figure 5.8B). The positive 
control infections with PR8 NS1 R38K41A and Udorn, as well as poly I:C transfection 
gave 3-5-fold increased levels of IRF3 phosphorylation (lanes 8, 9 and 10). IFN-treated 
cells did not show detectable levels of IRF3 phosphorylation (lane 11), indicating that 
IFN induction by the mutant viruses could be discarded as the cause of increased IRF3 
phosphorylation. Infection with segment 2 mutant viruses showed variable degrees of 
IRF3 phosphorylation dependent on the precise AUG codon that were mutated. 
Infections with ΔAUG5 and/or 10 viruses did not show a significant increase in IRF3 
phosphorylation compared to WT PR8 (lanes 3, 4 and 6). However, ΔAUG11-
containing virus infections resulted in a statistically significant 2-3-fold enrichment in 
levels of pIRF3 levels (lanes 5 and 7). Thus, these data partially supported the 
hypothesis that viruses unable to express PB1-N92 and/or -N111 would have defects 
in controlling IRF3 phosphorylation and were consistent with the results acquired in 
section 5.2.4, showing a correlation between the inhibitory effects of PB1-N111 and 
TBK1-induced IFN upregulation. 
 
5.2.6. Effects of IRF3 phosphorylation inhibition on fitness of segment 
2 mutant viruses 
As levels of IRF3 phosphorylation were increased following infection with 
ΔAUG11 mutant viruses, we asked if the fitness of such mutants would alter in the 
presence of an IRF3 inhibitor. To test this, the aminopyrimidine compound BX-795 
(Figure 5.9A), which was developed as an inhibitor of 3-phosphoinositide-dependent 
kinase 1 but was recently shown to be a potent inhibitor of the catalytic activity of the  
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Figure 5.9: Replication of segment 2 mutant viruses in the presence of BX-795. 
(A) Simplified schematic representation of the IRF3 induction pathway and inhibitory 
mechanisms of BX-795. Upon stimuli such as TLR3, TLR7, RIG or MDA-5 
activation, the IKKγ/TBK1.IKKε complex is formed and is responsible for the 
phosphorylation of IRF3. pIRF3 forms homodimers which translocate into the nucleus 
though nuclear pores where they act as a transcription factor to induce the expression 
of IFN-β. BX-795 prevents the formation of the IKKγ/TBK1/IKKε complex, therefore 
inhibiting the induction of IFN-β by pIRF3. (B) A549 cells were pre-treated with 
different concentrations of BX-795 and transfected with poly I:C. Twenty-four hours 
post stimulation, cells were lysed and levels of IRF3, phosphorylated IRF and -
tubulin were detected by western blot. Datum is a representative of two independent 
experiments performed with one single technical repeat. (C) A549 cells were mock-
pre-treated or pre-treated with 1, 2 or 5μM of BX-795 and infected with segment 2 
mutant viruses at a MOI of 0.001. BX-795 concentrations were kept during the entire 
time course of infection. Forty-eight hpi, viral titres were measured by plaque assay. 
Values were scaled to the PR8 WT titre of each drug concentration. Data are the mean 
± SEM of three independent experiments performed with a single technical repeat. 
Statistical symbols represent the result of a two-way ANOVA test. Multiple 
comparison tests were performed within each mutant, having the 0μM concentration 
as control. *p-value <0.05, **p-value <0.01.  
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TBK1/IKKε complex by blocking their phosphorylation was used (Bai et al. 
2015; Clark et al. 2009; Stewart et al. 2014). 
First, to determine the concentration at which the drug best inhibited the IRF3 
cascade, A549 cells were pre-treated with a range of concentrations of BX-795 for 2 
hours after which they were transfected with poly I:C. After a further 24-hour 
incubation with poly I:C and BX-795, cells were harvested and pIRF3 was detected 
by western blot (Figure 5.9A). Naïve non-phosphorylated IRF3 was present in all 
samples, as well as the loading control, α-tubulin. Non-stimulated cells showed 
undetectable levels of pIRF3 (lane 1), in contrast to a robust detection of pIRF3 in 
stimulated cells in absence of BX-795 (lane 2). The amounts of phosphorylated IRF3 
decreased with increased concentrations of the compound, being totally abrogated at 
5μM (lanes 3-8). Based on these results, concentrations of 1, 2 and 5μM were chosen 
to use in infection experiments. At these concentrations, drug-induced cytotoxicity 
levels in A549 cells were insignificant (section 8.3.4. Cytotoxicity assays). 
In order to assess the impact of this IRF3 inhibitor on replication of the ΔAUG 
segment 2 mutants, A549 cells were mock-pre-treated or pre-treated with 1, 2 or 5μM 
of BX-795 followed by infection at a MOI of 0.001. Forty-eight hpi, cell supernatants 
were collected, and viral titres were measured by plaque assay. Mutant virus titres from 
each drug concentration were scaled to the corresponding WT PR8 titre (Figure 5.9 
C). Infections performed in the absence of BX-795 gave comparable results to those 
previously described: single and double mutants ΔAUG10/11 and ΔAUG5,10/11 
showed titres at least 10-fold lower than WT PR8 while the double and triple mutants 
ΔAUG10,11 and ΔAUG5,10,11 replicated to at least 2 orders of magnitude less titre. 
Nevertheless, this panorama changed in the presence of the inhibitor. The ΔAUG5 
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and/or 10 viruses were insensitive to BX-795 treatment, giving titres that were not 
statistically different than those from the 0μM controls. However, ΔAUG11-
containing viruses (PR8 ΔAUG11, ΔAUG5,11, ΔAUG10,11 and ΔAUG5,10,11) all 
showed a recovery in virus propagation in cells treated with BX-795. Moreover, this 
recovery was dose-dependent, with generally better titres with higher doses of BX-
795. At 5µM BX-795, these viruses showed an at least 10-fold increase in viral titre, 
compared to those acquired from infections without the addition of inhibitor. Thus, 
viruses lacking AUG11 all replicated to higher viral titres when IRF3 phosphorylation 
was inhibited by BX-795, corroborating the results in the previous section which 
showed increased pIRF3 levels during AUG11 mutant virus infection. This strongly 
suggests that the PB1-N111 polypeptide expressed from AUG11 acts to counteract 
IRF3 phosphorylation. 
 
5.2.7. Effects of TLR3 inhibition on viral fitness of segment 2 mutants 
Studies have shown the requirement for TLR3 for maximum IFN-β induction 
in IAV infection (Wu et al. 2015; Leung et al. 2014; Le Goffic et al. 2007). TLR3 
activation is followed by the binding of its adapter, TRIF (Takeda and Akira 2005). 
Results from section 5.2.4 showed the capacity of the PB1-related peptides to arrest 
TRIF-induced IFN induction (Figures 5.4 and 5.5). Therefore, to corroborate those 
data, viral replication in the presence of a TRIF inhibitory peptide was assessed. 
The TRIF inhibitory peptide used is commercially available (TRIF Pepinh, 
InvivoGen) and contained the 14 amino acids that correspond to the sequence of the 
BB loop of TRIF (FCEEFQVPGRGELH) linked to the cell-penetrating 16-amino acid 
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Figure 5.10: Virus propagation in the presence of a TRIF inhibitor. (A) Sequences 
of the used TRIF inhibitor and control peptides (InvivoGen). Underlined amino acid 
peptides represent the BB loop of TRIF and a size-equivalent random control 
sequence. (B) Schematic representation of the interaction between TLR3 TIR and 
TRIF BB loops and the binding of the used TRIF and control peptides. (C) A549 cells 
were pre-treated with 10μM of either TRIF or control peptide for 6 hours after which 
cells were infected at MOI 0.001 for 48 hours. Viral titres were acquired by plaque 
assay. Values were scaled to the PR8 WT titres for each peptide. Data are mean ± SEM 
from three independent experiments performed with one technical repeat. Statistical 
symbols represent the result of a two-way ANOVA test. Multiple comparison tests 
were performed within each mutant, having the 0μM concentration as control. *p-
value <0.05, **p-value <0.01, ****p-value <0.0001.  
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sequence of the antennapedia homeodomain: RQIKIWFQNRRMKWKK. Addition of 
this domain enables translocation through the plasma membrane into the cytoplasm 
and nucleus of cells (Derossi et al. 1996; Derossi et al. 1998). In addition, a negative 
control peptide with a previously published random size-matching amino acid 
sequence was also purchased (Toshchakov et al. 2005) (Figure 5.10A). Thus, the TRIF 
inhibitory peptide will interact with the TLR3 TIR and prevent TLR3-driven IFN-β 
induction, while the control peptide will not (Figure 5.10B). 
A549 cells were pre-treated with either TRIF inhibitor or control peptides for 6 hours 
at a concentration of 20μM. After pre-treatment, cells were infected with segment 2 
AUG mutants and the NS1 R38K41A at a MOI of 0.001. Considering that R38K41A 
point mutation in NS1 confers an RNA-binding deficiency at the level of RIG-I 
recognition (Gack et al. 2009; Wang et al. 1999), the NS1 mutant virus used should 
therefore be a TRIF-insensitive control virus. Peptides were added to the infection 
overlay medium at the same concentration. Forty-eight hpi, virus titres were quantified 
by plaque assay (Figure 5.10C). WT PR8 virus reached titres of 108 PFU/mL in the 
presence of either control or TRIF inhibitory peptides, which were like the titres 
achieved from an A549 infection without the addition of any peptide (data not shown). 
The negative control NS1 R38K41A mutant showed a 500-fold reduction in viral titre 
in comparison to WT, which was not affected by the presence of the TRIF inhibitor 
peptide. In the presence of the control peptide, the PR8 PB1-N40 knockout virus 
showed a WT-type phenotype. PR8 ΔAUG10 and ΔAUG11 showed a 10-fold 
reduction in virus titre in comparison to WT in control peptide treated cells, as 
previously seen in A549 cells. This phenotype was shared by the PR8 ΔAUG5,10 and 
ΔAUG5,11 viruses, while PR8 ΔAUG10,11 and ΔAUG5,10,11 showed 100-1000-fold 
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reductions in titre. Similar to what was previously observed with the addition of BX-
795, incubation of cells with TRIF-inhibitor affected only a subset of the ∆AUG 
mutants. ΔAUG5/10-containing viruses were insensitive to inhibition of TRIF. 
However, treatment with the TRIF inhibition peptide led to better virus propagation of 
mutant viruses containing ΔAUG11. Recoveries of at least 10-fold in viral titre were 
observed for the single and double mutants ΔAUG11 and ΔAUG5,11, while 
ΔAUG10,11 and ΔAUG5,10,11 showed an approximate 100-fold increase in viral 
titre. Overall, data reported in this section supported the hypothesis that loss of TBK1 
complex antagonism was important to the IFN induction seen in ΔAUG11 mutant 
virus infections. 
 
5.2.8. P65 (NF-κB) phosphorylation in segment 2 mutant infected 
cells 
Despite not as well expressed as PB1-N111, the deletion of PB1-N92 initiation 
codon (ΔAUG10) in the context of PR8 infection also led to increased IFN induction 
(Figure 3.2). Moreover, as previously seen in this chapter, the overexpression of PB1-
N92 and –N111 resulted in the inhibition of MyD88-driven IFN-β induction. MyD88 
is the TLR7 ligand and acts via the TRAF6 complex, leading to NF-κB activation, 
cytokine secretion and the inflammatory response (Kawai et al. 2004). Moreover, as 
observed in the arrays performed in chapter 4 (section 4.2.5), stronger induction of 
inflammatory cytokines such as IL-6, IL-1, IL-1ra and CCL5/RANTES were strongly 
detected in lungs of PR8 ΔAUG10,11-infected mice and have been associated with 
increased levels of NF-κB(Son et al. 2008; Smith et al. 1994; Mori and Prager 1996;    
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Figure 5.11: P65 phosphorylation levels in PR8 segment 2 mutant-infected cells. 
(A) A549 cells were infected at a MOI of 5 for 24 hours, after which cell lysates were 
collected. Lysates were subjected to SDS-PAGE followed by the detection of naïve 
and phosphorylated forms of P65 by western immunoblot. Infection with PR8 NS1 
R38K41A, poly I:C transfection and TNFα incubation were used as positive controls. 
NP and α-tubulin detection were used to confirm infection and as loading control, 
respectively. (B) Relative quantification of the phosphorylated P65 form was 
performed in ImageJ and scaled to the PR8 WT infection values. Plotted data are the 
mean ± SEM from three independent experiments performed with one technical repeat. 
Statistic annotations are the result of an ordinary one-way ANOVA test. Multiple 
comparisons tests were performed against Mock and PR8 WT values. *p-value <0.05, 
**p-value <0.01, ***p-value<0.001, ****p-value <0.0001.  
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(Son et al. 2008; Smith et al. 1994; Mori and Prager 1996; Wickremasinghe et al. 
2004). Studies on the links between the NF-κB transcription factor binding sites and 
IL-12 (also stronger expressed in ΔAUG10,11-infected mice in comparison to WT 
PR8) production have also been described (Murphy et al. 1995; Yoshimoto et al. 
1997). Therefore, changes in the NF-κB P65 phosphorylation levels were assessed in 
the context of ΔAUG mutant virus infection in vitro. 
A549 cell were infected at a MOI of 5 with the panel of WT, PB1- and NS1-
mutant PR8 viruses. Twenty-four hpi, viral NP (to confirm infection), α-tubulin (as a 
loading control) and P65 naïve and phosphorylated forms were detected by western 
blot (Figure 5.11A). P65 species were quantified from replicate experiments (Figure 
5.11B). Similarly to pIRF3 detection, infection with PR8 NS1 R38K41A was used as 
a positive control (Wang et al. 2000). Additional positive controls included cells 
stimulated with TNFα or poly I:C (Schutze et al. 1995). Mock-infected cells had the 
lowest P65 phosphorylation levels (lane 1), followed by WT virus-infected cells (lane 
2). TNFα and poly I:C treated cells showed the strongest P65 phosphorylation, 
presenting 5- to 6-fold statistically increases over the mock-treated-cells (lanes 9 and 
10). The NS1 mutant also showed increased levels of pP65 (on average a 3-fold 
induction) in comparison to PR8 WT. Mutation of AUGs 5, 10 and/or 11 resulted in 
statistically significant 2-3-fold increase of P65 phosphorylation over their WT 
counterpart. However, in contrast to the IRF3 phosphorylation experiments, pP65 
levels were rather consistent between the different segment 2 mutant viruses. 
Overall, increased P65 phosphorylation was consistently augmented in all 
mutant viruses. Unlike IRF3, P65 phosphorylation was not strongly associated with a 
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particular AUG codon. Instead, the presence of pP65 was associated with all AUG 
codons 5, 10 and 11. 
 
5.2.9. Replication of segment 2 mutants following NF-κB inhibition  
To further analyse the importance of the counteraction of NF-κB for the fitness 
of the ΔAUG viruses, drugs which block directly of indirectly block P65 activity were 
used. Given the augmented levels of P65 phosphorylation in ΔAUG mutant viruses’ 
infection, it was hypothesised that the fitness of these mutants would recover in the 
presence of NF-κB inhibitors. To investigate this, two different compounds were used: 
IMD0354 and JSH23 (Figure 5.13A). IMD0354 blocks IκB phosphorylation (Sugita 
et al. 2009; Onai et al. 2004), while JSH-23 is a cell-permeable diamino compound 
that selectively blocks nuclear translocation of the NF-κB P65-P50 hetero-dimer and 
its ensuing transcription factor activity without affecting IκB degradation (Shin et al. 
2004). 
To determine the appropriate concentration of the inhibitors to use, 293T cells 
were transfected with 50ng of the IFN::Luc reporter plasmid. After 24 hours, cells 
were treated with several concentrations of either IMD0354 (Figure 5.12A) or JSH-23 
(Figure 5.12B) for 2 hours, after which they were either transfected with poly I:C or 
treated with 500 ng/ml TNFα (Sakurai et al. 2003). Twenty-four hours post 
stimulation, cells were lysed and luciferase activity was measured. Values were scaled 
to the luciferase sample with no added drug (Figure 5.12 B and C). In general, 
IMD0354 was a more powerful inhibitor than JSH-23, leading to a 40 and 80% 
reduction of poly I:C- and TNFα-stimulated IFN-β induction, respectively, at 0.1μM 
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and near complete inhibition at 0.5μM. JSH-23 achieved the same blockade of poly 
I:C-induced IFN-β activation at 1μM but was not particularly effective against TNFα 
stimulation. Based on these results and considering the cytotoxicity levels of these two 
compounds (Figure 8.1, section 8.3.4), concentrations of 0.1μM of IMD0354 and 1μM 
of JSH-23 were chosen to be used in infection experiments. 
In order to assess the impact of the NF-κB inhibitors on the replication of 
mutant viruses, A549 cells were mock-pre-treated or pre-treated with IMD0354 or 
JHS-23 for 2 hours followed by infection with WT and segment 2 mutants at MOI of 
0.001. Forty-eight hpi, virus-containing cell supernatants were collected, and viral 
titres were measured by plaque assay. Titre values were scaled to WT PR8 titre in each 
drug data set (Figure 5.12 D and E). Infections performed in the absence of inhibitors 
showed the previously observed attenuation of ΔAUG10 and/or 11 viruses, whereas 
mutation of AUG5 did not alter virus replication. However, despite statistically 
insignificant, all segment 2 mutant viruses presented higher replication rates in the 
presence of either inhibitor with a generalised 3- to 100-fold increase in viral 
propagation for all the mutant viruses. 
The general improved virus replication in NF-κB inhibiting conditions 
correlates with the P65 phosphorylation level increase generally observed in segment 
2 mutant viruses. This suggests that the AUG5, 10 and 11 expressing polypeptides 
(PB1-N40, -N92 and -N111) may act to counteract P65 phosphorylation and NF-κB 
transcription factor activity. 
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Figure 5.12: ΔAUG-mutants viral propagation in the presence of NFκB 
inhibitors. (A) Schematic representation of the NF-κB pathway and inhibition 
mechanisms of IMD0354 and JSH-23. Upon stimuli such as TLR3, TNFα or RIG-I, 
formation and activation of the IKKα/ IKKα/NEMO complex occurs, and is 
responsible for phosphorylation of IkBα. This step is inhibited by IMD0354. The 
phosphorylated IkBα is then targeted for proteasome degradation by ubiquitylation, 
leaving the P65/P50 hetero-dimer free to translocate into the nucleus though nuclear 
pores, process which is inhibited by JSH-23. Once in the nucleus, P65/P50 functions 
as a transcriptional factor to induce the expression of, among other, IFN-β. (B and C) 
293T cells were transfected with 25ng of IFN-β::Luc reporter plasmid. Twenty-four 
hours post transfection cells were stimulated with poly I:C or TNFα and incubated 
with different concentrations of IMD0354 (B) or JSH23 (C). After a further 24 hours, 
cells were lysed and luciferase activity was measured. Values were scaled to the 0µM 
stimulated cells sample. Data are mean ± SEM from two independent experiments 
performed with three technical repeats. (D and E) A549 cells were infected with PR8 
WT and segment 2 mutants at a MOI of 0.001. Virus was grown for 48 hours in the 
presence of absence of IMD0354 (D) or JSH23 (E). Viral titres were measured by 
plaque assay. Data are mean ± SEM from three independent experiments performed 
with a single technical repeat. Statistic annotations are the result of a two-way ANOVA 
test. Multiple comparisons tests were performed against the untreated control and no 
significantly statistical differences were found. 
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5.2.10. Effects of TRIM25 knockout on viral fitness of segment 2 
mutants 
IFN induction by IAV is highly attributed to RIG-I activation (Wu et al. 2015; 
Rehwinkel et al. 2010; Opitz et al. 2007). RIG-I viral RNA recognition and pathway 
activation are intrinsically linked to TRIM25. This mediates RIG-I ubiquitylation, 
leading to its activation and efficient recruitment of RIG-I’s downstream partners and 
triggering of interferon expression (Gack et al. 2007). So far, the systems employed 
and described in previous sections here (virus or poly I:C) induce type I IFN by 
signalling via TLR3 or RIG-I. To further test the importance of RIG-I activation for 
the attenuation of AUG mutant viruses, mock-edited and TRIM25-/- 293 cells 
(Choudhury et al. 2017), were infected at a MOI of 0.001 and plaque assays were used 
to quantify viral titres at 48 hpi (Figure 5.13). As a positive control, the NS1 R38K41A 
RNA-binding mutant was used, since these point mutations prevent inhibition of RNA 
recognition by RIG-I, causing therefore an attenuated growth phenotype (Pichlmair et 
al. 2006; Guo et al. 2007). WT PR8 replicated to titres of 107 PFU/mL in both WT and 
TRIM25 knockout cells and, consistent with previous data, an attenuated phenotype 
was seen for ΔAUG10 and/or 11 viruses in WT 293 cells. However, there was no 
increase in PB1 mutant virus replication on TRIM25-/- cells. On the other hand, the 
NS1 mutant virus was sensitive to TRIM25, having a 10-fold attenuation compared to 
WT PR8 in TRIM+/+ cells, which recovered in the counterpart knockout cells. Thus 
the segment 2 mutants were insensitive to the presence of TRIM25, suggesting that 
PB1-N92 and –N111 do not counteract RIG-I-mediated triggering of the IFN pathway. 
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Figure 5.13: Viral replication in TRIM25-/- cells. Mock-edited and TRIM25-/- 293 
cells were infected at a MOI of 0.001. Viral titres were quantified by plaque assay 48 
hpi. Data represent mean ± SEM from three independent experiments performed with 
a single technical repeat. Statistical symbols represent the result of a two-way ANOVA 
test. Multiple comparison tests were performed between naïve (TRIM+/+) and 
knockout (TRIM-/-) cells. **p-value <0.01. 
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5.3. Discussion 
Data from previous chapters showed that knocking out expression of PB1-N92 
and PB1-N111 increased the levels of type I IFN induced by virus infection, leading 
to the hypothesis that these polypeptides could be inhibiting involved in IFN induction. 
To test this, both polypeptides PB1-N92 and –N111 were examined outside of the 
infection context, through being cloned in expression plasmids, and their effects in 
IFN counteraction were independently tested in transfection-based assays. 
Initially, expression of PB1-related polypeptides from expression vectors 
showed the presence of products with corresponding predicted sizes. FLAG-tagged 
versions of these polypeptides were also created and used to observe their cytoplasmic 
localisation. The observed cytoplasmic localisation of PB1 in the absence of PA was 
consistent with previous studies showing a requirement for PB1-PA heterodimer 
formation prior to nuclear translocation. Moreover, transfection of PB1 along with a 
GFP-tagged PA expression plasmids resulted in the nuclear localisation of PA (Fodor 
and Smith 2004; Nieto et al. 1992). Due to their lack of PA-interacting N-terminal 
domain, PB1-N92 and –N111 were predicted not to localise in the nucleus regardless 
of the presence or absence of PA, as observed when transfecting FLAG-tagged PB1-
N92 and –N111. These findings are in agreement with previous studies where PB1-
N40, which also lacks this N-terminal region/function, also failed to localise in the 
nucleus (Wise et al. 2009). Nevertheless, cellular localisation was measured from 
FLAG-tagged CMV-driven expression plasmids, which result in more abundant 
protein levels than the ones detected in infected cells and therefore a potential different 
cellular localisation. Examples of differential protein cellular localisation dependent 
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on its mechanism of expression was observed in previous studies where, for instance, 
the single expression of PB1 from vaccinia virus resulted in its nuclear localisation 
(Smith et al. 1987), despite the fact that, in infected cells, PB1 requires the 
heterodimerisation with PA to undergo nuclear translocation. 
Virus-driven transcriptional and translational protein shut-off mechanisms 
have been related to PA-X, NS1 as well as the viral polymerase (Khaperskyy and 
McCormick 2015; Jagger et al. 2012; Marazzi et al. 2012). IAV RdRp has been shown 
to interact with the C-terminal domain of the transcriptionally engaged initiating form 
of Pol II and also associates with the promoter region of actively transcribed Pol II 
genes through its interaction with the large subunit of Pol II (reviewed in Vreede and 
Fodor 2010). Nevertheless, this polymerase shut-off activity has been mainly 
attributed to the PA subunit which exhibits cap-snatching endonuclease activity (Dias 
et al. 2009) and no shut-off activity has so far been shown for PB1, fitting the obtained 
results. 
Individual expression of PB1, PB1-N40, -N92 and –N111 did not result in a 
general protein shut-off effect, but were shown to inhibit poly I:C-induced IFN-β and 
ISRE promoter activation. As mentioned in chapter 3, IFN inhibition driven by the 
viral polymerase has been reported. The PB2 from human and avian viruses has been 
shown to accumulate in the mitochondrion and interact with MAVS (Graef et al. 2010; 
Long and Fodor 2016). Additional studies on the overall polymerase complex also 
reported IFN-β counteraction through MAVS inhibition in an NS1-independent 
manner (Iwai et al. 2010) and more recent studies also suggested RIG-I interaction 
with PB1/PA from incoming virions (Liedmann et al. 2014b). 
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Counteraction of RIG-driven IFN-β expression by PB1-expressing plasmids 
has been shown by Iwai et al. 2010. The same study has also shown that MAVS-
induced IFN-β and NF-κB can also be diminished by transient PB1 expression, 
consistent with results obtained in section 5.2.4. However, our study showed for the 
first time IFN-counteraction by PB1-truncated forms by both their untagged and 
FLAG-tagged versions, despite the fact that the FLAG-tagged polypeptides have 
shown a reduced counteractive effect in comparison to their untagged counterparts. 
However, this may be explained by the hydrophilic nature of the FLAG tag which, 
although did not seem to alter the predicted cellular localisation, could possibly impair 
the PB1-related polypeptides folding and function. 
Counteraction of the IFN-β promoter by PB1-related polypeptides was also 
seen following induction by RIG-I, MAVS as well as MyD88, TRIF and TBK1. 
However, the PB1 shorter products failed to counteract IFN-β induction by expression 
of IKKβ or any of the tested NF-κB subunits. Therefore, analysis of the pathway 
(Figure 1.6) suggested that inhibition of IFN induction by these polypeptides occurs at 
the stages of TBK1 or between MyD88 and the IKKα/β/NEMO complex. 
The action of the shorter products of PB1 was further evaluated in infected 
cells. IRF3 phosphorylation was enhanced in cells infected with ΔAUG11-containing 
viruses and their replication recovered when TBK1 and TRIF were inhibited. A 
general increase in p65 phosphorylation was seen for all mutant viruses whose 
replication fitness was also improved in the presence of NF-κB inhibitors. However, 
abrogation of RIG-I recognition by the knockout of TRIM25 did not alter virus fitness 
for any of the segment 2 mutant viruses. 
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Studies on IFN counteraction by other viruses have shown that, in addition to 
inhibition of RNA/DNA detection, they also express proteins which act at several 
downstream steps on the pathway leading to IFN-β expression. Example of this on the 
IRF3/7 arm are: 
 IE62 of varicella-zoster virus was shown to block IRF3 phosphorylation at key 
serine residues (Sen et al. 2010). 
 Ebola virus protein V35 has been shown to interact with IKKε and TBK1, 
modifying SUMOylation of IRF-7 (Prins et al. 2009; Chang et al. 2009). 
 Vpr and Vif of human immunodeficiency virus have been shown to bind to 
TBK1 and prevent its autophosphorylation (Harman et al. 2015). 
 Bovine viral diarrhea virus NPro has been shown to target IRF3 for 
proteasomal degradation (Hilton et al. 2006). 
Viral proteins responsible for the inhibition of the NF-κB cascade have also 
been described: 
 Vaccinia virus A52R has been shown to bind to IRAK2 and TRAF6 and 
disrupts downstream interactions (Harte et al. 2003). 
 NS5A is expressed by HCV and has been shown to prevent the interaction 
between IRAK and MyD88 (Abe et al. 2007). 
 HSV ICP27 has been shown to block phosphorylation and ubiquitylation of 
IκB (Kim et al. 2008). 
 West Nile virus NS1 has been shown to inhibit TLR3-induced NF-κB nuclear 
translocation (Wilson et al. 2008). 
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Reduction of IFN expression by IAV has been attributed to various functions 
of NS1, tNS1, PB1-F2, PB2-S1 and the viral polymerase (reviewed in Chapter 1). 
However, these are associated with counteraction of IFN at the very early stages of the 
pathway. Although the truncated version of NS1 (tNS1) was shown to inhibit IRF3 
phosphorylation, the study did not specify whether this was a shared function with full 
length NS1 at the RIG-I stage or if the inhibition was actually taking place at the IRF3 
step (Kuo et al. 2016). Given that both RIG-I and TLR3 may be required for full IFN 
induction following IAV infection (Wu et al. 2015), despite the shut-off activity of 
NS1 and PA-X at the level of blocking general Pol II-mediated gene expression, it 
would not be implausible that IAV could also encode an IFN inhibitor which acts 
downstream of RIG-I/MAVS to strengthen inhibition of TLR3-driven IFN induction. 
Due to the nested set nature of PB1, PB1-N40, -N92 and –N111, the expression 
of a larger peptide results in the co-production of a shorter peptide. Hence, it was not 
possible to solely express PB1-N92. One could argue the possibility of deleting 
AUG11 from the PB1-N92 expressing plasmid. However, potential changes in the 
phenotype given by such mutant plasmid would not provide a clear answer to whether 
it was due to the lack of PB1-N111, a single point mutation in PB1-N92 or both, 
making the determination of the individual functions of PB1-N92 challenging using 
expression plasmids. Nevertheless, analysis of IRF3 and NF-κB phosphorylation in 
infected cells and viral fitness in the presence of inhibitors suggested that whilst PB1-
N111 might counteract IRF3 phosphorylation, both PB1-N92 and –N111 could be 
involved in NF-κB inhibition. 
Overall, this chapter added two additional polypeptides to the group of 
inhibitors of IFN induction coded by IAV: PB1-N92 and –N11. Moreover, it showed 
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that counteraction of IFN expression in IAV infection is also performed in stages 
downstream of the initial RIG-I/MAVS recognition which also prevents TRL3/7-














Studies on the strain-dependency of AUG 
codons 10 and 11 
__________________________________________________________ 
 
6.1. Background and aims 
Previous chapters have described the expression of two additional products 
expressed from segment 2 AUG codons 10 and 11. These polypeptides were shown to 
block TBK1- and MyD88-induced IFN-β expression; their deletion from the virus led 
to increased phosphorylation of IRF3 and NF-κB P65 and reduced virus propagation 
in vitro and in vivo. However, the work so far only examined the PR8 strain of IAV. It 
was therefore important to determine if segment 2 AUG codons 10 and 11 are also 
important in the context of other IAV strains. Studies on the overall conservation of 
AUG codons in IAV segments 2 and 3 have been carried out (Gong et al. 2014; Gog 
et al. 2007). Although these studies found high conservation of PB1 AUG codons 10 
and 11, they failed to provide insights into any differential AUG conservation within 
specific hosts and subtypes of IAV. Therefore, a more in-depth analysis was performed 
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using a larger set of sequences that also considered the strength of Kozak signalling 
for AUG codons 5, 10 and 11, as well as their prevalence. Furthermore, in order to 
further test the importance of PB1 AUG codons 10 and 11 in IAV, six additional strains 
of virus were selected from avian, human and swine hosts. Segment 2 AUGs 10 and 
11 mutations were inserted into the background of these viruses and key elements of 




6.2.1. Conservation of frame 1 AUG codons in field isolates. 
In order to evaluate the conservation of segment 2 AUG codons within IAV 
subtypes from all known hosts, the available segment 2 sequences were downloaded 
from GenBank’s Influenza Virus Resource 
(http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html) on the 6th of May 2016. The 
31389 sequences found represented isolates from the main types of IAV host. Most 
sequences were from human isolates (45% of the total number of sequences). The next 
most abundant were sequences from avian hosts (42.5%), which were considered as 
one block, followed by swine (11.8%) and then equine (0.45%) and canine (0.25%) 
viruses (Figure 6.1). Sequences from other IAV hosts such as felines, aquatic 
mammals and bats were also retrieved but not considered due to the low number of 
samples (Figure 6.1). Once separated into hosts, sequences were further separated into 
groups of 500 using an R script. All R scripts used in this chapter were written by Dr 
Samantha Lycett (The Roslin Institute, The University of Edinburgh, UK). Each  
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Figure 6.1: Representation of the number of segment 2 sequences analysed. (A) 
A total of 31389 IAV segment 2 sequences were downloaded from NCBI. (B) After 
discarding poor quality sequences, 31012 sequences were retained, having maintained 
the overall representation of avian, canine, equine, human or swine sequences. (C) 
Numbers and percentages of total and analysed sequences. 
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individual group was aligned using the MUSCLE application within the MEGA6.0 
software followed by the selection of incomplete and erroneous sequences which were 
visually detected and discarded from the analysis. Reporting of UTR information was 
inconsistent between sequences, so in order to ensure a clear start for the alignments, 
any 5’ UTRs were removed. After sequence clean-up, the analysis was performed 
using 13278 avian, 80 canine, 134 equine, 14365 human and 3655 swine sequences, 
maintaining the original representation of each host category in the overall analysis 
(Figure 6.1 B and C). The “cleaned” alignments (containing up to 500 sequences each) 
were re-joined and the presence of AUGs at PB1 codons 1, 40, 92 and 111 (starting at 
nucleotides 1, 118, 274 and 331, respectively) was assessed using an R script (Figure 
6.2A). Sequences were further classified according to their H and N subtypes; 
considering the wide variety of these within each host grouping, subtypes which 
represented less than 1.5% of the total number of sequences per host were congregated 
into “Others”. The prevalence data were then plotted in contingency charts where the 
total prevalence of a specific AUG codon represents the sum of the percentage 
conservation for each subtype. Conservation of AUGs 5, 10 and 11 could therefore be 
compared to AUG1, which was always 100% conserved in every group of sequences. 
Overall, AUG codons 5, 10 and 11 were conserved at 99.4, 99.9 and 98.3% 
respectively. These high prevalence values were consistent with previous studies, 
which showed that AUGs 10 and 11 were present in at least 99 and 97% of the analysed 
sequences, respectively (Gong et al. 2014; Gog et al. 2007). Avian sequences 
presented a consistent AUG conservation independently of the subtype. Canine 
sequences presented 100% conservation of AUG codons 1, 5 and 10. AUG11 
prevalence was slightly decreased in this host (98.7%) due to the absence of this codon   




Figure 6.2: Conservation of segment 2 AUG codons 5, 10 and 11 and their Kozak consensus sequence. All available PB1 nucleotide 
sequences were downloaded from NCBI. (A) Sequences were separated into hosts and subtypes and the presence of AUGs 1, 5, 10 and 11 
in individual sequences was calculated. (B) The strength of Kozak signalling around the indicated AUG codons in the dataset was categorised 
as strong (-3A/G and +4G), medium (-3A/G or +4G) or weak (neither -3A/G nor +4G). “None” refers to sequences where no AUG codon 
was found in the stated positions. 
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in the single H9N2 (included in “Others”) sequence. Equine sequences also showed 
an overall 100% conservation of AUG codons 10 and 11, with the exception of H7N7 
isolates where these AUGs were only present in 4 of the 11 analysed sequences 
(36.3%). Similarly to avian isolates, human sequences had a high prevalence of all 
tested AUG codons (conservation varying between 99.4 and 99.9%). Conservation of 
frame 1 AUG codons was more variable in swine isolates, with AUG11 having the 
lowest levels in this host. AUG codons 5, 10 and 11 showed prevalence values of 96.3, 
99.9 and 90.8%, respectively. However, in contrast to other hosts, in swine sequences, 
the decrease of AUG conservation was not associated with a particular subtype. 
In addition to the ORF length and conservation of initiator codon, the nature of 
the Kozak motif is also an important factor in potentially dual-coding transcripts (Xu 
et al. 2010). Therefore, the same alignments were used to quantify the strength of each 
AUG Kozak signalling (Figure 6.2B). These sequences were categorised into strong (-
3A/G and +4G), medium (-3A/G or +4G) and weak (neither -3A/G nor +4G) (Kozak 
1986). Analysis revealed that in the case of present AUGs at in positions 40 (AUG5), 
92 (AUG10) or 111 (AUG11), Kozak sequence was strong in more than 99% of the 
occurrences. Cases of medium Kozak signalling represented 0.02, 0.03, 0.02% of the 
overall AUG-containing sequences for AUG codons 5, 10 and 11, respectively. Weak 
sequences were not detected. Analysis of Kozak signalling of AUG1 was not assessed, 
given the deletion of the 5’ UTR region post alignment. Total numbers of sequences 
where there were no AUG detected in the mentioned positions are shown under 
“None”. Overall, the majority of IAV strains (despite host or subtype) maintain AUG 
codons 10 and 11 in sequence context conducive to translation initiation. 
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6.2.2. Selected IAV strains 
In order to study the importance of segment 2 AUG codons 10 and 11 in other 
IAV strains, 6 additional viruses from avian, human and swine hosts were selected 
based on the availability of a reverse genetics system in the laboratory (Table 6.1). 
Alignments between the PB1 amino acid sequences of these viruses was performed, 
confirming the presence of AUG codons 10 and 11 (see later in Figure 6.11). Selected 
viruses included: 
 A pair of low- and high-virulence isolates from the 1983 United States poultry 
H5N2 outbreak (Kawaoka and Webster 1985) - Penn83 HP and Penn83 LP, 
 A laboratory-passaged H1N1 isolate derived from the mixed population present 
in an original isolate from a mallard duck (Bourret et al. 2012) – Mallard, 
 A lab-adapted human seasonal H3N2 strain (Chen et al. 2007) – Udorn, 
 A mouse-adapted derivative of the prototype human 2009 H1N1 pandemic virus 
(Ye et al. 2010) - Cal04, 
 An H3N2 swine isolate from 1987 (Wibberley et al. 1988) subsequently passaged 
8 times in eggs (Brown 2016) - Swine87. 
 
6.2.3. Translation initiation from segment 2 AUG codons 10 and 11 of 
the selected viruses 
As previously described for PR8 in section 2.2.1, protein expression from 
AUGs 10 and 11 of the selected panel of viruses was examined in the context of  
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Table 6.1: Selected virus strains used for reverse genetics analysis of PB1 AUGs 
10 and 11. Viral host, strain name and serotype are given. To simplify nomenclature 
of these viruses, abbreviations were also defined.  
Host Virus Abbreviation Serotype 
Avian 
A/chicken/Pennsylvania/1/1983 Penn83 HP H5N2 
A/chicken/Pennsylvania/1370/1983 Penn83 LP H5N2 
A/mallard/Netherlands/10-Cam/1999 Mallard H1N1 
Human 
A/Puerto Rico/8/34 PR8 H1N1 
A/Udorn/307/1972 Udorn H3N2 
A/California/04/2009 Cal04 H1N1 
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plasmid transfection. In order to do this, the first 380bp of Udorn, Cal04, Swine87 and 
Mallard segment 2 cDNAs were also cloned into a green fluorescent protein (GFP) 
expression plasmid, with the reporter gene positioned into frame with AUG codons 1, 
5, 10 and 11. Once confirmed by DNA sequencing, the panel of WT and mutated PR8 
constructs and the four new constructs were individually transfected into 293T cells. 
Forty-eight hours post-transfection, the expression of GFP-fused products was 
assessed by SDS-PAGE and western blot, using an antibody against GFP, as well as 
α-tubulin as a loading control. All samples contained similar amounts of tubulin 
(Figure 6.3), which confirmed comparable loading. 
As a negative control, a sample from mock transfected cells was included, 
which did not contain detectable GFP peptides, apart from the background bands 
(Figure 6.3, lane 1). The detection system was validated by the transfection of a GFP-
only plasmid positive control, where a polypeptide product was seen at 27kDa, the 
expected molecular mass for GFP (lane 2). As previously described in section 2.2.1, 
transfected cells with WT PR8 PB1-GFP plasmid, cells expressed fusion peptides 
corresponding to PB1, PB1-N40, PB1-N92 and PB1-N111 (lane 3) which were absent 
or reduced after the mutation of AUGs 1, 5, 10 and 11, respectively (lanes 4-8). Lanes 
9-12 represent GFP-tagged versions of Udorn, Cal04, Swine87 and Mallard 1-380bp 
of segment 2 mRNA, which also resulted in the expression of the four PB1-related 
polypeptides. 
Hence, translation initiation from AUG codons 10 and 11 is also observed from 
segment 2 cDNA of Udorn, Cal04, Swine87 and Mallard in transfected cells.  
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Figure 6.3. Expression of PB1 related species from Udorn, Cal04, Swine87 and 
Mallard segment 2 cDNA in transfected cells. 293T cells were transfected with the 
panel of PR8 GFP-fusion plasmids as well as the Udorn, Cal04, Swine87 and Mallard 
GFP-tagged segment 2 plasmids for 48 hours. Lysates from cells transfected (or mock 
transfected) with the indicated panel of plasmids were analysed by western blot with 
anti-GFP serum; α-tubulin was used as loading control. The position of molecular mass 
markers (in kDa) is indicated on the left. Datum is a representative of two independent 
experiments performed with one single technical repeat. 
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6.2.4. Evaluation of the transcription activity of mutant PB1 proteins 
of the selected viruses 
Single and double mutations of AUGs 10 and 11 were introduced into the 
segment 2 reverse genetics plasmids of the selected viruses by site-directed 
mutagenesis. As described in chapter 2, alteration of AUGs 10 and 11 led to the 
inevitable introduction of amino acid point mutations which could alter PB1 
polymerase activity. Therefore, as previously described in section 2.2.6, reverse 
genetics plasmids coding for the components of the viral ribonucleoprotein were used 
to measure transcription activity of mutant PB1 proteins of the different isolates in 
minireplicon assays. 
Mammalian IAVs and Mallard viral polymerase activity was assessed in 293T 
cells which were transfected with 50ng of each RNP plasmid and 20ng of a firefly 
luciferase vRNA-like reporter plasmid. Forty-eight hours later, cells were lysed and 
luciferase activity was measured (Figure 6.4 A-D). For all the viruses, a negative 
control substituting the PB1 segment for an empty pDUAL plasmid (2PNP), and 
mock-transfected cells were included. Assay validation was seen by statistically 
significant over 100-fold increase in luciferase activity between the 2PNP and the WT 
3PNP samples. Mutation of AUG codons 10 and/or 11 in the context of Udorn, Cal04, 
Swine87 or Mallard RNPs did not affect viral gene expression. Equivalent analyses 
were performed for the chicken viruses Penn83 HP and LP (Figure 6.4 E and F). 
However, these avian isolates possess a glutamic acid (E) at position 627 of PB2 which 
often does not support activity in mammalian cells (Luk et al. 2015; Subbarao et al. 
1993; Naffakh et al. 2000). Therefore, transcription activity of the mutant PB1   




Figure 6.4: Transcription activity of segment 2 mutant RNPs. (A-D) 293T or (E, 
F) QT-35 cells were transfected with 3PNP expressing plasmids and a vRNA-like 
luciferase reporter plasmid under a human or avian RNA PolI promoter respectively. 
Forty-eight hours post transfection, cells were lysed, and luciferase levels measured. 
Data represent mean ± SEM from three independent experiments performed with three 
technical repeats. Statistic annotations are the result of an ordinary one-way ANOVA 
test. *p-value, <0.05, **p-value <0.01, ***p-value <0.001, ****p-value <0.0001.  
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specimens in the context of Penn83 HP and LP polymerases was performed in avian 
cells. QT-35 quail fibroblasts were transfected with plasmids encoding the RNP 
proteins of Penn83 HP or LP along with a reporter plasmid expressing vRNA-Luc 
from an avian PolI promoter (Figure 6.4 E and F). Transcription activity of Penn38 HP 
was stronger than Penn83 LP with Penn83 HP having a near 100-fold induction of 
3PNP over 2PNP condition, compared with Penn83 LP where the fold induction was 
only 20-fold. Nonetheless, as observed for all the other tested viruses, RNPs 
harbouring ΔAUG10/11 PB1 subunits did not show any attenuation in transcription 
activity. Thus, as previously shown for PR8 ΔAUG mutants (section 2.2.6), mutated 
PB1 polypeptides of the the additional IAV strains tested shared a WT-like 
transcription phenotype. 
 
6.2.5. Propagation of the wider panel of segment 2 mutant viruses in 
MDCK cells 
Having tested the transcriptional activity of PB1 mutants, the reverse genetics 
plasmids were used to rescue the actual viruses, in WT and mutant forms. Attempts at 
rescuing Penn83 HP and LP viruses as either 6:2 (using HA and NA of PR8 for 
biosafety reasons) or 4:4 (using the chicken virus 3PNP genes with the remaining 
segments from PR8) reassortant combinations were made in several mammalian and 
avian systems. However, despite several attempts, neither WT nor mutant viruses were 
successfully generated in any of the reassortment arrangements (data not shown). In 
contrast, the other viruses were generated readily and used to create P1 stocks (as in 
section 2.2.2). At least two independent stocks were created for each of the mutant  




Figure 6.5: Growth kinetic analyses of WT and mutant viruses in MDCK cells. 
MDCK cells were infected at a MOI of 0.001 and samples were collected at the 
indicated times post infection. Data are mean ± SEM from three independent 
experiments performed with a single technical repeat. Statistic annotations are the 
result of an ordinary one-way ANOVA test (performed individually for each time-
point). *p-value <0.05, **p-value <0.01. Dashed lines indicate the limit of detection 
for the plaque assays (2 PFU/ml). 
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viruses. Sequencing of segment 2 confirmed the presence of the desired sequences 
(data not shown). 
Rescued P1 stocks for the Udorn, Cal04, Swine87 and Mallard sets were used 
to perform growth kinetic analyses. Confluent monolayers of MDCK cells were 
infected at a MOI of 0.001, supernatants were collected at 6, 8, 12, 24, 36, and 48 hpi 
and viral titres were measured by plaque assay (Figure 6.5). WT Udorn steadily 
increased in titre with time, reaching a maximum of 4×107 PFU/mL at 36 hpi (Figure 
6.5A). A comparable outcome was observed for Udorn ΔAUG11, which showed no 
attenuation in this growth system. However, although not statistically significant, 
mutation of AUG10 resulted in 10-fold lower titres from 24 hours onwards. This 
phenotype was shared by the double mutant virus Udorn ΔAUG10,11 whose growth 
pattern overlapped the single mutant ΔAUG10. Cal04 WT reached titres of 108 
PFU/mL and a WT-like phenotype was observed for Cal04 ΔAUG10 during the entire 
course of infection (Figure 6.5B). However, loss of AUG11 resulted in delayed virus 
replication kinetics which nevertheless recovered to WT-like titres at 36 and 48 hpi. 
An even more accentuated attenuation of replication was seen for the double mutant 
Cal04 ΔAUG10,11, which had a 106-fold decrease in viral titre compared with its WT 
counterpart at 24 hpi and did not show any recovery throughout the remaining course 
of infection. WT Swine87 virus also propagated to high titres in this system, reaching 
a maximum titre of 4×107 PFU/mL at 36 hpi (Figure 6.5C). Similar to PR8 and Cal04 
mutants, deletion of AUG10 did not induce changes in virus replication. On the other 
hand, deletion of AUG11 led to statistically significant 100-fold decreases in virus 
titres, seen for both single and double mutants ΔAUG11 and ΔAUG10,11. Replication 
of Mallard WT resulted in titres of 5×107 PFU/mL which peaked at 24 hpi (Figure 
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6.5D). However, introduction of mutations in AUG codons 10 and/or 11 in this viral 
context did not affect virus titres. In general terms, this section showed that either AUG 
codons 10 and/or 11 are important for WT-like virus replication of mammalian isolates 
in MDCK cells, but dispensable in the context of the duck virus used here. 
 
6.2.6. IFN induction by the wider panel of segment 2 mutant viruses 
Next, we asked if, as found for PR8, the larger panel of segment 2 AUG 
mutants would induce a stronger IFN expression in the context of viruses, which might 
explain the attenuated phenotype of some of them. To investigate this, A549 cells were 
infected at a MOI of 3 (for Udorn and Cal04 sets) or 0.03 (for Swine and Mallard sets). 
The diminished MOI used for the last two sets was due to the lower titres acquired for 
some of the P1 stocks (data not shown) which did not allow high MOI infections. 
Infections with the mutant viruses Cal04 ΔAUG10,11 and Swine87 ΔAUG10,11 were 
not performed as the P1 stocks were too low titre to allow even this reduced MOI (data 
not shown). Twenty-four hpi, IFN levels were measured using the HEK Blue cell 
bioassay (as previously described in section 3.2.1). As a control for all the infections, 
PR8 WT and NS1 R38K41A were used as negative and positive controls, respectively. 
A strong IFN induction was seen for the mutant NS1 virus while background levels 
were observed for PR8 WT (data not shown). Moreover, a standard curve using 
universal type I IFN was also added and a dose-dependent increase in A600 was 
observed, confirming assay function (data not shown). WT Udorn virus infection 
induced only background levels of IFN, whereas the virus with a mutation in AUG10 
resulted in statistically significantly increased IFN induction. Equivalent results were  
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Figure 6.6: Type I IFN induction during infection with selected ΔAUG10 and/or 
11 viruses isolated from different hosts. A549 cells were infected with MOI of 3 for 
(A) Udorn and (B) Cal04 and 0.03 for (C) Swine87 and (D) Mallard mutant viruses. 
Twenty-four hpi, cell supernatants were harvested, UV-inactivated and type I IFN 
levels measured using HEK Blue cell bioassay. Absorbance values at 600nm are 
shown, which are proportional to the amount of type I IFN present in the cell 
supernatants. Data are mean ± SEM from four independent experiments performed in 
duplicates. Statistical symbols represent the results of ordinary one-way ANOVA 
tests. **p-value <0.01, ***p-value <0.001, ****p-value <0.0001.  
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seen for infection with the ΔAUG10,11 virus. On the other hand, loss of AUG11 did 
not result in different IFN secretion from WT virus (Figure 6.6A). WT Cal04 infection 
also resulted in background levels of IFN induction. However, this was significantly 
increased in ΔAUG10, and more prominently in ΔAUG11 mutant viruses (Figure 
6.6B). As with PR8, high MOI infections with the double mutant ΔAUG10,11 were 
not possible because of the low titres of the recovered P1 stocks (data not shown). In 
contrast to all the other tested WT viruses, A549 infections with WT Swine87 induced 
IFN levels well above background/mock levels. Nonetheless, similarly to the Cal04 
and PR8 sets of viruses, mutation of AUG codons 10 and 11 resulted in augmented 
IFN induction, which was statistically significant when the ΔAUG11 Swine87 virus 
was compared to WT (Figure 6.6C). Mallard WT infections induced background levels 
of type I IFN. However, unlike all the ΔAUG10/11 mutant viruses so far tested, 
alteration of AUG codons 10 and/or 11 did not cause increased IFN expression in A549 
cells (Figure 6.6D). 
Overall, this section corroborated the data observed in the kinetic analysis by 
showing a good correlation between the inability to replicate normally in vitro and an 
increased induction of type I IFN. 
 
6.2.7. Phosphorylation of IRF3 in cells infected with the panel of 
segment 2 mutants 
Following the sequence of experiments performed to characterise the PR8 
AUG mutant viruses, we next analysed the levels of IRF3 phosphorylation in cells 
infected with the mutants. As in section 6.2.5, A549 cells were infected with the 
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different sets of segment 2 mutant viruses at MOIs of 3 (Udorn and Cal04) or 0.03 
(Swine87 and Mallard). Twenty-four hpi, phosphorylation of IRF3 was detected by 
western immunoblot, along with total IRF3 levels. Detection of viral NP was used to 
confirm infection and α-tubulin monitored as loading control (Figure 6.7). Mock-
infected samples had undetectable or very low levels of IRF3 phosphorylation (Figure 
6.7 A-D lanes 1). For each individual experiment of each set of viruses, PR8 NS1 
R38K41A and transfection with poly I:C were used as positive controls, which showed 
increased levels of pIRF3 compared to the cells-only control (data not shown). Readily 
detectable amounts of pIRF3 were detected in Udorn WT-infected cells, which were 
not substantially increased by the introduction of the ΔAUG10/11 mutations (Figure 
6.7A). Quantification of replicate experiments by densitometry corroborated that, 
despite a slight increase in pIRF3 amounts in the Udorn ΔAUG11 mutant, there were 
no significant differences between the mutants and WT Udorn (Figure 6.7E). Cal04 
WT infections also resulted in low levels of pIRF3 detection. However, in contrast to 
the Udorn mutants, single deletion of AUG codons 10 or 11 resulted in substantially 
increased levels of IRF3 phosphorylation. This increment was more pronounced with 
Cal04 ΔAUG11 (Figure 6.7B). This was confirmed by quantification of IRF3 
phosphorylation which showed statistically significant 3- and 5-fold increases of 
pIRF3 levels with ΔAUG10 and ΔAUG 11 Cal04 viruses, respectively (Figure 6.7F). 
Phosphorylation of IRF3 was also readily detectable in the context of Swine87 WT 
virus infection. However, increased levels of pIRF3 were seen following infection with 
AUG10 and, especially, ΔAUG11 Swine87 viruses (Figure 6.7C). Quantification by 
densitometry from three independent experiments showed statistically significant 
differences only for Swine87 ΔAUG11 in comparison to the WT virus (Figure 6.7G).   
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Figure 6.7: IRF3 phosphorylation in infection of selected viruses’ segment 2 
mutants. (A-D) A549 cells were infected at a MOI of 5 for 24 hours, after which cell 
lysates were collected. Lysates were subjected to SDS-PAGE followed by the 
detection of naïve and phosphorylated forms of IRF3 by western blot. NP and α-
tubulin were detected to confirm infection and as a loading control, respectively. (E-
H) Relative quantification of the phosphorylated IRF3 form was performed in ImageJ 
and scaled to the respective values from WT virus infections. Data represent mean ± 
SEM from three independent experiments performed with a single technical repeat. 
Statistic annotations are the result of an ordinary one-way ANOVA test. *p-value, 
<0.05, **p-value <0.01, ****p-value <0.0001. 
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In concordance with the previous sections and in contrast to the other viruses, mutation 
of AUG codons 10 and/or 11 in the context of a Mallard virus infection did not lead to 
stronger phosphorylation of IRF3 in comparison to WT virus (Figure 6.7D). 
Quantifications of the western blots reflected this result (Figure 6.7H). Thus, IRF3 
phosphorylation levels were upregulated in ΔAUG10/11 mutant viruses in general 
agreement with increased IFN induction and lowered replication values. 
 
6.2.8. Effect of BX-795 on the propagation of the panel of segment 2 
mutant viruses 
Next, the effects of chemically inhibiting IRF3 phosphorylation on segment 2 
AUG mutant virus propagation were measured for Udorn, Cal04, Swine87 and 
Mallard virus sets; again following the hypothesis that if the growth defect arose from 
the lack of a viral IRF3 antagonist, exogenous suppression of TBK1/IKKε complex 
activity should complement the defect. As previously described in section 5.2.6, A549 
cells were pre-treated with varying concentrations of BX-795 for 2 hours, following 
which cells were infected at MOI of 0.001 and overlaid with the same concentrations 
of drug. Virus-containing cell supernatants were collected at 48 hpi and viral titres 
were measured by plaque assay (Figure 6.8). For the Udorn set, in the absence of drug, 
deletion of AUG10 was more deleterious for virus replication than the loss of AUG11 
in A549 cells (as previously seen in section 6.2.5 for MDCK cells). Infection with the 
ΔAUG10 mutant resulted in a 20-fold reduction in viral titre in comparison with WT 
Udorn, while ΔAUG11 replication was only reduced in 8-fold (Figure 6.8A). The 
double mutant presented an 80-fold reduction in viral titre, compared its WT  
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Figure 6.8: Replication of ΔAUG mutant viruses in the presence of BX-795. A549 
cells were pre-treated with 1, 2, 5μM of BX-795 and infected with (A) Udorn, (B) 
Cal04, (C) Swine or (D) Mallard segment 2 mutant viruses at a MOI of 0.001. BX-795 
concentrations were kept during the entire time course of infection. Forty-eight hpi, 
viral titres were measured by plaque assay. Values were scaled to the WT viral titres 
of each drug concentration. Data represent mean ± SEM from three independent 
experiments performed with a single technical repeat. Statistical symbols represent the 
result of a two-way ANOVA test. Multiple comparison tests were performed within 
each mutant, having the 0μM concentration as control. *p-value <0.05, **p-value 
<0.01, ***p-value <0.001. 
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counterpart. However, despite the modestly augmented pIRF3 levels in ΔAUG10 
and/or 11 mutant viruses, replication of mutant ΔAUG10-containing Udorn viruses 
recovered in the presence of BX-795. This recovery was most obvious, and statistically 
significant, with the highest dose of inhibitor, 5µM for the ∆AUG10 virus. Cal04 
ΔAUG10 and/or 11 mutants were attenuated in A549 cells in the absence of BX-795 
with reductions of 100- to 1000-fold in end point viral titres in comparison to WT 
Cal04 (Figure 6.8B). However, the addition of BX-795 resulted in the increased virus 
propagation of the AUG mutants, correlating with the enriched phosphorylation levels 
of IRF3 in the both single ΔAUG10 and ΔAUG11 Cal04 mutant viruses. As previously 
seen in MDCK cells, the ΔAUG10 Swine87 mutant replicated with a WT-like 
phenotype in A549 cells (Figure 6.8C), while a >100-fold attenuation of AUG11 
mutant viruses (ΔAUG11 and ΔAUG10,11) was observed in the absence of BX-795. 
However, addition of the IRF3 inhibitor resulted in the recovery of viral propagation 
of the attenuated mutants, this phenotype being most pronounced using 5µM of the 
drug. As seen for the Cal04 mutants, these data corroborated the IRF3 phosphorylation 
data, where the strongest levels of pIRF3 were seen with the ΔAUG11 mutant. 
Consistent with all the data acquired for the Mallard mutants so far in this chapter, 
modification of AUG codons 10 and 11 did not alter viral fitness in the absence or 
presence of BX-795 in A549 cells (Figure 6.8D). These findings also correlate with 
the lack of changes in pIRF3 in ΔAUG10/11 Mallard-infected cells. 
Overall, these data supported the hypothesis that mutation of segment 2 AUGs 
10 and/or 11 result in reduced control of IRF3 phosphorylation in most, but not all of 
a wider panel of IAVs. 
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6.2.9. Fitness of Mallard segment 2 mutants in avian cells 
The avian virus, Mallard, was the only one of the tested IAV strains which was 
not sensitive to the mutation of either AUG codon 10 and/or 11. However, the fitness 
of, and cell responses against, WT and mutant Mallard viruses were assayed in 
mammalian cell lines. Type I IFN pathways in mammalian and avian cells differ in 
several ways, such as the absence of RIG-I in chickens and other members of the order 
Galliformes (Santhakumar et al. 2017; Karpala et al. 2011). Therefore, we postulated 
that Mallard had evolved to better counteract the IFN system in avian systems and that 
the products arising from AUGs 10 and 11 might more efficiently counteract 
components of avian IFN pathways. To test this, the fitness of Mallard WT and AUG 
mutant viruses was assessed in avian cells: QT-35 quail fibroblasts and DF1 chicken 
fibroblasts. Cells were infected at a MOI of 0.001 and a multicycle infection was 
allowed to proceed until 48 hpi, after which cell supernatants were collected and viral 
titres measured by plaque assay. In both cell lines, Mallard WT replicated to over 104 
PFU/mL (Figure 6.9). Single mutations of AUGs 10 or 11 led to non-statistically 
significant 5-fold decreases in viral titre in QT-35 cells (Figure 6.9A). However, 
despite the lack of attenuation in mammalian systems, a 9-fold statistically significant 
attenuation in virus propagation was seen for the double mutant Mallard ΔAUG10,11. 
In DF1 cells, multicycle infection with ΔAUG10 Mallard resulted in non-significant 
differences compared to its WT counterpart (Figure 6.9B). However, in the same cell 
type, mutation of AUG11 or both AUGs 10 and 11 lead to a 40-fold statistically 
significant decrease in viral titre, compared to WT virus. Thus, although Mallard virus 
was indifferent to the loss of segment 2 AUG codons 10 and/or 11 in mammalian cells,  




Figure 6.9: Replication of Mallard mutant viruses in avian cells. (A) QT-35 and 
(B) DF1 cells were infected at MOI 0.001 and supernatants were collected 48 hpi. 
Viral titres were quantified by plaque assay. Data are mean ± SEM from three 
independent experiments performed with a single technical repeat. Statistical symbols 
represent the result of an ordinary one-way ANOVA test. Multiple comparison tests 
(within data from each cell type) were performed against WT Mallard. *p-value <0.05. 
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the same was not the case in avian cells, where the single and/or double mutation of 
these codons resulted in the attenuation of the Mallard mutant viruses. 
 
6.3. Discussion 
In this chapter, in order to corroborate the characterisation performed for PR8, 
the importance of segment 2 AUG codons 10 and 11 was evaluated in the context of 
other viruses. A bioinformatics analysis of all available segment 2 sequences showed 
that AUGs 10 and 11 are more than 90% conserved in IAV isolates, in a host-
independent manner. Moreover, Kozak signalling analysis confirmed the strong 
translation start potential in the majority of the sequences examined. These data 
complemented previous bioinformatics studies on the search for alternative open 
reading frames which also showed the high prevalence of AUG codons 10 and 11 of 
99 and 97%, respectively (Gong et al. 2014; Gog et al. 2007). Moreover, based on 
criteria such as strong Kozak consensus sequence, AUG location (within the first third 
of the transcript), and high prevalence, the study by Gong and colleagues considered 
there to be a high likelihood of protein expression from these AUG codons (Gong et 
al. 2014).  
However, despite the overlapping PB1-F2 ORF encoded between nucleotides 
119 and 382 of PR8 segment 2, other AUG codons within that region (such as AUGs 
6, 7, 8 or 9, Figure 2.1) are not highly conserved (data not shown) (Gong et al. 2014). 
The high AUG conservation of AUGs 10 and 11 contrasts with other AUG 
codons present in the 5’ end of IAV segment 2 (schematic representation in Figure 
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2.1). Parallel bioinformatics analysis also performed in this study suggested that apart 
from AUG4 which drives the expression of PB1-F2 (Chen et al. 2001) and shows high 
AUG prevalence and conserved strong Kozak signalling, the remaining AUG codons 
4, 6, 7, 8 and 9 can be present in between 10 and 100% in field isolates and Kozak 
signalling is very often of medium power (Figure 6.10), despite the overlapping PB1 
and PB1-F2 ORFs encoded in that same region (between nucleotides 119 and 382). 
Here it is hypothesised that AUG codons 10 and 11 are conserved to drive 
expression of an IRF3 antagonist which were shown important for IAV life cycle, 
which is correlated with the observed high conservation of AUG5 driving expression 
of PB1-N40 (Wise et al. 2009). Nevertheless, given the coding restrains of IAV, it 
must be admitted that the observed conservation of AUG codons and respective strong 
Kozak consensus could reflect other reasons: 
 The main product PB1 requires methionines at positions 92 and 111. 
However, for none of the tested viruses the deletion of AUG codons 10 and/or 
11 resulted in a deficit in polymerase activity as measured by RNP 
reconstitution assays. 
 The conserved strong Kozak signalling can be due to the need to preserve the 
amino acids immediately adjacent to positions M40, M92 and M111 (which 
was not tested by RNP reconstitution assays). A strong Kozak signalling of a 
given AUG was defined as having A/G in -3 and G in +4 positions (Kozak 
1986). According to Gog and colleagues, PB1 position 39 fluctuates between 
adenine and threonine whilst 41 is invariably an asparagine (Table 6.2A). 
Analysis of all the possible codons of either A39 or T39 results in the first 
nucleotide being always G or A. Likewise, the immediately downstream   
Chapter 6   
222 
 
Figure 6.10: Conservation of segment 2 AUG codons 4, 6, 7, 8 and 9 and their Kozak consensus sequence. All available PB1 nucleotide 
sequences were downloaded from NCBI. (A) Sequences were separated into hosts and subtypes and the presence of AUGs 4, 6, 7, 8 and 9 
in individual sequences was calculated. (B) The strength of Kozak signalling around the indicated AUG codons in the dataset was categorised 
as strong (-3A/G and +4G), medium (-3A/G or +4G) or weak (neither -3A/G nor +4G). “None” refers to sequences where no AUG codon 
was found in the stated positions.  
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Table 6.2. Kozak context of AUG codons 5, 10 and 11. Observed neighbouring 
amino acids of AUG codons 5-M40 (A), 10-M92 (B) and 11-M111 and respective 
possible codons. Most prevalently observed amino acids are marked with an asterisk 
(*). Nucleotides responsible for the strength of the Kozak consensus (-3 and +4) 
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D41 is either coded by GAT or GAC, both resulting in a G in +4 and providing 
the strong Kozak consensus of AUG5. Parallel analysis performed for AUGs 
10 and 11 revealed that AUG10 (M92) is neighboured by A91 or V91 (both 
giving a G in -3) and A93 (G in +4) or T93 (A in +4) (Table 6.2B). Despite not 
providing a strong Kozak context, T93 occurs in less than 1% of all the 
analysed sequences (Gog et al. 2007). Similar to AUG5, all the possible amino 
acids surrounding AUG11 (M111) always provide an A/G at -3 and G at +4 
(Table 6.2C). Given the high amino acid conservation of PB1 (Gog et al. 2007) 
and the lack of diversity of the potential codons of the amino acids adjacent to 
M92 and M111, it is difficult to differentiate between PB1 protein conservation 
and PB1-N92/-111 expression conservation. This could though be tested my 
mutagenesis followed by RNA reconstitution assays and further explored by 
serial passage a ΔAUG10,11 attenuated virus in type I IFN/IRF3 knockout cells 
and compare their evolution/reversion. 
To further test whether the findings obtained for PR8 suggesting an IRF3 
antagonist are a generalised feature of IAV, 6 additional viruses were selected (but 
only 4 could be rescued) and ΔAUG10 and/or 11 mutant reverse genetics plasmids 
were constructed. 
Swine87 and Cal04 viruses behaved similarly to PR8 where the deletion of 
AUG11 was shown to be more deleterious to virus replication and resulted in higher 
levels of IRF3 phosphorylation and increased IFN induction in human cells than 
AUG10. However, multicycle infections using H3N2 Udorn mutant viruses showed 
that the AUG10 was more important than AUG11, with replication defects seen only 
for the single mutant ΔAUG10 and the double mutant ΔAUG10,11 viruses. Udorn was 
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the only virus to which AUG10 seems to be more important. However, the phenotype 
of ΔAUG10 in the context of Udorn is not as severely attenuated as ΔAUG11 in PR8, 
Swine and/or Cal04. Differences between the importance of different AUG codons in 
different isolates can be due to: 
 Differential expression of PB1-N92 and PB1-N111 in Udorn, in comparison to 
the other tested strains. Both GFP-tagged segment 2 constructs and infections 
with PR8 mutant viruses showed a stronger expression of –N111 in comparison 
to –N92. However, levels of expression of PB1-N92 and –N111 were not 
assessed from Udorn-infected cells nor Udorn segment 2-GFP plasmids. 
Speculating that if in Udorn expression of PB1-N92 is higher that –N111, it is 
reasonable to consider that its deletion would cause a more severe impact in 
virus replication, despite PR8 and Udorn PB1-N92 could potentially share the 
same function. However, given the conservation of the adjacent amino acids 
91, 93, 110 and 112, as previously explained in this subchapter, the Kozak 
surroundings of AUG codons 10 and 11 are the same for all the tested viruses 
(Figure 6.11). 
 Differential protein activity of PB1-N92 and PB1-N111 between Udorn and 
the other tested mammalian IAV strains. Comparative analysis between PB1 
amino acid sequences from Udorn and the other viruses tested revealed minor 
differences. However, Udorn PB1 presents unique lysine residues in positions 
121 and 393 whereas the other selected viruses have arginines (Figure 6.4). 
Given that the structures of the PB1-N92 and –N111 polypeptides have not 
been resolved, although both amino acids are positively charged, the loss of the  
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. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 1 M D V N P T L L F L K V P A Q N A I S T T F P Y T G D P P Y S H G T G T G Y T M D T V N R T H Q Y S E K G R W T T N T E T G A P Q L N P I D G P L P E D N E P S
HP 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . R . K . . . . . . . . . . . . . . . . . . . . . . . . . .
LP 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . R . K . . . . . . . . . . . . . . . . . . . . . . . . . .
Mallard 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . .
Udorn 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . .
Cal04 1 . . . . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . . . . . . . . . . . . . . . . . . . . .
90 100 110 120 130 140 150 160
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 81 G Y A Q T D C V L E A M A F L E E S H P G I F E N S C I E T M E V V Q Q T R V D K L T Q G R Q T Y D W T L N R N Q P A A T A L A N T I E V F R S N G L T A N E S
HP 81 . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LP 81 . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mallard 81 . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Udorn 81 . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cal04 81 . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine 81 . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
170 180 190 200 210 220 230 240
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 161 G R L I D F L K D V M E S M N K E E M G I T T H F Q R K R R V R D N M T K K M I T Q R T M G K K K Q R L N K R S Y L I R A L T L N T M T K D A E R G K L K R R A
HP 161 . . . . . . . . . . . . . . D . . . . E . . . . . . . . . . . . . . . . . R . V . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LP 161 . . . . . . . . . . . . . . D . . . . E . . . . . . . . . . . . . . . . . R . V . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mallard 161 . . . . . . . . . . . . . . D . . . . E . . . . . . . . . . . . . . . . . . . V . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Udorn 161 . . . . . . . . . . . . . . D . . . . E . . . . . . . . . . . . . . . . . . . V . . . . I . . . . . . V . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cal04 161 . . . . . . . . . . . . . . . . . . I E . . . . . . . . . . . . . . . . . . . V . . . . I . . . . . . . . . . G . . . . . . . . . . . . . . . . . . . . . . . .
Swine 161 . . . . . . . . . . . . . . D R . . . E . . . . . . . . . . . . . . . . . . . V . . . . I . . . . . K V . . . T . . . . . . . . . . . . . . . . . . . . R . . .
250 260 270 280 290 300 310 320
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 241 I A T P G M Q I R G F V Y F V E T L A R S I C E K L E Q S G L P V G G N E K K A K L A N V V R K MM T N S Q D T E L S F T I T G D N T K W N E N Q N P R M F L A
HP 241 . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LP 241 . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mallard 241 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Udorn 241 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cal04 241 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . .
Swine 241 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
330 340 350 360 370 380 390 400
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 321 M I T Y M T R N Q P E W F R N V L S I A P I M F S N K M A R L G K G Y M F E S K S M K L R T Q I P A E M L A S I D L K Y F N D S T R K K I E K I R S L L I E G T
HP 321 . . . . I . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . P . . . D . .
LP 321 . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . P . . . D . .
Mallard 321 . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N . . . . . . . E . . . . . . . . . . P . . . D . .
Udorn 321 . . . . I . K . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . . . . R . . . . . . . . . . . . . . . . . . . . . E . . . . . . . . . K P . . . D . .
Cal04 321 . . . . I . . . . . . . . . . I . . M . . . . . . . . . . . . . . . . . . . . . R . . I . . . . . . . . . . . . . . . . . . E . . K . . . . . . . P . . . D . .
Swine 321 . . . . I . K . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . . . . K . . . . . . . . . . . . . . . E . . . . . E . . . Q . . . . . . P . . V N . .
410 420 430 440 450 460 470 480
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 401 A S L S P G MMM G M F N M L S T V L G V S I L N L G Q K R Y T K T T Y WW D G L Q S S D D F A L I V N A P N H E G I Q A G V D R F Y R T C K L L G I N M S K K
HP 401 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . .
LP 401 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . .
Mallard 401 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . .
Udorn 401 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . .
Cal04 401 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . .
Swine 401 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . .
490 500 510 520 530 540 550 560
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 481 K S Y I N R T G T F E F T S F F Y R Y G F V A N F S M E L P S F G V S G I N E S A D M S I G V T V I K N N M I N N D L G P A T A Q M A L Q L F I K D Y R Y T Y R
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LP 641 . . . . V . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mallard 641 . . . . V . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Udorn 641 . . . . V . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cal04 641 . . . . V . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine 641 . . . . V . . . . . . . . S V . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . H . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
730 740 750
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . .
PR8 721 R A R I D A R I D F E S G R I K K E E F T E I M K I C S T I E E L R R Q K *
HP 721 . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . *
LP 721 . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . *
Mallard 721 . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . *
Udorn 721 . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . *
Cal04 721 . . . . . . . V . . . . . . . . . . . . S . . . . . . . . . . . . . . . . *
Swine 721 . . . . . . . . . . . . . . . . . A . . S . . . . . . . . . . . . . . . . *




Figure 6.11: Sequence alignment of PB1 proteins of selected viruses. Nucleotide sequences of selected viruses were downloaded from 
NCBI. In silico translation and protein alignment was performed using the MEGA6 software. PR8 PB1 was used as reference sequence. 
Avian viruses are represented on the top, followed by two additional human strains and the swine strain. Conservation of M40, M92 and 
M111 is highlighted in green. Specific changes in Udorn are marked by dashed red boxes. Specific changes in Mallard are marked by dashed 
blue boxes. Avian-to-mammalian adaptation mutations found in the literature are marked by yellow boxes. Alignment was created and kindly 
provided by Dr Carina Conceição. 
 
  
10 20 30 40 50 60 70 80
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 1 M D V N P T L L F L K V P A Q N A I S T T F P Y T G D P P Y S H G T G T G Y T M D T V N R T H Q Y S E K G R W T T N T E T G A P Q L N P I D G P L P E D N E P S
HP 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . R . K . . . . . . . . . . . . . . . . . . . . . . . . . .
LP 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . R . K . . . . . . . . . . . . . . . . . . . . . . . . . .
Mallard 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . .
Udorn 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . .
Cal04 1 . . . . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . . . . . . . . . . . . . . . . . . . . .
90 100 110 120 130 140 150 160
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 81 G Y A Q T D C V L E A M A F L E E S H P G I F E N S C I E T M E V V Q Q T R V D K L T Q G R Q T Y D W T L N R N Q P A A T A L A N T I E V F R S N G L T A N E S
HP 81 . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LP 81 . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mallard 81 . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Udorn 81 . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cal04 81 . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine 81 . . . . . . . . . . . . . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
170 180 190 200 210 220 230 240
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 161 G R L I D F L K D V M E S M N K E E M G I T T H F Q R K R R V R D N M T K K M I T Q R T M G K K K Q R L N K R S Y L I R A L T L N T M T K D A E R G K L K R R A
HP 161 . . . . . . . . . . . . . . D . . . . E . . . . . . . . . . . . . . . . . R . V . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LP 161 . . . . . . . . . . . . . . D . . . . E . . . . . . . . . . . . . . . . . R . V . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mallard 161 . . . . . . . . . . . . . . D . . . . E . . . . . . . . . . . . . . . . . . . V . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Udorn 161 . . . . . . . . . . . . . . D . . . . E . . . . . . . . . . . . . . . . . . . V . . . . I . . . . . . V . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cal04 161 . . . . . . . . . . . . . . . . . . I E . . . . . . . . . . . . . . . . . . . V . . . . I . . . . . . . . . . G . . . . . . . . . . . . . . . . . . . . . . . .
Swine 161 . . . . . . . . . . . . . . D R . . . E . . . . . . . . . . . . . . . . . . . V . . . . I . . . . . K V . . . T . . . . . . . . . . . . . . . . . . . . R . . .
250 260 270 280 290 300 310 320
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 241 I A T P G M Q I R G F V Y F V E T L A R S I C E K L E Q S G L P V G G N E K K A K L A N V V R K MM T N S Q D T E L S F T I T G D N T K W N E N Q N P R M F L A
HP 241 . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LP 241 . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mallard 241 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Udorn 241 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cal04 241 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . .
Swine 241 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
330 340 350 360 370 380 390 400
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 321 M I T Y M T R N Q P E W F R N V L S I A P I M F S N K M A R L G K G Y M F E S K S M K L R T Q I P A E M L A S I D L K Y F N D S T R K K I E K I R S L L I E G T
HP 321 . . . . I . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . P . . . D . .
LP 321 . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . . . P . . . D . .
Mallard 321 . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N . . . . . . . E . . . . . . . . . . P . . . D . .
Udorn 321 . . . . I . K . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . . . . R . . . . . . . . . . . . . . . . . . . . . E . . . . . . . . . K P . . . D . .
Cal04 321 . . . . I . . . . . . . . . . I . . M . . . . . . . . . . . . . . . . . . . . . R . . I . . . . . . . . . . . . . . . . . . E . . K . . . . . . . P . . . D . .
Swine 321 . . . . I . K . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . . . . K . . . . . . . . . . . . . . . E . . . . . E . . . Q . . . . . . P . . V N . .
410 420 430 440 450 460 470 480
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 401 A S L S P G MMM G M F N M L S T V L G V S I L N L G Q K R Y T K T T Y WW D G L Q S S D D F A L I V N A P N H E G I Q A G V D R F Y R T C K L L G I N M S K K
HP 401 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . .
LP 401 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . .
Mallard 401 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . .
Udorn 401 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . .
Cal04 401 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . .
Swine 401 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . .
490 500 510 520 530 540 550 560
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 481 K S Y I N R T G T F E F T S F F Y R Y G F V A N F S M E L P S F G V S G I N E S A D M S I G V T V I K N N M I N N D L G P A T A Q M A L Q L F I K D Y R Y T Y R
HP 481 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LP 481 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mallard 481 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Udorn 481 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cal04 481 . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine 481 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
570 580 590 600 610 620 630 640
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 561 C H R G D T Q I Q T R R S F E I K K L W E Q T R S K A G L L V S D G G P N L Y N I R N L H I P E V C L K W E L M D E D Y Q G R L C N P L N P F V S H K E I E S M
HP 561 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V
LP 561 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V
Mallard 561 . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V
Udorn 561 . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V
Cal04 561 . . . . . . . . . . . . . . . L . . . . D . . Q . . V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D . . R . . . . . . . . . . . . . . . . D . V
Swine 561 . . . . . . . . . . . . . . . L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V
650 660 670 680 690 700 710 720
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . |
PR8 641 N N A V MM P A H G P A K N M E Y D A V A T T H S W I P K R N R S I L N T S Q R G V L E D E Q M Y Q R C C N L F E K F F P S S S Y R R P V G I S S M V E A M V S
HP 641 . . . . V . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
LP 641 . . . . V . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mallard 641 . . . . V . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Udorn 641 . . . . V . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cal04 641 . . . . V . . . . . . . . S . . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine 641 . . . . V . . . . . . . . S V . . . . . . . . . . . . . . . . . . . . . . . . . . I . . . . H . . . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
730 740 750
. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . .
PR8 721 R A R I D A R I D F E S G R I K K E E F T E I M K I C S T I E E L R R Q K *
HP 721 . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . *
LP 721 . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . *
Mallard 721 . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . *
Udorn 721 . . . . . . . . . . . . . . . . . . . . A . . . . . . . . . . . . . . . . *
Cal04 721 . . . . . . . V . . . . . . . . . . . . S . . . . . . . . . . . . . . . . *
Swine 721 . . . . . . . . . . . . . . . . . A . . S . . . . . . . . . . . . . . . . *
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amino group in the lysine residues could lead to conformational and functional changes 
within the structure of both polypeptides and may explain the phenotypic differences 
between Udorn and the other tested mammalian viruses. 
Assessment of the importance of AUG codons 10 and 11 in avian IAVs was 
only performed using the Mallard H1N1 duck isolate. In contrast to the mammalian 
mutants, mutations introduced in either AUG 10 or 11 did not result in attenuation of 
virus fitness in either of the two mammalian cell types tested; MDCK or A549 cells. 
Moreover, IFN induction and IRF3 phosphorylation levels were also unchanged 
following infection by the AUG mutant viruses in comparison to WT Mallard. 
Comparison of Mallard PB1 amino acid sequence to the other mammalian viruses 
revealed two Mallard specific residues: an alanine in position 56 and an asparagine in 
position 375 (Figure 6.10). Of these two, only amino acid 375 is shared by PB1-N92 
and –N111, given that position 52 is upstream of their starting codons. Amino acid 
375 has been shown to be a host-range signature amino acid (Kawaoka et al. 1989; 
Cauldwell et al. 2014). Most avian strains have an asparagine or threonine at this 
position, whereas the majority of human isolates have a serine. Moreover, all PB1 
sequences from the 1918, 1957 and 1968 human pandemics viruses strictly possess a 
serine at position 375 (Naffakh et al. 2008; Kawaoka et al. 1989; Taubenberger et al. 
2005). However, given that Mallard still harbours an avian-like 375 residue and 
segment 2 AUG mutants are still able to establish a successful infection in mammalian 
cells, the host restriction related to the residue 375 may not be related to PB1–N92 or 
–N111 function. 
Additional PB1 residues have also been associated with avian to mammalian 
adaptations (Gabriel et al. 2007). An avian H7N7 strain showed a leucine and a serine 
Chapter 6   
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at positions 13 and 678 while its mouse-adapted variant showed serine and asparagine 
at the same residues. An independent study also identified the avian-to-mammalian 
N105S mutation in H5N1 in vitro adaptation (Taft et al. 2015). Moreover, additional 
PB1 mutations D175N, T182L, K198R, K214R, P627L have also been identified in 
infected patients with an H5N1 duck virus (Arai et al. 2016). Nevertheless, the 
majority of these amino acids did not differ in the selected viruses, without a specific 
incidence of either avian- or mammalian-associated polymorphisms. For example, all 
the selected isolates share P13 (mammalian), N105 (avian) and S678 (avian), and the 
avian-like R198 was only present in two of the three avian selected isolates (Penns HP 
and LP). Nevertheless, in order to possibly assess the importance of these residues, 
site-directed mutagenesis can be performed followed by the generation of mutant 
viruses and assessment of viral propagation in mammalian and avian cell lines. 
As previously mentioned, despite not showing attenuation in mammalian cells, 
when grown in avian cells (chicken and quail fibroblasts), the Mallard AUG mutant 
viruses showed reduced virus fitness. Avian and mammalian type I IFN systems 
present several divergences (Santhakumar et al. 2017). Therefore, the simplest 
hypothesis would predict that Mallard would strongly induce IRF3 phosphorylation 
and present reduced growth kinetics. However, that was not the case and led the 
hypothesis that, perhaps the difference lays within the differences of the mechanisms 
which induce IRF3 phosphorylation within the mammalian and avian IFN systems. 
Despite the differences between these two pathways some of their constituents, such 
as TBK1, have been shown to be present in both pathways and is considered to be 
evolutionarily conserved (Wang et al. 2017). Therefore, even considering the high 
prevalence of PB1, it can be hypothesised that avian IAVs have evolved to counteract 
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avian IFN systems and mammalian viruses have developed to better inhibit the 
mammalian IFN pathway. 
As introduced in chapter 1, viral-encoded mechanisms to counteract an IFN 
response can either be directly acting on the IFN-induction pathway or be more broad 
spectrum, by induction of host protein shutdown and are shared between several viral 
proteins, such as PB1-F2, PA-X and NS1. Studies on the NS1 CPSF30 binding have 
suggested that NS1 proteins encoded by H3N2 (such as Udorn), H2N2 and seasonal 
H1N1 viruses strongly bind to CPSF30, thereby inhibiting the 3’ end processing of 
host pre-mRNAs and the production of mature mRNA, among which IFN-β (Nemeroff 
et al. 1998; Noah et al. 2003). However, NS1 proteins from PR8 and 2009 pandemic 
H1N1 viruses (such as Cal04) present inefficient binding to CPSF30 (Twu et al. 2007; 
Hale et al. 2010; Steidle et al. 2010). Therefore, these viruses depend on other 
counteractive measurements, such as the inhibition of IRF3 phosphorylation to restrain 
IFN induction/expression. Moreover, studies on IRF3 phosphorylation in different 
IAV strains have suggested a correlation between the levels of phosphorylated IRF3 
and the ability of these viruses to control host proteins synthesis, therefore being able 
to block the consequences of IRF3 phosphorylation (Kuo et al. 2010).  
The effects of the deletion of AUG codons as well as the predicted shut-off 
activity by NS1 and PA-X as well as MAVS-driven IFN counteraction by NS1 and 
PB1-F2 are summarised in table 6.3. Whilst PR8 NS1 exhibits weak CPSF30-binding 
activity, harbouring amino acids 103S and 106I, Udorn possessed a phenylalanine and 
a methionine in the respective positions, which are associated with a strong CPSF30-
binding (Rodriguez et al. 2018; Das et al. 2008). Therefore, the counteraction of IRF3 
phosphorylation is essential in PR8, but obsolete in Udorn and the deletion of an IRF3   
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Table 6.3. Summary of phenotypes of all tested IAV strains and respective predicted host protein shut-off activity and IFN 
counteraction. Observed viral fitness defects, type-I IFN induction, and IRF3 phosphorylation for all the tested viruses are resumed. The 
symbols “+++”, “++”, “+” and “-” represent the degree of the defect by the deletion of a given AUG in the measured criteria. Light grey 
squares represent non-performed experiments. Bold amino acid mutations represent differences between the specific virus and PR8. 
 
Virus 
Fitness defects IFN induction 
Increased IRF3 
phosphorylation 
Predicted host cell 
protein shut-off 
Predicted IFN counteraction 
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Figure 6.12: Sequence alignment of NS1, PB1-F2 and PA-X proteins of selected viruses. CDSs of NS1 (A), PB1-F2 (B) and PA-X (C) 
polypeptides of selected viruses were downloaded from NCBI using the accession numbers in table 8.3. In silico translation and protein 
alignment was performed using the MEGA6 software. PR8 proteins were used as reference sequence. Conservation of NS1 dsRNA binding 
domain key residues is highlighted in amber. NS1 CPSF30 binding domains are marked in red. The PB1-F2 determinant of virulence N66S 
single nucleotide polymorphism (Conenello et al. 2011; Conenello et al. 2007) is highlighted in green. Key residues in PA-X which determine 
shutoff activity are highlighted in blue (Chung, et al., unpublished). Alignment was created and kindly provided by Dr Carina Conceição.
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phosphorylation inhibitor such as PB1-N111 would not affect viral fitness (as observed 
throughout this chapter). 
Despite presenting a predicted Udorn-like CPSF30-binding by its NS1, Cal04 
was one of the viruses which was shown very sensitive to the deletion of AUG codons 
10 and/or 11. However, this sensitivity can be explained by a truncated PA-X which 
was previously shown to impair shut-off activity in H1N1 2009 pandemic strains (Gao 
et al. 2015a; Lee et al. 2017). The impairment of the shut-off activity due to the 
truncated PA-X can justify the need to express an IRF3 inhibitor. Moreover, Cal04 
also possesses a truncated PB1-F2. However, despite the expression of a short 11-
amino acid PB1-F2, studies when PB1-F2 ORF was restored to its full length have 
shown minimal differences when compared to the original truncated version (Pena et 
al. 2012; Hai et al. 2010). 
Although not to the same extent as Cal04, Swine87 was also shown to be 
sensitive to the deletion of AUG codons 10, but mainly 11. However, predicted NS1 
CPSF30-binding, PA-X activity as well as PB1-F2 IFN counteraction seem to be 
Udorn-like. Nevertheless, levels of protein expression of NS1 and/or PA-X and/or 
PB1-F2 and/or PB1-N111 can perhaps be different than in Udorn and the balance 
between these four polypeptides may be required to ensure full IFN-counteraction and 
subsequent viral propagation of Swine 87. 
Overall, this chapter showed that AUG codons 10 and 11 are highly conserved 
among IAV sequences and that PB1-N92 and -N111 potentially encoded by them 
could play important roles in the virus life cycle for more than one virus, thus not being 
















7.1. General conclusion 
This project aimed to investigate initiation of translation from segment 2 AUG 
codons in order to identify and characterise suspected novel accessory proteins in IAV. 
The data presented describe the expression of two additional accessory polypeptides 
from AUG codons 10 and 11. The proteins, named PB1-N92 and PB1-N111, are both 
detected from transfected GFP-fusion plasmids and PB1-N111 was also detected in 
the context of virus infection. The mutation of AUGs 10 and 11 abrogated the 
expression of the two peptides and led to an attenuated replication phenotype in the 
lab adapted IAV strain PR8. However, despite the alterations of PB1 ORF (M92V and 
M111V), polymerase transcription and replication activity were seemingly kept 
unchanged in comparison to the original WT enzyme. 
Infection of human cells with ΔAUG10/11 mutant viruses resulted in increased 
secretion of type I IFNs, while replication of the attenuated mutant viruses recovered  
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Figure 7.1: Proposed model of expression and function of PB1-N92 and PB1-N111. Alongside PB1 and PB1-N40, PB1-N92 and PB1-
N111 are expressed from segment 2 mRNA. PB1 complexes with PA which are further imported to the nucleus and interact with PB2 to 
support viral transcription and replication. PB1-N92 and PB1-N111 are not as strongly expressed as the main product PB1, or PB1-N40, but 
PB1-N111 may accumulate to higher levels than PB1-N92. Once expressed, PB1-N111 is believed to prevent the phosphorylation of IRF3, 
while the inhibition of the MyD88-driven NF-κB pathway is potentially carried out by all PB1-N40, PB1-N92 and N111. Nevertheless, the 
stages and the mechanisms by which this happens are still not fully understood. 
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in in vitro, in ovo and in vivo IFN-defective systems. Expression of the newly identified 
viral polypeptides from transfected plasmids made it possible to determine their ability 
to inhibit the induction of IFN-β at the MyD88 and TBK1 pathway stages and to 
prevent the phosphorylation of NF-κB subunit P65 and IRF3. However, the exact 
stage(s) at which this inhibition took place were not fully clarified (Figure 7.1). 
An overview of the expression and potential mechanisms of action of PB1-N92 
and PB1-N111 can be seen in Figure 7.1. In addition to PB1 which dimerises with PA 
and undergoes nuclear import to fulfil its main function of transcription and replication 
of the virus genome, the PB1 shorter polypeptides remain in the cytoplasm where they 
act to prevent induction of IFN-β. 
Bioinformatic analysis showed the high conservation of AUG codons 10 and 
11 in field isolates as well as a sequence context conducive to translation initiation of 
these codons. Therefore, in addition to the firstly tested lab adapted strain PR8, the 
introduction of ΔAUG10 and/or 11 mutations was carried out for further human, swine 
and avian viruses. Similar to PR8, minigenome reporter assays revealed a WT-like 
polymerase transcription and replication activity. However, the deletion of AUGs 10 
and 11 did not result in the same phenotype in all the viruses. While, like PR8, Swine87 
and Cal04 presented a more attenuated phenotype with the deletion of AUG11, Udorn 
was more affected with the deletion of AUG10 and growth of Mallard in mammalian 
cells was not affected by the deletion of either codon. However, these mutations 
conferred an attenuated phenotype in Mallard propagation in avian cells. Moreover, 
the importance of AUG codon 11 was associated with a lack of host shut-off activity 
and IFN counteraction by NS1, PA-X and PB1-F2, respectively. 
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7.2. Future work and directions 
7.2.1. Identification of the potential function of AUG 10 and 11 in 
virus packaging 
Work presented in chapter 2 showed that the simultaneous mutation of AUG 
codons 10 and 11 resulted in a worse genome copy to infectious particle ratio, which 
could suggest a packaging defect. Virus purification of the mutant PR8 viruses was 
performed aiming to determine if PB1-N92 and/or -N111 are present in virions, but 
only full-length PB1 was detected (data not shown). However, it is not clear whether 
a) these AUG codons (CAU residues in the vRNA sequence) are involved in 
RNA/RNA interactions between vRNP molecules at the budding site, b) PB1-N92 and 
-N111 are involved in trafficking of RNPs or responsible for packaging, c) the 
induction of type I IFN, which results in the upregulation of ISGs (e.g. BST2/tetherin) 
which have been shown to have an effect on budding of H1N1 influenza viruses 
(Gnirss et al. 2015), can contribute to the observed genome:PFU increased ratio. 
 
7.2.2. Identification of binding partners of PB1-N92 and -N111 
Data presented in chapter 4 went some way to identifying the stage(s) in the 
interferon pathway at which PB1-N92 and -N111 interfere. However, despite the low 
levels of TBK1- and MyD88-driven IFN-β induction in the presence of PB1-N92 and 
PB1-N111, the data are insufficient to conclude that there is a direct interaction 
between the PB1-related polypeptides and any component of the IFN induction 
pathway. For instance, the increased levels of phosphorylated IRF3 and, to a lesser 
Chapter 7   
242 
extent, P65 could also be due to an interaction of PB1-N92 and –N111 with 
phosphatases responsible for reversing activation of the transcription factors. 
Therefore, to fully understand the mechanisms behind the perceived inhibition of IFN-
β synthesis by the truncated PB1 products, plasmids expressing the FLAG-tagged 
versions of PB1-N92 and –N111 could be transfected in cells and FLAG pull-down 
immunoprecipitations then performed followed by mass-spectrometry analysis to 
identify interaction partners. Moreover, given the tagged nature of some of the IFN 
induction plasmids (with GST or GFP, described in chapter 5 and 8), 
immunoprecipitations could also be performed using those tags. 
 
7.2.3. Elucidation of the mechanism of expression of PB1-N92 and -
N111 
Expression of PB1-N92 and –N111 from AUG codons 10 and 11 was shown 
in chapter 2. However, the mechanism by which this translation initiation occurs was 
not fully elucidated. Previous studies on translation regulation of segment 2 coding 
polypeptides suggested that the expression of PB1-F2 and PB1-N40 from AUG codons 
4 and 5 occurs through ribosomal leaky scanning and termination reinitiation, 
respectively (Wise et al. 2011). Nevertheless, it is still not clear how the ribosome 
reaches even further ahead in the mRNA to initiate protein expression from AUG 
codons 10 and 11. Additional data not shown in this dissertation showed the expression 
of individual polypeptides from segment 2 AUG codons 7, 8 and 9. However, the 
deletion of these AUG codons did not alter the expression of PB1-N92 and –N111 
(data not shown), potentially discarding leaky scanning as the main translation control 
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mechanism of AUGs 10 and 11. As has been demonstrated for the expression of the 
IAV proteins NS2/NEP and M2, we also considered that alternative splicing might 
account for expression of PB1-N92 and -N111. However, the expression of PB1-
related polypeptides was not decreased in the presence of splicing inhibitors (data not 
shown). Although never described for IAV, internal ribosomal entry sites (IRES) and 
ribosome shunts have been shown to be used by several RNA viruses as a mechanism 
to control translation initiation (reviewed in Firth and Brierley 2012). Moreover, when 
the same RNA region that was introduced into the eGFP-N1 plasmid (segment 2 
nucleotides 1-380) was submitted into IRES prediction website (IRESPred; Kolekar 
et al. 2016), this resulted in a prediction of a “potential IRES” (data not shown). In 
addition to explaining the expression of AUG codons 10 and 11, the existence of an 
IRES/RNA loop could explain the apparently stronger expression of AUG11 in 
comparison to AUG10. 
Overall, the work in this thesis has defined at least one further IAV gene 
product - PB1-N111 - and suggested a role for it in the virus life cycle as an antagonist 


















8.1.1. General reagents 
General purpose reagents were supplied by Sigma-Aldrich, Scientific 
Laboratory Supplies and Fisher Scientific. The Roslin Institute Central Services Unit 
(CSU) prepared and provided sterile water and phosphate-buffered saline (PBS). 
Additional specific reagents and kits and their respective suppliers are listed below.  
 30% acrylamide:bisacrylamide (37.5:1)   BioRad 
 Agarose (UltraPureTM)     Invitrogen 
 Avicel       FMC Biopolymer 
 BCA Protein Assay Kit     ThermoFisher Scientific 
 Beetle Luciferin      Promega 
 Beta-Galactosidase Enzyme Assay System  Promega 
 Cell-Titre Glo      Promega 
 Dimethyl sulphoxide (DMSO)    ThermoFisher Scientific 
 DNA molecular weight markers    Promega 
 dNTPs       InvitrogenTM 
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 Isofluorane      Merial Animal Health 
 Lipofectamine 2000     ThermoFisher Scientific 
 Neutral Buffered Formalin (NBF)   Leica 
 Odyssey® TBST Blocking Buffer   LI-COR 
 Nitrocellulose membrane (0.2 and 0.45µm)  BioRad 
 NP-40 (10%)      VWR International Ltd 
 Precision plus dual colour molecular weight marker BioRad 
 Polyinosinic:polycytidylic acid (poly I:C)  InvivoGen 
 Protein A-Sepharose Beads    Roche 
 QIAamp Viral RNA Kit     Qiagen 
 QIAGEN Plasmid Midi Kit    Qiagen 
 QIAprep Spin Miniprep Kit    Qiagen 
 QIAquick Gel Extraction Kit    Qiagen 
 QIAquick PCR Purification kit    Qiagen 
 QUANTI Blue reagent     InvivoGen 
 QuikChange Lightning site-directed mutagenesis kit Agilent Technologies 
 Renilla Luciferase Assay kit    Promega 
 Resolving buffer for acrylamide gels   Protogel 
 RIPA lysis buffer      Source BioScience 
 SensiFAST SYBR Lo-ROX One-Step Kit  Bioline 
 Stacking buffer for acrylamide gels   Protogel 
 Stainless Steel Beads (5 mm)    Qiagen 
 SYBR DNA gel stain      Invitrogen 
 Tetramethylethylenediamine (TEMED)   Protogel 
 Tris-Buffered Saline with 1% Tween20 (TBST) Santa Cruz 
 Trizol reagent      Invitrogen 
 TrueBlue Peroxidase Substrate    Kirkegaard & Perry Labs 
 Tween20       Sigma-Aldrich 
 X-ray films      ThermoFisher Scientific 
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8.1.2. Radiochemicals 
 EasyTag™ Protein Labeling Mix (L-[35S] Met and L-[35S] Cys)          Perkin Elmer 
 
8.1.3. Enzymes 
DNA restriction endonucleases and their respective reaction buffers were 
supplied by Promega and New England Biolabs and used according to manufacturer’s 
instructions, unless otherwise stated. The following enzymes were acquired from the 
specified companies: 
 Taq DNA polymerase     Invitrogen 
 (TPCK)-treated bovine pancreas trypsin   Sigma-Aldrich 
 T4 DNA ligase      New England Biolabs 
 
8.1.4. Bacterial cells 
 XL10-Gold ultra-competent cells   Agilent Technologies 
 XL1-Blue competent cells    Agilent Technologies 
 
8.1.5. Eukaryotic cells 
 
Table 8.1: Avian cell lines 
Cell line Source Reference 
Chicken Embryonic 
Fibroblasts (DF1) 
Dr Lonneke Vervelde (The Roslin 
Institute, The University of 
Edinburgh, UK) 
(Himly et al. 
1998) 
Japanese Quail 
Fibrosarcoma Cells (QT35) 
Dr Laurence Tiley (The University 
of Cambridge, UK) 
(Moscovici et al. 
1977) 
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Table 8.2: Mammalian cell lines 
Cell line Source Reference 
HEK 293-Blue IFN-α/β 
Cells (HEK Blue) 
InvivoGen 
(Turnbull et al. 
2016) 
HEK 293 Naïve 
Dr Gracjan Michlewski (The 
University of Edinburgh, UK) 
- 
HEK 293 TRIM25-/- 
Dr Gracjan Michlewski (The 
University of Edinburgh, UK) 
- 
Human Embryonic Kidney 
293T Cells (293T) 
American Type Culture 
Collection (ATCC) 
(DuBridge et al. 
1987) 
Human Adenocarcinomic 
Alveolar Basal Epithelial 
Cells (A549) 
ATCC (Giard et al. 1973) 
Madin-Darby Canine 
Kidney Cells (MDCK) 
Prof Bernadette Dutia (The 
Roslin Institute, The University of 
Edinburgh, UK) 




Prof John McCauley (The Francis 




8.1.6. Solutions and media 
8.1.6.1. Eukaryotic cell culture media and cell passage solutions 
 0.25% Trypsin-EDTA     Life Technologies 
 Blasticidin      InvivoGen 
 Bovine serum albumin (BSA)    Fisher Scientific 
 Dialysed foetal bovine serum    Gibco 
 Dulbecco’s Modified Eagle Medium (D-MEM)  Sigma-Aldrich 
 Foetal Bovine Serum (FBS)    Life Technologies 
 Geneticin (G418)      Life Technologies 
 L-Glutamine      Life Technologies 
 Methionine- and Cysteine-free D-MEM   Gibco 
 Opti-MEM      Life Technologies 
 Penicillin/Streptomycin     Life Technologies 
 Roswell Park Memorial Institute (RPMI) medium Sigma-Aldrich 
 Zeocin       InvivoGen 
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The previously listed supplies were used to prepare the following media: 
 Complete medium: D-MEM or RPMI supplemented with 10% (v/v) FBS, 2mM 
glutamine, 100 U/ml penicillin, and 100μg/ml streptomycin. 
 Serum free medium: Complete D-MEM or RPMI without FBS. 
 Virus growth medium: D-MEM or RPMI supplemented with 2mM glutamine, 100 
U/ml penicillin, 100μg/ml streptomycin, 0.14% (w/v) BSA, and 1μg/ml N-tosyl-
L-phenylalanine chloromethyl ketone (TPCK)-treated trypsin. 
 Transfection media: Complete D-MEM without penicillin and streptomycin. 
 
8.1.6.2. Bacterial media 
 Ampicillin sodium salt (used at 100μg/mL)  Sigma-Aldrich 
 Kanamycin sulphate salt (used at 50μg/mL)  Gibco 
Luria-Bertani (LB) broth and LB-agar were prepared and provided by the 
Roslin Institute CSU according to the following formulae: 
 Luria-Bertani (LB) Broth: 10g/L tryptone, 5g/L yeast extract, 5g/L sodium 
chloride (pH 7.0). 
 Super Optimal Broth (SOB): 20g/L tryptone, 5g/L yeast extract, 10mM NaCl, 
2.5mM KCl, 10mM MgCl2, and 10mM MgSO4. 
 LB agar 15g/L agar, 20g/L tryptone, 5g/L yeast extract, 10g/L sodium chloride 
(pH 7.0). 
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8.1.6.3. Competent bacteria preparation solutions 
 CCMB buffer: 10mM potassium acetate, 10% (v/v) glycerol, 80mM CaCl2, 
20mM MnCl2, 10mM MgCl2, pH 6.4. 
 
8.1.6.4. Nucleic acid gel electrophoresis buffers 
TAE buffer was prepared and supplied by the Roslin Institute CSU according to the 
following formulae: 
 TAE buffer: 40mM Tris, 20mM acetic acid, 1mM EDTA. 
 6x DNA loading buffer: 10mM Tris-HCl (pH 7.6) 0.15% (w/v) Orange G dye, 
0.03% (w/v) xylene cyanol FF, 60% (v/v) glycerol, 60mM EDTA. 
 
8.1.6.5. Protein buffers and solutions 
8.1.6.5.1. Lysis Buffers 
 Laemmli’s sample buffer: 20% (v/v) glycerol, 2% (w/v) SDS, 100mM DTT, 
24mM Tris, 0.016 % (v/v) bromophenol blue, 0.016% (v/v) xylene cyanol 
solution. 
 
8.1.6.5.2. Acrylamide gel electrophoresis 
 SDS-PAGE running buffer. 25mM Tris, 192 mM glycine, 0.1% (w/v) SDS. 
 4 x resolving buffer (Protogel) 1.5M Tris-HCl, 0.4% (w/v) SDS, pH 8.8. 
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 4 x stacking buffer (Protogel) 0.5M Tris-HCl, 0.4% (w/v) SDS, pH 6.8. 
 Resolving polyacrylamide gel: 7-15% acrylamide:bisacrylamide (37.5:1), 1× 
resolving buffer, 0.1% (w/v) APS, 0.1% (v/v) TEMED. This formula was adapted 
to make gels containing 7-15% polyacrylamide by altering the added amounts 
30% acrylamide solution and water. 
 Stacking polyacrylamide gel: 4% acrylamide:bisacrylamide (37.5:1), 1× stacking 
buffer, 0.5% (w/v) APS, 0.1% (v/v) TEMED. 
 Polyacrylamide gel fix solution: 50% (v/v) methanol, 10% (v/v) acetic acid. 
 
8.1.6.5.3. Western blotting 
 Protein transfer buffer: 25mM Tris, 192mM glycine, 0.1% (w/v) SDS, 20% (v/v) 
methanol. 
 Blocking solution: PBS/0.1% (v/v) Tween20, 5% (w/v) skimmed milk. 
 Washing solution (PBST): PBS/0.1% (v/v) Tween20 
 
8.1.6.5.4. Autoradiography 
 Gel fixing solution: 50% methanol (v/v), 10% acetic acid (v/v) 
 
8.1.6.6. Fluorescence-activated cell sorting buffers 
 Intracellular (IC) Fixation Buffer  eBioscienceTM 
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8.1.7. Drugs, inhibitors and compounds 
 BX-795 (DMSO; used at 1, 2 and 5 µM) Merck Chemicals 
 IMD0325 (DMSO; used at 0.1µM)  Cayman Chemical company 
 JHS-23 (DMSO; used at 1µM)   Calbiochem 
 TNFα (H2O, used at 500 ng/ml)   LifeTechnologies 
 Universal type I interferon   PBL Assay Science 
 Pepinh-TRIF (H2O, used at 20µM)  InvivoGen 
 
8.1.8. Viruses and reverse genetics systems 
Table 8.3: Sequence accession numbers for the viral cDNA inserts in reverse 
genetics plasmids. Colour coding: Blue - segments cloned into pDUAL; Green - 
segments cloned into pHH21; Yellow - segments cloned into both pHH21 and 
pcDNA3.1. 





1 EF467818 M91712 CY116312 FJ966079 KC209512 CY015114 CY015080 
2 EF467819 CY009642 CY116313 FJ966080 KC209513 GU052777 CY015079 
3 EF467820 CY009641 CY116314 FJ966081 KC209514 GU052776 CY015078 
4 EF467821 M54895 CY115996 FJ966082 KC209515 - - 
5 EF467822 D00051 CY115997 FJ966083 KC209516 CY015076 
6 EF467823 J02168 CY116317 FJ966084 KC209517 - - 
7 EF467824 J02167 CY116318 FJ966085 KC209518 - - 
8 EF467817 V01102 CY116000 FJ966086 KC209519 - - 
a A/Puerto Rico/8/34. Gift from Prof Ron Fouchier (Erasmus University Medical 
Center, Rotterdam, The Netherlands) (de Wit et al. 2004). 
b A/Udorn/307/1972. Gift from Prof Robert Lamb (Department of Molecular 
Biosciences, Northwestern University, Illinois, USA) (Chen et al. 2007). 
c A/swine/England/87842/1990. Cloned and kindly provided by Dr Russell Brown 
(Digard laboratory) (Brown 2016; Wibberley et al. 1988). 
d A/California/04/2009. Gift from Dr Daniel Perez (Department of Populational 
Health, The University of Georgia, USA) (Ye et al. 2010). 
e A/mallard/Netherlands/10-Cam/1999. Gift from Dr Laurence Tiley (The University 
of Cambridge) (Bourret et al. 2012). 
f A/chicken/Pennsylvania/1370/1983. Cloned and kindly provided by Dr Lita Murphy 
(Digard laboratory) (Murphy et al, unpublished). 
g A/chicken/Pennsylvania/1/1983. Cloned and kindly provided by Dr Lita Murphy 
(Digard laboratory) (Murphy et al, unpublished). 
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8.1.9. Plasmids 
Table 8.4: Expression and reverse genetics plasmids 
Name Description Selection Source 
pDUAL 
Reverse genetics plasmid. Bidirectional 
pol I and pol II promoters either side of 
insert lead to mRNA and vRNA-like RNA 
synthesis. Used for PR8, Mallard, Cal 04, 
Penn83 LP and Penn83 HP. 
Ampicillin 
Gift from Prof Ron 
Fouchier (Erasmus 
University Medical 
Center, Rotterdam, The 
Netherlands 
pHH21 
Reverse genetics plasmid. Pol I 
promoter leads to vRNA-like RNA 
synthesis. Used to rescue Udorn. 
Ampicillin 
Gift from Prof Robert 
Lamb (Department of 
Molecular Biosciences, 
Northwestern 
University, Illinois, USA) 
pcDNA3.1 
CMV pol II promoter upstream of insert 
leads to constitutive high protein 
expression. Used for Udorn. 
Ampicillin 
 
Table 8.5: Reporter plasmids 




Reporter for RNP reconstitution assays. 
Contains firefly luciferase reporter gene 
in the reverse (-) orientation, flanked by 
the UTRs of PR8 segment 8, under the 
control of a pol I promoter. 
Ampicillin 
Gift from Dr Laurence 
Tiley (The University of 




Reporter for RNP reconstitution assays. 
Contains firefly luciferase reporter gene 
in the reverse (-) orientation, flanked by 
the UTRs of PR8 segment 8, under the 





Reporter for RNP reconstitution assays. 
Contains firefly luciferase reporter gene 
in the (+) sense orientation, flanked by 
the UTRs of PR8 segment 8, under the 
control of a pol I promoter. 
Ampicillin This study 
pRL 
Constitutively expressed Renilla 





Constitutively expressed β-gal under 
control of CMV Immediate-Early (IE) 
promoter. 
Ampicillin Digard lab 
pIFN-
β::Luc 
Firefly luciferase under control of 
human IFN-β promoter. 
Ampicillin Gift from Prof Rick 
Randall (The University 
of St Andrews, UK) 
pISRE::Luc 




Chapter 8   
254 
Table 8.6: Other expression plasmids 
Name Description Selection Reference Source 
pEGFP-
N1 
Constitutively expresses eGFP 
under control of CMV IE promoter. 
Multiple cloning site upstream 
allows opportunity to clone C-
terminally tagged proteins. 
Kanamycin - Clontech 
pGST-
IRF7 
SV40 pol II promoter upstream of 
insert leads to constitutive 
expression of IRF7 fused to GST. 
Ampicillin - 




of Leeds, UK) 
pGST-
TBK1 
SV40 pol II promoter upstream of 
insert leads to constitutive 







SV40 pol II promoter upstream of 
insert leads to constitutive 




SV40 pol II promoter upstream of 
insert leads to constitutive 




SV40 pol II promoter upstream of 
insert leads to constitutive 




SV40 pol II promoter upstream of 
insert leads to constitutive 




CMV IE pol II promoter upstream 
of insert leads to constitutive 




CMV IE pol II promoter upstream 
of insert leads to constitutive 




CMV IE pol II promoter upstream 
of insert leads to constitutive 







CMV IE pol II promoter upstream 
of insert leads to constitutive 




CMV IE pol II promoter upstream 
of insert leads to constitutive 
expression of GFP-tagged RelA. 
Kanamycin - 
pCFP-P50 
CMV IE pol II promoter upstream 
of insert leads to constitutive 
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8.1.10. Oligonucleotides 
8.1.10.1. Oligonucleotides used for sequencing of constructs and viruses 
Table 8.7: Sequencing oligonucleotides 
Primer name Sequence (5'-3') Description/Application 
pDUAL Fw ATGTCGTAACAACTCCGCCC 
Forward primer to sequence the 3’ end of 
vRNA of segments inserted in pDUAL 
plasmid 
pDUAL Rv TTTTTGGGGACAGGTGTCCG 
Reverse primer to sequence the 5’ end of 
vRNA of segments inserted in pDUAL 
plasmid 
Uni 12 AGCAAAAGCAGG 
Complementary to the 3’ end of all IAV 
vRNA segments 
eGFP-N1 Fw GGCGGTAGGCGTGTA 
To sequence peGFP-N1 inserts from the 5' 




Reverse primer sequence for the 5' end of 
PR8 segment 2 cDNA 
Udorn seg 2 
611-592 Rv 
ACCATTTTCTTGGTCATGTT 
Reverse primer to sequence the 5’ end of 
Udorn segment 2 cDNA 
Cal04 seg 2 
611-592 Rv 
GTTCTTTGCGTGACCATCTT 
Reverse primer to sequence the 5’ end of 
Cal04 segment 2 cDNA 
Swine87 seg 2 
611-592 Rv 
GTTCTTTGCGTGACCATTTT 
Reverse primer to sequence the 5’ end of 
Swine87 segment 2 cDNA 
Mallard seg 2 
611-592 Rv 
GTCATGTTGTCCCTTACTCT 
Reverse primer to sequence the 5’ end of 
Mallard segment 2 cDNA 
 
8.1.10.2. Oligonucleotides used to subclone viral sequences into the indicated 
vectors 
Table 8.8: Cloning oligonucleotides 
Name Sequence (5'-3') Description/Application Enzyme 




Used to clone full length 
PB1 into pcDNA3.1 vector 








Used to clone PB1-N40 
into pcDNA3.1 vector and 







Used to clone PB1-N92 
into pcDNA3.1 vector and 
add an N-terminal FLAG-
tag 
HindIII 
Chapter 8   
256 
Table 8.8: Cloning oligonucleotides (continuation) 






Used to clone PB1-N111 
into pcDNA3.1 vector and 





Used to clone full length 





Used to clone PB1-N40 





Used to clone PB1-N92 





Used to clone PB1-N111 






Used to clone tagged and 
untagged full-length PB1 




8.1.10.3. Oligonucleotides used for site-directed mutagenesis 
Table 8.9: Oligonucleotides used to introduce mutations into PR8 segment 2 






















Table 8.10: Oligonucleotides used to introduce mutations into Cal04 segment 2 
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Table 8.11: Oligonucleotides used to introduce mutations into Udorn segment 2 






















Table 8.12: Oligonucleotides to introduce mutations into Swine87 segment 2 






















Table 8.13: Oligonucleotides to introduce mutations into Mallard segment 2 
























Table 8.14: Oligonucleotides to introduce mutations into Penn HP/LP segment 2s 
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8.1.10.4. Oligonucleotides used for RT-qPCR 
Table 8.15: Primers used for RT-qPCR analysis. Kindly designed and provided by 
Dr Elly Gaunt, Dr Matthew Turnbull and Dr Christine Tait-Burkark. 
Primer name Sequence (5'-3') 
Segment 2 Fw GGAACAGGATACACCATGGA 
Segment 2 Rv AGTGGYCCATCAATCGGGTT 
Segment 5 Fw ATCATGGCGTCTCAAGGCAC 
Segment 5 Rv CCGACGGATGCTCTGATTTC 
Segment 7 Fw TGCAGGGAAGAACACCGATC 
Segment 7 Rv GGGCATTTTGGACAAAGCGT 
PRRSV-1 (LT3 ORF5) Fw  GGATACTATCACGGGCGGTA 
PRRSV-1 (LT3 ORF5) Rv GGCACGCCATACAATTCTTA 
 
8.1.11. Immunological reagents and dyes 
Table 8.16: Primary antibodies raised against IAV proteins 
Antibody Supplier/Reference Applied dilution 
Rabbit polyclonal anti-PA (V34/V35) (Blok et al. 1996) WB (1:500) 
Rabbit polyclonal anti-PB1 (V19) (Digard et al. 1989) WB (1:500), IF (1:50) 
Rabbit polyclonal anti-MBP-NP (2915) (Digard et al. 1999) WB (1:500) 
Mouse monoclonal anti-PR8 NP (AA5H) Abcam (abAA5H) IF (1:1000) 
Mouse monoclonal anti-M2 Abcam (ab5416) WB (1:1000) 
Rabbit polyclonal anti-PR8 NS1 (V29) (Turnbull et al. 2016)- WB (1:500) 
Rabbit polyclonal anti-PR8 NEP (V13) (Turnbull et al. 2016) WB (1:500) 
 
Table 8.17: Primary antibodies raised against cellular proteins 
Antibody Supplier Applied dilution 
Rat monoclonal anti-α-tubulin BioRad WB (1:1000) 
Rabbit monoclonal anti-IRF3 Cell Signalling WB (1:1000) 
Rabbit monoclonal anti-phospho IFR3 Cell Signalling WB (1:1000) 
Rabbit monoclonal anti-P65 (NFκB) Cell Signalling WB (1:1000) 
Rabbit monoclonal anti-phospho P65 (NFκB) Cell Signalling WB (1:1000) 
 
Table 8.18: Primary antibodies raised against tags 
Antibody Supplier Applied dilution 
Rabbit monoclonal anti-DYKDDDDK Tag 
(D6W5B) 
Cell Signalling WB (1:1000) 
Mouse monoclonal anti-DYKDDDDK Tag 
(9A3) 
Cell Signalling IF (1:750) 
Mouse monoclonal anti-GFP  Clontech (JL8) WB (1:5000) 
Purified Rat Anti-Mouse CD16/CD32 (Mouse 
BD Fc Block™) 
BD Bioscience FACS (1:200) 
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Table 8.19: Secondary antibodies 
Antibody Supplier Applied dilution 
IRDye® 680LT Goat anti-Rat IgG (H + L) LI-COR 926-68076 WB (1:10000) 
IRDye® 800CW Donkey anti-Mouse IgG (H + 
L) 
LI-COR 925-32212 WB (1:10000) 
IRDye® 800CW Donkey anti-Rabbit IgG (H + 
L) 
LI-COR 926-32213 WB (1:10000) 
IRDye® 680LT Donkey anti-Mouse IgG (H + 
L) 
LI-COR 925-68022 WB (1:10000) 
IRDye® 680LT Donkey-anti-Rabbit IgG (H + L) LI-COR 926-68023 WB (1:10000) 
IRDye® 800CW Goat anti-Rat IgG (H + L) LI-COR 926-32219 WB (1:10000) 
IRDye® 800CW Streptavidin LI-COR 925-32230 
Cytokine array 
(1:2000) 
Goat Anti-Rabbit IgG (H+L)-HRP Conjugate Bio-Rad 1721019 
Immunostaining 
(1:1000) 





















Table 8.20: Fluorescent dyes 
Dye Supplier Applied dilution 
ProLong Gold Antifade Mountant with 4’,6-
Diamidino-2-phenylindole (DAPI) 
Invitrogen IF (neat) 
Hoechst 33342 Thermo Fisher IF (1:2000) 
eBioscience™ Fixable Viability Dye eFluor™ 
780 
Thermo Fisher FACS (1:1000) 
 
8.2. Molecular techniques and nucleic acid handling 
8.2.1. Polymerase chain reaction (PCR) 
PCR was used for cloning applications. Different size fragments were 
amplified using forward and reverse primers from section 8.1.10.2 (Oligonucleotides 
used to subclone viral sequences into indicated vectors). Each PCR mix contained 
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200nM of each primer, 400µM of each dNTP, 30nM of MgCl2 and 2.5 units of Taq 
DNA polymerase. The PCR was carried out in a Veriti 96 well ThermalCycler 
(Applied Biosystems). PCR conditions included a denaturation step performed at 94ºC 
for 2 minutes, followed by 30 cycles of 30 seconds at 94°C, 30 seconds at 55-60°C 
and 1-6 minutes at 72°C (1 minute per 1Kb), finishing with 10 minute incubation at 
72°C. Annealing temperature and extension time varied depending on melting 
temperature of primers and amplicon length, respectively. PCR product length was 
confirmed by 1% (w/v) agarose gel electrophoresis. 
 
8.2.2. DNA gel electrophoresis 
DNA electrophoresis was performed in agarose gels. 0.8-2 % agarose gels were 
prepared by dissolving agarose in a microwave oven in TAE buffer containing 1× 
SYBR DNA gel stain. Melted agarose was poured into a gel tray with a comb 
containing the desired number of wells. Once set, the gel was immersed in 1× TAE 
buffer. 8μL of 1kb DNA ladder was loaded alongside the samples containing 1× DNA 
loading buffer. Gels were electrophoresed at 80V for approximately 1 hour and imaged 
using an Ultraviolet transilluminator (FluorChem® HD2, Alpha Innotech). 
 
8.2.3. Purification of DNA fragments 
PCR amplified or restriction digested fragments were purified using the 
QIAquick PCR purification kit (Qiagen) according to manufacturer’s instructions. 
Briefly, a DNA-containing sample was diluted in binding buffer which allows binding 
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to a silica-gel membrane. Throughout a series of centrifugation steps, contaminants 
were removed by an ethanol-based buffer wash and silica matrix-retained DNA was 
eluted with nuclease free water. Purified DNA was analysed by spectrophotometry and 
electrophoresis. 
 
8.2.4. Restriction enzyme digestion 
PCR product or 1μg of plasmid DNA was digested using 1-5 units of enzyme. 
Enzymatic reaction mixes were prepared using the manufacturer’s recommended 
buffer and temperature and digested for at least 3 hours. When digesting with multiple 
enzymes with a compatible reaction buffer, enzymes were combined. Otherwise, 
sequential digestions were performed with an intermediate PCR purification step. 
 
8.2.5. Extraction of DNA fragments from agarose gels 
When subcloning, restriction digested vector DNA fragments were separated 
by electrophoresis, visualised in a UV transilluminator and excised with a scalpel. The 
agarose slice was extracted using the QIAquick Gel Extraction Kit in a bind-wash-
elute procedure. Concisely, gel slices were dissolved at 50°C in a high salt, neutral pH 
buffer and the nucleic acid-containing mixture was applied to a silica membrane. 
Impurities were sequentially washed away using an ethanol-based solution and pure 
DNA was eluted in 30μL of water. DNA was assessed by spectrophotometry for its 
content and purity and further used in subsequent applications such as restriction 
digestions or ligations. 
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8.2.6. Ligation of DNA fragments 
DNA fragments were ligated using T4 DNA ligase according to 
manufacturer’s recommendations. A typical ligation reaction included 100ng of 
linearised vector DNA, insert DNA fragment at a molecular ratio of 5:1 (insert:vector), 
1x reaction buffer and 2 units of T4 DNA ligase in a total volume of 20μL. The reaction 
was place on ice and left overnight, during which it warmed up to room temperature. 
Five µL aliquots of the ligation reactions were transformed into home-made competent 
E. coli according to section 8.2.8, or commercially sourced - XL10-Gold ultra-
competent or XL1-Blue competent - bacterial cells according to manufacturer’s 
instructions. 
 
8.2.7. Preparation of antibiotic-selection agar plates 
Previously prepared LB agar was microwave-heated until liquefied. After 
cooling, the appropriate selection antibiotic was added and mixed. Molten LB agar 
was poured into sterile 10cm dishes, allowed to set at room temperature and stored at 
4°C until further use. 
 
8.2.8. Preparation of competent bacterial cells 
Each new batch of competent bacterial cells was prepared from a previously 
competent bacterial cell liquid culture. After overnight culture, in antibiotic free broth, 
E. coli DH5α were diluted 1:100 in SOB and incubated for a further 3 hours (to an 
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OD550 of 0.3). After a 10-minute incubation on ice, cells were harvested by 
centrifugation (3000rpm, 10 minutes at 4°C). Supernatant was decanted and cells were 
resuspended in CCMB buffer in 1/4 of the initial volume. Following a 4-hour 
incubation on-ice, bacteria were pelleted as before and resuspended in CCMB, this 
time in 1/12 of the starting volume. This cell suspension was aliquoted into 100µL 
individual dosages, snap frozen on dry ice and store at -80°C until required for plasmid 
transformation. 
 
8.2.9. Transformation of competent bacterial cells 
Plasmid DNA was transformed into chemically competent E. coli using the 
heat shock method. Briefly, 100ng of plasmid DNA was added to 25μL of cells. 
Following a 30-minute incubation on ice, cells were heated at 42°C for 45 seconds, 
allowing the opening of bacterial membrane pores and the entry of plasmid DNA. 
Following a further 2 minutes incubation on ice, 900μL of LB broth was added and 
cells were allowed to recover by incubating for 1 hour in a 37 °C shaker (180rpm) 
before being plated on previously prepared selective LB agar medium (section 8.2.7.).  
 
8.2.10. Bacterial culture 
E. coli strains were grown (from single colonies or previously amplified mini 
cultures) in LB broth supplemented with 100µg/mL of ampicillin or 50µg/mL of 
kanamycin and incubated overnight in a 180rpm shaker at 37ºC. 
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8.2.11. Plasmid DNA extraction and quantification 
Plasmid DNA was prepared in small or large scales. Small-scale preparations 
(mini-prep) was performed from 2-5 mL of overnight E. coli cultures, whilst large-
scale plasmid DNA preparations (midi-preps) used 50mL of overnight culture. Mini- 
and midi-preps were performed using Qiagen’s Plasmid DNA Mini Prep and Plasmid 
Plus Midi kits, respectively. DNA concentration was determined by measuring the 
absorbance at 260nm using a Nanodrop spectrophotometer. Purity of the same 
preparations was assessed through the analysis of absorbance ratios A260/A280 and 
A260/A230 which indicate protein and ethanol/phenol/EDTA contaminations, 
respectively. 
 
8.2.12. Site-direct mutagenesis 
Introduction of single nucleotide mutations in the pDUAL-PB1 plasmid was 
performed using the QuikChange Lightning Site-Directed Mutagenesis kit (Agilent) 
according to manufacturer’s instructions with minor changes. Briefly, a PCR was 
performed using synthetic oligonucleotides containing the desired mutation in a total 
volume of 25µL followed by the addition of 1µL of DpnI restriction enzyme and 
incubation at 37ºC for 1 hour. Five µL of the reaction mix was used to transform XL10-
Gold ultra-competent cells which were plated on antibiotic-containing agar plates. 
Following an overnight 37°C incubation, individual colonies were selected, regrown 
in broth for a following overnight period and used to extract plasmid DNA. 
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8.3. Eukaryotic cell culture, isolation and manipulation 
8.3.1. Cell passage 
Madin-Darby canine kidney (MDCK), human embryonal kidney (293T) and 
adenocarcinomic human alveolar basal epithelial (A549) cell lines were cultured in 
Dulbecco’s modified Eagle’s medium (D-MEM) supplemented with 10% (v/v) heat 
inactivated foetal bovine serum (FBS), 2mM L-glutamine, 100U/mL penicillin and 
100µg/mL streptomycin. HEK-Blue™ IFN-α/β cells were grown in complete medium 
further supplemented with 100µg/mL Zeocin and 30µg/mL Blasticidin. MDCK-SIAT 
cells were grown in compete medium further supplemented with 50µg/mL geneticin. 
Regular cell passage was performed twice a week. Complete medium was 
removed, cells were washed once with PBS and incubated with 0.25% trypsin-EDTA 
at 37°C until cells detached from the flask (12mL of PBS and 2mL of trypsin for 75cm2 
flasks; 25mL of PBS and 4mL of trypsin for 150cm2 flasks). Cells were resuspended 
in fresh complete medium and 10-50% of the cells were transferred to a clean flask 
containing complete medium (total volumes: 12mL for 75cm2 and 30mL for 150cm2 
flasks). 
 
8.3.2. Cell counting 
All cell types were counted using a haemocytometer (Neubauer counting 
chamber). Usually, 10μL of cell suspension was supplied into one side of the chamber 
under a glass cover slip. Under a light microscope, the number of cells was counted in 
Chapter 8   
266 
a designated squared area equivalent to 0.1mm3 (1×10-4mL). Cell concentration was 
then estimated to be: number of counted cells × 1×104 cells/mL. 
 
8.3.3. Isolation of bone marrow-derived macrophages 
129Sv/Ev wild-type and IFN-α/β receptor knockout (IFNAR-/-) mice on the 
same background were bred in the Biomedical Research Facility (BRF) at The Roslin 
Institute. Femurs from female mice aged 7 to 13 weeks old were extracted and the 
bone marrow was flushed out with 10mL of complete RPMI, using a 25G needle and 
syringe. Bone marrow cells were plated in 10cm bacteriological squared dishes in 
complete RPMI further supplemented with 1µg/mL porcine Colony Stimulating 
Factor 1 (CSF1). Four days post isolation, adherent cells were incubated with D-PBS 
and detached from the plastic by vigorous washing with an 18G needle and syringe 
and pelleted by centrifugation at 1500rpm. The content of each single dish was 
reseeded in two to three new plates in CSF1-supplemented complete RPMI. At day 7 
post isolation, differentiated macrophages were harvested and seeded for infection. 
 
8.3.4. Cytotoxicity assays 
Drug cytotoxicity was measured using the CellTiter-Glo viability assay kit, 
which judges cell viability on cellular ATP content. Cells were seeded at 1.5 ×104 
cells/well in a flat clear bottom, opaque-walled 96-well plate. On the following day, 
cells were incubated with increasing concentrations of drug and/or DMSO (vehicle) in 
a total volume of 100μL of complete D-MEM at 37 °C in 5 % CO2 for 12, 24 and/or   




Figure 8.1: Cytotoxicity effects of IRF3- and NF-κB-inhibiting drugs. 293T and 
A549 cells were incubated with increasing concentrations of BX-795 (A and B), 
IMD0354 (C and D) or JSH-23 (E and F) for 12 (green), 24 (blue) and 48 (magenta) 
hours after which cell viability was measured using the CellTitre-Glo according to 
manufacturer’s instructions. Dashed lines represent 90 and 50% of cell viability. 
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48 hours. At the end of each time point, 100μL of CellTiter-Glo reagent was 
added to each well and mixed on a horizontal orbital shaker for 2 minutes. Following 
a further 10-minute steady incubation at room temperature, the luminescent signal was 
measured in a GLOMAX® multidetection system using an integration time of 0.24 
seconds per well. 
This assay was used to determine cytotoxicity levels of mammalian cell lines 
(293T and A549 cells) in the presence of IRF3 and NF-κB inhibition drugs (BX-795, 
IMD0354 and JSH-23). Analysis of relative cell viability was performed at three time 
points (12, 24 and 48 hours), ranging the drug concentration from 100 to 0.1µM 
(Figure 8.1). 
 
8.3.5. Plasmid transfection of mammalian and avian cells 
Mammalian and avian cells were routinely transfected with Lipofectamine 
2000 reagent following manufacturer’s instructions. Briefly, cells were seeded the day 
before in order to get 70-80% confluency on the day of transfection. Plasmid DNA or 
poly I:C and lipofectamine were separately diluted in Opti-MEM (detailed amounts of 
plasmid and lipofectamine are later described in each section). Following a 5-minute 
incubation period, the two mixtures were combined and incubated for further 20 
minutes. Cells culture medium was changed to Opti-MEM and the mixture was 
dripped over cells.  
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8.3.6. RNP reconstitution reporter assays 
8.3.6.1. Transcription (firefly luciferase) reporter plasmid 
Sub-confluent monolayers of 293T or QT-35 cells (2×105 cells 24-well plates 
seeded on the previous day) were co-transfected in triplicate with 50ng of each 
pDUAL plasmid encoding PB2, PA, NP along with a PolI plasmid containing a reverse 
oriented firefly luciferase reporter flanked by the 5 and 3’ UTRs of segment 8, and 
various PB1 plasmids. As a negative control, transfections lacking the PB1 plasmid 
(empty vector was used to balance plasmid intake) were also performed (2PNP). Two 
days post transfection, medium was removed and cells were lysed with 120µL of 
reporter lysis buffer. Cell debris was scraped off, lysates were collected into clean 
tubes and clarified by centrifugation (10,000rpm, 5 minutes, 4°C) in a benchtop 
centrifuge. Luminescence was measured using 60μL of lysate in opaque 96-well plates 
and injecting 15pmol of luciferin using a GLOMAX® multidetection system (injection 
speed: 200μL/second; gap: 0.5 seconds; integration time: 5 seconds). 
A dose-dependent variety of this protocol was also performed. For this, 50ng 
of PB2, PA and NP pDUAL plasmids were transfected into 293T cells along with 
varying amounts of PB1 pDUAL plasmid (from 100 to 0.001ng). 2PNP, lipofectamine 
only and mock controls were also included. Incubation time, lysis and luciferase 
activity measurements were performed as previously described. A wide-range dose-
dependent experiment was performed with PB1 WT only (Figure 8.2A). Parallel 
western blot analysis of PB1 confirmed that PB1 accumulation and luciferase 
expression declined with decreasing plasmid amount without similar decreases in NP  
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Figure 8.2. Wide-range dose-dependent replication and transcription 
minireplicon assays. (A) 293T cells were transfected as described in section 8.3.6.1. 
Luciferase levels were scaled to 50ng of PB1 pDUAL plasmid (B) Expression levels 
of PB1 and NP were confirmed by western blot (α-tubulin was used as loading 
control). Inconsistencies in the levels of NP and α-tubulin could be associated with 
experimental artefacts at the gel-to-membrane transfer step. (C) 293T cells were 
transfected as described in section 8.3.6.3. Luciferase levels were scaled to 50ng of 
PB1 pDUAL plasmid. In both (A) and (C), point represent independent replicated 
within at least 3 independent experiments. Dotted boxes represent the selected amounts 
of PB1 plasmid used to apply to the remaining segment 2 mutants.  
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abundance (Figure 8.2B). From this analysis, 6 amounts of PB1 pDUAL plasmid (50, 
2, 1, 0.1, 0.01, 0.001ng) were selected and the method applied to segment 2 mutants. 
 
8.3.6.2. Transcription (GFP) reporter plasmid 
RNP reconstitution assays with a transcription GFP reporter plasmid were 
performed as in section 8.3.6.1. with minor changes. Transfection was performed with 
100ng of each pDUAL plasmid and 1000ng of reporter plasmid. GFP readings were 
taken by measuring fluorescence levels (excitation: 485/20, emission: 528/20, 
sensitivity: 35) using a plate reader (Synergy HT, BioTek®). 
 
8.3.6.3. Replication (firefly luciferase) reporter plasmid 
293Ts (2×105 cells 24-well plates seeded on the previous day) were co-
transfected with 50ng of each 3PNP-expressing reporter plasmids and 25ng of cRNA-
like firefly luciferase reporter plasmid using 1μL of Lipofectamine2000. Twenty-four 
hours post transfection, cells were lysed with 120μL of 1×RLB and luciferase levels 
were read as in section 8.3.6.1. An equivalent wide-range as in Figure 8.2A was 
applied using the replication reporter plasmid (Figure 8.2C). 
 
8.3.7. Cellular gene expression shut-off assays 
Sub-confluent monolayers of 293T cells were co-transfected in triplicate with 
400ng of pcDNA effector plasmids (expressing PB1-related peptides) and 100ng of 
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pRL or 20ng of β-gal expressing plasmids using 1μL of Lipofectamine2000 as 
described in 8.3.5. A pcDNA3.1 plasmid expressing A/chicken/Rostock/34 (fowl 
plague or FPV) PA segment was added as positive control effector plasmid (Hussain 
et al. 2018). Negative controls included a temperature-sensitive FPV PA mutant (Bell 
2006) and empty control pcDNA plasmids. A mock transfection condition was also 
included. Successful transfection efficiencies were confirmed by western blot analysis 
against PB1 and PA (data not shown). Renilla luciferase or β-gal expression levels 
were assessed 48 hours post transfection. 
 
8.3.7.1. Renilla luciferase measurement 
Quantification of renilla luciferase expression was performed using a Renilla 
Luciferase Assay kit. Briefly, cells were lysed with 100μL of 1× lysis buffer and frozen 
overnight at -20°C. Cells were scraped off the plate, cell debris was removed by 
centrifugation (8000rpm, 5 minutes, 4°C) and 20μL of each sample was transferred to 
a white-bottomed 96-well plate and luminescence was measured in a Promega GloMax 
Multi Detection Unit injecting 100μL of 1× Renilla luciferase substrate (speed: 
200μL/second, delay: 2 seconds, integration time: 10 seconds). 
 
8.3.7.2. β-galactosidase measurement  
Expression levels of β-gal were measured using a β-Galactosidase Enzyme 
Assay System. Cells were lysed with 100μL of 1× reporter lysis buffer. Lysates were 
transferred to clean 1.5mL tubes, vortexed and cleared by centrifugation. Fifty μL of 
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cleared lysate was transferred to a clear bottomed 96-well plate and 50μL of ortho-
nitrophenyl-D-galactopyranoside (ONPG)-containing 2× assay buffer was added to 
each well. β-galactosidase catalyses the hydrolysis of β-galactosidase such as ONPG. 
Hydrolysis of ONPG results in the production of ONP anion which has a bright yellow 
colour. After a 30 minute incubation at 37°C, the reaction was stopped by the addition 
of 150μL of 1M sodium carbonate and absorbance at 420nm was measured using a 
plate reader (FLUOStartOmega, BGM Labtech). 
 
8.3.8. Plasmid-based β-IFN and ISRE promoter reporter studies 
Under confluent (80%) monolayers of 293T cells (2×105 cells per 24 well 
seeded on the previous day) were co-transfected with 50ng of reporter plasmid (IFN-
β::Luc or ISRE::Luc) and 400ng of pcDNA3.1 expressing PB1-related peptides using 
1μL of Lipofectamine 2000 as described in section 8.3.5 Plasmid transfection of 
mammalian and avian cells. For positive control, a plasmid expressing the A/green-
winged teal/Ohio/175/1986 NS1 ORF was used (Turnbull et al. 2016). Negative 
controls included a plasmid expressing the PR8 NP ORF and the pcDNA3.1 empty 
plasmid. 24 hours post transfection, cells were stimulated with 5μg of poly I:C by 
transfection using 2μL of Lipofectamine/well. Mock-stimulated cells were also 
included where poly I:C was replaced by milliQ H2O. Each assay was performed in 
triplicates. Twenty-four hours post stimulation, cells were lysed with 120μL of 
reporter lysis buffer and luciferase activity was measured as described in section 
8.3.6.1 Transcription (firefly luciferase) reporter plasmid. 
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8.4. Virological assays 
8.4.1. Generation of P0 viral stocks 
PR8 wild-type and mutant viruses were rescued using a previously described 
reverse genetics system (section 2.2.2. Virus rescue of PR8 segment 2 mutants). 
Briefly, 80%-confluent monolayers of 293T cells in 6-well plates were transfected 
with PR8 segment cDNAs cloned into the pDUAL plasmid (250ng of each) along with 
4µL of Lipofectamine2000 in a total volume of 800µL of Opti-MEM. After overnight 
incubation at 37ºC, the transfection medium was replaced with fresh virus growth 
medium (DMEM, 2mM L-glutamine, 100U/mL penicillin, 100µg/mL streptomycin, 
0.14% BSA, 1µg/ml TPCK trypsin). Cells were incubated for 48 hours, after which 
supernatants were harvested, cleared by centrifugation and stored at -80°C until future 
use. 
 
8.4.2. Generations of cell-grown P1 viral stocks 
A first passage stock was grown in confluent monolayers of MDCKs (4×106 
cells/T25 flask or 1.2×107 cells/T75 flask seeded the previous day) where cells were 
infected with an estimated MOI of 0.01 using the P0 stock. Following a minimum of 
48 hour incubation, or when infected cells showed cytopathic effect (CPE), cell 
supernatants were harvested, cleared by centrifugation (1500rpm, 5 minutes), 
aliquoted and stored at -80ºC until titrated by plaque assay. 
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8.4.3. Quantification of viral stocks and samples by plaque assay 
MDCK cells were seeded in 6-well plates (2×106 cells/well) in 2 mL D-
MEM/10% FBS and incubated overnight at 37°C/5% CO2. Medium was removed 
from the wells and the cells were washed once with 2mL of PBS and then infected 
with 500µL of 10-fold serial dilutions of virus and incubated for 60 minutes to allow 
virus adsorption to the cells. Following adsorption, medium was removed and cells 
were overlaid with 2mL of DMEM/0.14% BSA/1µg/mL TPCK/1.2% Avicel. 
Incubation continued undisturbed for 2 days at 37°C/5% CO2 after which cells were 
fixed with 10% NBF. After overnight fixation, the Avicel-NBF overlay was removed 
and cells were stained with 0.1% Toluidine Blue. After a 1-hour incubation at room 
temperature, staining solution was rinsed under tap water, plates were air dried and 
plaques were counted. 
 
8.4.3.1. Plaque assay staining of pandemic human IAVs (Cal04) 
Plaque assays for Cal04 backbone viruses were performed essentially as 
described in the previous section (8.4.3. Quantification of viral stocks and samples by 
plaque assay), but using MDCK-SIAT cells and a 3 day incubation period at 35°C. 
Cells were then fixed as previously described, fixing solution was removed and cells 
were washed with PBS and permeabilised using 1 mL PBS/0.2% (v/v) Triton X-100 
per well for 10 minutes. After two PBS washes, cells were incubated with 400μL/well 
of A2915 rabbit polyclonal anti-MBP-NP (diluted 1:1000 in PBS/2% BSA) for 1 hour 
on a rocking platform at room temperature. Following two PBS washes, cells were 
incubated with 400μL of goat anti-rabbit IgG-HRP conjugated secondary antibody 
Chapter 8   
276 
(diluted to 1:1000 in PBS/2%BSA) for 1 hour in the same conditions. Cells were 
washed three times with PBS, 0.5mL of TrueBlue peroxidase substrate was added per 
well and cells were incubated at room-temperature covered from direct light. When 
blue-stained plaques were visible, cells were washed with water, allowed to dry, and 
plaques were counted under a stereo microscope. 
 
8.4.4. Quantification of viral stocks and samples by 
haemagglutination assay 
Virus stocks grown in eggs were 2-fold serial diluted in PBS in a final volume 
of 50µL after which 50µL of 1% chicken blood cells were added to each well. After a 
30 minute incubation at room-temperature, haemagglutination-positive wells were 
recorded. Each plate contained a negative (PBS only) and a positive sample for 
haemagglutination comparison. 
 
8.4.5. Quantification of plaque sizes 
After plaque assay incubation, fixation and staining (performed as described in 
section 8.4.3 Quantification of viral stocks and samples by plaque assay), 6-well plates 
were scanned in an Epson Perfection V750 Pro Scanner at a resolution of 1200dpi. 
Images were converted to grey scale and a Photoshop software used to apply a level 4 
posterisation. The area of each plaque was then determined in ImageJ. At least 50 
plaques were analysed per condition. 
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Individual plaque area values of WT PR8 were averaged and used as a 
reference to scale the individual plaque sizes of each one of the analysed mutant PR8 
segment 2 mutants. 
 
8.4.6. Viral RNA isolation and sequencing 
First passage viral stocks had RNA extracted using the QIAamp Viral RNA 
Kit via the spin protocol according to manufacturer’s guidelines. Briefly, 140µL of P1 
stock or virus sample was mixed with a lysis buffer to release RNA from the virions 
which was then bound to a silica-based membrane. After a series of alcohol-based 
washes, RNA was eluted from the column using 40µL of milliQ water. 
cDNA production was performed with the Verso cDNA kit (Thermo 
Scientific), using 5μL of RNA and 10nM of Uni12 primer (Table 8.7) in a final volume 
of 10µL. For RNA denaturation, the mixture was heated to 65°C for 10 minutes in a 
Veriti® Thermocycler (Applied Biosystems®, LifeTechnologies) after which, final 
concentrations of 50nM of each dNTP, 1× RT Buffer and 1µL of Verso™ Enzyme 
Mix were added in a total 20μL reaction. The final mixture was incubated at 42°C for 
60 minutes followed by 95ºC for 2 minutes. 
A 611bp fragment of segment 2 was amplified using Uni12 and one of the Seg2 
611-592 reverse oliognucleotides (for each different virus) (Table 8.7) as forward and 
reverse primers, respectively. Each PCR contained 200nM of each primer, 200µM of 
each dNTP, 1.5mM MgCL2 and 2.5 units of Taq DNA Polymerase (Invitrogen, Life 
Technologies). PCR were carried out in a Veriti® Thermocycler, using conditions of 
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1 cycle of 2 minutes at 95°C, followed by 30 cycles of 30 seconds at 95°C, 1 minute 
at 55°C and 2.5 minutes at 72°C, finishing with a 10-minute incubation at 72°C. PCR 
product length was confirmed by 1% agarose gel electrophoresis. PCR products were 
purified according to section 8.2.3. Purification of DNA fragments. Five µL of DNA 
was sent for sequencing using a final concentration of 5µM of Uni12 primer in a total 
volume of 10µL. Sequencing analysis was performed by GATC Biotech. 
 
8.4.7. Quantification of viral genome by quantitative RT-PCR 
Viral genome quantification was performed by single step real-time PCR in a 
Rotor-Gene Q cycler (Qiagen) and data were analysed using the Rotor-Gene Software. 
RT qPCR mixes were prepared with 400nM of primers against PR8 segments 2, 5 and 
7. Other mix components included 1× SensiFAST SYBR® Lo-ROX One-Step Mix 
(Bioline), 2µL of template RNA, reverse transcriptase and RiboSafe RNA inhibitor in 
a 20µL reaction. Samples for all targets were analysed in duplicates or triplicates using 
the following cycling thermal profile: 45°C for 10 minutes, 95°C for 2 minutes and 40 
amplification cycles at 95°C for 10 seconds and 60°C for 30 seconds. Melting curves 
were acquired by consecutive 1° C temperature increments from 50 to 99°C. 
Alongside the RNA samples, standard curves constructed with serial diluted 
pDUAL plasmids of segments 2, 5 and 7 were ran (Figure 8.3). All these showed a 
decrease of CT values with the increase of number of copies and satisfactory 
efficiencies.  
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Figure 8.3: qPCR standard curves. Known concentrations of PR8 segment 2 (A), 5 
(B) and 7 (C) pDUAL plasmids were run alongside viral samples. CT equations and 
respective R2 values were calculated using GraphPad Prism. Efficiencies were 
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8.4.8. Virus infection of eukaryotic cells 
To all adherent cells, a wash with the appropriate serum free medium was 
performed to ensure the removal of residual FBS. Infections were carried out using 
serum free medium in small volumes: viruses were diluted in 150μL for 24-well plates, 
300μL for 12-well and 500μL for 6-well plates). Following a 1 hour incubation which 
allowed virus adsorption, plates were incubated at the propagation temperature for 1 
hour (shaking every 15 minutes). Infectious medium was then removed and the desired 
medium was added to cells (generally 1mL for 24 and 12-well plates and 2mL for 6-
well plates). 
 
8.4.9. Viral multicycle growth kinetic analysis 
Confluent monolayers of MDCK, QT-35 or bone-marrow derived macrophage 
cells were infected with PR8 viruses at a MOI of 0.001 in 300µL of serum free DMEM 
in 12-well plates. After a 1-hour incubation at 37°C (which allowed virus attachment 
to the cells) inoculum was replaced by 1mL of fresh virus growth medium 
(DMEM/0.14% BSA/1µg/ml TPCK trypsin). At different times post infection, 
supernatants were snap frozen in dry ice and samples were stored at -80°C until titrated 
by plaque assay. 
 
8.4.10. HEK Blue assay 
90% confluent monolayers of A549 cells were infected with the mentioned 
viruses at a range of different MOIs (0.003, 0.03, 0.3 and 3) in serum free medium in 
  Materials and Methods 
281 
triplicate. After a 1-hour virus adsorption at 37ºC, inoculum was replaced with 1mL 
of DMEM/0.14% BSA. Twenty-four hpi, UV inactivation was performed. 300µL of 
supernatant was moved to a clean 24-well plate and exposed to 120MJ/cm2 for 10 
minutes in a CL-1000 Ultraviolet Crosslinker on ice. Type I interferon levels were 
measured using 20µL of either original or UV inactivated supernatants along with 
5×104 HEK Blue cells in a total volume of 200µL of heat inactivated complete medium 
in 96 well plates. After a 24-hour incubation (37ºC, 5% CO2), 20μL of each sample 
was mixed with 180μL of QUANTI-Blue reagent in 96-well plates. Following a 1.5-2 
hour incubation, absorbance values at 600nm were acquired using a GLOMAX® 
multidetection system. 
 
8.5. Protein purification and detection 
8.5.1. SDS Polyacrylamide gel electrophoresis 
Polypeptides were separated using sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE). Polyacrylamide gels were cast using approximately 
5mL per gel of the resolving gel recipe described in 8.1.6.5.2 using 0.75 or 1mm spacer 
plates with appropriate short plates. Acrylamide:bisacrylamide content was dependent 
on the size of the proteins of interest, with smaller proteins requiring a higher 
polyacrylamide percentage gel to allow efficient resolution and vice-versa. Stacking 
gels were always cast with 4% acrylamide:bisacrylamide. 
Lysates were typically generated by adding 200μL of 2× Laemmli’s buffer to 
24-well plates (generally 5×105 cells). Lysates were transferred into clean 1.5mL 
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tubes, boiled at 95°C for 7 minutes and centrifuged at 13000rpm for 1 minute. Each 
lane was loaded with 5-20μL of lysate. 3μL of protein molecular weight marker was 
added to the last lane and gels were run at 80V. Once the sample had past the stacking 
gel barrier and entered the running gel, voltage was increased up to 150V for the 
desired length of time. 
 
8.5.2. Western blot 
After separation by SDS-PAGE according to the previous section (section 
8.5.1. SDS Polyacrylamide gel electrophoresis), proteins were transferred to a 0.2 or 
0.45µm nitrocellulose membrane in a Trans-Blot®TurboTM apparatus using a 
commercial transfer buffer. Membranes were blocked with milk-based blocking buffer 
(or Odyssey TBS blocking buffer, when detecting phosphorylated peptides) for 1 hour 
and stained with primary antibodies diluted in blocking buffer overnight at 4ºC. After 
three 5-minute PBST washes (TBST for phosphorylated targets), a secondary antibody 
was incubated for one hour at room temperature protected from direct light. Following 
three more washes, membranes were imaged using the LI-COR Odyssey Imaging 
platform and the ImageStudio Lite software. 
 
8.5.3. Densitometry 
Densitometric analysis of polypeptide abundance was performed using Image 
J software (https://imagej.nih.gov/ij/) (Hartig 2013). Concisely, ImageStudio acquired 
images were compiled and saved as TIFF files. Those images were opened on ImageJ 
and the image type was transformed into a 32-bit format. Sample lanes were defined 
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using the gel analysing tool. Once selected, each lanes’ pixel intensity was plotted and 
the area under each peak curve was calculated. 
 
8.6. Radioactive isotope experiments 
8.6.1. 35S-methionine/cysteine metabolic labelling of infected cells 
Confluent A549 cell monolayers were infected at a MOI of 10 in 6-well plates. 
Following a 7-hour infection, cells were washed twice with Methionine/Cysteine free 
D-MEM and incubated with 500μL of Met/Cys free D-MEM supplemented with 10% 
dialysed FBS and 2MBq/mL 35S-Met/Cys (1MBq/well) for 1 hour (37°C, 5% CO2). 
Cells were further washed with PBS and lysed with 500μL of RIPA buffer containing 
phosphatase inhibitors and stored overnight at -80°C. 
 
8.6.2. Autoradiography of dried polyacrylamide gels 
SDS-PAGE was performed as described in section 8.5.1. SDS Polyacrylamide 
gel electrophoresis and gels were fixed in gel fixing solution for 15 minutes with the 
gel fixing solution being replaced every 5 minutes. Fixed gels were transferred to 3mm 
filter paper, covered with film and dried in a gel dryer (Model 5432, BioRad) under 
80°C heating and vacuum pressure for 2 hours. Once dried, gels were placed in a flat, 
light-tight cassette and overlaid with an X-ray film. Overnight or longer exposures 
were developed using a Konica SRX-101A (FAPJ) X-ograph film processer. 
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8.7. Fluorescent imaging and detection 
8.7.1. Immunofluorescence staining 
The desired cell lines were seeded on 13mm round glass coverslips in 24 well 
dishes. After infection/transfection, cells were fixed with 4% neutral buffered 
formaldehyde (NBF) in PBS for 20 minutes followed by three 1mL PBS washes. Cells 
were permeabilised with 1% Triton X-100 in PBS for 10 minutes at room temperature. 
Following three washes with PBS, cells were blocked with 1mL of PBS/1% BSA) for 
30 minutes. A single wash with PBS was then followed by incubation for 1 hour with 
200µL of primary antibodies at the appropriate dilutions. Three 1mL PBS washes were 
then executed to remove unbound antisera followed by incubation of secondary 
antibodies in the same volume. 4’,6-Diamidino-2-phenylindole (DAPI) (100ng/mL) 
was diluted in blocking buffer and incubated for 10 minutes. After labelling steps were 
completed, coverslips were washed three more times and mounted upside down on 
glass slides with ProLong reagent. 
 
8.7.2. Confocal microscopy 
Confocal fluorescent imaging was carried out using a Zeiss laser confocal 
microscope LSM710. Machine settings were generally kept unchanged during image 
acquisition for each fluorophore during an individual experiment. Post-capture tarring 
up of images was performed using Adobe Photoshop, using only linear transformation 
methods. 
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8.7.3. Fluorescence-activated cell sorting (FACS) 
In order to verify the degree of differentiation, CSF1-differentiated bone-
marrow-derived macrophages were subjected to FACS analysis. This protocol was 
performed in polypropylene FACS tubes. Washes were performed by a 5-minute 
centrifugation at 1500rpm. 5×105 cells were washed, resuspended in 50μL of PBS/2% 
FBS (FACS buffer) and blocked with FACS buffer/Fc block for 30 minutes. Staining 
was performed using CD11b-APC and F4/80-488 primary conjugated antibodies in a 
total volume of 100µL for 15 minutes. From this stage, all incubation and washing 
steps were performed protected from direct light. After two 500μL PBS washes, 
live/dead cell staining was performed in 100μL of eFluor™ 780 diluted in PBS for 30 
minutes. Cells were washed once with 500μL of FACS buffer and fixed on ice with 
100μL of IC Fixation buffer. After a final 500μL FACS buffer wash, cells were 
maintained at 4°C and read on the following day using a FACSCalibur cell analyser 
(BD biosciences). 
Negative (secondary antibodies only), single and double staining conditions 
were performed for both WT (Figure 8.4A) and IFNAR-/- BMDM (Figure 8.4B). In 
average, 3000 cells per condition were scanned and gated. The secondary antibodies-
only staining was used to set the regions of each quadrant. Single staining with the α-
F4/80 antibody resulted in the staining of 94.3 and 94.0% of cells (for WT and KO 
BMDM, respectively), which shifted to Q3. A similar percentage of positive stained 
BMDM was observed when cells were single stained for CD11b. In this case, 97.4 and 
94.6% of WT and IFNAR-/- cells were seen in Q1. The simultaneous use of both 
primary antibodies resulted in the double staining of over 92% of CSF1-differentiated   
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Figure 8.4: Use of FACS to verify the differentiation of BMDMs CSF1 treatment. 
WT (A) and IFNAR-/- BMDMs (B) were stained against macrophage markers CD11b 
and F4/80. No primary antibody, individual single staining and double staining were 
performed. Data acquisition was performed by Dr Marlynne Quigg-Nicol.  
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BMDM. These percentages are consistent with previously published studies and 
allowed us to be certain of the successful differentiation of the used BMDM 
differentiation protocol. 
 
8.8. Mouse experiments 
8.8.1. Ethics statement 
The following statement was provided by Prof. Bernadette Dutia (The Roslin 
Institute, The University of Edinburgh, UK), under whose license and authority the 
experiments were performed: “All animal experiments were carried out under the 
authority of a UK Home Office Project Licence (60/4479) within the terms and 
conditions of the strict regulations of the UK Home Office ‘Animals (scientific 
procedures) Act 1986’ and the Code of Practice for the housing and care of animals 
bred, supplied or used for scientific purposes.” Individual studies were performed after 
a study request protocol had been submitted to and approved by the Roslin Institute 
Animal Welfare and Ethics Review Board. 
 
8.8.2. Viral infections and sampling 
129Sv/Ev WT and IFNAR-/- mice were bred and housed in the Roslin Institute 
Biomedical Research Facility (BRF). All work was carried out under a UK Home 
Office licence according to the Animals (Scientific Procedures) Act 1986. Mouse 
infections were conducted by Prof. Bernadette Dutia and Dr. Marlynne Quigg-Nicol 
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(The Roslin Institute, The University of Edinburgh, UK). Five to seven week old 
female mice were anaesthetised using isoflurane in an incubation chamber and 
intranasally infected with 200 PFU of virus in 40μL of PBS through both nostrils 
simultaneously. Mice were weighed and assessed visually for clinical signs (inactivity, 
ruffled fur and laboured breathing) on a daily basis. At the fifth day post infection, 
mice were humanely euthanised by CO2 asphyxiation. Upon confirmation of death, 
mice were dissected, and tissue collection was performed. The tip of the left lung was 
collected into 500μL of RNA later solution and the remainder of the left lung was snap 
frozen in 2mL tubes on dry ice and stored at -80°C until downstream processing. The 
left main bronchus airway was constricted, the right lung was inflated with 1mL of 
10% (v/v) NBF and stored in the same solution. 
 
8.8.3. Tissue homogenisation and viral quantification 
Left lungs were added to 1.5mL of serum-free D-MEM and a 5mm diameter 
stainless steel bead in 2mL tubes and homogenised using a Tissue Lyser II (Qiagen) 
system at 28kHz for 2 sets of 2 minutes. Homogenised tissue was clarified by 
centrifugation (3000rpm, 5 minutes, 4°C). Mouse lung homogenates were titrated for 
infectious virus (as described in section 8.4.3. Quantification of viral stocks and 
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8.8.4. Histopathological analysis 
Inflated and formalin-fixed mouse right lungs were dehydrated and embedded 
in paraffin and 5μm sections were cut, applied to slides and stained with haematoxylin 
and eosin (performed by the University of Edinburgh Easter Bush Histopathology 
Laboratory). Lesion scoring was performed blindly by Dr Philippa Beard (The 
Pirbright Institute, Surrey, UK). The scoring system was designed by Dr Beard and 
provided as follows: 
 0, no lesions 
 1, mild, focal inflammation and rare degeneration and necrosis 
 2, moderate, multifocal inflammation with frequent necrotic cells 
 3, marked, multifocal inflammation with common necrosis and occasional 
fibrin accumulation. 
 
8.8.5. Enzyme-linked immunosorbent assay (ELISA) 
IFN-β was detected in mouse lung homogenates by ELISA using a DuoSet® 
ELISA Development Systems kit (R&DSystems). The capture antibody was diluted 
1:3000 and used to coat 96-well plates (50µL/well). Plates were incubated overnight 
at room-temperature. Following 3 washes with the provided wash buffer, wells were 
blocked for 1 hour and individual lung homogenates and standard solutions of known 
IFN-β concentration were added. After 2 hours incubation at room temperature, wells 
were washed three times. Detection antibody was added for 2 hours at room-
temperature, cells were washed three times and a streptavidin-HRP solution was 
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applied. A 20-minute incubation was performed in the dark, followed by the addition 
of a 2N sulphuric acid solution and the measurement of absorbance at 560nm. 
 
8.8.6. Mouse cytokine arrays 
Cytokines and chemokines were quantified from mouse lungs using the Mouse 
Cytokine Antibody Array Panel A (R&D Systems). First, protein quantification of 
lung homogenates was performed with a BCA Protein Assay Kit according to 
manufacturer’s instructions. 
Homogenates of up to 5 mice per cohort were pooled and applied to the array 
membrane according to the manufacturer’s instructions. Briefly, a homogenate was 
incubated with a cocktail of biotinylated antibodies against 40 cytokines. This mixture 
was then applied overnight to a nitrocellulose membrane containing anti-cytokine 
antibodies spots (printed in duplicate), which capture the detection antibody/cytokine 
complex. After a wash to remove unbound cocktail antibodies, the nitrocellulose 
membrane was incubated with a streptavidin-tagged secondary antibody mixture and 
imaged using the LI-COR Odyssey Imaging platform and the ImageStudio Lite 
software. Protein quantification was measured through signal intensity, assuming a 
proportional correlation between the signal intensity of each membrane spot and the 
quantity of the specific cytokine. Subsequent analyses and heat map construction were 
performed in Microsoft Excel and GraphPad Prism respectively. 
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8.9. Bioinformatic analyses 
Bioinformatic analyses were performed in collaboration with Dr Samantha 
Lycett (The Roslin Institute, University of Edinburgh). PB1 nucleotide sequences were 
acquired from the NCBI Influenza Virus Database 
(https://www.ncbi.nlm.nih.gov/genomes/FLU/Database/nph-select.cgi?go=database) 
on the 4th of May 2016. Sequences were downloaded by host (avian, canine, equine, 
human and swine) in combined FASTA files. Avian, human and swine sequences were 
separated into groups of 500 sequences using a script written in R software and each 
group was uploaded and aligned in MEGA6, after which poor quality/incomplete 
sequences were discarded. Complete sequences were then re-joined and AUG codon 
preservation (and respective Kozak strength) was quantified using R scripts and further 
analysed in Microsoft Excel. All R scripts were written and kindly provided by Dr 
Samantha Lycett. 
 
8.10. Statistical analysis 
All statistic tests were performed in GraphPad Prism 7 Software. Specific 
statistical tests were chosen for different analyses and are stated in each figure legend. 
 ns: non-significant 
 *: p<0.05 
 **: p<0.01 
 ***: p<0.001. 
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8.11. Structure modelling 
The previously published model of IAV polymerase was obtained from RCSB 
Protein Data Bank (reference 4WSB). Protein structure predictions were performed 
through the i-TASSER online server, using the pre-set parameters 
(https://zhanglab.ccmb.med.umich.edu/I-TASSER/) (Roy et al. 2011; Yang et al. 
2015). All proteins models were analysed and visualized using PyMOL Molecular 
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